<SEC-DOCUMENT>0001654954-24-001793.txt : 20240214
<SEC-HEADER>0001654954-24-001793.hdr.sgml : 20240214
<ACCEPTANCE-DATETIME>20240214163112
ACCESSION NUMBER:		0001654954-24-001793
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240214
DATE AS OF CHANGE:		20240214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		24639123

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cvm_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cvm="http://cvm.com/20231231"><head><title>cvm_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2023-10-01to2023-12-31" id="ixv-5730">0000725363</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2023-10-01to2023-12-31" format="ixt:booleanfalse" id="ixv-5731">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2023-10-01to2023-12-31" id="ixv-5732">--09-30</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2023-10-01to2023-12-31" id="ixv-5733">Q1</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2023-10-01to2023-12-31" id="ixv-5734">2024</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" unitRef="USDPShares" decimals="INF" id="ixv-5735">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-5736">200000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-5737">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" unitRef="Shares" decimals="0" id="ixv-5738">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-5739">0</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" unitRef="USDPShares" decimals="INF" id="ixv-5740">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-5741">600000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" unitRef="Shares" decimals="0" id="ixv-5742">50018601</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-5743">47422304</ix:nonFraction><ix:nonFraction name="cvm:EquityWarrantsExercisePrice" contextRef="From2023-10-01to2023-12-31" unitRef="USDPShares" decimals="INF" id="ixv-5744">0</ix:nonFraction><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2022-10-01to2022-12-31" unitRef="USD" decimals="0" id="ixv-5745">700000.0</ix:nonFraction><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-10-01to2022-12-31" unitRef="USD" decimals="0" id="ixv-5746">100000.0</ix:nonFraction><ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2022-10-01to2022-12-31" unitRef="USD" decimals="0" id="ixv-5747">100000.0</ix:nonFraction><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2022-10-01to2022-12-31_cvm_ErgomedMember" unitRef="USD" decimals="0" id="ixv-5748">100000.0</ix:nonFraction><ix:nonFraction name="cvm:PatentImpairmentCharges" contextRef="From2022-10-01to2022-12-31" unitRef="USD" decimals="0" id="ixv-5749">0</ix:nonFraction><ix:nonFraction name="cvm:PatentImpairmentCharges" contextRef="From2023-10-01to2023-12-31" unitRef="USD" decimals="0" id="ixv-5750">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvm-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="From2023-10-01to2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-02-09_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-02-01to2024-02-09_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-01-11_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-10-28_cvm_CEOGeertKerstenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:CEOGeertKerstenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-11-01to2023-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-10-28_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_ConsultantsMember_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_ConsultantsOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_ConsultantsMember_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_ConsultantsMember_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_IncentiveStockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_StockCompensationPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_StockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-02-07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:DocumentType" id="ixv-6263">10-Q</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(Mark One)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="ixv-6264">&#9746;</ix:nonNumeric>&#160;&#160;&#160; QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the quarterly period ended <strong><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" id="ixv-6265">December 31, 2023</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">OR</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="ixv-6266">&#9744;</ix:nonNumeric>&#160;&#160;&#160; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THE SECURITIES EXCHANGE ACT OF 1934</p><p style="font-size:10pt;font-family:times new roman;margin:0px">For the transition period from _______________ to ______________.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Commission File Number <strong><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityFileNumber" id="ixv-6267">001-11889</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:50%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityRegistrantName" id="ixv-6268">CEL-SCI CORPORATION</ix:nonNumeric></span></strong></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="ixv-6269">Colorado</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityTaxIdentificationNumber" id="ixv-6270">84-0916344</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;State or other jurisdiction incorporation</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;(IRS) Employer Identification Number</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityAddressAddressLine1" id="ixv-6271">8229 Boone Boulevard</ix:nonNumeric>, <ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityAddressAddressLine2" id="ixv-6272">Suite 802</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<span style="text-decoration:underline"><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityAddressCityOrTown" id="ixv-6273">Vienna</ix:nonNumeric>, <ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="ixv-6274">Virginia</ix:nonNumeric> <ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityAddressPostalZipCode" id="ixv-6275">22182</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Address of principal executive offices</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<span style="text-decoration:underline">(<ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:CityAreaCode" id="ixv-6276">703</ix:nonNumeric>) <ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:LocalPhoneNumber" id="ixv-6277">506-9460</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Registrant's telephone number, including area code</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Title of Each Class</p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Trading Symbol(s)</p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Name of Each Exchange on Which Registered</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:Security12bTitle" id="ixv-6278">Common Stock</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:TradingSymbol" id="ixv-6279">CVM</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-6280">NYSE American</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityCurrentReportingStatus" id="ixv-6281">Yes</ix:nonNumeric> &#9746; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityInteractiveDataCurrent" id="ixv-6282">Yes</ix:nonNumeric> &#9746; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Large&#160;accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="ixv-6283">Non-accelerated filer</ix:nonNumeric></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746; </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="ixv-6284">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging growth company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="ixv-6285">&#9744;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Yes <ix:nonNumeric contextRef="From2023-10-01to2023-12-31" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="ixv-6286">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Class of Stock</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;No. Shares Outstanding</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction contextRef="AsOf2024-02-07" name="dei:EntityCommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-6287">50,104,231</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">February 7, 2024</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="tooc">TABLE OF CONTENTS </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PART I FINANCIAL INFORMATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Item 1.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Page</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#bs">Condensed Balance Sheets at December 31, 2023 (unaudited) and September 30, 2023</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#op">Condensed Statements of Operations for the three months ended December 31, 2023 and 2022 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#eq">Condensed Statements of Stockholders&#8217; Equity for the three months ended December 31, 2023 and 2022 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#cf">Condensed Statements of Cash Flows for the three months ended December 31, 2023 and 2022 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#fs">Notes to Condensed Financial Statements<strong>&#160;</strong>(unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">16</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3">Item 3.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3">Quantitative and Qualitative Disclosures about Market Risks</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">25</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4">Item 4.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4">Controls and Procedures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">25</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><a href="#p2">PART II</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i22">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i22">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">26</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#p2i5">Item 5.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#p2i5">Other Information</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">26</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i6">Item 6.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i6">Exhibits</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">26</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#sig">Signatures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">27</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="bs">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED BALANCE SHEETS</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>DECEMBER 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SEPTEMBER 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">ASSETS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_755" contextRef="AsOf2023-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,241,440</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_756" contextRef="AsOf2023-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,145,735</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_757" contextRef="AsOf2023-12-31" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">549,835</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_758" contextRef="AsOf2023-09-30" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">520,368</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_759" contextRef="AsOf2023-12-31" name="us-gaap:InventoryNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,347,049</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_760" contextRef="AsOf2023-09-30" name="us-gaap:InventoryNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,072</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_761" contextRef="AsOf2023-12-31" name="us-gaap:DepositsAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,129</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_762" contextRef="AsOf2023-09-30" name="us-gaap:DepositsAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,245</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_763" contextRef="AsOf2023-12-31" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,154,453</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_764" contextRef="AsOf2023-09-30" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,918,420</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_765" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,680,732</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_766" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,131,987</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_767" contextRef="AsOf2023-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,649,020</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_768" contextRef="AsOf2023-09-30" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,698,243</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_769" contextRef="AsOf2023-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,644,158</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_770" contextRef="AsOf2023-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,188,126</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patent costs, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_771" contextRef="AsOf2023-12-31" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,294</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_772" contextRef="AsOf2023-09-30" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,704</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_773" contextRef="AsOf2023-12-31" name="us-gaap:DepositsAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_774" contextRef="AsOf2023-09-30" name="us-gaap:DepositsAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_775" contextRef="AsOf2023-12-31" name="cvm:SuppliesUsedForRDAndManufacturingNonCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,457</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_776" contextRef="AsOf2023-09-30" name="cvm:SuppliesUsedForRDAndManufacturingNonCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,669</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_813" contextRef="AsOf2023-12-31" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,710,215</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_814" contextRef="AsOf2023-09-30" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,528,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_779" contextRef="AsOf2023-12-31" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,144,425</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_780" contextRef="AsOf2023-09-30" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,009,786</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_781" contextRef="AsOf2023-12-31" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">985,657</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_782" contextRef="AsOf2023-09-30" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,049,581</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Due to employees </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_783" contextRef="AsOf2023-12-31" name="cvm:DueToEmployeeCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">705,698</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_784" contextRef="AsOf2023-09-30" name="cvm:DueToEmployeeCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557,244</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Finance lease obligation, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_785" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827,363</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_786" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,771,804</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease obligation, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_787" contextRef="AsOf2023-12-31" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,167</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_788" contextRef="AsOf2023-09-30" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,431</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Total current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_789" contextRef="AsOf2023-12-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,867,310</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_790" contextRef="AsOf2023-09-30" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,585,846</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Finance lease obligations, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_791" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,468,149</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_792" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,949,565</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease obligations, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_793" contextRef="AsOf2023-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,599,496</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_794" contextRef="AsOf2023-09-30" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,652,949</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_795" contextRef="AsOf2023-12-31" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_796" contextRef="AsOf2023-09-30" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_797" contextRef="AsOf2023-12-31" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,059,955</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_798" contextRef="AsOf2023-09-30" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,313,360</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Commitments and contingencies (refer to Note E)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Preferred stock, $<ix:nonFraction id="fid_340" contextRef="AsOf2023-12-31" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_342" contextRef="AsOf2023-12-31" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_344" contextRef="AsOf2023-12-31" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">0</ix:nonFraction> shares issued and outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_801" contextRef="AsOf2023-12-31" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_802" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock, $<ix:nonFraction id="fid_332" contextRef="AsOf2023-12-31" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_334" contextRef="AsOf2023-12-31" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">600,000,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_336" contextRef="AsOf2023-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,018,601</ix:nonFraction> and <ix:nonFraction id="fid_335" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">47,422,304</ix:nonFraction> shares issued and outstanding at December 31, 2023 and September 30, 2023, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_803" contextRef="AsOf2023-12-31" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,186</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_804" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,223</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_805" contextRef="AsOf2023-12-31" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505,950,994</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_806" contextRef="AsOf2023-09-30" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,832,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_807" contextRef="AsOf2023-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">493,800,920</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_808" contextRef="AsOf2023-09-30" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">487,091,396</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total stockholders' equity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_809" contextRef="AsOf2023-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,650,260</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_810" contextRef="AsOf2023-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,214,890</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_811" contextRef="AsOf2023-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,710,215</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_812" contextRef="AsOf2023-09-30" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,528,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="op">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED STATEMENTS OF OPERATIONS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THREE MONTHS ENDED DECEMBER 31, 2023 and 2022</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_816" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,352,509</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_817" contextRef="From2022-10-01to2022-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,392,546</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_818" contextRef="From2023-10-01to2023-12-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,133,378</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_819" contextRef="From2022-10-01to2022-12-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,258,003</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_820" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,485,887</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_821" contextRef="From2022-10-01to2022-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,650,549</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_822" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,485,887</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_823" contextRef="From2022-10-01to2022-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,650,549</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_824" contextRef="From2023-10-01to2023-12-31" name="us-gaap:InterestIncomeExpenseNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">197,696</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_825" contextRef="From2022-10-01to2022-12-31" name="us-gaap:InterestIncomeExpenseNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">152,789</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_826" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OtherNonoperatingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,941</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_827" contextRef="From2022-10-01to2022-12-31" name="us-gaap:OtherNonoperatingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,171</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_828" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_829" contextRef="From2022-10-01to2022-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,853,509</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_830" contextRef="From2023-10-01to2023-12-31" name="cvm:ModificationOfWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_831" contextRef="From2022-10-01to2022-12-31" name="cvm:ModificationOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">171,552</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_832" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_833" contextRef="From2022-10-01to2022-12-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,025,061</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_834" contextRef="From2023-10-01to2023-12-31" name="cvm:EarningPerShareBasicAndDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.14</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_835" contextRef="From2022-10-01to2022-12-31" name="cvm:EarningPerShareBasicAndDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.18</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_836" contextRef="From2023-10-01to2023-12-31" name="cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">48,470,600</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_837" contextRef="From2022-10-01to2022-12-31" name="cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,440,387</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="eq">CEL-SCI CORPORATION</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Additional</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Paid-In</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Capital</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT SEPTEMBER 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_838" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">47,422,304</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_839" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,223</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_844" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,832,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_849" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">487,091,396</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_854" contextRef="AsOf2023-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,214,890</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="white-space: nowrap;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_880" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,724</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_883" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">177</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_921" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,730</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_922" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_923" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,907</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_886" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">88,573</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_889" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">886</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_924" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,421</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_925" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_926" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,307</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_895" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,490,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_892" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,900</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_927" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,955,100</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_928" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_929" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,980,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_898" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_930" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,383,909</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_931" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_932" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,383,909</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_901" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_933" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">470,229</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_934" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_935" contextRef="From2023-10-01to2023-12-31" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">470,229</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_840" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_845" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_850" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_855" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT DECEMBER 31, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_841" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,018,601</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_842" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,186</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_847" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505,950,994</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_852" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">493,800,920</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_857" contextRef="AsOf2023-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,650,260</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Additional </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Paid-In</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2">Capital</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT SEPTEMBER 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_858" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,448,317</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_859" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434,484</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_864" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">486,625,816</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_869" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">454,897,093</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_874" contextRef="AsOf2022-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,163,207</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant exercises</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_902" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="cvm:WarrantExercisesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">217,752</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_905" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,177</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_906" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,114</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_907" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" name="cvm:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_908" contextRef="From2022-10-01to2022-12-31" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,291</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="white-space: nowrap;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_878" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">21,331</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_881" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_909" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,965</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_910" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_911" contextRef="From2022-10-01to2022-12-31" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,178</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_884" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,236</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_887" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_912" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,221</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_913" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_914" contextRef="From2022-10-01to2022-12-31" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,623</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2014 incentive stock forfeited</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_893" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="cvm:IncentiveStockForfeitedShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">2,000</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_890" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="cvm:IncentiveStockForfeitedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_915" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:IncentiveStockForfeitedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,080</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_916" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" name="cvm:IncentiveStockForfeitedAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_917" contextRef="From2022-10-01to2022-12-31" name="cvm:IncentiveStockForfeitedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,100</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_896" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_918" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,703,931</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_919" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_920" contextRef="From2022-10-01to2022-12-31" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,703,931</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_860" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_865" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_870" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,853,509</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_875" contextRef="From2022-10-01to2022-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,853,509</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT DECEMBER 31, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_861" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,725,636</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_862" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437,256</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_867" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">488,904,967</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_872" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">462,750,602</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_877" contextRef="AsOf2022-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,591,621</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="cf">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED STATEMENTS OF CASH FLOWS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THREE MONTHS ENDED DECEMBER 31, 2023 and 2022</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_936" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_937" contextRef="From2022-10-01to2022-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,853,509</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_939" contextRef="From2023-10-01to2023-12-31" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,004,633</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_940" contextRef="From2022-10-01to2022-12-31" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">988,543</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Non-cash lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_941" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OtherNoncashExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,504</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_942" contextRef="From2022-10-01to2022-12-31" name="us-gaap:OtherNoncashExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,078</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Share-based payments for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_943" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,386</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_944" contextRef="From2022-10-01to2022-12-31" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,858</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Equity-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_945" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,383,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_946" contextRef="From2022-10-01to2022-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,692,831</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Common stock contributed to 401(k) plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_947" contextRef="From2023-10-01to2023-12-31" name="cvm:CommonStockContributedToEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,907</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_948" contextRef="From2022-10-01to2022-12-31" name="cvm:CommonStockContributedToEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,178</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">(Increase)/decrease in assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Prepaid expenses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_950" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,546</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_951" contextRef="From2022-10-01to2022-12-31" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">111,537</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_952" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,765</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_953" contextRef="From2022-10-01to2022-12-31" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">212,687</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_954" contextRef="From2023-10-01to2023-12-31" name="cvm:IncreaseDecreaseInDepositAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,884</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_955" contextRef="From2022-10-01to2022-12-31" name="cvm:IncreaseDecreaseInDepositAssets" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Increase/(decrease) in liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_957" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">765,078</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_958" contextRef="From2022-10-01to2022-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">115,285</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_959" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,924</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_960" contextRef="From2022-10-01to2022-12-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,346</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_961" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,454</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_962" contextRef="From2022-10-01to2022-12-31" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,087</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_963" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,887,928</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_964" contextRef="From2022-10-01to2022-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,666,649</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Purchases of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_966" contextRef="From2023-10-01to2023-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,650</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_967" contextRef="From2022-10-01to2022-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,580</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Expenditures for patent costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_968" contextRef="From2023-10-01to2023-12-31" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,211</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_969" contextRef="From2022-10-01to2022-12-31" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash used in investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_970" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">64,861</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_971" contextRef="From2022-10-01to2022-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">53,580</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Proceeds from issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_973" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,980,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_974" contextRef="From2022-10-01to2022-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Payments of stock issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_975" contextRef="From2023-10-01to2023-12-31" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">504,913</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_976" contextRef="From2022-10-01to2022-12-31" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,010</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Proceeds from the exercise of warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_977" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_978" contextRef="From2022-10-01to2022-12-31" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Payments on obligations under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_979" contextRef="From2023-10-01to2023-12-31" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">426,593</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_980" contextRef="From2022-10-01to2022-12-31" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,871</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_981" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,048,494</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_982" contextRef="From2022-10-01to2022-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,410</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NET DECREASE IN CASH AND CASH EQUIVALENTS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_983" contextRef="From2023-10-01to2023-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">904,295</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_984" contextRef="From2022-10-01to2022-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,654,819</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_985" contextRef="AsOf2023-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,145,735</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_986" contextRef="AsOf2022-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,672,138</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, END OF PERIOD</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_987" contextRef="AsOf2023-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,241,440</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_988" contextRef="AsOf2022-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,017,319</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED STATEMENTS OF CASH FLOWS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THREE MONTHS ENDED DECEMBER 31, 2023 and 2022</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment purchases included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_990" contextRef="From2023-10-01to2023-12-31" name="cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_995" contextRef="From2022-10-01to2022-12-31" name="cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,318</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease obligation included in accounts payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_991" contextRef="From2023-10-01to2023-12-31" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">714</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_996" contextRef="From2022-10-01to2022-12-31" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,853</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid consulting services paid with issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_992" contextRef="From2023-10-01to2023-12-31" name="cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,307</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_997" contextRef="From2022-10-01to2022-12-31" name="cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,623</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Financing costs included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_993" contextRef="From2023-10-01to2023-12-31" name="cvm:FinancingCostsIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,019</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_998" contextRef="From2022-10-01to2022-12-31" name="cvm:FinancingCostsIncludedInCurrentLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash paid for interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_994" contextRef="From2023-10-01to2023-12-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,659</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_999" contextRef="From2022-10-01to2022-12-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,853</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="fs">CEL-SCI CORPORATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>NOTES TO CONDENSED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>THREE MONTHS ENDED DECEMBER 31, 2023 AND 2022 (UNAUDITED)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_680" contextRef="From2023-10-01to2023-12-31" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="cont_4448fb"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A. <span style="text-decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the &#8220;Company&#8221;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#8217;s financial position as of December 31, 2023 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2023 is derived from the September 30, 2023 audited financial statements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Summary of Significant Accounting Policies:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_689" contextRef="From2023-10-01to2023-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_691" contextRef="From2023-10-01to2023-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_692" contextRef="From2023-10-01to2023-12-31" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_693" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_694" contextRef="From2023-10-01to2023-12-31" name="cvm:LeasesPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_4448fb" continuedAt="cont_1ff1eb"><ix:nonNumeric id="fid_696" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_697" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_698" contextRef="From2023-10-01to2023-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_699" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2023 and September 30, 2023.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_1ff1eb"><ix:nonNumeric id="fid_690" contextRef="From2023-10-01to2023-12-31" name="cvm:ImpairmentOfLongLivedAssetsPolicyTextblock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_700" contextRef="From2023-10-01to2023-12-31" name="us-gaap:UseOfEstimates" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_695" contextRef="From2023-10-01to2023-12-31" name="cvm:NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Recently Adopted Accounting Standards</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-13,<em> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). </em>ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#8217;s financial position, results of operations, or cash flows. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_701" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em> &#8211; The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements. </p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_681" contextRef="From2023-10-01to2023-12-31" name="cvm:LiquidityDisclosureTextBlock" escape="true" continuedAt="cont_16ae97"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">B. <span style="text-decoration:underline">LIQUIDITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#8217;s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_16ae97"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_682" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="cont_b692a9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">C. <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the Company sold <ix:nonFraction id="fid_1062" contextRef="AsOf2023-11-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,490,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_1063" contextRef="AsOf2023-11-30" name="us-gaap:SaleOfStockPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction> per share and received aggregate gross proceeds of approximately $<ix:nonFraction id="fid_1064" contextRef="From2023-11-01to2023-11-30" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">5.0</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Equity Compensation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Underlying share information for equity compensation plans as of December 31, 2023 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_702" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total Shares </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Reserved </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1000" contextRef="AsOf2023-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">138,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1001" contextRef="AsOf2023-12-31_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,787,200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1002" contextRef="AsOf2023-12-31_cvm_StockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,283,760</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1003" contextRef="AsOf2023-12-31_us-gaap_StockCompensationPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">634,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1004" contextRef="AsOf2023-12-31_cvm_IncentiveStockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">640,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;<span style="text-decoration:underline">Stock option activity</span>:</p><ix:nonNumeric id="fid_703" contextRef="From2023-10-01to2023-12-31" name="cvm:ScheduleOfStockOptionActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1005" contextRef="From2022-10-01to2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1009" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1008" contextRef="From2022-10-01to2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">96,832</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1012" contextRef="From2022-10-01to2022-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">45,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Share-Based Compensation Expense</span>:</p><ix:nonNumeric id="fid_704" contextRef="From2023-10-01to2023-12-31" name="cvm:ScheduleOfCompensatingBalancesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1013" contextRef="From2023-10-01to2023-12-31" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,383,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1014" contextRef="From2022-10-01to2022-12-31" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,692,831</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1015" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,386</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1016" contextRef="From2022-10-01to2022-12-31" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,858</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_b692a9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Warrants and Non-Employee Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following chart represents the warrants and non-employee options outstanding at December 31, 2023:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_705" contextRef="From2023-10-01to2023-12-31" name="cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1017" contextRef="From2023-10-01to2023-12-31_cvm_SeriesNMember" name="cvm:IssueDate1">8/18/2008</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1025" contextRef="AsOf2023-12-31_cvm_SeriesNMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">85,339</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1033" contextRef="AsOf2023-12-31_cvm_SeriesNMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1041" contextRef="From2023-10-01to2023-12-31_cvm_SeriesNMember" name="cvm:ExpirationDate">8/18/2024</ix:nonNumeric> </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1018" contextRef="From2023-10-01to2023-12-31_cvm_SeriesUUMember" name="cvm:IssueDate1">6/11/2018</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1026" contextRef="AsOf2023-12-31_cvm_SeriesUUMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">93,603</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1034" contextRef="AsOf2023-12-31_cvm_SeriesUUMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1042" contextRef="From2023-10-01to2023-12-31_cvm_SeriesUUMember" name="cvm:ExpirationDate">6/30/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1019" contextRef="From2023-10-01to2023-12-31_cvm_SeriesXMember" name="cvm:IssueDate1">1/13/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1027" contextRef="AsOf2023-12-31_cvm_SeriesXMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">120,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1035" contextRef="AsOf2023-12-31_cvm_SeriesXMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.25</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1043" contextRef="From2023-10-01to2023-12-31_cvm_SeriesXMember" name="cvm:ExpirationDate">7/13/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1020" contextRef="From2023-10-01to2023-12-31_cvm_SeriesYMember" name="cvm:IssueDate1">2/15/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1028" contextRef="AsOf2023-12-31_cvm_SeriesYMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1036" contextRef="AsOf2023-12-31_cvm_SeriesYMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1044" contextRef="From2023-10-01to2023-12-31_cvm_SeriesYMember" name="cvm:ExpirationDate">8/15/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1021" contextRef="From2023-10-01to2023-12-31_cvm_SeriesMMMember" name="cvm:IssueDate1">6/22/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1029" contextRef="AsOf2023-12-31_cvm_SeriesMMMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">333,432</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1037" contextRef="AsOf2023-12-31_cvm_SeriesMMMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1045" contextRef="From2023-10-01to2023-12-31_cvm_SeriesMMMember" name="cvm:ExpirationDate">6/22/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1022" contextRef="From2023-10-01to2023-12-31_cvm_SeriesNNMember" name="cvm:IssueDate1">7/24/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1030" contextRef="AsOf2023-12-31_cvm_SeriesNNMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,087</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1038" contextRef="AsOf2023-12-31_cvm_SeriesNNMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1046" contextRef="From2023-10-01to2023-12-31_cvm_SeriesNNMember" name="cvm:ExpirationDate">7/24/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1023" contextRef="From2023-10-01to2023-12-31_cvm_SeriesRRMember" name="cvm:IssueDate1">10/30/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1031" contextRef="AsOf2023-12-31_cvm_SeriesRRMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">234,009</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1039" contextRef="AsOf2023-12-31_cvm_SeriesRRMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1047" contextRef="From2023-10-01to2023-12-31_cvm_SeriesRRMember" name="cvm:ExpirationDate">10/30/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1024" contextRef="From2023-10-01to2023-12-31_cvm_ConsultantsMember_srt_MinimumMember" name="cvm:IssueDate1">7/28/2017</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_1050" contextRef="From2023-10-01to2023-12-31_cvm_ConsultantsMember_srt_MaximumMember" name="cvm:IssueDate1">9/2/2023</ix:nonNumeric> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1032" contextRef="AsOf2023-12-31_cvm_ConsultantsOptionMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">110,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1144" contextRef="AsOf2023-12-31_cvm_ConsultantsMember_srt_MinimumMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.39</ix:nonFraction> - $<ix:nonFraction id="fid_1040" contextRef="AsOf2023-12-31_cvm_ConsultantsOptionMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.18</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_1048" contextRef="From2023-10-01to2023-12-31_cvm_ConsultantsMember_srt_MinimumMember" name="cvm:ExpirationDate">7/27/2027</ix:nonNumeric> - <ix:nonNumeric id="fid_1049" contextRef="From2023-10-01to2023-12-31_cvm_ConsultantsMember_srt_MaximumMember" name="cvm:ExpirationDate">9/1/2028</ix:nonNumeric></p></td><td>&#160;</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">1. <span style="text-decoration:underline">Equity Warrants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity were exercised during the three months ended December 31, 2023. The following warrants recorded as equity were exercised during the three months ended December 31, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_706" contextRef="From2023-10-01to2023-12-31" name="cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1051" contextRef="From2023-10-01to2023-12-31_cvm_SeriesRRMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1052" contextRef="From2023-10-01to2023-12-31_cvm_SeriesRRMember" name="cvm:EquityWarrantsExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1053" contextRef="From2023-10-01to2023-12-31_cvm_SeriesRRMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series SS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1054" contextRef="From2023-10-01to2023-12-31_cvm_SeriesSSMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1056" contextRef="From2023-10-01to2023-12-31_cvm_SeriesSSMember" name="cvm:EquityWarrantsExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1055" contextRef="From2023-10-01to2023-12-31_cvm_SeriesSSMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1057" contextRef="From2023-10-01to2023-12-31" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">217,752</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1058" contextRef="From2023-10-01to2023-12-31" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,291</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity expired or were extended during the three months ended December 31, 2023. On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $<ix:nonFraction id="fid_1061" contextRef="From2022-10-01to2022-10-28_cvm_SeriesRRMember" name="cvm:IncrementalCostDeemedDividend" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,000</ix:nonFraction>, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2022. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2. <span style="text-decoration:underline">Options and Shares Issued to Consultants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2023 and 2022, the Company issued <ix:nonFraction id="fid_1065" contextRef="From2023-10-01to2023-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">88,573</ix:nonFraction> and <ix:nonFraction id="fid_1066" contextRef="From2022-10-01to2022-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,236</ix:nonFraction> shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $<ix:nonFraction id="fid_1067" contextRef="From2023-10-01to2023-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.56</ix:nonFraction> and $<ix:nonFraction id="fid_1068" contextRef="From2022-10-01to2022-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.53</ix:nonFraction> during the three months ended December 31, 2023 and 2022, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No options were issued to a consultant during the three months ended December 31, 2023. During the three months ended December 31, 2022, <ix:nonFraction id="fid_1069" contextRef="From2022-10-01to2022-12-31_cvm_ConsultantsMember" name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000</ix:nonFraction> options with an exercise price of $<ix:nonFraction id="fid_1070" contextRef="From2022-10-01to2022-12-31_cvm_ConsultantsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.61</ix:nonFraction> issued to a consultant expired. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2023 and 2022, the Company recorded total expense of approximately $<ix:nonFraction id="fid_1071" contextRef="From2023-10-01to2023-12-31_cvm_ConsultingAgreementsMember" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,000</ix:nonFraction> and $<ix:nonFraction id="fid_1072" contextRef="From2022-10-01to2022-12-31_cvm_ConsultingAgreementsMember" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,000</ix:nonFraction>, respectively, relating to the share-based compensation under various consulting agreements. On December 31, 2023 and September 30, 2023, consulting fees of approximately $<ix:nonFraction id="fid_1060" contextRef="AsOf2023-12-31_cvm_ConsultingAgreementsMember" name="cvm:ConsultingFeesIncluedPrepaidExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,000</ix:nonFraction> and $<ix:nonFraction id="fid_1073" contextRef="AsOf2023-09-30_cvm_ConsultingAgreementsMember" name="cvm:ConsultingFeesIncluedPrepaidExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,000</ix:nonFraction>, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_684" contextRef="From2023-10-01to2023-12-31" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2023, no restricted shares of the Company&#8217;s common stock were purchased by related parties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $<ix:nonFraction id="fid_1074" contextRef="From2022-10-01to2022-10-28_cvm_CEOGeertKerstenMember" name="cvm:IncrementalCostDeemedDividend" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,000</ix:nonFraction>, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_685" contextRef="From2023-10-01to2023-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="cont_6f4a50"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Clinical Research Agreement</em>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:right;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $<ix:nonFraction id="fid_1104" contextRef="From2023-10-01to2023-12-31_cvm_ErgomedMember" name="cvm:ClinicalServiceTrial" format="ixt:numdotdecimal" decimals="-6" unitRef="USD" scale="6">12</ix:nonFraction> million towards the Company&#8217;s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, <em>Collaborative Arrangements</em>. The Company determined the payments to Ergomed are within the scope of ASC 730, <em>Research and Development</em>. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $<ix:nonFraction id="fid_1100" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">35.8</ix:nonFraction> million for Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of approximately $<ix:nonFraction id="fid_1105" contextRef="From2023-10-01to2023-12-31" name="cvm:NetOfDiscount" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">11.9</ix:nonFraction> million. During the three months ended December 31, 2023 and 2022, the Company recorded, net of Ergomed&#8217;s discount, approximately $<ix:nonFraction id="fid_1101" contextRef="From2023-10-01to2023-12-31_cvm_ErgomedMember" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million for each quarter as research and development expense related to Ergomed&#8217;s services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The San Tomas lease is classified as a finance lease on the Company&#8217;s balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the three months ended December 31, 2023 and 2022 was approximately $<ix:nonFraction id="fid_1106" contextRef="From2023-10-01to2023-12-31" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.7</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_1108" contextRef="From2023-10-01to2023-12-31" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> and $<ix:nonFraction id="fid_1109" contextRef="From2022-10-01to2022-12-31" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.3</ix:nonFraction> million was for interest, respectively. As of December 31, 2023, the weighted average discount rate of the Company&#8217;s finance leases is <ix:nonFraction id="fid_1115" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">8.44</ix:nonFraction>% and the weighted average time to maturity is <ix:nonNumeric id="fid_1110" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1" format="ixt-sec:duryear">4.83</ix:nonNumeric> years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $<ix:nonFraction id="fid_1117" contextRef="From2023-01-01to2023-01-11_cvm_LandlordMember" name="cvm:FinancingArrangementDepositBaseRentAmount" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.3</ix:nonFraction> million to its landlord, equivalent to one year&#8217;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Approximate future minimum lease payments under finance leases as of December 31, 2023 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_708" contextRef="From2023-10-01to2023-12-31" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nine months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1075" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,995,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1076" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,741,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1077" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,832,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1078" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,923,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1079" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,015,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1080" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1081" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total future minimum lease obligation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1082" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,758,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1083" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,463,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1084" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,295,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1085" contextRef="AsOf2023-12-31" name="cvm:FinanceLeaseLiabilityCurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1086" contextRef="AsOf2023-12-31" name="cvm:FinanceLeaseLiabilityNoncurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,468,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_6f4a50"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $<ix:nonFraction id="fid_1111" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OperatingLeaseExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> for both the three months ended December 31, 2023 and 2022. Total cash paid related to operating leases during the three months ended December 31, 2023 and 2022 was approximately $<ix:nonFraction id="fid_1113" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OperatingLeasePaymentsUse" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million for each quarter. The weighted average discount rate of the Company&#8217;s operating leases is <ix:nonFraction id="fid_1103" contextRef="AsOf2023-12-31" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">10.19</ix:nonFraction>% and the weighted average time to maturity is <ix:nonNumeric id="fid_1116" contextRef="From2023-10-01to2023-12-31" name="us-gaap:RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1" format="ixt-sec:duryear">7.74</ix:nonNumeric> years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of December 31, 2023, future minimum lease payments on operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_709" contextRef="From2023-10-01to2023-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nine months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1087" contextRef="AsOf2023-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1088" contextRef="AsOf2023-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1089" contextRef="AsOf2023-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1090" contextRef="AsOf2023-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1091" contextRef="AsOf2023-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1092" contextRef="AsOf2023-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1093" contextRef="AsOf2023-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">746,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1094" contextRef="AsOf2023-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,523,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1095" contextRef="AsOf2023-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">720,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1096" contextRef="AsOf2023-12-31" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,803,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1097" contextRef="AsOf2023-12-31" name="cvm:OperatingLeaseLiabilityCurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1098" contextRef="AsOf2023-12-31" name="cvm:OperatingLeaseLiabilityNoncurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,599,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_686" contextRef="From2023-10-01to2023-12-31" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;G. <span style="text-decoration:underline">PATENTS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2023 and 2022, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately&#160;<ix:nonNumeric id="fid_1130" contextRef="From2023-10-01to2023-12-31" name="cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" format="ixt-sec:duryear">8</ix:nonNumeric>&#160;years. Amortization expense for the three months ended December 31, 2023 and 2022 totaled approximately $<ix:nonFraction id="fid_1126" contextRef="From2023-10-01to2023-12-31" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,000</ix:nonFraction>&#160;and $<ix:nonFraction id="fid_1127" contextRef="From2022-10-01to2022-12-31" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction>, respectively. The total estimated future amortization is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_710" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nine months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1118" contextRef="AsOf2023-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1119" contextRef="AsOf2023-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1120" contextRef="AsOf2023-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1121" contextRef="AsOf2023-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1122" contextRef="AsOf2023-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1123" contextRef="AsOf2023-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1124" contextRef="AsOf2023-12-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1125" contextRef="AsOf2023-12-31" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_687" contextRef="From2023-10-01to2023-12-31" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="cont_bb9038"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">H. <span style="text-decoration:underline">LOSS PER COMMON SHARE </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and unveseted restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_bb9038"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_711" contextRef="From2023-10-01to2023-12-31" name="cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Three months ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss available to common &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1132" contextRef="From2023-10-01to2023-12-31" name="cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1133" contextRef="From2022-10-01to2022-12-31" name="cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,025,061</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1134" contextRef="From2023-10-01to2023-12-31" name="cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">48,470,600</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1135" contextRef="From2022-10-01to2022-12-31" name="cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,440,387</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1136" contextRef="From2023-10-01to2023-12-31" name="cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.14</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1137" contextRef="From2022-10-01to2022-12-31" name="cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.18</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_712" contextRef="From2023-10-01to2023-12-31" name="cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1138" contextRef="From2023-10-01to2023-12-31_cvm_OptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,839,028</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1139" contextRef="From2022-10-01to2022-12-31_cvm_OptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">13,917,352</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1140" contextRef="From2023-10-01to2023-12-31_cvm_UnvestedRestrictedStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">147,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1141" contextRef="From2022-10-01to2022-12-31_cvm_UnvestedRestrictedStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">149,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1142" contextRef="From2023-10-01to2023-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,986,278</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1143" contextRef="From2022-10-01to2022-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">14,066,602</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_688" contextRef="From2023-10-01to2023-12-31" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">J. <span style="text-decoration:underline">SUBSEQUENT EVENTS</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On February 9, 2024, the Company sold <ix:nonFraction id="fid_1145" contextRef="From2024-02-01to2024-02-09_us-gaap_SubsequentEventMember" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,875,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_1146" contextRef="AsOf2024-02-09_us-gaap_SubsequentEventMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction> per share for gross proceeds of approximately $<ix:nonFraction id="fid_1147" contextRef="From2024-02-01to2024-02-09_us-gaap_SubsequentEventMember" name="cvm:ProceedsFromSaleOfCommonStock" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">7.8</ix:nonFraction> million.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="i2">Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Company Overview</span>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body&#8217;s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates, under development for the potential treatment of rheumatoid arthritis.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company&#8217;s future anticipated regulatory submission for approval. None of the Company&#8217;s product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline">MULTIKINE AND THE PHASE III CLINICAL TRIAL RESULTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Immunotherapy is a large, high growth market.</span></strong> Immunotherapies use the patient&#8217;s own immune system to fight disease. These &#8220;targeted therapies&#8221; are at the forefront of modern cancer research. A recent Bloomberg report from January 2023 asserted that:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. (<span style="text-decoration:underline">https://www.bloomberg.com/press-releases/2023-01-18/cancer-immunotherapy-market-worth-196-45-billion-by-2030-grand-view-research-inc</span>)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine&#174; (Leukocyte Interleukin, Injection). Multikine has already been tested in approximately 750 human patients in multiple clinical trials, including a well-controlled, multicenter, global, 928 patient Phase III randomized controlled trial. Multikine is unique among approved cancer immunotherapies because it is <em><span style="text-decoration:underline">given first</span></em><span style="text-decoration:underline">, right after diagnosis and before surgery</span>. CEL-SCI believes that the Phase III clinical trial demonstrated that Multikine caused tumors to reduce in size and/or caused the disease to &#8220;downstage&#8221; within just a few weeks of treatment before surgery. Importantly, patients with these reductions and/or downstages had their <em><span style="text-decoration:underline">risk of death cut in half at five years</span></em> of follow up. CEL-SCI is in discussions with regulators in Europe, the U.K., the U.S., and Canada with a view to obtaining marketing authorization and approval for immediate patient access to Multikine without waiting for the results of a confirmatory trial. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2023, the Multikine target patient population is estimated to include about 145,000 patients per year worldwide, with more than two-thirds of those outside the United States. Global growth rates of eligible cases are expected to rise 30% by 2030. (<span style="text-decoration:underline">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304137</span>) </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">What is Multikine and who is it for?</span></strong> Multikine is a biological medicinal immunotherapy comprised of a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment <em><span style="text-decoration:underline">before</span></em> the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikine&#8217;s rationale for use is to incite a locoregional immune response against the tumor before the local immune system has been compromised by the standard of care and/or disease progression.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Multikine target population is treatment-na&#239;ve adult patients with resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity or soft palate and who have:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>No lymph node involvement</strong> (via PET scan)</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Low PD-L1 tumor expression</strong> (TPS&lt;10) (via biopsy)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">PD-L1 is a protein receptor on the tumor cell surface that helps the tumor repel the immune system. CEL-SCI believes that patients with tumors having&#160;low PD-L1 would be more likely to respond to Multikine because their tumors have lower defenses against the patient&#8217;s immune system. CEL-SCI estimates that patients with tumors having&#160;low PD-L1&#160;represent about 70% of locally advanced primary SCCHN patients.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Multikine leads to longer survival with no safety issues.</span></strong> Clinical investigations of Multikine have demonstrated in the randomized controlled Phase III trial (RCT)&#160;the following in the target population:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong><em><span style="text-decoration:underline">risk of death cut in half at five years</span> </em></strong>versus the control;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">28.6% absolute 5-year overall survival benefit versus control (p=0.0015);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&gt;35% rate of pre-surgery reductions and/or downstages (p&lt;0.01); and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">low PD-L1 tumor expression (vs high PD-L1 where Keytruda and Opdivo work best).</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There were no demonstrable safety signals or toxicities observed in approximately 750 Multikine-treated subjects across multiple clinical trials. Adverse event (AE) and serious adverse event (SAE) incidences were not significantly different among treatment and control groups. There were no Multikine-related deaths and only two discontinuations. Multikine-related AEs before surgery were local and resolved after surgery. Although the literature reports that some of Multikine&#8217;s components may be toxic when administered systemically (e.g., TNF&#945;, IFN &#947;, IL-1&#946;), these toxicities did not emerge with Multikine, even at doses many times higher than those administered in the Phase III trial, primarily due to Multikine&#8217;s delivery by local injection and dosage.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI published its data as abstracts and posters at the annual conferences for the 2022 American Society of Clinical Oncology (ASCO), 2022 and 2023 European Society for Medical Oncology (ESMO), and the 2023 European Head and Neck Society&#8217;s (EHNS&#8217;s) annual European Conference On Head And Neck Oncology (ECHNO) and the 2023 European Society for Therapeutic Radiology and Oncology (ESTRO) and 2023 American Head and Neck Society (AHNS). These publications can be accessed at <span style="text-decoration:underline">http://www.cel-sci.com/</span>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Multikine works by inducing pre-surgical responses.</span></strong> CEL-SCI observed statistically significant pre-surgical responses after Multikine treatment, and therefore CEL-SCI believes in the following: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine causes pre-surgical responses;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-surgical responses lead to longer life;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Therefore, selecting more patients predicted to have a pre-surgical response should lead to much better survival in the target population.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A &#8220;pre-surgical response&#8221; is a significant change in disease before surgery. CEL-SCI saw two kinds of responses in the Phase III trial. First, there were &#8220;reductions&#8221; in the size of the tumor&#8212;a reduction of 30% or more qualified as a &#8220;pre-surgical reduction&#8221; or &#8220;PSR&#8221; for short. Second, there were disease &#8220;downstages,&#8221; (e.g., the disease improved from Stage IV to Stage III) pre-surgery. CEL-SCI calls this a &#8220;pre-surgical downstaging&#8221; or &#8220;PSD&#8221; for short. CEL-SCI&#8217;s 2022 ESMO cancer conference presentation reported on PSR, and CEL-SCI&#8217;s new 2023 ESMO presentation reported on PSD.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Across the whole Phase III trial, PSRs were seen in 8.5% of Multikine patients compared to <em><span style="text-decoration:underline">none</span><strong> </strong></em>in the control group. PSDs were seen in 22% of Multikine patients as compared to 13% in the control group. Because Multikine was the only therapy given to these patients before surgery, it is CEL-SCI&#8217;s strong belief that Multikine had to be the cause of the higher rates of PSR and PSD. These data are presented visually below. The taller blue columns show PSR and PSD rates in all 529 Multikine-treated patients in the Phase III trial, and the gray columns show PSR and PSD rates for all 394 control patients. The p-values above the columns show comparisons between Multikine and the control groups. With Multikine, statistically speaking, CEL-SCI believes there is a better than 95% chance that the increases in PSR/PSD in the Phase III study were caused by Multikine. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg15.jpg" alt="cvm_10qimg15.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">It was not enough for us to show that Multikine likely leads to PSRs and PSDs as compared to a control group, CEL-SCI also had to test if PSRs and PSDs lead to improved survival. CEL-SCI&#8217;s Phase III trial demonstrated that PSR patients were 72% likely to be alive after five years, whereas control patients were only about 49% likely to be alive after five years. Patients with PSD saw similar improvement in CEL-SCI&#8217;s Phase III trial. Their five-year chance of survival was approximately 68%. Therefore, CEL-SCI&#8217;s Phase III trial demonstrated statistically that those patients who had PSR or PSD resulting from Multikine lived longer than those who were not treated with Multikine. It is important to note that these results are from the entire Phase III study population, not from a subgroup. The p-values of less than 0.005 means there was at least a 99.5% chance that these results are due to Multikine rather than random chance.<span style="text-decoration:underline"> </span>The likelihood of living at least five years is shown in the graphic below for patients with PSR (blue), patients with PSD (orange) and patients who did not receive Multikine (gray). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg16.jpg" alt="cvm_10qimg16.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">CEL-SCI&#8217;s target population can be readily selected by doctors upon diagnoses using standard tests.</span></strong><strong> </strong>Having shown a potential causal link supported by strong statistics between Multikine and survival benefit, CEL-SCI believes that Multikine should be approved quickly. But recall that the Phase III study&#8217;s primary endpoint of 10% survival benefit was not met. How then can we say that Multikine actually benefits patients? The answer is that while Multikine has shown that it can help patients with PSR/PSD, there were not enough PSR/PSD in the Phase III study population to yield a 10% survival benefit for the whole population. In other words, the benefits from PSR/PSD were too diluted when averaged with the other patients in the study. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">None of this changes the fact that CEL-SCI observed statistical significance when analyzing Multikine&#8217;s ability to cause PSR/PSD and that these PSR/PSD statistically appear to lead to a higher chance of living five years or longer&#8212;CEL-SCI simply had to define a target population who would have a larger number of PSR/PSD. To do so, CEL-SCI analyzed Multikine&#8217;s biological mechanism of action, talked to regulators and physicians who knew best, and were guided by the Phase III data, including patient-specific data down to the cellular level. All this of course took time, but CEL-SCI believes it has succeeded and is ready to move forward. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">One of the first things we reported from the Phase III study was that Multikine was shown to work best in patients who were deemed &#8220;low risk&#8221; after surgery, about 40% of the study population. These patients saw a significant 14.1% absolute 5&#8209;year survival benefit vs the &#8220;low risk&#8221; control group not receiving Multikine. It made sense biologically that these patients would benefit most from Multikine, because they tended to have immune systems that were not yet compromised by the disease. &#8220;High risk&#8221; patients, by contrast, typically had lymph nodes invaded by the tumor, and needed chemotherapy after surgery. Because their lymph nodes were compromised, this made it harder for their immune systems to work, and they needed surgery as soon as possible without waiting an extra three weeks to receive Multikine. CEL-SCI initially developed criteria for selecting &#8220;low-risk&#8221; patients at diagnosis&#8212;i.e., those having no lymph nodes invaded by the tumor (N0) or only one lymph node invaded by the tumor (N1) as well as no extracapsular spread as determined by PET scan. CEL-SCI published these criteria at the ASCO conference in 2022. However, after discussions with regulators and physicians, CEL-SCI saw that outcomes could be improved further if the N1 patients were excluded, and only the N0 patients were included in the target population. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI also saw from the Phase III data that Multikine was more effective for patients with low PD-L1 tumor expression than for patients with high PD-L1 expression. This analysis was pre-specified in the statistical analysis plan. Targeting low PD-L1 also&#160;differentiates Multikine from other immunotherapies. For example, checkpoint inhibitors like Keytruda and Opdivo appear to best serve patients having high PD-L1, because these drugs work by blocking PD1/PD-L1 receptors interactions; when this interaction (PD1/PD-L1) happens it leads to inactivation/death of the immune cells attacking the tumor. While none of these drugs are currently approved as a first-line treatment before surgery, even if such approvals were to come in the future, the large majority of patients in this group having low PD-L1 would still be expected to need Multikine. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI&#8217;s target population is now directed to patients who present at diagnosis with N0 nodal involvement and also with low PD-L1 tumor expression (defined as tumor proportions score (TPS) &lt; 10). These patients can be readily identified&#160;upon diagnosis&#160;with tests that physicians routinely use in cancer screening, a crucial achievement towards Multikine becoming available for use. For instance, a PET scan should be used to determine the N0 nodal status and a screening tumor biopsy should be used to determine the low PD-L1 expression. Doctors already routinely screen head and neck cancer patients using PET scans and biopsy. Therefore, doctors can screen for Multikine patients without new tests or new costs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg17.jpg" alt="cvm_10qimg17.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span style="text-decoration:underline">Multikine cut the 5-year risk of death in half in the target population.</span></strong><strong> </strong>CEL-SCI&#8217;s results show that Multikine can cut the risk of death in half at five<strong> </strong>years versus the control group in the finalized target population. Survival increased from 45% in the control group to 73% in the Multikine group, at five years. This means the risk of death fell to 27% in the Multikine group from 55% in the control, shown below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg18.jpg" alt="cvm_10qimg18.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Another way to see the survival benefit of Multikine in the target population is the Kaplan-Meier curve from our ESMO &#8217;23 poster, shown below. On the vertical axis is the probability of survival and the horizontal axis is time in months. The blue Multikine line is far above the green control line, meaning the chance of survival is much higher in the Multikine group at every point in time compared to the control. These results had a low p-value of 0.0015, which is very significant as a statistical matter. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg19.jpg" alt="cvm_10qimg19.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI&#8217;s physician consultants tell it that the early separation of these two survival curves (e.g., at 12 months) adds validation to the potential positive effects of Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Another measure of survival benefit is called the &#8220;hazard ratio,&#8221; which compares the chances of dying between two different groups. Here, in the Multikine target population, the hazard ratio was 0.35, which means that deaths occurred in the Multikine group about one-third as frequently as in the control group. It is also important to note that the hazard ratio&#8217;s 95% confidence interval remained far below 1.0. In the case of Multikine, statistically speaking, there is a 95% chance that the hazard ratio would fall between 0.18 and 0.66 if Multikine were tested in the target population in another study. A hazard ratio of 0.66 as the &#8220;so called worst case scenario&#8221; is still below (better) than the hazard ratio required for most drug approvals. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">These positive survival outcomes&#8212;increased overall survival, reduced risk of death, widely separated Kaplan-Meier curves with early separation, low hazard ratio, low p-values, low confidence intervals&#8212;CEL-SCI believes were driven by high PSR/PSD rates in the target population, as shown in the graphic below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg20.jpg" alt="cvm_10qimg20.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI&#8217;s regulatory strategy going forward is to seek immediate approval of Multikine wherever possible. CEL-SCI intends to seek approval for Multikine based on the data generated to date, using a conditional approval pathway with a follow-on confirmatory study since the survival benefit is high and statistics are strong. This view is based on advice from regulators and consultants, and CEL-SCI believes that the accelerated/conditional approval regulatory pathways are specifically designed for our situation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">When the Phase III trial was designed, there was no evidentiary basis for excluding either of the low-risk or high-risk patient groups before surgery. Therefore, the study had to include a large percentage of high-risk patients with immune systems already compromised by disease. These subjects generally did not respond to Multikine. CEL-SCI has narrowed its target population as compared to the overall Phase III study population to focus on patients most likely to have PSR/PSD and to exclude the rest. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI acknowledges that efficacy in the target population has not been tested prospectively, but CEL-SCI believes that the data generated to date already presents a compelling patient need in the target population that justifies immediate access to Multikine. This is why the conditional approval pathways were created in the first place. CEL-SCI intends to base its request for regulatory approval, in part, on its view that patients should not have to wait many more years before gaining access to the benefits of Multikine PSRs/PSDs and increased survival, particularly given Multikine&#8217;s safety profile and data that mechanistically and empirically supports the target population definition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The benefit-risk balance favoring immediate patient access to Multikine is described below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg21.jpg" alt="cvm_10qimg21.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">An &#8220;unmet need&#8221; is a factor for approval considered by all major regulatory bodies worldwide. In the Multikine target population, there is also a tremendous unmet need for improved survival. The current standard of care provides only about a 50/50 chance of surviving five years, whereas Multikine could increase that survival rate to over 70% based on the Phase III data. Chemotherapy has improved outcomes for some head and neck patients, but chemotherapy is only indicated for high-risk patients, who are not likely to fall within the Multikine target population. Currently available immunotherapies are given after surgery or where surgery is not indicated, in contrast to Multikine, which is given before surgery to patients with resectable tumors. Available checkpoint inhibitors work best on tumors with high PD-L1 expression, whereas Multikine works best in tumors with low PD-L1 expression. Therefore, Multikine&#8217;s target population is underserved, and will continue to be underserved, by current therapies, but Multikine can meet the need for improved survival.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The major regulatory bodies with whom we are working, U.S. FDA, Health Canada, European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) all have conditional approval pathways designed for situations where the target population has not been fully tested prospectively and there is strong data supporting clinical benefit for patients. The reason is that regulators understand that in many cases patients should not have to wait for additional data before being offered the chance to benefit from a new drug. Every situation is different and depends on the specific facts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI had meetings with the FDA and Health Canada earlier in 2023, but they have not yet seen the new data presented for the first time on October 22, 2023 at the ESMO conference, and CEL-SCI plans to provide it to the FDA in Q1 2024. In Canada, CEL-SCI plans to ask for conditional approval under their Notice of Compliance with Conditions (NOC/C) pathway, as they had suggested in 2023. This permits approval of drugs based on safety and &#8220;promising&#8221; efficacy data while a post-market confirmatory study is ongoing. The approval can be given <em><span style="text-decoration:underline">before</span></em> the post-market study. In the U.S., the FDA has an accelerated approval pathway that is similar, but a new law in December 2022 requires enrollment in the confirmatory study to be underway before approval will be given in the U.S. Therefore, CEL-SCI plans to start this confirmatory trial as soon as possible in 2024 and will then seek accelerated approval using data from that study as well. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI&#8217;s first priority, however, is seeking approval in Europe and the UK, where CEL-SCI has submitted its final target population data. There are more than twice as many patients in the target population overseas than in North America. In Europe and the UK, CEL-SCI has submitted requests for Scientific Advice and are hopeful for meetings in H1 2024. Once a meeting date has been set, CEL-SCI will be able to discuss the data and gain advice on the path forward. It is possible that CEL-SCI may be advised at that time to proceed with a formal application.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Liquidity and Capital Resources</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Since inception, the Company has financed its operations through the issuance of equity securities, convertible notes, loans and certain research grants. The Company will likely continue to generate net operating losses as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist the Company&#8217;s capital requirements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Capital raised by the Company has been expended primarily for patent applications, research and development, administrative costs, the construction and upgrade of the Company&#8217;s manufacturing and laboratory facilities and clinical trials. The Company does not anticipate realizing significant revenues until entering into licensing arrangements for its technology and know-how or until it receives regulatory approval to sell its products (which could take several years). Thus, the Company has been dependent upon the proceeds from the sale of its securities to meet all of the Company&#8217;s liquidity and capital requirements and anticipates having to do so in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations. Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Since the Company launched its Phase 3 clinical trial for Multikine, the Company has incurred expenses of approximately $64.5 million as of December 31, 2023 on direct costs for the Phase 3 clinical trial and the filing of the clinical study report to the FDA. The Company estimates it will incur additional expenses of approximately $0.7 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report to the FDA. It should be noted that this estimate is based only on the information currently available from the CROs responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g., the manufacturing of the drug. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company uses two CROs to manage the global Phase 3 study; ICON and Ergomed, who are both international leaders in managing oncology trials. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Under a co-development agreement, Ergomed agreed to contribute up to $12 million towards the study where it will perform clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount. Approximately $11.9 million of the committed $12 million contribution has been realized as of December 31, 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2023, the Company&#8217;s cash decreased by approximately $0.9 million.&#160;Significant components of this decrease included cash used to fund the Company&#8217;s regular operations of approximately $4.9 million and approximately $0.4 million in payments on their finance lease obligations, offset by net proceeds from the November 2023 financing of approximately $4.5 million. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2022, the Company&#8217;s cash decreased by approximately $4.7 million. The significant component of this decrease included cash used to fund the Company&#8217;s regular operations, including its Phase 3 clinical trial, of approximately $4.7 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2023, no warrants were exercised. During the three months ended December 31, 2022, 217,752 warrants were exercised at a weighted average exercise price of $2.05 for total proceeds of approximately $0.5 million. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Results of Operations and Financial Condition</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company incurred a net operating loss of approximately $6.5 million for the three months ended December 31, 2023. This net operating loss consists of significant non-cash expenses including approximately $1.6 million in share-based compensation to employees and non-employees, and approximately $1.0 million in depreciation and amortization expense.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2023, research and development expenses decreased by approximately $1.0 million, or 19%, compared to the three months ended December 31, 2022. Major components of this decrease include an approximately $0.2 million decrease in costs incurred to prepare for the potential commercial sale of Multikine, an approximately $0.6 million decrease in expenses related to the Phase 3 study and a decrease of approximately $0.2 million of employee stock compensation expense. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2023, general and administrative expenses decreased by approximately $0.1 million, or 6%, compared to the three months ended December 31, 2022. This decrease is primarily due to a decrease in consulting fees of approximately $0.1 million, and a decrease of approximately $0.1 million of employee stock compensation expense. These decreases were offset by a net increase of approximately $0.1 million of other general and administrative expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Net interest expense, which consists primarily of interest paid on lease liabilities, remained relatively constant at approximately $0.2 million for the three months ended December 31, 2023 and December 31, 2022, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Research and Development Expenses</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s research and development efforts involve Multikine and LEAPS. The table below shows the research and development expenses associated with each project.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">MULTIKINE</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,329,252</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,294,377</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">LEAPS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,257</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">98,169</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">TOTAL</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,352,509</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,392,546</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company&#8217;s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company&#8217;s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Critical Accounting Estimates </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Management&#8217;s discussion and analysis of the Company&#8217;s financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company believes some of the more critical estimates that affect its financial condition and results of operations are in the areas of leases and share-based compensation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The measurement of the finance and operating lease right-of-use asset and lease liabilities requires the determination of an estimated lease term and an incremental borrowing rate, which involves complex judgment by management. Significant judgment is required by management to develop inputs and assumptions used to determine the incremental borrowing rate for lease contracts. The fair value of the stock options is calculated using the Black-Scholes option pricing model which requires various judgmental assumptions including volatility and expected option life. The compensation cost is recognized as expense over the requisite service or vesting period. Performance-based options are valued using a Monte-Carlo simulation model, which requires inputs based on estimates, including the likelihood of the occurrence of performance and market conditions, volatility and expected option life.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For more information regarding the Company&#8217;s critical accounting estimates, see Part II, Item&#160;7 of the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2023. The application of these critical accounting estimates has been discussed with the Audit Committee of the Company&#8217;s Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="i3">Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company does not believe that it has any significant exposure to market risk.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="i4">Item 4. CONTROLS AND PROCEDURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Evaluation of Disclosure Controls and Procedures</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Under the direction and with the participation of the Company&#8217;s management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of December 31, 2023. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and regulations, and that such information is accumulated and communicated to the Company&#8217;s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company&#8217;s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s Chief Executive Officer and Chief Financial Officer has concluded that the Company&#8217;s disclosure controls and procedures were not effective as of December 31, 2023 due to the material weaknesses described in the Company's Annual Report on Form 10-K for the year ended September 30, 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span style="text-decoration:underline">Changes in Internal Control over Financial Reporting</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There were no changes in the Company&#8217;s internal control over financial reporting that occurred during the three months ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="p2">PART II</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="i22">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2023, the Company issued 88,573 restricted shares of common stock to consultants for investor relations services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding the Company&#8217;s business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend which provides they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="p2i5">Item 5. Other Information</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in item 408(c) of Regulation S-K) during the quarterly period ending December 31, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span class="atag" style="display: inline" id="i6"><strong>Item 6.</strong> <strong>Exhibits</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Number</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exhibit</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">31</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">Rule 13a-14(a) Certifications</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">32</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">Section 1350 Certifications</a></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#tooc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="sig">SIGNATURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CEL-SCI CORPORATION</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Date: February 14, 2024</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">By: </p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">/s/ Geert Kersten</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Geert Kersten&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Principal Executive Officer*&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">* Also signing in the capacity of the Principal Accounting and Financial Officer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>cvm_ex31.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cvm_ex31.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS</strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">c)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">d)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>&nbsp; <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#ffffff"> <td style="width:50%;"> <p style="margin:0px">February 14, 2024</p></td> <td style="width:3%;"> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="margin:0px">/s/ Geert Kersten</p></td> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Geert Kersten </p> <p style="margin:0px">Principal Executive Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u><strong>CERTIFICATIONS</strong></u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">c)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">d)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>&nbsp; <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#ffffff"> <td style="width:50%;"> <p style="margin:0px">February 14, 2024</p></td> <td style="width:3%;"> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="margin:0px">/s/ Geert Kersten</p></td> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Geert Kersten </p> <p style="margin:0px">Principal Financial Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>cvm_ex32.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cvm_ex32.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong><strong>EXHIBIT 32</strong></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In connection with the Quarterly Report of CEL-SCI Corporation (the &#8220;Company&#8221;) on Form 10-Q for the period ending December 31, 2023 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Geert Kersten, the Principal Executive and Principal Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:3%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Geert Kersten</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert Kersten</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Executive and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Financial Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">February 14, 2024</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cvm-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/10/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cvm="http://cvm.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cvm.com/20231231">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cvm.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
        <link:definition>000002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
        <link:definition>000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" id="CondensedStatementsOfOperationsUnaudited">
        <link:definition>000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" id="StatementsOfStockholdersEquityUnaudited">
        <link:definition>000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" id="CondensedStatementsOfCashFlowsUnaudited">
        <link:definition>000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LIQUIDITY" id="LIQUIDITY">
        <link:definition>000008 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>000009 - Disclosure - STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>000010 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>000011 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PATENTS" id="PATENTS">
        <link:definition>000012 - Disclosure - PATENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShare" id="LossPerCommonShare">
        <link:definition>000013 - Disclosure - LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000014 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsTables" id="PatentsTables">
        <link:definition>000018 - Disclosure - PATENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareTables" id="LossPerCommonShareTables">
        <link:definition>000019 - Disclosure - LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>000020 - Disclosure - STOCKHOLDERS EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
        <link:definition>000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
        <link:definition>000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
        <link:definition>000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
        <link:definition>000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
        <link:definition>000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
        <link:definition>000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
        <link:definition>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetails" id="PatentsDetails">
        <link:definition>000030 - Disclosure - PATENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetailsNarrative" id="PatentsDetailsNarrative">
        <link:definition>000031 - Disclosure - PATENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetails" id="LossPerCommonShareDetails">
        <link:definition>000032 - Disclosure - LOSS PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetails1" id="LossPerCommonShareDetails1">
        <link:definition>000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <import namespace="http://fasb.org/srt-roles/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd" />
  <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <element id="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" name="SuppliesUsedForRDAndManufacturingNonCurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DueToEmployeeCurrent" name="DueToEmployeeCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ModificationOfWarrants" name="ModificationOfWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EarningPerShareBasicAndDiluted" name="EarningPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercisesShares" name="WarrantExercisesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercisesAmount" name="WarrantExercisesAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncentiveStockForfeitedShares" name="IncentiveStockForfeitedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncentiveStockForfeitedAmount" name="IncentiveStockForfeitedAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ShareIssuanceCosts" name="ShareIssuanceCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockContributedToEmployeeBenefitPlan" name="CommonStockContributedToEmployeeBenefitPlan" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncreaseDecreaseInDepositAssets" name="IncreaseDecreaseInDepositAssets" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" name="PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseObligationIncludedInAccountsPayable" name="FinanceLeaseObligationIncludedInAccountsPayable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" name="PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingCostsIncludedInCurrentLiabilities" name="FinancingCostsIncludedInCurrentLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LiquidityDisclosureTextBlock" name="LiquidityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeasesPolicyTextBlock" name="LeasesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" name="ImpairmentOfLongLivedAssetsPolicyTextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" name="NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfStockOptionActivityTableTextBlock" name="ScheduleOfStockOptionActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfCompensatingBalancesTableTextBlock" name="ScheduleOfCompensatingBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" name="ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" name="ScheduleOfDerivativeLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" name="ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" name="ScheduleOfAntiDilutiveSecuritiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockIssuedDuringPeriodShareStockOptionsExercised" name="StockIssuedDuringPeriodShareStockOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IssueDate1" name="IssueDate1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuableUponExerciseOfWarrantOptions" name="SharesIssuableUponExerciseOfWarrantOptions" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpirationDate" name="ExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityWarrantsExercised" name="EquityWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityWarrantsExercisePrice" name="EquityWarrantsExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromEquityWarrantsExercised" name="ProceedsFromEquityWarrantsExercised" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncrementalCostDeemedDividend" name="IncrementalCostDeemedDividend" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ConsultingFeesIncluedPrepaidExpenses" name="ConsultingFeesIncluedPrepaidExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityCurrentPortion" name="FinanceLeaseLiabilityCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityNoncurrentPortion" name="FinanceLeaseLiabilityNoncurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseLiabilityCurrentPortion" name="OperatingLeaseLiabilityCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseLiabilityNoncurrentPortion" name="OperatingLeaseLiabilityNoncurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetOfDiscount" name="NetOfDiscount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ClinicalServiceTrial" name="ClinicalServiceTrial" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingArrangementDepositBaseRentAmount" name="FinancingArrangementDepositBaseRentAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PatentImpairmentCharges" name="PatentImpairmentCharges" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" name="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" name="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" name="WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" name="IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromSaleOfCommonStock" name="ProceedsFromSaleOfCommonStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LIQUIDITYAbstract" name="LIQUIDITYAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommitmentsAndContingenciesAbstract" name="CommitmentsAndContingenciesAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="NonQualifiedStockOptionsPlansMember" id="cvm_NonQualifiedStockOptionsPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockBonusPlansMember" id="cvm_StockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockBonusPlansMember" id="cvm_IncentiveStockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNMember" id="cvm_SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesUUMember" id="cvm_SeriesUUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesXMember" id="cvm_SeriesXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesYMember" id="cvm_SeriesYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesMMMember" id="cvm_SeriesMMMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNNMember" id="cvm_SeriesNNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesRRMember" id="cvm_SeriesRRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsOptionMember" id="cvm_ConsultantsOptionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsMember" id="cvm_ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesSSMember" id="cvm_SeriesSSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStocksMember" id="cvm_RestrictedStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementsMember" id="cvm_ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CEOGeertKerstenMember" id="cvm_CEOGeertKerstenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ErgomedMember" id="cvm_ErgomedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LandlordMember" id="cvm_LandlordMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionsMember" id="cvm_OptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnvestedRestrictedStockMember" id="cvm_UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cvm-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/10/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_c525d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_c525d6" xml:lang="en-US">CONDENSED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_c04eee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_c04eee" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_97727a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_97727a" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_4133eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_4133eb" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl_21d9eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl_21d9eb" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl_c7b6ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl_c7b6ad" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_66abf0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_66abf0" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_7" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_825f20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_825f20" xml:lang="en-US">Finance lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_f992aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_f992aa" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_3fedb5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_3fedb5" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_75c23a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_75c23a" xml:lang="en-US">Patent costs, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl_fb22dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepositsAssets_lbl_fb22dd" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl_12" xml:lang="en-US">[Deposits Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:to="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_b75e02" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_b75e02" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:to="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_13" xml:lang="en-US">[Supplies used for R&amp;D and manufacturing]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_d0b1f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_d0b1f4" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_14" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_4c9315" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_4c9315" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_eebbba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_eebbba" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_0e3bc0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_0e3bc0" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_5a88ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_5a88ce" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_DueToEmployeeCurrent" xlink:label="cvm_DueToEmployeeCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DueToEmployeeCurrent" xlink:to="cvm_DueToEmployeeCurrent_lbl_92824f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DueToEmployeeCurrent_lbl_92824f" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_b358a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_b358a6" xml:lang="en-US">Finance lease obligation, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_6610be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_6610be" xml:lang="en-US">Operating lease obligation, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_525eeb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_525eeb" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_22" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_b73407" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_b73407" xml:lang="en-US">Finance lease obligations, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_6a7bf9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_6a7bf9" xml:lang="en-US">Operating lease obligations, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl_7253cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl_7253cd" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_9bdc44" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_9bdc44" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_26" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_87cd7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_87cd7a" xml:lang="en-US">Commitments and contingencies (refer to Note E)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_7bbe76" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_7bbe76" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_e1ea6b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_e1ea6b" xml:lang="en-US">Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_f57d2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_f57d2f" xml:lang="en-US">Common stock, $.01 par value; 600,000,000 shares authorized; 50,018,601 and 47,422,304 shares issued and outstanding at December 31, 2023 and September 30, 2023, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_a632e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_a632e6" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_69b3a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_69b3a9" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_0c1fe0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_0c1fe0" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_33" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_31cea7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_31cea7" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_34" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_34" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_dbc9a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_dbc9a7" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_8457bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_8457bd" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_c332b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_c332b2" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_ddf967" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_ddf967" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_c002a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_c002a3" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_73137f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_73137f" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_ff0dde" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_ff0dde" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_ca36b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_ca36b1" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_548860" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_548860" xml:lang="en-US">CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_feef90" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_feef90" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_fb0578" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_fb0578" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_6ae447" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_6ae447" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_7c3ca2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_7c3ca2" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_5" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_518cdb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_518cdb" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_6" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl_3022ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl_3022ef" xml:lang="en-US">Interest expense, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl_df1fa2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl_df1fa2" xml:lang="en-US">Other expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl_8" xml:lang="en-US">[Other Nonoperating Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_75073d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_75073d" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_9" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ModificationOfWarrants" xlink:label="cvm_ModificationOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrants" xlink:to="cvm_ModificationOfWarrants_lbl_e18ad6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ModificationOfWarrants_lbl_e18ad6" xml:lang="en-US">Modification of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_4b32be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_4b32be" xml:lang="en-US">Net loss available to common shareholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_11" xml:lang="en-US">[Net Income (Loss) Available to Common Stockholders, Basic]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_EarningPerShareBasicAndDiluted" xlink:label="cvm_EarningPerShareBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EarningPerShareBasicAndDiluted" xlink:to="cvm_EarningPerShareBasicAndDiluted_lbl_6ecf10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EarningPerShareBasicAndDiluted_lbl_6ecf10" xml:lang="en-US">Net loss per common share - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:label="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:to="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_lbl_b34952" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_lbl_b34952" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_039492" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_039492" xml:lang="en-US">STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_ca90e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_ca90e5" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_2997dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_2997dd" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_fdef7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_fdef7d" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_8a1029" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_8a1029" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_98bb60" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_98bb60" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_a23b41" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_a23b41" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_527ec5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_527ec5" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_35f895" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_35f895" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_WarrantExercisesShares" xlink:label="cvm_WarrantExercisesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercisesShares" xlink:to="cvm_WarrantExercisesShares_lbl_473f6b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercisesShares_lbl_473f6b" xml:lang="en-US">Warrant exercises, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_WarrantExercisesAmount" xlink:label="cvm_WarrantExercisesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercisesAmount" xlink:to="cvm_WarrantExercisesAmount_lbl_e34ba8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercisesAmount_lbl_e34ba8" xml:lang="en-US">Warrant exercises, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_bb32a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_bb32a0" xml:lang="en-US">401(k) contributions paid in common stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_e3ef5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_e3ef5d" xml:lang="en-US">401(k) contributions paid in common stock, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_472847" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_472847" xml:lang="en-US">Stock issued to nonemployees for service, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_db39c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_db39c8" xml:lang="en-US">Stock issued to nonemployees for service, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="cvm_IncentiveStockForfeitedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockForfeitedShares" xlink:to="cvm_IncentiveStockForfeitedShares_lbl_3bab0b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockForfeitedShares_lbl_3bab0b" xml:lang="en-US">2014 incentive stock forfeited, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="cvm_IncentiveStockForfeitedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockForfeitedAmount" xlink:to="cvm_IncentiveStockForfeitedAmount_lbl_033611" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockForfeitedAmount_lbl_033611" xml:lang="en-US">2014 incentive stock forfeited, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_240596" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_240596" xml:lang="en-US">Equity based compensation - employees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_bae59b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_bae59b" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_e350f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_e350f8" xml:lang="en-US">Proceeds from the sale of common stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_38394f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_38394f" xml:lang="en-US">Proceeds from the sale of common stock, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ShareIssuanceCosts" xlink:label="cvm_ShareIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShareIssuanceCosts" xlink:to="cvm_ShareIssuanceCosts_lbl_5a4e7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ShareIssuanceCosts_lbl_5a4e7d" xml:lang="en-US">Share issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_e12b1a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_e12b1a" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_23c879" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_23c879" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_315dd4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_315dd4" xml:lang="en-US">CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_d597ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_d597ee" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_999d97" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_999d97" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_baa528" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_baa528" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl_bc23d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl_bc23d7" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_7d43c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_7d43c6" xml:lang="en-US">Share-based payments for services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_81447e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_81447e" xml:lang="en-US">Equity-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:to="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_b87682" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_b87682" xml:lang="en-US">Common stock contributed to 401(k) plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_1a8d6e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_1a8d6e" xml:lang="en-US">(Increase)/decrease in assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_d4def6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_d4def6" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_10" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_fd0623" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_fd0623" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_11" xml:lang="en-US">[Increase (Decrease) in Inventories]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseInDepositAssets" xlink:to="cvm_IncreaseDecreaseInDepositAssets_lbl_67bafa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvm_IncreaseDecreaseInDepositAssets_lbl_67bafa" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncreaseDecreaseInDepositAssets" xlink:label="cvm_IncreaseDecreaseInDepositAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseInDepositAssets" xlink:to="cvm_IncreaseDecreaseInDepositAssets_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncreaseDecreaseInDepositAssets_lbl_12" xml:lang="en-US">[Deposits]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_37fee1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_37fee1" xml:lang="en-US">Increase/(decrease) in liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_5479bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_5479bd" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_14" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_d2908e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_d2908e" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_15" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_9bb1ab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_9bb1ab" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_16" xml:lang="en-US">[Increase (Decrease) in Employee Related Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_f03166" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_f03166" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_17" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_d4aacf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_d4aacf" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_319d0b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_319d0b" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_19" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_dde382" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_dde382" xml:lang="en-US">Expenditures for patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_20" xml:lang="en-US">[Payments to Acquire Intangible Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_cf4a49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_cf4a49" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_21" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_1cf0f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_1cf0f1" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_ab0755" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_ab0755" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_c83844" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_c83844" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_24" xml:lang="en-US">[Payments of Stock Issuance Costs]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_8e916e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_8e916e" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_61557d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_61557d" xml:lang="en-US">Payments on obligations under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_26" xml:lang="en-US">[Repayments of Debt and Lease Obligation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_18261b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_18261b" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_27" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_3ffe70" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_3ffe70" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_28" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_1d7247" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_1d7247" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_12e6ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_12e6ee" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_60f692" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_60f692" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:label="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:to="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_lbl_abb873" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_lbl_abb873" xml:lang="en-US">Property and equipment purchases included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:to="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_fa2276" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_fa2276" xml:lang="en-US">Finance lease obligation included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" xlink:to="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock_lbl_8af6b8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock_lbl_8af6b8" xml:lang="en-US">Prepaid consulting services paid with issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:label="cvm_FinancingCostsIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:to="cvm_FinancingCostsIncludedInCurrentLiabilities_lbl_d3bbb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingCostsIncludedInCurrentLiabilities_lbl_d3bbb4" xml:lang="en-US">Financing costs included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_134274" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_134274" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_25892e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_25892e" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2cdc82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2cdc82" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_LIQUIDITYAbstract" xlink:label="cvm_LIQUIDITYAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LIQUIDITYAbstract" xlink:to="cvm_LIQUIDITYAbstract_lbl_4f1c0a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LIQUIDITYAbstract_lbl_4f1c0a" xml:lang="en-US">LIQUIDITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquidityDisclosureTextBlock" xlink:to="cvm_LiquidityDisclosureTextBlock_lbl_465914" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_LiquidityDisclosureTextBlock_lbl_465914" xml:lang="en-US">LIQUIDITY</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_LiquidityDisclosureTextBlock" xlink:label="cvm_LiquidityDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquidityDisclosureTextBlock" xlink:to="cvm_LiquidityDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LiquidityDisclosureTextBlock_lbl_2" xml:lang="en-US">[LIQUIDITY]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_33db0a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_33db0a" xml:lang="en-US">STOCKHOLDERS EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_486337" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_486337" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_1967b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_1967b1" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_29458f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_29458f" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="cvm_CommitmentsAndContingenciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommitmentsAndContingenciesAbstract" xlink:to="cvm_CommitmentsAndContingenciesAbstract_lbl_ff373c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommitmentsAndContingenciesAbstract_lbl_ff373c" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_c73f28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_c73f28" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_8594b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_8594b7" xml:lang="en-US">PATENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_50129e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_50129e" xml:lang="en-US">PATENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl_455c3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl_455c3e" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_071bdc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_071bdc" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_2" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_655089" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_655089" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_e75123" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_e75123" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_ea163b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_ea163b" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_560629" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_560629" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_e610cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_e610cd" xml:lang="en-US">Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_7d93a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_7d93a2" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_4" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_864671" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_864671" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_LeasesPolicyTextBlock" xlink:label="cvm_LeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeasesPolicyTextBlock" xlink:to="cvm_LeasesPolicyTextBlock_lbl_6b6201" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeasesPolicyTextBlock_lbl_6b6201" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_cd4a23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_cd4a23" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_954c4a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_954c4a" xml:lang="en-US">Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_4b6c73" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_4b6c73" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_e45d1a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_e45d1a" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_e408b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_e408b5" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:label="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:to="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock_lbl_ad3251" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock_lbl_ad3251" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" xlink:label="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" xlink:to="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock_lbl_232852" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock_lbl_232852" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_59b250" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_59b250" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_082c8e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_082c8e" xml:lang="en-US">Schedule of equity compensation plans</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:label="cvm_ScheduleOfStockOptionActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:to="cvm_ScheduleOfStockOptionActivityTableTextBlock_lbl_b5e427" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfStockOptionActivityTableTextBlock_lbl_b5e427" xml:lang="en-US">Schedule of Stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:label="cvm_ScheduleOfCompensatingBalancesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:to="cvm_ScheduleOfCompensatingBalancesTableTextBlock_lbl_8de567" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfCompensatingBalancesTableTextBlock_lbl_8de567" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:label="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:to="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_lbl_1fbe25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_lbl_1fbe25" xml:lang="en-US">Schedule of warrants and non-employee options outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" xlink:label="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" xlink:to="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock_lbl_5034e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock_lbl_5034e0" xml:lang="en-US">Schedule of derivative liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_bd2bf5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_bd2bf5" xml:lang="en-US">Schedule of future minimum payments under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_f5c4ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_f5c4ed" xml:lang="en-US">Schedule of future minimum payments under operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_8f8864" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_8f8864" xml:lang="en-US">Schedule of total estimated future amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:to="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_lbl_9146cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_lbl_9146cc" xml:lang="en-US">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:label="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:to="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock_lbl_e562a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock_lbl_e562a3" xml:lang="en-US">Schedule of anti-dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_b72f5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_b72f5a" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="cvm_NonQualifiedStockOptionsPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonQualifiedStockOptionsPlansMember" xlink:to="cvm_NonQualifiedStockOptionsPlansMember_lbl_b9fbc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonQualifiedStockOptionsPlansMember_lbl_b9fbc2" xml:lang="en-US">Non-Qualified Stock Option Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_StockBonusPlansMember" xlink:label="cvm_StockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockBonusPlansMember" xlink:to="cvm_StockBonusPlansMember_lbl_ae9f6b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockBonusPlansMember_lbl_ae9f6b" xml:lang="en-US">Stock Bonus Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl_89365c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl_89365c" xml:lang="en-US">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="cvm_IncentiveStockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlansMember" xlink:to="cvm_IncentiveStockBonusPlansMember_lbl_d06fc6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockBonusPlansMember_lbl_d06fc6" xml:lang="en-US">Incentive Stock Bonus Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_11448f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_11448f" xml:lang="en-US">Remaining Options/shares Under Plans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_42c4e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_42c4e5" xml:lang="en-US">Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:label="cvm_StockIssuedDuringPeriodShareStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:to="cvm_StockIssuedDuringPeriodShareStockOptionsExercised_lbl_77a9e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockIssuedDuringPeriodShareStockOptionsExercised_lbl_77a9e9" xml:lang="en-US">Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_5ee777" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_5ee777" xml:lang="en-US">Options Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_5d1be6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_5d1be6" xml:lang="en-US">Options Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl_710431" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl_710431" xml:lang="en-US">Employees Stock Based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_85c6ca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_85c6ca" xml:lang="en-US">Non- Employees Stock Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_8e71bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_8e71bf" xml:lang="en-US">Class Of Warrant Or Right Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_9d80a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_9d80a8" xml:lang="en-US">Related Party Transactions By Related Party Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl_eb900e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl_eb900e" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesNMember" xlink:label="cvm_SeriesNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNMember" xlink:to="cvm_SeriesNMember_lbl_b8362c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNMember_lbl_b8362c" xml:lang="en-US">Series N [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesUUMember" xlink:label="cvm_SeriesUUMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesUUMember" xlink:to="cvm_SeriesUUMember_lbl_5c3bac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesUUMember_lbl_5c3bac" xml:lang="en-US">Series UU [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesXMember" xlink:label="cvm_SeriesXMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesXMember" xlink:to="cvm_SeriesXMember_lbl_95c914" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesXMember_lbl_95c914" xml:lang="en-US">Series X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesYMember" xlink:label="cvm_SeriesYMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesYMember" xlink:to="cvm_SeriesYMember_lbl_6d19e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesYMember_lbl_6d19e9" xml:lang="en-US">Series Y [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesMMMember" xlink:label="cvm_SeriesMMMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesMMMember" xlink:to="cvm_SeriesMMMember_lbl_2e7f47" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesMMMember_lbl_2e7f47" xml:lang="en-US">Series MM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesNNMember" xlink:label="cvm_SeriesNNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNNMember" xlink:to="cvm_SeriesNNMember_lbl_3e005b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNNMember_lbl_3e005b" xml:lang="en-US">Series NN [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesRRMember" xlink:label="cvm_SeriesRRMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesRRMember" xlink:to="cvm_SeriesRRMember_lbl_9a48bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesRRMember_lbl_9a48bf" xml:lang="en-US">Series RR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultantsOptionMember" xlink:label="cvm_ConsultantsOptionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsOptionMember" xlink:to="cvm_ConsultantsOptionMember_lbl_e71803" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsOptionMember_lbl_e71803" xml:lang="en-US">Consultants Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultantsMember" xlink:label="cvm_ConsultantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_72c4dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsMember_lbl_72c4dc" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_fb9549" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl_fb9549" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_16ee95" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl_16ee95" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IssueDate1" xlink:label="cvm_IssueDate1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IssueDate1" xlink:to="cvm_IssueDate1_lbl_38634b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IssueDate1_lbl_38634b" xml:lang="en-US">Issue Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="cvm_SharesIssuableUponExerciseOfWarrantOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:to="cvm_SharesIssuableUponExerciseOfWarrantOptions_lbl_8c331e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuableUponExerciseOfWarrantOptions_lbl_8c331e" xml:lang="en-US">Shares Issuable Upon Exercise Of Warrant/options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ExercisePrice" xlink:label="cvm_ExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePrice" xlink:to="cvm_ExercisePrice_lbl_405e77" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePrice_lbl_405e77" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ExpirationDate" xlink:label="cvm_ExpirationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDate" xlink:to="cvm_ExpirationDate_lbl_c52333" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpirationDate_lbl_c52333" xml:lang="en-US">Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesSSMember" xlink:label="cvm_SeriesSSMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesSSMember" xlink:to="cvm_SeriesSSMember_lbl_f4c534" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesSSMember_lbl_f4c534" xml:lang="en-US">Series SS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_EquityWarrantsExercised" xlink:label="cvm_EquityWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercised" xlink:to="cvm_EquityWarrantsExercised_lbl_420323" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityWarrantsExercised_lbl_420323" xml:lang="en-US">Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="cvm_EquityWarrantsExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercisePrice" xlink:to="cvm_EquityWarrantsExercisePrice_lbl_292fe2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityWarrantsExercisePrice_lbl_292fe2" xml:lang="en-US">Equity Warrants Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="cvm_ProceedsFromEquityWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromEquityWarrantsExercised" xlink:to="cvm_ProceedsFromEquityWarrantsExercised_lbl_a048bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromEquityWarrantsExercised_lbl_a048bc" xml:lang="en-US">Proceeds from Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_4b86aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_4b86aa" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_d54e48" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_d54e48" xml:lang="en-US">Plan Name Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_RestrictedStocksMember" xlink:label="cvm_RestrictedStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedStocksMember" xlink:to="cvm_RestrictedStocksMember_lbl_05e8f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedStocksMember_lbl_05e8f8" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_c0dbf4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ConsultantsMember_lbl_c0dbf4" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultingAgreementsMember" xlink:label="cvm_ConsultingAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingAgreementsMember" xlink:to="cvm_ConsultingAgreementsMember_lbl_1a5883" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingAgreementsMember_lbl_1a5883" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="cvm_IncrementalCostDeemedDividend" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncrementalCostDeemedDividend" xlink:to="cvm_IncrementalCostDeemedDividend_lbl_dcc534" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncrementalCostDeemedDividend_lbl_dcc534" xml:lang="en-US">Incremental cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_ae98b8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_ae98b8" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:label="cvm_ConsultingFeesIncluedPrepaidExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:to="cvm_ConsultingFeesIncluedPrepaidExpenses_lbl_2f282e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingFeesIncluedPrepaidExpenses_lbl_2f282e" xml:lang="en-US">Consulting fees inclued prepaid expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_e2d6f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_e2d6f3" xml:lang="en-US">Common stock issued for service, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_5e29f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_5e29f9" xml:lang="en-US">Common stock shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl_dd2a84" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl_dd2a84" xml:lang="en-US">Public offering price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_a9874e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_a9874e" xml:lang="en-US">Proceeds from the Sale of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_b17704" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_b17704" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_lbl_3c35a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_lbl_3c35a9" xml:lang="en-US">Options issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl_de0181" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl_de0181" xml:lang="en-US">Total expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_CEOGeertKerstenMember" xlink:label="cvm_CEOGeertKerstenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CEOGeertKerstenMember" xlink:to="cvm_CEOGeertKerstenMember_lbl_b1115b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CEOGeertKerstenMember_lbl_b1115b" xml:lang="en-US">CEO, Geert Kersten [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncrementalCostDeemedDividend" xlink:to="cvm_IncrementalCostDeemedDividend_lbl_3ecafb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_IncrementalCostDeemedDividend_lbl_3ecafb" xml:lang="en-US">Incremental cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_f828b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_f828b5" xml:lang="en-US">Three months ending September 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_6a9856" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_6a9856" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_2a8a9f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_2a8a9f" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_9a3183" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_9a3183" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_170286" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_170286" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_5fd3b8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_5fd3b8" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_3a44e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_3a44e8" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_bc4b32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_bc4b32" xml:lang="en-US">Total future minimum lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_93a27d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_93a27d" xml:lang="en-US">Less imputed interest on finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_10" xml:lang="en-US">[Finance Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_dd81f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl_dd81f8" xml:lang="en-US">Net present value of financing lease obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityCurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_607a1c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_607a1c" xml:lang="en-US">Less net present value of financing lease obligations - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FinanceLeaseLiabilityCurrentPortion" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityCurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_12" xml:lang="en-US">[Less net present value of financing lease obligations - current portion]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:label="cvm_FinanceLeaseLiabilityNoncurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityNoncurrentPortion_lbl_4f1294" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityNoncurrentPortion_lbl_4f1294" xml:lang="en-US">Net present value of financing lease obligations - non-current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_61032e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_61032e" xml:lang="en-US">Three months ending September 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_2" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_ffde41" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_ffde41" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_3" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_f9c2dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_f9c2dc" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_4" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_188fae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_188fae" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_5" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_713eec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_713eec" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_6" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_34f5e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_34f5e9" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_7" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_82dad6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_82dad6" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_8" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, after Year Five]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_c1ee24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_c1ee24" xml:lang="en-US">Total Future Minimum Lease Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_19102d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_19102d" xml:lang="en-US">Less Imputed Interest On Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_10" xml:lang="en-US">[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_98ca33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_98ca33" xml:lang="en-US">Net Present Value Of Operating Lease Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityCurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_0c9767" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_0c9767" xml:lang="en-US">Net present value of lease finance lease obligations - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_OperatingLeaseLiabilityCurrentPortion" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityCurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_12" xml:lang="en-US">[Net present value of lease finance lease obligations - current portion]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:label="cvm_OperatingLeaseLiabilityNoncurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityNoncurrentPortion_lbl_0616b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseLiabilityNoncurrentPortion_lbl_0616b2" xml:lang="en-US">Net present value of lease finance lease obligations - non-current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl_30b385" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl_30b385" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ErgomedMember" xlink:label="cvm_ErgomedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ErgomedMember" xlink:to="cvm_ErgomedMember_lbl_f0d7fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ErgomedMember_lbl_f0d7fb" xml:lang="en-US">Ergomed [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_LandlordMember" xlink:label="cvm_LandlordMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LandlordMember" xlink:to="cvm_LandlordMember_lbl_a6eb09" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LandlordMember_lbl_a6eb09" xml:lang="en-US">Landlord [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_NetOfDiscount" xlink:label="cvm_NetOfDiscount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetOfDiscount" xlink:to="cvm_NetOfDiscount_lbl_0dd8ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetOfDiscount_lbl_0dd8ee" xml:lang="en-US">Net Of Discount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_fbba17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_fbba17" xml:lang="en-US">Total cash payment for financing lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl_2a8103" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl_2a8103" xml:lang="en-US">Interest amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1" xlink:label="us-gaap_ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1" xlink:to="us-gaap_ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1_lbl_368acc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1_lbl_368acc" xml:lang="en-US">Weighted average time of maturity of financing lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl_72018e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl_72018e" xml:lang="en-US">Lease expense for operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl_890ca3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl_890ca3" xml:lang="en-US">Total cash payment for oprating lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl_033fcd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl_033fcd" xml:lang="en-US">Weighted average discount rate of financing lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1" xlink:label="us-gaap_RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1" xlink:to="us-gaap_RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1_lbl_f3b08f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1_lbl_f3b08f" xml:lang="en-US">Weighted average time of maturity of operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl_5b714d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl_5b714d" xml:lang="en-US">Research And Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_d54fae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_d54fae" xml:lang="en-US">Weighted Average Discount Rate Operating Lease</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ClinicalServiceTrial" xlink:label="cvm_ClinicalServiceTrial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ClinicalServiceTrial" xlink:to="cvm_ClinicalServiceTrial_lbl_824d0b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ClinicalServiceTrial_lbl_824d0b" xml:lang="en-US">Clinical Service Trial</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FinancingArrangementDepositBaseRentAmount" xlink:label="cvm_FinancingArrangementDepositBaseRentAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingArrangementDepositBaseRentAmount" xlink:to="cvm_FinancingArrangementDepositBaseRentAmount_lbl_a7c2cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingArrangementDepositBaseRentAmount_lbl_a7c2cf" xml:lang="en-US">Financing arrangement deposit base rent amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_4217c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_4217c4" xml:lang="en-US">Three months ending September 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_2" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_1e4414" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_1e4414" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_3" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_7e3fb3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_7e3fb3" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_4" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5393d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5393d4" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_ca6df3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_ca6df3" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_6" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_ff03f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_ff03f9" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_7" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_819a13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_819a13" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_8" xml:lang="en-US">[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_1750b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_1750b2" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_9" xml:lang="en-US">[Other Indefinite-Lived Intangible Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_PatentImpairmentCharges" xlink:label="cvm_PatentImpairmentCharges" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PatentImpairmentCharges" xlink:to="cvm_PatentImpairmentCharges_lbl_8de4e2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PatentImpairmentCharges_lbl_8de4e2" xml:lang="en-US">Patent Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl_2604a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl_2604a6" xml:lang="en-US">Amortization expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:label="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:to="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod_lbl_fc1d05" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod_lbl_fc1d05" xml:lang="en-US">Weighted average amortization period for patents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl_abefc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl_abefc2" xml:lang="en-US">Loss per share- basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl_c7d607" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl_c7d607" xml:lang="en-US">Net loss available to common shareholders - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:label="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:to="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted_lbl_d853a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted_lbl_d853a5" xml:lang="en-US">Weighted average shares outstanding - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" xlink:label="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" xlink:to="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares_lbl_cb5d6a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares_lbl_cb5d6a" xml:lang="en-US">Basic and diluted loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_OptionsMember" xlink:label="cvm_OptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionsMember" xlink:to="cvm_OptionsMember_lbl_dcf103" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OptionsMember_lbl_dcf103" xml:lang="en-US">Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="cvm_UnvestedRestrictedStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_UnvestedRestrictedStockMember" xlink:to="cvm_UnvestedRestrictedStockMember_lbl_a34dd2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_UnvestedRestrictedStockMember_lbl_a34dd2" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_ab02b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_ab02b1" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_1004ca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_1004ca" xml:lang="en-US">Subsequent Event Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_4f7d1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_4f7d1e" xml:lang="en-US">Subsequent Event</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_b60002" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_b60002" xml:lang="en-US">Sale of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl_6b1148" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl_6b1148" xml:lang="en-US">Public offering price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ProceedsFromSaleOfCommonStock" xlink:label="cvm_ProceedsFromSaleOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromSaleOfCommonStock" xlink:to="cvm_ProceedsFromSaleOfCommonStock_lbl_cc0343" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromSaleOfCommonStock_lbl_cc0343" xml:lang="en-US">Gross proceeds from sale of stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_ShareIssuanceCosts" xlink:to="cvm_ShareIssuanceCosts_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_ShareIssuanceCosts_d">Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cvm-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/10/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20231231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20231231.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20231231.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20231231.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20231231.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20231231.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20231231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20231231.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20231231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20231231.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20231231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20231231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20231231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20231231.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20231231.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails4" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20231231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20231231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20231231.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20231231.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20231231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20231231.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_DueToEmployeeCurrent" xlink:label="loc_cvmDueToEmployeeCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cvmDueToEmployeeCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_cvmModificationOfWarrants" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncreaseDecreaseInDepositAssets" xlink:label="loc_cvmIncreaseDecreaseInDepositAssets" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmIncreaseDecreaseInDepositAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000010 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000011 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000013 - Disclosure - LOSS PER COMMON SHARE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000018 - Disclosure - PATENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000019 - Disclosure - LOSS PER COMMON SHARE (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000020 - Disclosure - STOCKHOLDERS EQUITY (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails4" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000030 - Disclosure - PATENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000031 - Disclosure - PATENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000032 - Disclosure - LOSS PER COMMON SHARE (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cvm-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/10/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20231231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20231231.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20231231.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20231231.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20231231.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20231231.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20231231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20231231.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20231231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20231231.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20231231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20231231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20231231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20231231.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20231231.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails4" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20231231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20231231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20231231.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20231231.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20231231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20231231.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_00e75e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_b1acad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_00e75e" xlink:to="loc_us-gaapAssetsCurrentAbstract_b1acad" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca3734" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca3734" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_513a7a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_us-gaapPrepaidExpenseCurrent_513a7a" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_cc1582" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_us-gaapInventoryNet_cc1582" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent_8767d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_us-gaapDepositsAssetsCurrent_8767d2" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_521e19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_us-gaapAssetsCurrent_521e19" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_2c1cae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_2c1cae" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_458df3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_458df3" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_b7dc3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_b7dc3f" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_5b27dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_5b27dd" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets_9970a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_us-gaapDepositsAssets_9970a7" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent_77a91d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent_77a91d" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_bc9fa2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_us-gaapAssets_bc9fa2" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_465166" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_b1acad" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_465166" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_465166" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_a953d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" xlink:to="loc_us-gaapAccountsPayableCurrent_a953d0" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_425007" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_425007" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_DueToEmployeeCurrent" xlink:label="loc_cvmDueToEmployeeCurrent_21ce67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" xlink:to="loc_cvmDueToEmployeeCurrent_21ce67" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_f86221" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_f86221" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_3ea31c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_3ea31c" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_3cce30" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" xlink:to="loc_us-gaapLiabilitiesCurrent_3cce30" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_365fb3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_365fb3" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_d4059e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_d4059e" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_2b546e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_2b546e" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_0194cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" xlink:to="loc_us-gaapLiabilities_0194cb" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_539cbb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_1427f9" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_539cbb" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_0bdbf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_539cbb" xlink:to="loc_us-gaapStockholdersEquityAbstract_0bdbf3" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_ca91f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_0bdbf3" xlink:to="loc_us-gaapPreferredStockValue_ca91f1" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_c93bee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_0bdbf3" xlink:to="loc_us-gaapCommonStockValue_c93bee" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_aafce0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_0bdbf3" xlink:to="loc_us-gaapAdditionalPaidInCapital_aafce0" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_62684a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_0bdbf3" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_62684a" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_80ea63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_0bdbf3" xlink:to="loc_us-gaapStockholdersEquity_80ea63" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_852a14" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_0bdbf3" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_852a14" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_698120" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_f5571e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_698120" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_f5571e" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_c3e041" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_698120" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_c3e041" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_b9f922" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_698120" xlink:to="loc_us-gaapPreferredStockSharesIssued_b9f922" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_5baae2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_698120" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_5baae2" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_22afb2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_698120" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_22afb2" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_8d844f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_698120" xlink:to="loc_us-gaapCommonStockSharesAuthorized_8d844f" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_1e6a0a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_698120" xlink:to="loc_us-gaapCommonStockSharesIssued_1e6a0a" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_3392af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_698120" xlink:to="loc_us-gaapCommonStockSharesOutstanding_3392af" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_6a1e04" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_ad46c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_6a1e04" xlink:to="loc_us-gaapOperatingExpensesAbstract_ad46c5" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_01b203" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_ad46c5" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_01b203" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_2f82d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_ad46c5" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_2f82d9" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_9b936b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_ad46c5" xlink:to="loc_us-gaapOperatingExpenses_9b936b" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_f3c377" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_ad46c5" xlink:to="loc_us-gaapOperatingIncomeLoss_f3c377" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_c9bc73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_ad46c5" xlink:to="loc_us-gaapInterestIncomeExpenseNet_c9bc73" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense_d810f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_ad46c5" xlink:to="loc_us-gaapOtherNonoperatingExpense_d810f9" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_46d3c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_ad46c5" xlink:to="loc_us-gaapNetIncomeLoss_46d3c9" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants_9cd616" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_ad46c5" xlink:to="loc_cvmModificationOfWarrants_9cd616" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_ac0d26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_ad46c5" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_ac0d26" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_EarningPerShareBasicAndDiluted" xlink:label="loc_cvmEarningPerShareBasicAndDiluted_353aa6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_ad46c5" xlink:to="loc_cvmEarningPerShareBasicAndDiluted_353aa6" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:label="loc_cvmWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_abbb5e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_ad46c5" xlink:to="loc_cvmWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_abbb5e" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_f7ca14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_750211" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_f7ca14" xlink:to="loc_us-gaapStatementTable_750211" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_e20101" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_750211" xlink:to="loc_us-gaapStatementLineItems_e20101" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_ada15e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_750211" xlink:to="loc_us-gaapStatementEquityComponentsAxis_ada15e" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_b3b4b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_ada15e" xlink:to="loc_us-gaapEquityComponentDomain_b3b4b5" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_777ae5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_b3b4b5" xlink:to="loc_us-gaapCommonStockMember_777ae5" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_95003a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_b3b4b5" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_95003a" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_4ca3c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_b3b4b5" xlink:to="loc_us-gaapRetainedEarningsMember_4ca3c2" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_56681a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_us-gaapSharesIssued_56681a" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_a41c38" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_us-gaapStockholdersEquity_a41c38" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_WarrantExercisesShares" xlink:label="loc_cvmWarrantExercisesShares_c394b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_cvmWarrantExercisesShares_c394b0" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_WarrantExercisesAmount" xlink:label="loc_cvmWarrantExercisesAmount_bacdcd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_cvmWarrantExercisesAmount_bacdcd" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_d93c66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_d93c66" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_c95081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_c95081" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_24be7a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_24be7a" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_8ef028" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_8ef028" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="loc_cvmIncentiveStockForfeitedShares_ea21b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_cvmIncentiveStockForfeitedShares_ea21b1" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="loc_cvmIncentiveStockForfeitedAmount_173e57" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_cvmIncentiveStockForfeitedAmount_173e57" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_90dce7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_90dce7" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_707b4e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_us-gaapNetIncomeLoss_707b4e" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_64a4c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_64a4c8" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_bbbc2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_bbbc2c" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ShareIssuanceCosts" xlink:label="loc_cvmShareIssuanceCosts_25d741" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_cvmShareIssuanceCosts_25d741" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_00f336" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_us-gaapSharesIssued_00f336" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_9ab05e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e20101" xlink:to="loc_us-gaapStockholdersEquity_9ab05e" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_3b13a8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_6c9ede" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_3b13a8" xlink:to="loc_us-gaapNetIncomeLoss_6c9ede" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf914e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_3b13a8" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf914e" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_5c564a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf914e" xlink:to="loc_us-gaapDepreciationAndAmortization_5c564a" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense_9d26b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf914e" xlink:to="loc_us-gaapOtherNoncashExpense_9d26b9" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_f19ec2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf914e" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_f19ec2" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_c9a499" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf914e" xlink:to="loc_us-gaapShareBasedCompensation_c9a499" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan_b9be0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf914e" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan_b9be0c" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_e1927d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf914e" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_e1927d" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_ffc0e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_e1927d" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_ffc0e7" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_9fd22e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_e1927d" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_9fd22e" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncreaseDecreaseInDepositAssets" xlink:label="loc_cvmIncreaseDecreaseInDepositAssets_88891f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_e1927d" xlink:to="loc_cvmIncreaseDecreaseInDepositAssets_88891f" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8dfb62" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_e1927d" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8dfb62" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_fb5842" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8dfb62" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_fb5842" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_c97d8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8dfb62" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_c97d8f" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_3a9890" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8dfb62" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_3a9890" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_a8c303" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8dfb62" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_a8c303" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_1d7244" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8dfb62" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_1d7244" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_2d392a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_1d7244" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_2d392a" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_62c816" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_1d7244" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_62c816" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_086f0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_1d7244" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_086f0c" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_6fda4c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_1d7244" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_6fda4c" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_52d554" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_6fda4c" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_52d554" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_4bf4c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_6fda4c" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_4bf4c6" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_ce23fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_6fda4c" xlink:to="loc_us-gaapProceedsFromWarrantExercises_ce23fd" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_88d3d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_6fda4c" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_88d3d4" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_57dfde" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_6fda4c" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_57dfde" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_6e8506" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_6fda4c" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_6e8506" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_91e569" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_6fda4c" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_91e569" order="28" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75fb38" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_6fda4c" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75fb38" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_eb57d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_6fda4c" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_eb57d3" order="30" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:label="loc_cvmPropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_3d540e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_eb57d3" xlink:to="loc_cvmPropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_3d540e" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_d1bb6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_eb57d3" xlink:to="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_d1bb6d" order="32" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="loc_cvmPrepaidConsultingServicesPaidWithIssuanceOfCommonStock_77f815" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_eb57d3" xlink:to="loc_cvmPrepaidConsultingServicesPaidWithIssuanceOfCommonStock_77f815" order="33" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:label="loc_cvmFinancingCostsIncludedInCurrentLiabilities_c96d96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_eb57d3" xlink:to="loc_cvmFinancingCostsIncludedInCurrentLiabilities_c96d96" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_eaed18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_eb57d3" xlink:to="loc_us-gaapInterestPaidNet_eaed18" order="35" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e729e9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_fa5189" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e729e9" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_fa5189" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY">
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_LIQUIDITYAbstract" xlink:label="loc_cvmLIQUIDITYAbstract_48510d" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_LiquidityDisclosureTextBlock" xlink:label="loc_cvmLiquidityDisclosureTextBlock_8341e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmLIQUIDITYAbstract_48510d" xlink:to="loc_cvmLiquidityDisclosureTextBlock_8341e2" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_208d7c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_223bf1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_208d7c" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_223bf1" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000010 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_5617ad" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_480a4f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_5617ad" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_480a4f" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000011 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_de3233" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_66bb4a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_de3233" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_66bb4a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_635b91" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock_8c595f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_635b91" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock_8c595f" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000013 - Disclosure - LOSS PER COMMON SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_255075" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock_02499f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_255075" xlink:to="loc_us-gaapEarningsPerShareTextBlock_02499f" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_55ff94" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_7e972e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_55ff94" xlink:to="loc_us-gaapSubsequentEventsTextBlock_7e972e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_3492d0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_faedb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_faedb8" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_824243" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_824243" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock_75860b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_us-gaapInventoryPolicyTextBlock_75860b" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_4cad6c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_4cad6c" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_LeasesPolicyTextBlock" xlink:label="loc_cvmLeasesPolicyTextBlock_3d3a09" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_cvmLeasesPolicyTextBlock_3d3a09" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_bf82e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_bf82e3" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_e37ed0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_e37ed0" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_dde67e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_dde67e" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_a5c917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_a5c917" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_0084a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_us-gaapUseOfEstimates_0084a2" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:label="loc_cvmImpairmentOfLongLivedAssetsPolicyTextblock_eb8e68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_cvmImpairmentOfLongLivedAssetsPolicyTextblock_eb8e68" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" xlink:label="loc_cvmNewAccountingPronouncementEarlyAdoptionPolicyTextBlock_4c3c6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_cvmNewAccountingPronouncementEarlyAdoptionPolicyTextBlock_4c3c6d" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_060ec6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_3492d0" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_060ec6" order="13" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_c2a170" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_315398" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_c2a170" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_315398" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:label="loc_cvmScheduleOfStockOptionActivityTableTextBlock_0c40a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_c2a170" xlink:to="loc_cvmScheduleOfStockOptionActivityTableTextBlock_0c40a8" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:label="loc_cvmScheduleOfCompensatingBalancesTableTextBlock_22d786" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_c2a170" xlink:to="loc_cvmScheduleOfCompensatingBalancesTableTextBlock_22d786" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:label="loc_cvmScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_27531a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_c2a170" xlink:to="loc_cvmScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_27531a" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" xlink:label="loc_cvmScheduleOfDerivativeLiabilitiesTableTextBlock_6c19dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_c2a170" xlink:to="loc_cvmScheduleOfDerivativeLiabilitiesTableTextBlock_6c19dd" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_a64660" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_1f95f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a64660" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_1f95f0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_2de58c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_a64660" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_2de58c" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000018 - Disclosure - PATENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_792ff3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3154c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_792ff3" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3154c9" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000019 - Disclosure - LOSS PER COMMON SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_6c6bbb" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:label="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_73067c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_6c6bbb" xlink:to="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_73067c" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:label="loc_cvmScheduleOfAntiDilutiveSecuritiesTableTextBlock_1192ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_6c6bbb" xlink:to="loc_cvmScheduleOfAntiDilutiveSecuritiesTableTextBlock_1192ed" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000020 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_3db7cf" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_eab1e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_3db7cf" xlink:to="loc_us-gaapStatementTable_eab1e3" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_7224cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eab1e3" xlink:to="loc_us-gaapStatementLineItems_7224cc" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_45e39d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eab1e3" xlink:to="loc_us-gaapAwardTypeAxis_45e39d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4007d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_45e39d" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4007d8" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember_13d7d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4007d8" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember_13d7d7" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember_45ec4e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4007d8" xlink:to="loc_cvmStockBonusPlansMember_45ec4e" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember_f911f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4007d8" xlink:to="loc_us-gaapStockCompensationPlanMember_f911f0" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="loc_cvmIncentiveStockBonusPlansMember_5c1f0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4007d8" xlink:to="loc_cvmIncentiveStockBonusPlansMember_5c1f0e" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f92765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7224cc" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f92765" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_95a2fd" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b48e6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_95a2fd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b48e6a" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodShareStockOptionsExercised_e57c4f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_95a2fd" xlink:to="loc_cvmStockIssuedDuringPeriodShareStockOptionsExercised_e57c4f" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_45eef4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_95a2fd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_45eef4" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_712209" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_95a2fd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_712209" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_66d5f6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_5de13c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_66d5f6" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_5de13c" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_6cb215" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_66d5f6" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_6cb215" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_79ef01" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_b20443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_79ef01" xlink:to="loc_us-gaapStatementTable_b20443" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_eca887" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b20443" xlink:to="loc_us-gaapStatementLineItems_eca887" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_69f6ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b20443" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_69f6ab" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_399f1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_69f6ab" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_399f1d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_141d79" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b20443" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_141d79" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_180c37" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_141d79" xlink:to="loc_us-gaapRelatedPartyDomain_180c37" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_3a21e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b20443" xlink:to="loc_srtRangeAxis_3a21e5" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_01c660" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_3a21e5" xlink:to="loc_srtRangeMember_01c660" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember_bc49bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_399f1d" xlink:to="loc_cvmSeriesNMember_bc49bc" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember_3a7e34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_399f1d" xlink:to="loc_cvmSeriesUUMember_3a7e34" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember_e80b7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_399f1d" xlink:to="loc_cvmSeriesXMember_e80b7b" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember_206ab9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_399f1d" xlink:to="loc_cvmSeriesYMember_206ab9" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember_3588d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_399f1d" xlink:to="loc_cvmSeriesMMMember_3588d9" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember_b37e96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_399f1d" xlink:to="loc_cvmSeriesNNMember_b37e96" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_8a2eae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_399f1d" xlink:to="loc_cvmSeriesRRMember_8a2eae" order="67" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultantsOptionMember" xlink:label="loc_cvmConsultantsOptionMember_8abe97" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_180c37" xlink:to="loc_cvmConsultantsOptionMember_8abe97" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_4dff9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_180c37" xlink:to="loc_cvmConsultantsMember_4dff9c" order="69" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_3677f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_01c660" xlink:to="loc_srtMinimumMember_3677f2" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_8cff54" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_01c660" xlink:to="loc_srtMaximumMember_8cff54" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IssueDate1" xlink:label="loc_cvmIssueDate1_030448" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eca887" xlink:to="loc_cvmIssueDate1_030448" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="loc_cvmSharesIssuableUponExerciseOfWarrantOptions_9015dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eca887" xlink:to="loc_cvmSharesIssuableUponExerciseOfWarrantOptions_9015dd" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice_65cab5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eca887" xlink:to="loc_cvmExercisePrice_65cab5" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate_b5f940" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eca887" xlink:to="loc_cvmExpirationDate_b5f940" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails4" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_5b640a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_076e8b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_5b640a" xlink:to="loc_us-gaapStatementTable_076e8b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_442c78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_076e8b" xlink:to="loc_us-gaapStatementLineItems_442c78" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_74e256" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_076e8b" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_74e256" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_450721" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_74e256" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_450721" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_8e623e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_450721" xlink:to="loc_cvmSeriesRRMember_8e623e" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember_49d724" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_450721" xlink:to="loc_cvmSeriesSSMember_49d724" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised_2472fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_442c78" xlink:to="loc_cvmEquityWarrantsExercised_2472fc" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="loc_cvmEquityWarrantsExercisePrice_d08e27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_442c78" xlink:to="loc_cvmEquityWarrantsExercisePrice_d08e27" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="loc_cvmProceedsFromEquityWarrantsExercised_a4f2ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_442c78" xlink:to="loc_cvmProceedsFromEquityWarrantsExercised_a4f2ca" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_f79edb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_e164cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_f79edb" xlink:to="loc_us-gaapStatementTable_e164cc" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_3f2234" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e164cc" xlink:to="loc_us-gaapStatementLineItems_3f2234" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_b39871" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e164cc" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_b39871" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_7ecfcf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_b39871" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_7ecfcf" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2552f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e164cc" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2552f6" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_fe689e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2552f6" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_fe689e" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_51f6b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e164cc" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_51f6b0" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_d2c85b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_51f6b0" xlink:to="loc_us-gaapRelatedPartyDomain_d2c85b" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_9aea2e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e164cc" xlink:to="loc_us-gaapPlanNameAxis_9aea2e" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_96bbc2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_9aea2e" xlink:to="loc_us-gaapPlanNameDomain_96bbc2" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_3881c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_7ecfcf" xlink:to="loc_cvmSeriesRRMember_3881c9" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember_b88ce2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_fe689e" xlink:to="loc_cvmRestrictedStocksMember_b88ce2" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_86bdcb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_d2c85b" xlink:to="loc_cvmConsultantsMember_86bdcb" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember_933482" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_96bbc2" xlink:to="loc_cvmConsultingAgreementsMember_933482" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend_6a8882" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f2234" xlink:to="loc_cvmIncrementalCostDeemedDividend_6a8882" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52d41a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f2234" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52d41a" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:label="loc_cvmConsultingFeesIncluedPrepaidExpenses_59ec46" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f2234" xlink:to="loc_cvmConsultingFeesIncluedPrepaidExpenses_59ec46" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_dc273e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f2234" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_dc273e" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_14a7fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f2234" xlink:to="loc_us-gaapCommonStockSharesIssued_14a7fb" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_b9ac90" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f2234" xlink:to="loc_us-gaapSaleOfStockPricePerShare_b9ac90" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_e15f58" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f2234" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_e15f58" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ac6c90" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f2234" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ac6c90" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_f68823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f2234" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_f68823" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_ce3639" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f2234" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_ce3639" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_40df0b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_99673f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_40df0b" xlink:to="loc_us-gaapStatementTable_99673f" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_130782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_99673f" xlink:to="loc_us-gaapStatementLineItems_130782" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_6bc0af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_99673f" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_6bc0af" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_b7a2e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_6bc0af" xlink:to="loc_us-gaapRelatedPartyDomain_b7a2e9" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_CEOGeertKerstenMember" xlink:label="loc_cvmCEOGeertKerstenMember_4bb666" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_b7a2e9" xlink:to="loc_cvmCEOGeertKerstenMember_4bb666" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend_f8b4c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_130782" xlink:to="loc_cvmIncrementalCostDeemedDividend_f8b4c0" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_3f346a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_3f346a" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e8560f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e8560f" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_d397d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_d397d0" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_8c6624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_8c6624" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_56e438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_56e438" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_79d55d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_79d55d" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive_3336a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive_3336a1" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_8aaf03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_8aaf03" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_74eeb3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_74eeb3" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_3110cd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" xlink:to="loc_us-gaapFinanceLeaseLiability_3110cd" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FinanceLeaseLiabilityCurrentPortion" xlink:label="loc_cvmFinanceLeaseLiabilityCurrentPortion_9e40cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" xlink:to="loc_cvmFinanceLeaseLiabilityCurrentPortion_9e40cf" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:label="loc_cvmFinanceLeaseLiabilityNoncurrentPortion_4bd039" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_125bd7" xlink:to="loc_cvmFinanceLeaseLiabilityNoncurrentPortion_4bd039" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_18888c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_67994b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_18888c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_67994b" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dbe0cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_18888c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dbe0cc" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_60ebe8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_18888c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_60ebe8" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_294cad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_18888c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_294cad" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_1669a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_18888c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_1669a9" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_191745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_18888c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_191745" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_291cbe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_18888c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_291cbe" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_b27b0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_18888c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_b27b0f" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_981d4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_18888c" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_981d4d" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_6dc8bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_18888c" xlink:to="loc_us-gaapOperatingLeaseLiability_6dc8bb" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_OperatingLeaseLiabilityCurrentPortion" xlink:label="loc_cvmOperatingLeaseLiabilityCurrentPortion_7f786f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_18888c" xlink:to="loc_cvmOperatingLeaseLiabilityCurrentPortion_7f786f" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:label="loc_cvmOperatingLeaseLiabilityNoncurrentPortion_f7e5c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_18888c" xlink:to="loc_cvmOperatingLeaseLiabilityNoncurrentPortion_f7e5c5" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_b99825" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_d2a5db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_b99825" xlink:to="loc_us-gaapStatementTable_d2a5db" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_c47bd7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d2a5db" xlink:to="loc_us-gaapStatementLineItems_c47bd7" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_5a5f13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d2a5db" xlink:to="loc_us-gaapPlanNameAxis_5a5f13" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_96f1eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_5a5f13" xlink:to="loc_us-gaapPlanNameDomain_96f1eb" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_66ffff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d2a5db" xlink:to="loc_srtTitleOfIndividualAxis_66ffff" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_a9a455" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_66ffff" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_a9a455" order="30" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_085ae1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_96f1eb" xlink:to="loc_cvmErgomedMember_085ae1" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember_c7797c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_a9a455" xlink:to="loc_cvmLandlordMember_c7797c" order="32" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_NetOfDiscount" xlink:label="loc_cvmNetOfDiscount_3d1644" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c47bd7" xlink:to="loc_cvmNetOfDiscount_3d1644" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments_003f2a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c47bd7" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments_003f2a" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_2e73bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c47bd7" xlink:to="loc_us-gaapInterestPaid_2e73bd" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1" xlink:label="loc_us-gaapResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1_6b2f3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c47bd7" xlink:to="loc_us-gaapResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1_6b2f3f" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_42de50" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c47bd7" xlink:to="loc_us-gaapOperatingLeaseExpense_42de50" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse_2211e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c47bd7" xlink:to="loc_us-gaapOperatingLeasePaymentsUse_2211e5" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_c81255" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c47bd7" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_c81255" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1_bcd153" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c47bd7" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1_bcd153" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_60f131" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c47bd7" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_60f131" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_4d76d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c47bd7" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_4d76d2" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ClinicalServiceTrial" xlink:label="loc_cvmClinicalServiceTrial_3b2673" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c47bd7" xlink:to="loc_cvmClinicalServiceTrial_3b2673" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FinancingArrangementDepositBaseRentAmount" xlink:label="loc_cvmFinancingArrangementDepositBaseRentAmount_e9b81e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c47bd7" xlink:to="loc_cvmFinancingArrangementDepositBaseRentAmount_e9b81e" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000030 - Disclosure - PATENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_a2de89" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e712cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_a2de89" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e712cc" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d63f3b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_a2de89" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d63f3b" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_54c46d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_a2de89" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_54c46d" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_248d84" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_a2de89" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_248d84" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_81fa59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_a2de89" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_81fa59" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4fa7c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_a2de89" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4fa7c2" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_547c61" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_a2de89" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_547c61" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_9781a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_a2de89" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_9781a8" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000031 - Disclosure - PATENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_03220a" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_PatentImpairmentCharges" xlink:label="loc_cvmPatentImpairmentCharges_34cb77" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_03220a" xlink:to="loc_cvmPatentImpairmentCharges_34cb77" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_53e970" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_03220a" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_53e970" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:label="loc_cvmFiniteLivedIntangibleAssetsRemainingAmortizationPeriod_2c9942" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_03220a" xlink:to="loc_cvmFiniteLivedIntangibleAssetsRemainingAmortizationPeriod_2c9942" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000032 - Disclosure - LOSS PER COMMON SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_bfa9c7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_f40ac1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_bfa9c7" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_f40ac1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="loc_cvmNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_184e4a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_f40ac1" xlink:to="loc_cvmNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_184e4a" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:label="loc_cvmWeightedAverageNumberOfShareOutstandingBasicsAndDiluted_35172b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_f40ac1" xlink:to="loc_cvmWeightedAverageNumberOfShareOutstandingBasicsAndDiluted_35172b" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" xlink:label="loc_cvmIncomeLossFromContinuingOperationsPerBasicAndDilutedShares_89e45b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_f40ac1" xlink:to="loc_cvmIncomeLossFromContinuingOperationsPerBasicAndDilutedShares_89e45b" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_298b58" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_962e7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_298b58" xlink:to="loc_us-gaapStatementTable_962e7c" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_3e7ac7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_962e7c" xlink:to="loc_us-gaapStatementLineItems_3e7ac7" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a175af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_962e7c" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a175af" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_124c07" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a175af" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_124c07" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember_bc19e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_124c07" xlink:to="loc_cvmOptionsMember_bc19e1" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember_d6bbd5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_124c07" xlink:to="loc_cvmUnvestedRestrictedStockMember_d6bbd5" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4cc1cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3e7ac7" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4cc1cb" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_78faa4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_039cc0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_78faa4" xlink:to="loc_us-gaapStatementTable_039cc0" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_70388e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_039cc0" xlink:to="loc_us-gaapStatementLineItems_70388e" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_858f8c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_039cc0" xlink:to="loc_us-gaapSubsequentEventTypeAxis_858f8c" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_461a93" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_858f8c" xlink:to="loc_us-gaapSubsequentEventTypeDomain_461a93" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_6ae8ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_461a93" xlink:to="loc_us-gaapSubsequentEventMember_6ae8ce" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_26082f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_70388e" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_26082f" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_4ae20b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_70388e" xlink:to="loc_us-gaapSharePrice_4ae20b" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ProceedsFromSaleOfCommonStock" xlink:label="loc_cvmProceedsFromSaleOfCommonStock_590425" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_70388e" xlink:to="loc_cvmProceedsFromSaleOfCommonStock_590425" order="3" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cvm-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/10/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20231231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20231231.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20231231.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20231231.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20231231.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20231231.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20231231.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20231231.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20231231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20231231.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20231231.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20231231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20231231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20231231.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20231231.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails4" xlink:href="cvm-20231231.xsd#StockholdersEquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20231231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20231231.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20231231.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20231231.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20231231.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20231231.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_WarrantExercisesShares" xlink:label="loc_cvmWarrantExercisesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercisesShares" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_WarrantExercisesAmount" xlink:label="loc_cvmWarrantExercisesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercisesAmount" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="loc_cvmIncentiveStockForfeitedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncentiveStockForfeitedShares" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="loc_cvmIncentiveStockForfeitedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncentiveStockForfeitedAmount" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ShareIssuanceCosts" xlink:label="loc_cvmShareIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmShareIssuanceCosts" order="15" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000010 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000011 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000013 - Disclosure - LOSS PER COMMON SHARE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000018 - Disclosure - PATENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000019 - Disclosure - LOSS PER COMMON SHARE (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000020 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmStockBonusPlansMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockCompensationPlanMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="loc_cvmIncentiveStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmIncentiveStockBonusPlansMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesUUMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesXMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesYMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesMMMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNNMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultantsOptionMember" xlink:label="loc_cvmConsultantsOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsOptionMember" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="69" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IssueDate1" xlink:label="loc_cvmIssueDate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssueDate1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="loc_cvmSharesIssuableUponExerciseOfWarrantOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuableUponExerciseOfWarrantOptions" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePrice" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDate" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails4" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesSSMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercised" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="loc_cvmEquityWarrantsExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercisePrice" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="loc_cvmProceedsFromEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromEquityWarrantsExercised" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmRestrictedStocksMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmConsultingAgreementsMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncrementalCostDeemedDividend" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:label="loc_cvmConsultingFeesIncluedPrepaidExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmConsultingFeesIncluedPrepaidExpenses" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" order="10" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_CEOGeertKerstenMember" xlink:label="loc_cvmCEOGeertKerstenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmCEOGeertKerstenMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncrementalCostDeemedDividend" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cvmLandlordMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_NetOfDiscount" xlink:label="loc_cvmNetOfDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetOfDiscount" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestPaid" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1" xlink:label="loc_us-gaapResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePaymentsUse" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ClinicalServiceTrial" xlink:label="loc_cvmClinicalServiceTrial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmClinicalServiceTrial" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_FinancingArrangementDepositBaseRentAmount" xlink:label="loc_cvmFinancingArrangementDepositBaseRentAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinancingArrangementDepositBaseRentAmount" order="12" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000030 - Disclosure - PATENTS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000031 - Disclosure - PATENTS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000032 - Disclosure - LOSS PER COMMON SHARE (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmOptionsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmUnvestedRestrictedStockMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20231231.xsd#cvm_ProceedsFromSaleOfCommonStock" xlink:label="loc_cvmProceedsFromSaleOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromSaleOfCommonStock" order="3" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cvm_10qimg19.jpg
<TEXT>
begin 644 cvm_10qimg19.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %G G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[+HQ0*RM4
MU6ST>".XOIO*CDE2%3M+$NYPHP/>A*^B U*6L6WUO3KK6I])MYC-=6RAI@BD
MK%GHK-T#>W6MG-%FMQ"T5FZEJ%MI>E76I7+$06L;2R%1DX R<>]2VEPMU9PW
M2*RK,BR*KC# $9Y'K3MI<+EVBBBD,*;7/:?XMT/4X]4DM;]6CTN9H;MR"HB9
M1D]>H]Q5S1=:T_7M%M]8TN8S6=PI:.0J5W#.,X//:FTUNB5)/9FO15"XO(8;
MRWM7\SS+@,5*H2HVC)R>@_&K](H2DI:Y*_\ 'GAC2[R2UN]0?= VV>2.%Y([
M<^DCJ"%_$T)-[(3:6YUU%01RQS1K+&X=' 96!R"#T(J?- PHHINX $YZ=: '
M45S.G^+M)U2;3H;7SR^HK,\.Y,?+$VUF// ST]:GUKQ'I>@QQ'4;A@\Q(BBB
MC:220CKM102<4^5WM8GF5KW-ZEZUBZ/KEAKMFUUI[2[%;8RS0M$ZMZ%6 -;/
M:DTT[,:=Q:*3-4OML+:D;$"3S1'YN=AV8SC[W3/M0,O44=JR-8U>UT/2)]5O
MM_V>  L(UW,<D  #N<FA*XF[&O15*\OK>PTV;4+R00V\,9ED=OX5 R:S]#UI
M=<L#>+I][8H6PBW<7ELXZA@,G@T[.UPNKV-VBCM61K6L6&@Z-=:OJD_D6=JG
MF2R;2=H^@Y-)*^B!NQK<4M<O?>+-!TVRTR]N[X+#JLB1VF%+-,SC*X &?\*Z
M?BG9K<$[BT5SG_"3:.NIWME-<>2UG+#!(\@PADD&413W/^-2:EK]CH\-W->^
M<$M+8W4C+&2NP'& >A;VSFEROL+F1OT5ERZC!'I7]I.DHB$8E**A9\$?W1SG
MFM!7#*&Z!AQG@T[%$E%%4+Z]L]-MS=7UPEO"&5=[G R3@#\2:6X%^BC-% !1
M110 451LM0L]1A>6SN$N$CD:)F0Y =3AA^!J]1L 4444 %%%8\^M6L'B"UT5
MO,:[N87G7:N5"+@$D]N2*+7%>QL455N+JVL[22ZNIEB@A4O)(QP% ZDU6.IV
MO^A;&>5;W_4O&I92-N[)(Z#'<T[,+FG1112&)UHZ5D:MJ]IHFFM>WC,4!"(D
M:[GD<\!5'=B>U7H9?-ACD9&B+*#L?JN>Q]Z+.PKEJBBJEU=6UC:R7=Y<1V]O
M&-SRR,%51ZDF@9:HK&T_7])U31!K5G=H^G?,1<M\J$*2"V3VX/-.T?6],U[3
MSJ&DW2W5KYC1B5/NL5.#@]QGO3LT*Z-:E_"L.S\2Z3?ZGJ&EV%T+J[T]0UPD
M0)"$YPN>F>.F:L:-JUIKFD0:I8EC!-G <892"05([$$$4--;@FGL:M%9]G>Q
M7BR-")%6.1HSYB%.5.#C/4>]:%+8845D2:YI<=KJ5Q]J61--#?:@G)C(7<0?
M?%6+&\AU#3K:^A5TCN(UE57&& 89&1V/-%F*Z+_:DZ4M<QKGB[1O#MS#:ZE)
M<&>=&D6.WMWF;8O5B%!P.:$FW9 VEJSIZ*YW3_%&DZG?V=K8SFX^UVK7D4D:
MY3RPP7)/8Y.,5T5-IK<$T]@HHHI#$^M)36=41F8X4#)/H*YG2_&F@ZMJQTJT
MN)ENRIDC2>W>+S5'4H6 W >U"3>J$VEN=5115".\M7U&73EN$:ZB19'B!^95
M/ )^N#0,O8HHS67JVL6NCP0370D;SYX[:-8UW,7<X'%"5]A&K1110,*\\\>6
M.J:UJF@:'I5XUA(TSWCW8B\P1"-#MX/&=S#&:]#IM.,N5W)E'F5CQ^XU(:=\
M/XM#;2183/=FQU*61)72-\;C,2GSOOP"#GO@GBN:MMECX6DL+^ZO(=,U/74B
M7RH9H2EO$H:1E3)= 2*^AL5F3:;9W&IVNIS0[KJT5UA<Y^0,,-Q[XJU42Z&3
MI-]3R1M-6:QU*WT&VO+;0M<O+2SMXY1)\^&+33 /RJE1C)QG%4+Z2X\0>-;*
MXA5K34!JB6WD1VUQYD$4;?>:4D(N57. "#FO?J.*%4MT!TK]3Q74M"74],U+
MQ%)!?-JU_K*PV+"61?LZ+($5E4' X5B3CFO0+X>(-.NK[5I-6AETJ&!Y%LTM
M/WN0O'S[N>?:NJHJ7.YHH)'BA\*:CI_A0:E)(1I\NEBXOK-5)ENKK+,@/^SE
M^>YP!5#7=-N;:33?#^L:@VG:3:Z;"+=6L99X[B<Y\P_NR,.#T!]:]YQ3=M"J
M.]VB'270\;O+?Q!IUCJ']F75]=W&CZ/!9QW+1,78RONDD"=V5 ..M9EAIJPZ
M)K=YHNN7&H-?0QZ>4@LYH%,DC@>82Y)+@9R1TKWFBJ4[+8/9^9SVG>'K+0=)
MN;?18V2>2/[\DC.SN%PI)8GVKSS1M8CA^'I\(V>DW<WB2:*2WN+-[9UQ,Y(>
M61R-NWG.[)R,5['14J=M]2W'MH>136.MZ;KR^$-+^TD:EIEM$]\N?+MEBRDK
MY[,5P /4^U86N:2]YXEO-#U#6)]+2W:.UTFW^PS3$1!1B2-U8 L3G)/3%>]T
ME.-1IWL2Z=^IY1)9L&\2>*KNQN]4N-,=(+*%WD4.84 ,FT=<L2<X/2N7T/[1
M9ZIK6L:;<//%'H\DC?9K6>*.6>1L*/WA)D(.><#%>_TM-5;)JPG3OU/./!^D
M26?BHPM&PBT;2;>P1F!PTC_O)"/7M4?C2ZT6/Q1:S76J:IH>KVD)6WNX+5I8
MYD?JF-K*QR!QP:],I,"IYM;E<GN\IY"VN:M#+X0O?%D=Q!$LMS(TD=NX,A"[
M8=Z+G:S DX]:CL[>X\2MI:W$=[%;ZQJMQJ4BDR1,L$2[8U;NN3CBO8L4?C3Y
M^R%[/NSR2\T^_L?%=]X-T"WN;2QU:VAD-RA8I:Q+E9<,3P[# 'USVIFH6]U#
MHGBC5K6&Z6+3+NVCLX4W%C';;<[1WSEOK7K]%'/Y#Y/,\:UB74(]&.J:M;M!
M+XDF$3F=9733K91NCC*Q\[CWZ<G!Z5G^&]/O)M'M=+/GO9ZAKX:-&ADB5((5
MW,=CDE S+T)YKW6DHY[*UB?9ZWN<+\2+%-8\/6FAO;M.NHW\$#!<_*N[<Q)'
M08!KB=8T[2H=0U70;BQU(W-NJQZ%96YFV+E<^:C XSO/)8\ 5[C3<"B,VE8J
M4+NYYOHN@?VWXEU"^U[[1<OIJVUG%OD=8VEC0,\FT$!OG;K[5I^.('U(Z)H0
MA>2&^U!#<8!(\J,%VS[' %=O14<SYE+L5RJUCQVU\*ZA:>(O#MGJD@O)H;J6
M2 QJ3';6L661<_WF8KD^P':JVFZM_:FFZ=X?5;\:I?ZR\^H*T,BBW19"[*7(
MP/E50 #S7M5&!6GM+[HS]G;9GANHVFFW\6EWGB6SF_L[4]=N;R1C'(=JJI2)
M6VC(S@8JSJEC?7%CK&FZ/:LD=YJ%KI5G%/O\I8HAO9CWVDYR>]>TT4<_D'L_
M,\A5;F]TZVM[F.\&NWVK16NI.=P$:QG>1'C@1;5&,=<\\U4O-!_M33Y?$1AO
M1J^IZXJ6DGFR*;:(2A00N<*-J$GCG->T;:6ESVV0^2^YX1?V-]X@\:7D.L:]
M<:;JBZALLX%T^9WAA5AL:.16";2.22.YS78?%"'3[BST"TUBWDETMM21KJ15
M=@BJI(SLYY.!7HV**3J7:TV!0T:[GS[XPCCNKB?2],M38R:<T=KI\*V]S+*Z
MN01*'!"(,MU.3QS77RZ3-J&H^)M:EM[F^N=+CCMM/CDD<*\L4>XOMR Q+GK[
M5ZGMYJE?V=OJ6GSV-RA>&9"CJ&*D@^XY%7[2]D3[/=GC&F0Z3J'B70;C15OK
MO6X+6:_OI[GSD::41X",&P/]8W0# Q4?A.QFO-;M=8N-<NKG6[>.2>]M?[/F
MBD=MAS#([-LQG@ #L,5ZUHOAG2- \QM/MF624!7DEE:5V Z#<Q)Q[5OXH]I:
MZB)4MFSS7X4Z7X=MO#,=[I5JT>H.NV^9UD5A(6+%2']">WI7(W3:3XCO?$$D
M::A>>([J_:'3TB\Y5MUCPBR@C"  AB37NY'!':L_3-/L]+T^.QL8?)MXL[$!
M)QDDGK[DU"EJY=6:..BB>1ZU%_:>I:Q8W\>I7'BM)TATI8_-1(8P%VS*PP@!
M.YF)^E5;Y])\0:EXE\Y-0U#7Y+C[%IL</G*J&- HE!&$ #[B6]J]VK,TW3;+
M2[);+3X1# K,X4$GEB6)Y]235*=EL)T[GEU]K]QHVH^*+:\^W3:NUG;V=FJ0
MR.)?W>#*"!@#>QR?:DU!KG19=1N/L[RQV-C9Z(LT@D*H'&Z64[/F('&2.:]F
MQ1BE[3R#V;[GSQ#I_E^$/%R?OY](EDM;;$=K-$F-P,DH1B6P >O?TKI;J!;)
MYV\$VEQ':6&CR7-N(ED^>65@N0&Y+!%) ^E>Q8HP*'4;Z"5.W4\/7[+:QW^L
M>#4U)[1-+DAN9Y?-_P!+NG*JG#\EU))) XS70^'_  K!H/CO2K;3UNH_(TEF
MOIGFDD%PY*JH;<2"00QKT_M1VI.3:L6HI:G%W^+SXJ:79W S#9V$MY"IZ&4N
M$W?4*3^=<5KVBKK.G>)?$4MO>R:A+J"66F[9)$\D(RH'50<#G<<XKU:;2[.X
MU&UU*>#==6H98I,D%0PPP]P?>M.CFM:PN6][GGGB>Q\2/J4/]FPZU/&L"JTE
MEJ4-NC,.N5=2<^])=:M)X;^'MQ)X@BO#<2+(D<5ZXO))'(^4$QKC'X5Z)24<
M^UUL')K=,\^TC6-#T'X26%V\ADM([41;?L[GS),'*[-N>6R.F*S-#L]4U;X3
MZ79^%-0ALYF;-XT\4D><DM)&, %3DXR*]4I.]+GWTZW#D[OI8\O\"QWVCCQ+
MK&N1Z=8V,<OE(+:-XPJ0KMR-W\)YQW)S6UX9:?1_AY<ZG/ Z22?:-0$(7+*'
M9G5<>N,<>]=#J&EV.K1Q1WUOY\44@E$;,=I8=-P[X]#Q6O3E/FU[A&'*>/V.
M@KJ;Z39:]'=SVFFZ0;V>,R2())YF+%3@C=@ \=J['X?6MS:^ =*CN_.\PQM(
M$E)+(K,2J\\\*0.:["DH<FU8:@D[G@UCI6CW/AC6#8V$\?B#4]0>UNLI*K0I
M+-@CGC[@ZC-:FJ:7?>'[SQ4WA&*\MD@L;:%V4O,2[/EY54GYF6/TKV6BGSNY
M/LT>5_#?1[6'6;[5-.UZ2_MVA6*2-+.6"-WSG>3(QW/ZX]:MW.G>(-:^(6L7
M>FZL-+MK2VBL/,>U\QGW?.Y0D@#&1SS7I%%)S;DY H))(\6NO">FI;^)I9+&
MZGM-&LDL+%/,D4R2!2[/\N-Q+N.:R/&4EY/:G1[Q7^WZ58PQVY>WN)I;F1D&
M9 4(10&XW')XKZ!Q3=M$:C3NT-TU:R/%=9MQ)XMTVSN#-KMU!#;VSZ?*MQ')
M$P W31RKA#UR2WI5,Z?>:]XQD75O$%Q8ZRFH'R8%T^9I((E?Y-D@;9L*CDX[
MG->\TVFIVZ"=._4S-4U2UT?3Y-0OC+Y$>-YBB:0@$XSA03BN(\+R3:WX]O-:
M6XN-3TN& K:7=S;^2('9OFCB&!N&T#+$9[5Z53?6HC+E3TW*<;M'D/CXK<^,
M($97U:2*)8UT:2.=-Y+9\R*2/Y=V.I;@8JL]GI0\1^,]372[AO$EI'FSC*R[
MMB0@!E/W6R2?RKVFC%6IV25B7"[N>-V>K2:E%H\/A];RZ_L+2);HM)#(@EN#
M&$5<L!N()8XJ#P]9:#JWB[PY-IZZA=7T,<EYJ%[=+,-\FS&T[\+D,QX XQ7M
MF*@EC6:%XWSM=2IP<'!]Z.?L@]GW9YCX*M]3UB>*UO?,72O#EY-%&V\G[=,'
M.UL]U13^+?2O5C6=IFGV>E:=!I^GPK!;0KM1%[#^OUK1J92YG=%QCRJP4444
MB@HHHH **** "BBB@ HHHH **Q_$$DL.@7<D,C12!0 Z'!&2!Q3QHL>!_P 3
M#4/_  ):@#5HK+_L6/\ Z"&H?^!#4?V+'_T$-0_\"&H U**R_P"Q8_\ H(:A
M_P"!#4?V+'_T$-0_\"&H U**R_[%C_Z"&H?^!#4?V+'_ -!#4/\ P(:@#4HK
M+_L6/_H(:A_X$-1_8L?_ $$-0_\  AJ -2BLO^Q8_P#H(:A_X$-1_8L?_00U
M#_P(:@#4HK+_ +%C_P"@AJ'_ ($-1_8L?_00U#_P(:@#4HK+_L6/_H(:A_X$
M-1_8L?\ T$-0_P# AJ -2BLO^Q8_^@AJ'_@0U']BQ_\ 00U#_P "&H U**R_
M[%C_ .@AJ'_@0U']BQ_]!#4/_ AJ -2BLO\ L6/_ *"&H?\ @0U']BQ_]!#4
M/_ AJ -2BLO^Q8_^@AJ'_@0U']BQ_P#00U#_ ,"&H U**R_[%C_Z"&H?^!#4
M?V+'_P!!#4/_  (:@#4HK+_L6/\ Z"&H?^!#4?V+'_T$-0_\"&H U**RCHL>
M/^0AJ'_@0U8T<D<\8EAAUZ2)ONN).&'KUH ZZBN4VM_S[:__ -_?_KT;6_Y]
MM?\ ^_O_ ->@#JZ*Y3:W_/MK_P#W]_\ KT;6_P"?;7_^_O\ ]>@#JZ*Y*1A%
M$TDD.O*B@LQ\SH!^-:<&FP7%O'<1ZCJ!210ZYN&Z$9H VJ*R_P"Q8_\ H(:A
M_P"!#4?V+'_T$-0_\"&H U**R_[%C_Z"&H?^!#4?V+'_ -!#4/\ P(:@#4HK
M+_L6/_H(:A_X$-1_8L?_ $$-0_\  AJ -2BLO^Q8_P#H(:A_X$-1_8L?_00U
M#_P(:@#4HK+_ +%C_P"@AJ'_ ($-1_8L?_00U#_P(:@#4HK+_L6/_H(:A_X$
M-1_8L?\ T$-0_P# AJ -2BLO^Q8_^@AJ'_@0U9]_;P6#0(;K5)I)F*HD,Q).
M!DT =)17*;6_Y]M?_P"_O_UZ-K?\^VO_ /?W_P"O0!U=%<IM;_GVU_\ [^__
M %Z-K?\ /MK_ /W]_P#KT =717*;6_Y]M?\ ^_O_ ->C:W_/MK__ ']_^O0!
MU=%<IM;_ )]M?_[^_P#UZ-K?\^VO_P#?W_Z] '5T5RFUO^?;7_\ O[_]>C:W
M_/MK_P#W]_\ KT =717*;6_Y]M?_ ._O_P!>C:W_ #[:_P#]_?\ Z] '5T5R
M:>3]J@@F_MFW,[[$>24[=V,XX/M6CX?:9K"=)II)C%<RQJTC9;:&X!- &W11
M10 4444 %%%% !1110 4444 %%%% !16=J.IZ?I-B]]J=Y%:6R$!I96VJ"3@
M#\ZS+GQAX;M'NX[C6((WM&59E))*D]!TY]\9QWH N>)/^1;N_H/_ $(5L#I6
M'KTL<_ABYFA821NBLK*<A@2,$5N#I0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 -?[C?2N>L5U-O#VE_P!E
MR0(0RF;SE)S'DY QWKHZQO\ A'-)'W;4J,YPLK@?EF@"KXLM]4N?"]Y#I)D^
MTL%^6)]CNFX;U5NS%<@&O.TE^)%CK,]KX7T6ZLM :$M;IJ1$\HD(Y.2Y* '&
M$).>37J'_".:3_S[O_W^?_&C_A'-)_Y]W_[_ #_XT <-]O\ BE#*T7V..YV6
M<P#^2B!I58['/S=2,?*,"J=QJ/Q>_P"$<NKJUM4^UCR5@26V3>5+-OD*AL;L
M!?ES@9KT7_A'-)_Y]W_[_/\ XT?\(YI/_/N__?Y_\: .)TMO&]UXIU2X\10R
M064>FO&BHJB#>=I!4AB6/WLY''2O0=*_Y UC_P!<$_\ 015-O#>CLI5K5BIX
M(,KX/ZUI1QI#&L4:A44!54= !0!-1110 4444 %%%% !1110 4444 %%%% !
M61J/_(<T?_KI)_Z :UZR-1_Y#FC_ /723_T T .9==WG;-9[<\91LX_.C;KW
M_/:R_P"_;_XT]M6MU8KY%UP<<0-_A2?VQ;_\^]W_ . [?X4^?R1-UW&[=>_Y
M[67_ '[?_&C;KW_/:R_[]O\ XT[^V+?_ )][O_P';_"D_MBW_P"?>[_\!V_P
MHYO)!==QNI17<WAV]MXVS>/;.JF,[?G*D#'IS7CNCP?%K1-2AN9[.[OHET\:
M<%:19<NA&R8@L,%LG<>ORU[-<7GDZ5->HH^2)I%64^6.!G!)Z?6O-K#XD:]J
M%RVEFTTNSU)(3=2?:9'2-8P,[ ?XF/9@<8YQ2W*,>TL_BM9W=K^YN;H6U[+*
M3,Z\0GH@(;YN"2 W?%7FO?C!;:)/)9:?%YC!A%"\"EH &4AOO?.Q!;@^E=#X
M7\;7WB1;?5/)TZQTV=GC^SSW!6[0JN2Q'0CC..NW!K$M?B]:R6]Q=36&R)+T
M1QJH8/+;L&".-P +%EQZ $<T :=]8_$:\T]Y[J[A:TDM+?S;"T7RK@N&S,JO
MG )7I^5<S)HFL3^)DA;0?$=MHTDL,D$ANC));HI)9 !)E-QQUW8 -=3-\6O#
M]O"\]Q8ZC'"D99I/*5AY@!)BX/WOE//3WKL/#VMVOB3P_::U9I+'!<KN5)EV
MNN#@@CZB@#@_$FD>-Y[2X&I74NH6YU$RVT6EQE=D.S"I*-ZLPSW4Y!YY%8O]
MC^/VLD6*WU.#Q#O+7-V;W=;O:[?]2G.-^. =H(;DFO;Z* . T>W%M#9K'I^I
M:?;MJ"F*'4)_,?\ U9R0,DJ,]B3GK73^'_\ CUN_^OR;_P!"HUC_ (_-)_Z^
MQ_Z"U'A__CUN_P#K\F_]"H V**** "BBB@ HHHH **** "BBB@ HHHH R-?T
M>/7=!NM+D<1B=<!R@;8<YS@UQUY\-Y+C4&OH-<\J2"21[,-;AA%YA_>A^?GS
MSCICWKTBB@#D-4T&QL_",<)1Y&L8(X8W9R#A2,9 .*Z_M6/XD_Y%N[^@_P#0
MA6P.E '-:AH-N\L5U:VK22^=OD7[0R[QW[XJ*:RAMX'FDT.0(BEFQ=DG _&N
MHJ*2-)8VCD4,C A@>A%)2DOA;1/+V,V/1-)DC606[8(##]Z_^-2?V#I?_/LW
M_?U_\:4:/IRJ%$. . -[?XU!IZM:ZE=V(_U?$T?S$D \$<^XHYI=6_O%MNBG
M/##HNK6EU'B.TES!*'E; )Y5N>.V/QK7_M73?^@C;?\ ?U:M.B2+MD0./0C(
MIGV2U_Y]X_\ OD4W)2MS7N78DBD2:-9(V5T89#*<@U)7.K;ZQI.FNEM);2Q0
M!F1#$VXC)..#5R/7-/>)':XVLR@D;&X/Y4W!_9U7D!K9I:JVUU!=0":WD$D9
MR P]JM5-FG9@%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_K5WM6/;R26^MSVLFTI.#.C!N>, @BEL1LS:HHHIEA1110 TKD8-4O[(TO\
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M_3.?6JC4E"ZCL1*C1F[R;^[_ ()B'X?^'TU&ZO56V2XO5\N:3RUWSJ/X6/\
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M'_\ A.O!OA&>1M<\1V>F:EXHOH]4U&WTM;BZM8T+;)$3821,Y&YL,!@;0,T
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M%XAUBRDN(;"WCNFBCD:W$BVD:]&?G.7.  ?7BO:JKM#"V_=$IWXW9 ^;'3-
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M4W*46G9;/34]/$TJ,:-.I"2<I)W2OIKH;X;<H8=Z6LU;C5%4#^RTX'_/P/\
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M+I=UXBU/X96&L6&M36O]AZK<Z8T<>L7%VU_=B>(I);2')GW!7C5'.T!R<\4
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M&]'_ * U=-Z5S&OP^7=^'8\YV7@_] :NG]*M;L]>7\.%^S_,DHHHJS(****
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M //Y!_WY/^-5VM]>_M"U==0MOLBD^?'Y)W.,<8.>*/D%_(VZ***905C>'O\
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MBB@ HHHH **** "L;P]_QZ7?_7Y-_P"A5LUC>'O^/2[_ .OR;_T*@#9HHHH
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MA_\ 7Y_[3:NB'6HCNS:I\,?1_F244459B%%%% !1110 4444 %%%% !1110
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MTH Z&BN>M]:U"[=DM+.RN&7[PBOE8CZX%6?MFO\ _0%B_P# H?X4 ;%%<_\
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M %%%% !1110 4444 %%%% !1110 4444 %8WA[_CTN_^OR;_ -"K9K&\/?\
M'I=_]?DW_H5 &S1110 4444 %%%% !1110 4444 %%%% !6+J'AW1=4^T?;M
M-AN#<;/-+#E]GW>?;)K:HH P]>1(O#-S'$H1%5555& !D<58L_\ D8-3_P!R
M'^35'XD_Y%N[^@_]"%<YXNUO4O#^F:[JFDPQ37L?V58XYL[6W-@CCV)H [NB
MO(].^+4,^NZJMS;JVEA(I-/>-@KR*<*^[)Y.\G&/[IJI+\4M6ALM2\[3X$DM
M%=HI4.\38+\%.HP$[9R: /9Z*\RG^)UO#Y,D.ES7B3QI($1T4Q)M9F8DGJ O
MW>H/%,_X6Q:W&I:QI^E^'M0O9["*5X]H \]HP"PP<8ZCZT =WK2^9H&HQK T
MY>WD41JNXN2I& .]>>:=_P )+8^ ?"NB:?HM_9BT2%=3\J-8Y(X@N&6/GEMV
M,X[9JQ'XNUJ_N6N!<6&@1VT-O++9:FO[V<R#)P0WRCL, Y/6BQ\6Z_JFKZ:E
MC?61 \V6^LA""XC61E4*Q8?.^  ,=B: .?\ !?B#Q=-XTM]+\3:Q,98)7BEB
MCC79)E/D1@.CKU9NA/%%OH.MV_Q O]:;0[MM,BUN2ZCC@B6.9V: (LH.?GBR
M&!7CG!YJ]>>--6FT^RUBUT&'0;Z9IS<&[@1YS'&V P&Y2R^N"2.P--N?B1KM
MOHLWBB.33KBVCN/LZZ(B,+EQTWAB<Y_BV[?N]Z ,I6^+%U"Z[=;L8WNI)(U/
ME-(L9MR55F_Z[ #\?2MWX8P^*K&_O8=>T>ZM(+V:2[24 *OFLJ>9YBCN3DJ1
MQUKH])\0ZE#8WMQ?ZCI^N&*T6\6/35VR(#U7&2"/0Y!.#Q5?1/B5I^N^)K?2
M;73YH[:[#-:WLKJ%N@HR2B]2.OY4 <[X-\'ZS!!>:Q';_P!F:K::AJ#6%O=P
M[(F6:3(>38=SKMZ#L:TKZW^(&GW.L&1KK4;9H8[R V$P5EFQL>WC#_PY^<9^
ME4M7^(6N:7K&H_-8R6BRR6]M&$++E<?,SJQ*E>2RLH&!P:F_X2[Q%'XHC\)G
M7M&EEFB%R-96']U&,?ZDIOQO.,CYONY.* .3@L?B5#K6EZ[<:7J3WT5N;:\E
MC";YH?M#%5//)V%3ZUUG@.?XA3:K!#XNM=2M_(M\LTGE&WF4CC)!+>:#G( Q
MBKOB+QQ?:-X0TB^M?LFH:G>R?,;2.2:)HT),CJ%&[&!@$\ D56T_XK07'F/+
M8_:+<3MF:*14V1,VV/"DYD;UV]* /5**\HNOC)8V>G13W'A^]%S)+M%NKJWR
M;-^_<./N_P /6KFI?$"_E,MGING_ -G;Y(8XM1O5)A028^=AP. >F[K0!Z71
M7E6H^.M87PWHUY;R65K/<P3W$\DZDI+Y/_+-!D8,G4=>/6GV/C;Q!>IJ4T*:
M>[FRGNK:T<,K6AB8#;,023NSGH.E 'J+?=-9GA__ ) %I_NG_P!"-<98^+-4
ME\8:5:W<EO%IM[:0A5B"O(]P\9<@C=N10.G!'O79^'_^0#:_[I_]"- &I111
M0 4444 %%%% !1110 4444 %%%% !1110!S>N_\ (3T3_KZ_]IM6\OWJP==_
MY">B?]?7_M-JWTZU*^(UG\,?1_F2T4451D%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5C>'O\ CTN_^OR;_P!"K9K&\/?\
M>EW_ -?DW_H5 &S1110 4444 %%%% !1110 4444 %%%% !7&>/+75;K1K=-
M-CNYHA.#<PV;[)G3!QM.1T;:3ST%=G10!QVJ1:Q#X)C;4+Z%9(K:/[5N3.YP
M1N.[/%37-S;-J%Q<0ZIH\L,ZQY2YE!P5S@\''>NEDCCEC:.55=&&&5AD$?2J
MW]BZ/_T";/\ [\+_ (4 <RRZ;(T>\>%V\HADSM^0CH1Z=33]UF9#(7\-ER,%
MLC.,Y_J:U].\/Z1:V"0'3[.;!8[_ "%YRQ/I[U<_L71_^@39_P#?A?\ "@#G
M1): MB3PUEB2?F')/6G17%O#>27D,_AV.YD 5YD<!V'H3U-:B^'=)757O/[/
ML]K1"/R_(7C!SGI5S^Q='_Z!-G_WX7_"@#GYYK6ZNHKNZE\.37$/^JED8,R?
M0GD5"(]-%^E^%\+B[0Y6<8#C\>O<UL7GAW2;B:T86%I'Y,PD(\A?GX/'2KW]
MBZ/_ - FS_[\+_A0!SUY-:ZD(UU&;PY=B)MR"=@^T^HSTINZS_M'^TO,\-_;
M=NW[1N'F8QC&[KTK>FT/1Y()(QI=FI92N?(7C/X5%8Z#H]O80VIT^SE:%0C-
MY"\D#Z4 9%I-:Z>DBV,WANU64[I!"P0.??'6FPR6<-S%<02>&XIHD\N.1& 9
M%_N@CH/:NC_L71_^@39_]^%_PJE!X>TF'4KNX:QLV%SMVIY"_+M&#VH Q]UB
M+V:\#^&A=3J4DER-\@/4$]2*C6WTE+%K%8_"RVC-O: !0A;UQTS74_V+H_\
MT";/_OPO^%9\WA_29-1MKH65F@MMP9/)7G<,#- %./4!&8S'?>'T,2[%VR8V
M+Z#G@<=*J[=.\V*0?\(R'@+&)OES&3U(],UTW]BZ/_T";/\ [\+_ (53U#0-
M'NM/FM%T^RB>92BMY"\'\J ,:4V,\0AF;PU)&&#!6((R. <>U6;B^6\M)+6[
MO/#\]LXVM%))N1AZ$$XK8CT31TB1#I=FQ50I/D+V'TIYTC1E!9M+LP!U)@7_
M  H YN9[*>...9_#<B1%6178$(5^Z0.V.U21W%O%/<7$<WAQ)KGB=U<!I>WS
M'O\ C6I8^'=)MI;MFL;.7SYC,H\A?E! &.GM5W^Q='_Z!-G_ -^%_P * .>6
M>V6[6]2?PXMTL?E+,& =4_N@]<>U:6FWVEV>EP6LNL6+O&N&99E )SGCFF-X
M>T?^UTOOL=F$6(P>7Y*\L6S^=:7]BZ/_ - FS_[\+_A0 ?VUH_\ T%K/_O\
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MY/-;O]L:/@?\3:S_ ._Z_P"-4[KP_H\UY;3"SLXQ;L7=?)7D%2.:N_V+H_\
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M'(/S=C5J'1-'C@CC.F6;%5"Y\A><#Z5<AAAMXEAMX4AC7HB*% _ 4 6****
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M$O-.U#6;Z\T=M+DNG51&MP)8Y0N?WG4G<223GM@=JZ/7+::\\/ZA:0QO))-
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M@1,N%], %,CZF@#V9YH8PQDE1=N-VY@,9Z9IRR(Q*JX)&,@'.,]*\5O?A_\
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M+C\PR;5#D;=V.<>E2=1SR* /(M/\>:]=""W:XTC^T?MOE&V#!Q.C8($;JVW
M3)9NQP,<UZ]61_8.A_N?^)19_NF+Q_N%^1B<DCC@YK7H \B\3?%+4M,\3ZIH
M6F:7@VL*".:YC90TAD56?)PIC4-UR,GO7H6@ZC+JWANRU)G4RSQ!F**5!/?
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MN56(Y /<4EUI>G7P9;ZQM[E3C<)HE<''3J.U6HXHX8DBA18XT 5548  [ 4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cvm_10qimg21.jpg
<TEXT>
begin 644 cvm_10qimg21.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $& C$# 2(  A$! Q$!_\0
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M_OFK6FQ:CJVI0:?8SL\\[%5W3;5& 2223@  $D]@#0\MHK5W^\/KE7R/LO\
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MQ5]IN?\ GXE_[[-'VFY_Y^)?^^S1_95/S^\/KE3R/M7_ (6EH/\ T#=4_P#
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MW*QW3I$V00$SD $=JY;:O'RCBEI0I<KO_73_ ""4[JP4445TD!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %;W@O_DH'AW_ +"5O_Z,6L&M[P7_ ,E \._]A*W_ /1BUC5_AL$?;5%%
M%?-'6=!1117F'MA1110 4444 %%%% !61;_\C??_ /7G;_\ H<U:]9%O_P C
M??\ _7G;_P#H<U-=27T-7O7+_$#_ ))MXD_[!MQ_Z+-=1WKE_B!_R3;Q)_V#
M;C_T6:*7QQ]13^%GQ19Z'J6M2:I-IZQLNGV[7=QYDBQXC'7;G[Q]A571XHKC
M7],MYT\R&6[AC=3_ !*7 (_(U7N?^/E_K3[*Z:QU*UOD0.UM,DP4\!BK!L'\
MJ^NBGJ?/::'<6?@O;XWO8;H:9+IT3WI6!-1A=PJ)*4 17W$@A>.O'-8>G^%6
MU+P\^H6EU<O<1VCW91["18&5!N=1-G!8 $],'&,YJC::Y+:>)Y]>6VC:69[A
MS$20H\U74\]>-YQ]*U(_&'ED7!TA'O3IYTQY3<N(S%Y/E96,<*VW'<C()P,U
M+55;>1=X,JOHFE?\(U-K4.MS!4D6&..>R\L3R'!948.<[5.XG&!P.K 5H'P/
M))%:RV=Y<M')>V]E(UWI\EMM,S%4D3<?G7(.>A'''-5;OQ/932:=/:Z"MK/I
MBQ"T'VII(8MC!L^65^;<P);)R23[583QHEO+/)9Z*L9N+ZWU&4S7DDS&6*0R
M  GHIRP[GGJ<5H_:]/T#W.OZE=O#.G0B_N;CQ$OV"PD6VEN(;5G,ERQ;]U$I
M(W !"2Y*C'KQF'Q78V.FG15L7BFCETJ*=IHE*B9B\GSD'D'  ([8J*RUZ.&'
M4;/4--2_T^_F%R\'FM$T4H+;71QG!PS*<@@@_0U!KFL+K3V>W3X;".SM5LXX
MX69AL5F*D[LG/S<GOU[TTJG,K[?(EN-M#6OO"=G8>)I-!?6Y+NY@W^<+*PDF
M*D8PJ@$;B0<GH%QC)JXOA/3].M==&K74V8]+@OK*7[(RN \Z)ED+ JWWD(.>
MI()P,YK>*VGUC7;Z[T]9(-; %Q!%.T3)A@PV. 2.5&0001U[5.WC".8M%<Z%
M#)9-IJ:8UNMS(I,:2^:C;^3N!P#V/M1)5=/EV*]P+KPY$EO'J6IWT&G:>EG9
MG?;6Q=Y9)8MZH$W#<^T$LQ('Y@5DZEHL]CJ=K9V\RWZ7T<<UG-$"HG20X7@\
MJ=P*D'H0?K6@?%2W-N;'4])CO-/,%M%Y*S-&R/!'L657&<$J2",$$'V!K.U+
M6KC4-3MKR&)+%;...*TA@)(MT0Y4 GDG.6)/4DFE'VE]27R]#0O/#-I#'J<-
MEKT=[?Z2C27D"V[*FQ&"R&)R?WFPGG(7(!(R*G\=0Z7I^M1Z/I$<9ALXHU+"
MU$4CL8T8EWW$R$DD\XQG XJO>^)H;B#4WL]#M[#4-6C:.\NHY68%6(:01QGB
M/>1SR>,@8!K+UK4Y-:UBXU*:%87F" HA) VHJ=?^ YJXJ;DG+]/(;<;61T%U
MX9TB.\U'0;>\O'UW3K>2:1V5/LTSQIOEB4?>& &PQ)#%3P,BLS0=/T?4I8;:
M^N-3-W<3"&.*PM5EV*<#S&W$9&3]T>AY'%6KKQ9]H6\NTTB&'6[Z VUSJ*RL
M=ZLH5V6/[JNZC#-SU. ,TNB7NDVVHKJD&N7OAJYCE!\NVA:<-%A<JK!@<D@Y
M#_*<CFI]]1=_Z_X _=OH6H?"=I!IMS>7Z:MJ BOKBU5]'A62/9#M#2LS= 2W
M'T-<>=N3MSMSQGKBNSM]:T>758M237=3T*WM=0EO(=-@B+I&C2;PL)5@JL1\
MIW#'N1Q7*ZA=)?:M>WT=NMLES/),L*=(PS$A1],XK2BY7?,3*W0JT445T$!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !6]X+_ .2@>'?^PE;_ /HQ:P:W
MO!?_ "4#P[_V$K?_ -&+6=7^'($?;5%%%?,'6=!17G_CCXGZ+X U32-*U'2]
M8U*_U@3-:VVDV9N9'$04O\H(/ 8'C/ /I5"X^,&DVO@^#Q'=>&_$MNUWJ2Z5
M9Z7<:<8;V[N&7<H2-F *D9^8D#Y37F'MGI]%>:3?%;3X_$</ARU\+^([W41I
MZ:C>PV]HC'35="R1S_/Q(=I&%W<]Z['1M875] L-8>SN=-%Y"DOV:^0130[A
MG8ZY.&'<9H VJ*B>1(\;W5<G R<9/I2NZ1H7D8(HZEC@4 244S<NXKN&X<X[
MTH96'RL#VXH =61;_P#(WW__ %YV_P#Z'-6O6!8R+/XFU.6+YHXH8+=F[>8#
M(Q7Z@.N?K374E]#=[UR_Q _Y)MXD_P"P;<?^BS74=ZY?X@?\DV\2?]@VX_\
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M_P!/^R _86A5=0B(C!D<E@'=PP9LHS#';'%8>V6]M_ZW+<&M#S\JIP" <4N
M.U>K0:3>?:M$+:'I#>&#IEI/J$\T,"E8FC4S2EQ^]#<D@C^+&.M<3H=E8HUY
MX@U"(S:1ITF(X9.#>3')BA/L0-S^B@^HIQK)I_U_3)<&CGB%;[P!^M!"Y!(&
M1TKT2TM=9E\':'J&BZ-H]P]S+=M=O=V]L%9A,-H/F8(0 D?+P!3G_P"$=2>_
MM?"=UH4-R-0E_P"0M&KI-!A=BPR2J4"AO,'.UB-IS2]MY?UY]A\AYSP/04N!
MSQUZUW%S]KT#PS?3S:)I]GJ9ULP2Q2V<<RQ)Y <(F\-A<G(P>0>N*Q_$,%I)
MINB:Y:V<5BVI0R^=;P@B,212%"Z _=5A@XZ AL<<5K&I=DN-CG\#CCI2;5SG
M:,^N*6BN@D,#)..3UI J@Y"@'UQ2T4 )M7=NVC/K2X&.E%% ";5W;MHSZTN!
MZ>]%% "  $X &:7 YXZT44 &*0 #H /I2T4 6=/O+C2]2M=0LV5+BUE6:(E<
M@,IR.._-5N-[-@ L<D@=:**/, I J@8"@#TI:* $VKNW;1GUHVKNW;1GUI:*
M !,QRK-&3'(I#*Z\,I'0@CH:TM2U[6M82./5=4N+Q(V+*LC<!CU;'=O<\UFT
M4K)NX7"BBBF 4444 %%%% !1110 4444 %%%% !1110 5O>"_P#DH'AW_L)6
M_P#Z,6L&M[P7_P E \._]A*W_P#1BUG5_AR!'VU1117S!UG04445YA[84444
M %%%% !1110 5D6__(WW_P#UYV__ *'-6O61;_\ (WW_ /UYV_\ Z'-374E]
M#5[UR_Q _P"2;>)/^P;<?^BS74=ZY?X@?\DV\2?]@VX_]%FBE\<?44_A9\+7
M(!N7R.]+:7,EG?VUY$%,EO*DR!NA*L&&?;(I+G_CY?ZU-IMBVIZM::;'-%!)
M=2K"DDQPBLQP,GL,X%?8JUM3YP6ZU*]NS>+)<.D-Y<F[E@1B(S(2?FV^HW$
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M8CWZC>64CFVF.Z919L)3NX8CS.&)QD]>M7[.\N+SQA=7VG^(+<:+/IEQ';V
MN,-$BVCX@,'5"A&=V .-V>>?+S:77VG[(UI.+@\>28FW_P#?.,UJR^(/$4EM
M+I\EQ)ED%M*1;J)V3@"-W"[R. ,$\]*AT=+1_K8KGUNSLH-;TU(M*U*Q6W-C
M::='#);SZN8D5ECVRPO;!27WMN.0"&WY)'..8\1S&\T/PW=1ZE%<10Z=':O!
M]IW20RJ\FX&,G(X*_-T/%80LV6.[-PWV:6V52898V#N2P&.G! .?FQQ[TR2U
MNH=AFM9HO,7<F^-EWCU&1R/>G&G&+NF2YMJQZ9'/>V^H^#;X^)K:RTNSTNT>
M[MY;G;MCY,B^3_RUWKQ@!LYP<8JC97_G-X=N]#\0VVB:9IQ/VJUFNO*:%O.9
MG=H^LV^,J. V<;3C%<3<C5KV>VBN8+F66*W2.%#"VX0J/EP,9*@=ZH\8SVIJ
MBN_]?TQNH>E74E[=>'?#TOAO7H=!MOME_<10S7GV7R4-R2C]<,%'&T9([ YJ
MAKSZ3XCM;D:/J%C9V]OK-U<%+F00?N94BQ*B'D@F-OE4$C(&*Y;R=8OI=,T1
MX)V?=Y=G;R1E3^\?)QD9(+'.:36M+71M5ET[[8MV\)*R.D3Q@,"00 X!(XX.
M,$5,::3WUU!RNMCO]1N-%U75=08^((+>T7Q-]L:XCG"2>0T2JLL>>3\PP< E
M>I'%2V.KV=G_ &$^H:A;6MS:>((KA@-5:]:*!D(=R^3A20N0#Z$@5Y=-!/;.
M%N;>6!B-P$J%"1Z\]JO:=H6J:EJ\.E06<D=U+&\J++&R955+$],XPIQ[XINC
M%1U>@U4=]CL]'OK;2K*&SU#6K0:BM_>F*[6X$ZV\LEK&L4Y9<\!N-PSM//\
M#4^AZFNCW&A0ZYKEK=W]OJ$UU%)]J6Z6TA-NZE6DR1\\A4A,G[N3C=SYV]JT
M=M;2;\S3,Z&WV,'C*D  Y&"3G@#)XYQ4<D$T,KPS0212H,LCH591UR0>11[%
M.^NXN=HWKC5Y]0^'R0ZEJ4EW?)JQF5)Y2\BHT'S$9Z*6"^V0*VI+J.?PJ)+_
M %&*W-KI\<5NUCJ65NMI4K!):GD-URP"C(R<]^'EAGMW"7$$D+%0P$B%20>A
MY[5'75[-/8GF9WVL"Q2]\<ZH-<TZ6+5[69[%(K@.\X>>.7! ^X0H/#8)(P :
MV_$%U-:^-_$%]J?B*WGT7[+);O8&YRTA,&$A$'4$2%6WXP,;LYKR8@$$$<&K
M%[>76HWTU]?3&>YF.Z21L98XQV^E8^P\_P"M"O:'I;W-S9^)=&U"]\26Z:+:
MZ59K>6;W."T9M4WP^1_RT,F>" 1SDD;>*&EZA_IGAK4K7Q%:V&A:=;11WMC)
M<[60KGST,/68R\X(!SN )&.."N[RYOIUGNYC-(L:1!CCA$4*H_!0!^%05*P^
MFK#VFIW4'B2.WOO \,.IM:Z99.DUQ"DA A_TR1OWF.I$9'7/!XZU;MY[>+2=
M1TEKN"ZU0ZDUU+)#K8MA<0E (R)AD/L(;*EAC=D ]O.J*OV"%[1GHVH:J=9L
M-0M=$U:STO4OMR37+K?&$7Z+"J+()F";B'#L0<9+[@#5*\U2S?XJZ%JDNK6]
MW;Q'3FGO4.8R42,2,<@="K9R!^M<-14K#H'4;.[FU+4-/TC6KF_\30:A+=30
MS::D%WY[+.DP<7 7_EB%0,N"%)W;<8'$?BJ:QM=&6;3=L9\3NFJ31+QY$2Y
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M\(9XM_Z%?5O_  !E_P#B:/:P[ARR[&!16_\ \(9XM_Z%?5O_  !E_P#B:/\
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M_0=U/_P%M?\ XW5?V?6[K\?\A?7*?9GU3\M'RU\K?\+RUC_H.ZG_ . MK_\
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M?_C=']GUNZ_'_(/KE/LSZJHKY5_X7IK'_0=U/_P%M?\ XW1_PO36/^@[J?\
MX"VO_P ;I?V?6[K\?\A_6J?9GU517RK_ ,+TUC_H.ZG_ . MK_\ &Z/^%Z:Q
M_P!!W4__  %M?_C=/^SJW=?C_D'UNGV9]545\J_\+TUC_H.ZG_X"VO\ \;H_
MX7IK'_0=U/\ \!;7_P"-TO[/K=U^/^0?6Z?9GU3\M-PO]VOEC_A>6L?]!W4_
M_ 6U_P#C='_"\M8_Z#NI_P#@+:__ !NCZA6[K\?\A?7*?9GU517RK_PO36/^
M@[J?_@+:_P#QNC_A>FL?]!W4_P#P%M?_ (W1_9];NOQ_R']:I]F?55%?*O\
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MUMK6=5M-2AU"-EW;XD="ISC:RN 0:T1X=:;19]1L]3M[R2VA%Q-;Q1R@K'D
ME790KE2PR >/?%)XDUM-=EM"L<^;: PFYNY%DN+C+%MTC  '&<#T ZFMJX\<
M12QZDT=K?QR:C8_9&@^V?Z-:G"X:&/;P,H.#T!/UK1NI961*4;LRKWPS]@,M
MM/KFG_VG 56>PR^^,L0"H;;L9US\R@Y&#UP:GN?!\UGJ=_9W6LZ>B:9D7]PI
M=TMFW[%3A<N['HJY[Y(P<,U#7=%U"ZGU9]$G76+J19I6%U_HZ2;@SR(@7=EB
M#\I8@;CUXH_X22VN-3U]M0T^233M;N#<20Q2A98'$C.C(Q!!(W,"",$$].*G
M]Y;_ (;R_P""/W07PC=-.[C4+9M-6S^WB_C621'AWB,D(%W[@YVE2!CG/'-1
M0>'(9K6ZU!]>LX],@F2W%Z(IG1W9=P& FY0 .2P&#P,U9'B2P%U9)#::C8V6
MG0&&S>SO=ES&S.7>1GVX8L2<C  &,=.;4?C"S_M^;5_LNIVDS>6-UE>K&;A4
M4*1."FURQ!9F '+'BB]3^K#]PYBUM([G41:27\%NF2/M#[F0X_NA06;/8 <^
MU= GAF.SM]4FN9([V Z/)?64\8>,;EF2,Y5@&# [@5(]^>*I:;K\5EK^HZD]
MD88[])H]MD_E/:B1LYA8@[2.G3[I(XS6I)XQLI[>&RNK"^FM4TZ?37DDO0\[
MK)*LH?<RX!#+C&,8Z5G-U+Z(4>6VIC^)+&WL=8M[:RA*K)96DNP$L6=X$9OS
M9CQ[U:E\,Q6-\MK=ZUI\E]!<11W6GJSATW.%95?;M=ESA@IXYZX-4]9UB'4K
MJPOK:WEM;NWMH89&,@=6:)%1608!'"@D'/-7-0UW1;R\GUB/0YH]8N)EN)";
MK_1XY-X=V1 H;YB#PS$+N.,\5/OV2#W;LT)/"4FH:M>:=I,-K /[;N[*"265
M@56*-I AS\H7:OWCSGKQ5:Q\+;[C3[BUOM.UFTNGN(&*M*B)+'"9"K94,?EP
MRL.#CZU9;QI9QZC/<VFDS+%-J%SJ!26X#$--;M$R@A1P"V1QT&/>LS0_$JZ-
M86MJUD9_(NIKG=YFW=YEL8-O3MG=G\*?[VQ7NW(G\.BWL$>\UJQM;][87:6,
MI<2&,KN4%@NQ79<$(3DY'0G%(WAUFT.XU.SU2VO&MH1<3PQQR@HA8*2'90K[
M2RA@#QGOBI;K6M'U&V6XU/2)Y]76U6U\Q+G9!(40(DK)MW;@H7(# $C/<BM.
M^\:0W5MK"K:7ZMJMG]E>%[S-M:G*$&*,+]W*#@] 2!ZT7J66GY$VB8_BFQL]
M.\:ZKIMH!;6D%R8TSEA&O'U)Q^=;.L>#K2/Q1XAM=+U>U@TW2&0RRW1D'E*S
M;0OW<NP..@.<C'>L'Q+JEMKFO76JVUK+:M=_O)HY)!(!(?O;2 /E] <GWK3U
MCQ19ZDVNR6VF36\NM"%Y_,G#K'(C[B4PH^4],')'K6]IVCZ:_@'NZD$VAPM<
M64=Q>VFFI)I\-R&5)IFF#9^;8JD[N,L. .*LS^%Y+/2;ZUFCCDU1-5M+2&5)
M#L=)HG=2"<##?(<D CVYI\?BZ!M,73YK:]ME6UM;?[1870BF)A#C!8J?D;?G
M;V*@\T[5/&%CK":@M_I$Y6ZDM)E5;OD/!"8B&8J2P93G/!!K']Y?;^M!^X8F
MLZ/%H]P]K_:UO=W,4K0SP)%+&\3+UX=1E<YP16571ZWXBAU/1K;2X8[Z80S&
M9;C4KA9Y8UV[?*1@H(3OSG) Z5SE=<.:WO&<K7T"M[P7_P E \._]A*W_P#1
MBU@UO>"_^2@>'?\ L)6__HQ:BK_#8D?;5%%%?-'6=!1117F'MA1110 4444
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M@:WE\*Z='>WLMW-'J6+9+B15PODHP8';$1O)/ )SD\"NURMO\0A>1I;Q3_\
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M+*S[RZOG<K!CD$$8[5%9_"GP59Z)K>CO975_#KD8AU":_OIKF>X0#"J9'8L
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MYD22";SA(XESN\P,=V?7/6D)))8DDDY)/4FAAM9E#!@"1N7H?<4E=1 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5O>"_^2@>'?\ L)6__HQ:P:WO!?\ R4#P[_V$K?\ ]&+6
M=7^'($?;5%%%?,'6=!1117F'MA1110 4444 %%%% !61;_\ (WW_ /UYV_\
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BQ:_\\1_WR*=MMO\ GBO_ 'R***+LTLB7:G]VBBBD*Q__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cvm_10qimg20.jpg
<TEXT>
begin 644 cvm_10qimg20.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &F ;T# 2(  A$! Q$!_\0
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M=@P/7K5G4_@[H^LGQ1)J&N:I/<>)=,MM+O9SY08K","083 =NIXQSP!7J5%
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M0S0[F64#=A=NYN!@<]*X*YOTO6EM/#^O:GXC\-QWVAS"[OI'G,=X=07S$5V
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ME@OO.FECM9'+M:P-(QBB)+,1M4C@LV.F3BO2Z "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBH99ECPO+.?NJ.IH >[K&A=V"J.I-5PU
MQ+\T>V).Q=22?PR,4V.%F<2W!#,.50?=3_$^]7: *^R[_P">\?\ WZ/_ ,51
MLN_^>\?_ 'Z/_P 55BB@"OLN_P#GO'_WZ/\ \51LN_\ GO'_ -^C_P#%58HH
M K[+O_GO'_WZ/_Q5&R[_ .>\?_?H_P#Q56** *^R[_Y[Q_\ ?H__ !5&R[_Y
M[Q_]^C_\55BB@"OLN_\ GO'_ -^C_P#%4;+O_GO'_P!^C_\ %58HH K[+O\
MY[Q_]^C_ /%4;+O_ )[Q_P#?H_\ Q56** *^R[_Y[Q_]^C_\51LN_P#GO'_W
MZ/\ \55BB@"OLN_^>\?_ 'Z/_P 51LN_^>\?_?H__%58HH K[+O_ )[Q_P#?
MH_\ Q5&R[_Y[Q_\ ?H__ !56** *^R[_ .>\?_?H_P#Q5&R[_P">\?\ WZ/_
M ,55BB@"OLN_^>\?_?H__%4;+O\ Y[Q_]^C_ /%58HH K[;O_GM%_P!^C_\
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M_P"@BK;_ .K/TJII/_($L/\ KWC_ /017-T-^I=HHHH&%%%% !1110 4444
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MHQ_RSDKS;4OB-X1N%UJTCTU5DFTA+2._$)'VAE1"L87&5.YI<L>"%6O4OC\
M? %IG_G_ $_]%R5\Q%%/517U.5815Z*E)O1O]#Y['5G3K-);I'>-X@\ Z;<W
MUUH=Q&#<QWR1A;>8&.*2V588FW#_ )Z;LX]>N*TO^$V\(_VT-6:YAA#2Z9(@
MM[:9&01$>?YB_=8C'&,\8QS7F/EI_=%'EI_=%>P\J3WFV]OU.)8IK:*/1FU[
MX<OJ%PR[ET^[FL9'@>.;?A97-SYN.')!!!'8@  @U%IFN?#&2[274-+@2=K3
M;Y6R=;82B=NN S!C%LY (SGH:\^V)_=%'EIG.T9J_P"S-/CE]Y/UG^ZON,?Q
M8;8ZXYLP1:Y?R023A-QV]>>F.M<_6QK_ /Q^0_\ 7/\ K6/3J:29M3UBCZ[_
M &988I/AEJ)DB1C_ &F_)7/_ "SCKW'[-;?\^\?_ 'R*\3_9A_Y)GJ/_ &$W
M_P#14=>YU\+C/X\_4^CH?PXD+VMML/\ H\?3^Z*J:5:VQT6Q_P!'C_U$?\(_
MNBM%_P#5GZ54TG_D"6'_ %[Q_P#H(KDZ&W4G^RVW_/O'_P!\BC[+;?\ /O'_
M -\BIJ*!D/V6V_Y]X_\ OD4?9;;_ )]X_P#OD5-10!#]EMO^?>/_ +Y%'V6V
M_P"?>/\ [Y%344 0_9;;_GWC_P"^11]FM_\ GWC_ .^14U% !1110 4444 %
M%%% !17$1W6KVOCFTTE=9?5(Y899[V%X(U6T3_ED05 (R<KAB20">U9.EZMX
M@MTFM]4N=5_X2![6XEMK*Y@@6VN'0<"-HUR<97@L#S0!Z;17F%GXFU2WM_(O
M+Z[\MIXI!<W%EY<_E!4\Q1&%&2966)?E_B.,[<UW>FZA:ZMIZ7UNS-$Q92'0
MHR,I*LK*>00000?2@#4J&21(TW.V!^I^E)*[H/W<9=CT'0?B:9##M?S)&\R3
MU[+[ =J &^7)<'=-\L?:/U_WO\*N=!110 4444 %%%% !1110 4444 %%%%
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MIB)<L%IWZ&%:O"DKR/9M:^+?@'P_JTFEZEK@^U1?ZQ887E"'T)4$9]NU4_\
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M7=5_Y"UQ_O?TJE7D5?B?J>E#X4?>'PC^U?\ "G_#.SRL?9!US_>-=Q_IV/\
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MXDNHHHKA D3N6W;<H?[[]<]:Z6RL6L[**U:\GNS&,>=<,&D?G/)  _2M"B@
MHK!L?$&EZEJNI:9;S,\VF[/M!((52V[C)ZXV'/:J5GXPTFZ#22+=6EN;>2[A
MGN(MJ7,*?>=.22 "#@@$@@@8H ZNBN3M/%FGW2EVM[NWG^T16_V6:,"4M( R
M' )&-I+9SP%;/2NLH **0D $G@#N:J;I+CB(F.+O)W;Z?XT +)-\QBA4/)W]
M%^O^%.BA\LF1F\R4]6/\AZ"IHXTB0)&NU:?0 4444 ?.G[07_(9T;_KA)_Z%
M7)_#&/Q%?>$O&6GK#-/I4NGR)9QJH*-<'AE4]2V,<5U'[0W_ "&M&_Z]Y/\
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M^O0?^A&N]K@OA#_R1OPS_P!>@_\ 0C7>U\%5_B2]6?24_@7H4M/_ ./G4O\
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M/QQ<>;#<?V3-YS36DMR#,/+Q , 1+CY=W?.:CM?&$T*V4=QI]Q*L27T<C+,
MS+<-D;21P5]^M8NZC=7G'4:J^*I[:[TIX[&>2VM=.?39%,P$CJV[]XIQ@, 1
MVJS+XH:^T^]L3I\D,<D5K!"[R!G"P@\N<#+'=VZ5@[J-U 'G6MM_Q/KW_KJ:
MS2>:NZT?^)[>_P#74UG$T ?;GP__ .2:>&_^P?#_ .@"NGKDOA_"[?#3PVPN
M9%SI\/ V_P!P>U=-Y,G_ #]2_P#CO^% $]%0>3)_S]2_^._X4>3)_P _4O\
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M0"1T]J=0 G0<<"EHHH **** /FK]I(XUW0O^O>3_ -"%>"[J]W_:5/\ Q/=
M_P"O>3_T(5X)FON,K?\ L\/ZZGRV,_CR_KH2;J-U1YHS7NW.,DW4;JCS1FBX
M'.:DW_$RG_WOZ52S5K4C_P 3*?\ WOZ52)KPZC]]^IZ4/A1^@WP;_P"2,>%_
M^O,?^A&N_P"PK@/@W_R1;PO_ ->8_P#0C7?]A7Q=7^)+U9]!3^!%'3_^/G4O
M^OG_ -II5^JEM;F&6ZD9@?.E\P8[#:H_]EJW6184444 %%%% !1110 4444
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M]GT^[/C#0/"_B6QLY8[G0-11FDW "W)XQ[5K_P!B:Y_T ]1_\!FKZX^VV_\
MM?\ ?#?X4OVVW_O-_P!\-_A7E5JLJM1U);L[J<%3BHKH?(W]B:Y_T ]1_P#
M9J/[$US_ * >H_\ @,U?7/VVW_O-_P!\-_A1]MM_[S?]\-_A6)H?(W]B:Y_T
M ]1_\!FH_L37/^@'J/\ X#-7US]MM_[S?]\-_A1]MM_[S?\ ?#?X4 ?&=K\,
M_%>L:W-(-$NDBDDR#)&5&/?->^>!?A-::&D=UJ<:R7(QQV%>H?;;?^\W_?#?
MX4?;;?\ O-_WPW^% $T<4<,82-0JCL*?5?[9;_WF_P"^&_PJ<'(!'2@!:***
M "BBB@ HHHH **** "BBB@"M<6\5Q;2V\T8DAE4HZ-T92,$?E6'H_AFWT>Z2
MZ6\O+V:*W%I ;J16\B'(.Q< 9Z+DG).T<UTM% ',WGAFUO6N9OM%S%=37$=R
MMS&R[XFC&$"Y!&T<\$'.YO6M32=,MM)TF#3;7>8H0<,[;F8DDEB?4DD_C6E1
M0 4444 %%%>6Z?8ZI>>+;Z]L[>=&M=8<S:@;L[&A51F 1;CG.0.0 .N<B@#U
M*BO+9_$'B2VT+0;I[Y)I-902-*D4,0M\1[MBF1@I+9_B/13@>G2Z;K&N7&EV
MTEYI<0=K=GDODN(C;JX!QG#$X.!G&0,]>* .MHKS/3?%FJ+!&NH:DC7"W=HM
MT6CB\F*.4L#LDC8@J2N!NPPXSUJ[:ZYJ^M:T++3M6MX;9KB\4310K*62(PA0
M#G'61LGF@#OZ*\HD\5:M<63SR:I:2B[L;^5].6,9M#$IVJQSNSGALXYZ8K9A
MUZX;5;]KG6(;&WTTA!IRPAY;E!"K[QD[CG<=H7^[W.< '?45Y'!XEU34K.YL
M]0O(KF(_8+R%T>,NH>Z1=K",X';C)/7DUW'B6\U"U72X--N8[:6\ODMFE>/S
M-JE')P,CGY10!TE%>8V7B3Q(WB26UD*7$5I<R6LD+-!&TJHIPX7=YF]B P 7
M;@\>M9R^(M1%P^N_VU:WMV=":[\N&-0EINEB)4@$D@<\MSP: /7Z*\\U/Q=-
M_:=]:Z=J=JEL+BUMA>8$B6OF*Y9FYP3\J@9X!89]*IWUU>0:QJ4S>*DO(UT,
MR+&(XPEV5,X.,'J,#.W]* /3Z*\Y?Q-J4-X=NH6L8M;BTM$TLQ@R7:2K'F0'
M.[_EHV,#'[LY[X;'KGB*&&+4/[0M94O+B]MXH)HA%'&8O.,;-)G/_+( ]L'M
MB@#TBBN1\'ZM-J4%Y#>7;W%W:R*L@:*-0FY0V T;,K#WSGUKKJ "BBB@ HKR
MVQL=2OO%VH7EC;SQ-:ZPQFU$W9V&%44M (MW.<XY  SG.13IO$7B:WT'0[Q[
MY)GUE0QD2*&);?$>[:ID8*2W^T?X3@>@!ZA17):3K&N7&EVK7NEQ%G@9Y+V.
MYB-NK#=C.&)YP,XR!D\\5@Z=XLU1+=1J6I1M<K=6@NLI%Y,4<K,IV2(Q!4D8
M&[##C/6@#TNBO/;77=6UK7?[/TW5[>&V:YNU$\4:RDI$(-H!SC.9&R>:R9O%
M6JW%LTSZI:,+NUOW?31&-UKY2-M#'.[.1\V<<],4 >L45P-KKUP^K7C7&LV]
MG;Z?L4:>(0TMRGDK)O&3N.2Q"A?[O<YK C\2ZIJ5E<V=]>17,+K8WD+JT?F(
M&ND&UA&<#(QQDGKR: /7:*YCQ-J5UI\5A;V]Y%8?;;H6[WLRAE@78S9P>,DJ
M%&>,M^%<?I^NWMO81VD'B"UM(2=0O#J,T:LEPR73#8HSM P=QP<X(QB@#U>B
MO,)O&FL1F%I(XH2+>WU:XC:,YBLC&!,!_M!\X)[5)+KOB233;W48]4@@6QTR
M+4C#]G#>;O,K!"<\#8JCCG/.: /2Z*\TUC7-7;5=4TV34A%'/#<0V<=HD<HR
M("XWG=YB2 ANJ[> .IK/O/$VJ:;X>TU=/\017=RFG&^>:80I'(H PA8GD@Y&
M%&>>2,B@#UNBO.)O%&H3:H9$U:TLD2]LK5=.,:M)<)-Y19\DYZ2,!@?P'/M'
M9ZKKEU%';Z?J4-@JVMY=,1;B7<R7+*!R>!CK^F* /2Z*\ON?%VK31_:X]4M]
M.,4=BRV9C5FNO/V%F!8YP-Q48[J<YK6T;7+^;Q=<:7J5\K>89S;P6ZQR1;$<
M '>K%U;!&0X'.<=* .ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ JNL<<>[8BKO)9L#&3ZFK%% %.2SLYK3[+-:Q26^ /*= 4P.G'2I(X
M8HH5ACC5(E&T(JX4#TQ5BB@#/33=-CMGM8["V2WDY>)8E".?<8P:DAM;:';Y
M-O'%MS@(H&,XST^@_(5<HH YJW\.V,.KS:K-+-=S.'4),(]J!\;A\J@MP /F
M+''%;+6=H]U'=-:PM/&-J2F,%E'H#U%7** ,Z+3]/@4K#8P1*>2$B4 \Y[#U
MY^M6VCCD*EU5BIW+D9P?45-10!3-C9M>K>M9PFY VB8QC>!Z;NM1QZ?8PM(T
M-G!&9,[RD:@OGKGCG-:%% &<FG:?';O;1V-ND#KM:-8E"L/0C&".::VFZ<RP
MK]A@VP K$/*7$8(P0O'&1Z5IT4 4_LEJ;B.X-K$9XUV))L&Y!Z ]0*:;6W,6
MTP1E020NT8&<Y_/)S]35ZB@"K;6EM9P""TMHK:,<A(D"+GZ"K5%% !1110!"
ML<<>XI&J[SN; QD^IJ"2SM)K3[+-:Q26^ /*= 4P.G'2KM% %>.&*&%88HUC
MB4;515PH'IBH$TW38[:2UCT^V2WDYDB6)0C_ %&,&K]% %&*TM8=ODVT46W.
MW8@&,XSC'T'Y"LBW\.V*ZU+JDTTUU,X<*DRQ[4#_ 'A\J@MP,?,6P.*Z6B@"
MFUG9M=1W+6L331#:DIC!9!Z ]14<>G6$(*PV-O&#R0D2C/.?3UY^M:%% %:X
MMX+J%H+B%)HG^]'(H96^H-0OI]C(J0R6,#Q(V]4:)2JMZ@8X/O5^B@"MY$+L
MS-"C,R[&)4$E?0^WM49MX6+*8$VLH1AM&&4= ?;D\5=HH IK9V<=X]XMK"MP
MXVM,(P'8>A/4U"-*TW:B_P!GVNU&+*ODKA2>I''!/>M*B@#F[KPW9W6M6VH3
M7$Y%N4:.W 01@H<KSMWX!P<;L9 XK96VMT/RPHO!7A0."<D?B>:MT4 <[?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cvm_10qimg15.jpg
<TEXT>
begin 644 cvm_10qimg15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %W 9T# 2(  A$! Q$!_\0
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MY'7OQ6!??$'Q;KFHV7BG3[Q=.OKSX;WNJ"".1_L\4RS [PN3\P4'!.><9XH
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M@:UCNV3,B1,<L@/H3VKG)?A3\-9["VT^;P3I#6MM))-!"ULI6)GQOVCL#@9
MXKNJ* .1_P"%?^"_,T63_A&; 2:%@:8_DC=9@'("'J!D9Q5:#X8_#VVUFZU:
M#P3HT=[<I)'-*MFF9%D!5P1C'S D'U!.>M=O10!R_AOP3X3\(B=/#/AVQTD7
M!'FFUA"%\= 3U('8=!74444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%1O)'& 9'5 ?[QQ3?M5O_S\1?\ ?8H FHJ'[5;_ //Q%_WV
M*/M5O_S\1?\ ?8H FHJ'[5;_ //Q%_WV*/M5O_S\1?\ ?8H FHJ'[5;_ //Q
M%_WV*/M5O_S\1?\ ?8H FK.CL;..]GOH;2)+NX55FF5 'D"YVACU.,G&>F:M
M_:K?_GXB_P"^Q1]JM_\ GXB_[[% $U%0_:K?_GXB_P"^Q1]JM_\ GXB_[[%
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M]]BC[5;_ //Q%_WV* )J*A^U6_\ S\1?]]BC[5;_ //Q%_WV* )J*A^U6_\
MS\1?]]BC[5;_ //Q%_WV* )J*A^U6_\ S\1?]]BC[5;_ //Q%_WV* )J*A^U
M6_\ S\1?]]BC[5;_ //Q'_WV* )J*.HHH **** "BBB@ HHHH **** "BBD)
M !)X'K0 M5))OF\J%=[]_1?K_A1N>X^6(E(O^>G=OI_C5B.-(T"HNT4 01P;
M27<^9(>K,/T'H*L>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q
M?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q
M?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q
M?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q
M?RIU% #?+3^XOY4>6G]Q?RKS#XL>)-5TF?PGH>B7.HPW>K:DQG&EQ)+=-:PP
MO)*(U<$9)\M<]MU/M8/B7'\#K*.XN))?'?V:,RO"UN'#EP2"9%,6X)P3C!(.
M.U 'IGEI_<7\J/+3^XOY5Y7H%I\3KCX6^)K/7+FXA\430W"Z;+<26NY&,.(R
M&MU51A^Y&1],5ROPDL_%GA.34)+CPGXCMM)OGTRS6RO+E9Y8KK8RWEY\TC8B
MW%"2#\V,A>U 'OWEI_<7\J/+3^XOY5\F:?X-^+2Z;XEAL;'7;+7)-(O(=3O)
M[_\ =ZM=M>*\36Q,A"G[.)%# )MW >]7M6\-^,A\%O$-AHOA[Q=8PW6O1S:'
MI"76ZYMX B;Q.3*Q$)=92$W'YBI[T ?4OEI_<7\J/+3^XOY5X?XJ\%MXZ^)7
MA'4K?P[JFDQB./5-4U&>>2%TCC_U5D$60IYC,?GXX5>N37N5 #?+3^XOY4>6
MG]Q?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU% !1110 4444
M%1LRHI9B%4#))X J2LG7+K3;+0+RZUA5>PCC+3*Z;PR^FWO]* +?VRS^R?:_
MM4/V?_GKY@V>G7I4:W]F\2S)>P-$[;%<2 J6] <]?:O-;>WT/4- U6\DU33]
M-@O-0M[D00!)H;/9M\M9%'R[FV9;MDXSQDROI;Z_X5:\DDT^VM+)[N 3BS*Q
M3P,H'VF- >'&T[3R#SC@B@#T\2(7*!@67&1W&>E2UYIINL:I:>*(K&XM8O/U
M*2*2:*1&,Y1HW(8-TVQA%4\'YBQR,C/I= $$DJQ+N8]> !R2?05$(VF(-P/E
M[1=OQ]?Y4](0KF1FWR'^(]AZ#TJS0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 9]Y/#;O"TD+2R,Q2/8FY@
M<$G'IP*3^TC_ - ^\_[]?_7IUY_Q_P"G?]=F_P#1;U=HT5M!:LH?VD?^@?>?
M]^O_ *]']I'_ *!]Y_WZ_P#KUHTE%UV%9]RA_:/_ %#[S_OU_P#7J.35ECC:
M22QNE1068^7T _&M.JNI?\@J[_ZXO_Z"::MV!W[EE6#H&7D$9%.J*W_X]8?]
MP?RJ6D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!155ILL5AC,A'4@X ]LT_P VX_Y]3_WV* )Z*@\VX_Y]3_WV*/-N/^?4_P#?
M8H GHJ#S;C_GU/\ WV*/-N/^?4_]]B@">BH/-N/^?4_]]BCS;C_GU/\ WV*
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MG&SN>CA*M2=2TW?0]DJIJ7_(+N_^N+_^@FG^;<?\^I_[[%5-0EG_ ++N\VI
M\E_XQ_=->&CU67;?_CUB_P!T?RJ:J5O+<?98O]%/W!_&/2IO-N/^?4_]]BD]
MP1/14'FW'_/J?^^Q1YMQ_P ^I_[[% R>BH/-N/\ GU/_ 'V*/-N/^?4_]]B@
M">BH/-N/^?4_]]BCS;C_ )]3_P!]B@">B@=/2B@ HHHH **** "BBB@ HHHH
M ***ADF6/ P6<_=0=30!(S*BEF8!1U)JK^^N#W2'\F?_  'ZT1PL[B28Y(Y5
M!]U?\3[U<H :JJBA54*HZ 4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:6WMI9H[>2Z=%RL46-SGT&2!^9JY69JAU+^R[EM'^S_;]A\C[22(PWJV!G%
M&"OBV%(;A;C2[J+4H+F.T^P[D9GDD4,FU@VW!4Y))XP<]*CF\;6EO9";^SKI
M[B-IQ<VPV;K<0 &4DEL' 92,$Y##%5;?P[K"Z3"WV>U34K:_346EDNFE-[)@
MJ^]O+79E3@8!"X Q@5=A\*^=I=\VK6=I=ZE<W4MZD;%C%$[*%5-V 67:JAN.
M>>* -RSU%=0O+I+=6,=LZQF0XVNQ4,0._ (S[\=C6M7 6_@^_M?$MC>0W49B
M@,;O<,S";(5_-0+C:1([[R<]<\' QW] %229F<Q0@,P^\Q^ZO^)]JEBA6,%N
M6=OO,>IJ155%"JH4#L*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %!Z44=J /COQ)H.JZYXX\7W&F6_VE=.O)99U5OG"M*P&U
M>K=.U<[JW@O5M)U2:SOM(DDN83AS /-7/E^80&'!(3YCZ"MOQ-KFN:%XZ\8Q
MZ)>FS>]OVW3Q\2QF.5B-A[=2#P>*J_\ "?>*&$ZR06$IE7AGC;,9^S_9RR_-
MU,?7.>>:^UI?6G2CRQ3C96[[(^5E&C=W;3O^HV;X;ZU!-'(UG%)"TZ6WGQ;I
M%#M&L@X52V,.!D#KQ44W@_5%EM5DMPT,]LMTDZ([Q@&,R!20I^;:"2,<=^.:
MEC\=>)$NXKIK;3Y)8+J*\A9HF_=2)"L.1AAD%% (.><D8IG_  G'B9K'3[.:
M&QD33H&MK5C"=T2/"87 .[G<IR<]P#[5<88Q?91+5%]64?\ A%]:AFM\Z#?)
M)=9\D&W;,GR[CCCG@Y^G-<KXIMY[6\BMKJ%X)XMRO'(I5E/'!!Z5WT/Q"\60
MW/G0FS&Z3S'7RVPP^SK 5^]D#8H/!!SSGM7$>--2NM7U<:E>8^T7&6?!8C@
M=6))X'<FNM>V<6JD4EY=[F:C34DXNYR]?:W[.W_)&;+_ *^9_P#T*OBFOM;]
MG;_DC5E_U\S_ /H5>)FO\'YK]3U\%_$^1Z[534O^07=_]<7_ /035NJFI?\
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M[?Z-_2N6O_#9K1^-&)7VG^SK_P D<M/^OJ?_ -"KXJK[2_9XC=O@W98F=/\
M2I^!C^]]*^)S3^'\SWL'_$^1['534O\ D%W?_7%__034GD2?\_4OY+_A534(
M7_LJ[_TJ4_N7_N_W3[5\ZMSV'L7+?_CUB_W1_*IJIV\,GV6+_2I?N#LOI]*E
M\B3_ )^I?R7_  I/<$3T5!Y$G_/U+^2_X4>1)_S]2_DO^% R>BH/(D_Y^I?R
M7_"CR)/^?J7\E_PH GHJ#R)/^?J7\E_PH\B3_GZE_)?\* )Z*.WK10 4444
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M[Q_]]"JEG'']MU']VO\ KE[?],TJ[Y4?_/-?RH8(;]HM_P#GO'_WT*/M%O\
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MZY\ 3_Q<F?\ [!\O_H<=?4=?+/[/_P#R4J?_ +!\O_H<=?4U !1110 4444
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MO?L]G_BYEQ_V#Y?_ $..OJJ@"MYMQ_SZM_WVM'FW'_/JW_?:U9HH K>;<?\
M/JW_ 'VM'FW'_/JW_?:U9HH .WI1110 4444 %%%% !16'XAUS^P+&"X-O\
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M^P6__HV.OL,?>-?&9A_'?HCWL)_#*5G_ ,?NH_\ 79?_ $6E7JHV?_'[J/\
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MZWP>V(KW_>7^1KR<T_W>?R_-';@?XT?G^1UVZC=4.ZC=7P9]*3;J-U0[J-U
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MZ;F (..A-?%XN49U6XNY[^'BXPLS[%ALVCEGF6ZDS,P9LA>"%"^GM5CR9?\
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M5C0FOECX@6?CWQGK45Y-X;U!EA4H@$)X!.:^O?M*_P#/&;_OV:/M(_YXS?\
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M[QUX9CTB_P# MUIT]Q):27DD]PSPEK:'R8_+C*@1@CDC)R:]F\#_  OTWPW
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MPKYG6KTW3FE9FE+!PI24XMGR3_PC_B#_ * &I_\ @*U'_"/^(/\ H :G_P"
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M7 !'WHR=K XX/K0!Z%16-X<FFN?">CW-Q(99I;.%Y';JS% 23^-;- !1110
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M0*S=6"J%!/Y5?HHH **** "BBB@ HHHH *Q[K28KO7].U<S.LE@DR(@QM?S
MH.?IM%1^(-6_L/0YM0-NURZ%(XX5;;YDCL$1<GIEF'/:N-CU[7M'US7KS7+.
MW>]2TL8K>TL[EFB=Y9I43YG4;26(!..@SS0!V\VE13^(K/6?-D$MK;RP+&,;
M6$A0DGOD;!^=8EGX173]:-Y8:M<P633M<M8B&%EWLVYL.4+A223@-W.,50D\
M7:WICWEKK6DVD5W:?9KAS:W#21O;2R^6S@E00R8)((P<=:L6OC2XO-4_L^+3
MT$LFI"W@)DXEM=KDSCC_ *92#'L/6@#I[ZVEO;&6UAO9;.1_NSQ!2R'KT8$'
MZ$=*Y2/P#!#82*NM7B:D]XE]]OCCB0K*B% 1&J"/&TD'Y><Y-1Z3XRUJ]NM+
MFOM'M(-+U*ZELHI(KEFF$B>80Q4J!M/ED=<@UC7GC;Q!J/A?Q"\$-CI=Y;V,
MD\=N;B1;RVVG!+HT8&0,\J2,@#H<T =7I_@V"QDMY9-4N[N:'4GU)I9]NZ21
MH3$0< #&#G@"N?\ &7A_7+[4M1A\/0ZC&FLVPANY([BW6V9@I0%PX,@PN,[!
M\PP/>M'6/%&N:!H]C)J#:)%J,Y8M UQ.P=1C'EA8F=CR,\8%10^,=7UFVT]O
M#^DVSS3:>FI3_;;EHTB1BRA%*J2S$H_.  ![T :=[X/M;][N62\N8IYUM?+E
MAPIMY("Q1TX/.6.0<C'%5;[P3/?BPN+SQ-?7%_9O(4NG@MV^1PH9 ACV#[HP
MV,CGGFH)O%4C6.CZTUF1-/H5UJ7E"X<1@JD3;"O1OO8W$9'..IIJ^.-5T\7,
MFO:/;P)_9C:I;K:W)E9E5E4QME5 8EUP1D<T ;.F^$;72XM#CAO)Y/[',YC+
M[<R>;G.[ [;NV*ZJO/V\6>*+"XO[;5/#]M)=0:<=0A@T^X>5I/GV[#E!R.^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cvm_10qimg16.jpg
<TEXT>
begin 644 cvm_10qimg16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %& 94# 2(  A$! Q$!_\0
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M#Z-HKYK\3?$;QEX!\0'X=>$]).NMX?TNWN;F\U61I9K_ '9+.9&E3RQP<O\
M/@\8 %6/$7QVUK2_'=K9Z3:6%_I7V^QL;V%K619;5KA5.#<>9L9QN. L;# Y
M:@#Z,HKR?P'XR\:>+_&'BR.\MM%A\.:%K%YI"&(2_:Y'B*;&.24 VL<GJ3T
MQSYGXDUR\U35?C!J&O>/=4\.ZEX4.-$LK74&M8XD$.^*0Q @3>:^!\P;K@8R
M* /J2BOFR?XU>.M'M-'T74M'L'\2>(]'TJYT-)(9%66YF=8[E)@&XV9+X&W
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MVYXKHZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &,
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MQA0Q&>2!^-/_ .$B\*_\)1_PBW]LZ5_;FSS/[.\Z/[1MQG.S.>G/3IS7B_Q
M^'OQ"\9:A/JT?AC2UN?$/AQ="N[>?4%<:/(+DR><K;/WJ[3T4 Y45:B^&/C*
M+XD1+]DM)-(C\5#Q1_;C7(\]D%KY/V4Q[=V2PZYV[??B@#U+0?&7@?Q1?SV'
MAOQ%I&KW4">9)#9SQRLBYQD@=!D@5U?V:W_Y]X_^^17BOPG\"^*?"OC"^G.E
MR>&O"GV'R(]%EU@ZD&N3+N,T;$#RDVY&WN3G KV^@"+[-;_\^\?_ 'R*/LUO
M_P ^\?\ WR*EHH B^S6__/O'_P!\BC[-;_\ /O'_ -\BI:* (OLUO_S[Q_\
M?(H^S6__ #[Q_P#?(J6B@"+[-;_\^\?_ 'R*/LUO_P ^\?\ WR*EHH B^S6_
M_/O'_P!\BC[-;_\ /O'_ -\BI:* (OLUO_S[Q_\ ?(H^S6__ #[Q_P#?(J6B
M@"+[-;_\^\?_ 'R*/LUO_P ^\?\ WR*EHH B^S6__/O'_P!\BC[-;_\ /O'_
M -\BI:* (OLUO_S[Q_\ ?(H^S6__ #[Q_P#?(J6B@"'[/;_\\(_^^14H  P!
M@"EHH **** "BBB@ HHHH **** "BBB@ HHJJTS,YCA 9AU8_=7_ .O[4 2R
M2K'@<LQ^ZHZFHEB9G$D_)'*H.B_XFI(X5CRWWG/WG/4U-0 4455\QICMA.U.
M[^OT_P : )6GAC;:\JJWH32?:;?_ )[)_P!]41QK&N$&.Y/<GWJ:@"'[3;_\
M]D_[ZH^TV_\ SV3_ +ZJ:B@"'[3;_P#/9/\ OJC[3;_\]D_[ZJ:B@"'[3;_\
M]D_[ZK.OK@-=V<,5]Y*R,VYHRN3A2>X-:]9MY_R%-._WI/\ T TXDRV&^2G_
M $&I_P#OJ/\ ^)H\J/\ Z#4__?4?_P 36GBC%%V.QF>5'_T&I_\ OJ/_ .)H
M\J/_ *#4_P#WU'_\36GBC%%V%C,\J/\ Z#4__?4?_P 31Y4?_0:G_P"^H_\
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M>R?]]5*"" 1R#2T4 %%%% !1110 5@:YK*Z+%;[;=KB:[G%O#&'5 7()Y9B
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M\H$--F5W#R9XW ,%&,\#Z =B0",$9% %3]Y/]W,<7KT9OIZ"K*HL:A44*HZ
M4^B@ IDDBQIN<X'\ZBDFV-Y:C?(?X1V]SZ"B.'#>9(V]_7LOTH 38TW,HVQ]
MH_7Z_P"%6>@HHH **KM<1J2OS,1P=JEL?E3OM,?]V3_OVW^% $U%0_:8_P"[
M)_W[;_"C[3'_ '9/^_;?X4 345#]IC_N2_\ ?IO\*/M,?]R7_OTW^% $U9]Y
M_P A73?]Z3_T U:^TQ_W)?\ OTW^%59O+EN[:?\ >CR"QQY3<Y&/2FA,T**A
M^TQ_W)?^_3?X4?:8_P"Y+_WZ;_"D,FHJ'[3'_<E_[]-_A1]IC_NR_P#?IO\
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M#\=-UY>>(CJL>O:F=3MI?/:R31EA)MF5<>5C.S:5^8L3G-5OBIXBU[5O$/\
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M;4,QC#J(49 0 2K@MCGC QUJ%/%VL/<:;J<ENT6G3VL%R\26S.K(\3-(WF]
M58*H7J<CKD8ZK5M"MM8DBDEFN;:>-7B$]K*8W,;XW(3Z' ]P0",5,VD6+6-E
M8K&8[6R:-HHD.%_=_<!]0" <>H% &?H.O0ZI#]FDN VHQ*7F18F11\Q4A"1A
MPK IN&>5]ZZ1FVH6VEL=AU-8FE^'].TJ_GO+/SB\@**)'++$A<N50=@68G\N
MP%;] %01-(P>XZ#E8QT'U]35NBB@ JM)-M;RU7?(>BC^9]!096FRL/W>\G8?
M3UJ2.-8UPHY/))ZD^] #8X3O\R5M[]O1?I4]%-9E52S$ #J3VH 2O'/V@/\
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M_P!:CS+G_GW3_OY_]:OO3X +O_CSG_ZYM_*H['_D&6O_ %R3^0IMT]S]CGS
MG^K;_EI[?2F6+W']FVW[E/\ 5)_RT]A[4^A/42'_ )#-]_USB_\ 9ZT*RH7N
M/[9O?W"9\J+_ ):?[_M5[?<_\^Z?]_/_ *U2]_N&BQ14'F7/_/NG_?S_ .M1
MYES_ ,^Z?]_/_K4QD]%0>9<_\^Z?]_/_ *U'F7/_ #[I_P!_/_K4 3T5!YES
M_P ^Z?\ ?S_ZU'F7/_/NG_?S_P"M0!/14'F7/_/NG_?S_P"M1YES_P ^Z?\
M?S_ZU $]%0>9<_\ /NO_ '\_^M4PS@9&#Z4 +1110 4444 %%<(TGB@:S//H
MDGEZ<)W63^V)E:)VW;<0[,NHW<#<<>BU8\3:AK45AH]G:P&"\U&Z$,HBF4&,
M"-Y&59&& 3LQNQG!.!G% '9T5YK-)K&J:;8W&FKJ/DZ>]S!?6_V\13F1& _U
MF"' *MCD9R,TDVI:TMSIVO6)O9]&:"WDMPTB[9$:-@4D!.XRL[1@'GKUZY /
M2Z*Y+PSKXOR--N/M#W<<1E,\NW;<8D9'9,'(4." " <;:ZIBP0E5W'L,XS0
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M=!XDTRSTC7KBQLY9Y+951D-RFR1=R@[6'J,XZ#Z"MWPZ/^),G^\W\ZXE<*,
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M_P ><_\ US;^51V/_(,M?^N2?R%/H3U*D(NO[:O?GBSY<7\)_P!OWJ]MN_\
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M'L?E;Z&O+B:]-8_(WT->89KU< OB^1Y.8?9^?Z!FO8/V>_\ DHM[_P!@]_\
MT9'7CI->A?"_Q%)X/U^YUJ;3S=1RVS6ZIYGE\EE.<X/]VOILOC*5:-EL?*9C
M.,:,KO<^RZ*\8_X7M%_T+9_\"_\ ["C_ (7O%_T+9_\  O\ ^PK[,^*/7[E=
MUI,JC)*, !WXIEFK+86Z,I5EC4$'J#BO(_\ A>T7_0MG_P "_P#["C_A>T7_
M $+9_P# O_["CR%YGK$,<BZO=R%2$:.,*V."1NS_ #%7^]>,?\+WB_Z%L_\
M@7_]A1_PO:'_ *%L_P#@7_\ 84/4-CV>BO&E^.D1!9O#95!U8W? _P#'*]%\
M)^(H/%7AJVURWA:&.<NNQCG!5BIY_"@9T%%%% !1110 4444 %%%% !1110
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MTXR>P90Z%6S@^G% %=I69C';X)'#.>B_XFIHXEC!Q\S'[S'J:>JJBA54*HZ
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M[)_WT* )**C\Z+_GLG_?0H\Z+_GLG_?0H DHJ/SHO^>R?]]"G]1[4 +1110
M4444 %%%9VH7T.F6<EY<,1&F  HRSL3@*H[L20 .Y- &C17&+XP2;2]-N+'2
M;JZN+ZU:\^RHR*\42X#$DD#.6  '4U(OC+3YKVTAAAF>UN%A;[62JHAEC:1
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MBQQWQDUH>!_AKI7AFQCW6ZF3AB#R2?5CW->A !0 HP!VH 4=/6BBB@ HHHH
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M9]?Q'\S,/JM+^4\$_P"&9-+_ .AFN?\ OTM'_#,FE_\ 0S7/_?I:][^U6_\
MST_0T?:K?_GI^AH^OXC^=A]5I?RG@G_#,NE_]#-<_P#?I:/^&9-+_P"AFN?^
M_2U[W]JM_P#GI^AH^U6__/3]#1]?Q'\[#ZK2_E/ _P#AF;3/^AFN?^_2UHVO
M[/MG:6P@C\13%02<M"N>:]H^U0X_UGZ&F_:(&_Y:?H:X\14EBJ?LZSYHWO9]
MSJP[^K2YZ7NO:Z/(/^%"V_\ T'I/^_(H_P"%"V__ $'I/^_(KV3[5;_\]/T-
M'VJW_P">GZ&O+_L[#_R(]+^TL5_.SQO_ (4+;_\ 0>D_[\BC_A0MO_T'I/\
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cvm_10qimg17.jpg
<TEXT>
begin 644 cvm_10qimg17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" #F A4# 2(  A$! Q$!_\0
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M^&#K6J2K:V$=TB">/:I4W2?W2#D)U&>: -/;^TY_SV^&_P#WQ>_XT;?VG/\
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M(=I68[4VLK+WY4_6@!-O[3G_ #V^&_\ WQ>_XT;?VG/^>WPW_P"^+W_&N/\
MBC\6O&L/P]T+5]!\*Z_X<OI=>CLKR*[6.)AM/^J4MD.LF2 Z\#8<X[]2WC"W
MM?C9:R>()M<T.2/P>^JWFG2W:/8VB+*=Y=5SNE7&-P.,=* )]O[3G_/;X;_]
M\7O^-&W]IS_GM\-_^^+W_&J.G?'^UN+C2=2U7P3K>C^%=;NA::?KMUY?E2,Q
M(0N@.Y%;'!.?7I4.K?M"+8W7BVWTSX>ZYJQ\*7DL&I3P/&L,,4?'FESZX8A
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M4 >-[?VG/^>WPW_[XO?\:-O[3G_/;X;_ /?%[_C7LE% 'C>W]IS_ )[?#?\
M[XO?\:-O[3G_ #V^&_\ WQ>_XU[)10!XWM_:<_Y[?#?_ +XO?\:-O[3G_/;X
M;_\ ?%[_ (U[)10!XWM_:<_Y[?#?_OB]_P :-O[3G_/;X;_]\7O^->R44 >-
M[?VG/^>WPW_[XO?\:-O[3G_/;X;_ /?%[_C7LE% 'C>W]IS_ )[?#?\ [XO?
M\:-O[3G_ #V^&_\ WQ>_XU[)10!XWM_:<_Y[?#?_ +XO?\:-O[3G_/;X;_\
M?%[_ (U[)10!XWM_:<_Y[?#?_OB]_P :-O[3G_/;X;_]\7O^->R44 >-[?VG
M/^>WPW_[XO?\:-O[3G_/;X;_ /?%[_C7LE% 'R+\1/VA/BY\)?$<&@>*M+\(
MZC=7-LMW&^G+<A%0LRX.]@<Y4T5YY^VG_P EET?_ + L?_HZ6B@#Z1\??\G/
M_![_ *XZO_Z3I6MKWP]O-=^.ECXNNUM)M 309]'NK61F\R4R,Q(QC!4JV#S6
M%\2H[R3]H_X1QV-REM<&'5]LKQ^8%_<)GY<C/'O7IO\ 9OBS_H9+3_P7_P#V
MRKC%26K2^_\ R,9SE':+?I;]3RBX^ <&AZ'X'T/P3/&MIH'B:/7+R34)/WMP
MH//*K@L%VJ.!PHYK/N_A'\38;[XA^']"UCP_!X6\:74]Y+=7*2O=V_FJ0\:H
M/EY^[N).!R!GBO:?[-\6?]#):_\ @O\ _ME']F^+/^ADM?\ P7__ &RJ]G'^
M9?C_ )$>UE_(_P /\SQ[3OAA\2M#UOX=ZYI,WAZ:^\/:+_8>HPW,DPC,>[_6
M1E5R6V^N.?8TW_A5/Q$MI/BAH-G=>'Y/#OC!KR[@EE>4744\R812 NT(#U/)
MXR/2O8O[-\5_]#);?^"__P"V4G]F^*O^ADM?_!?_ /;*7)'^9?C_ )![67\K
M_ \4N/V=SXBUGP@OC#['=Z1HWA*/0YUAFD61;M=P$L? !4;LC/<#BM:/X9_$
M2^G^&S^)-6TZ^G\':I+)->++)OO;7:JQ,05_UN!A@3CC.3DUZM_9OBK_ *&2
MV_\ !?\ _;*/[-\5?]#);?\ @O\ _ME')'^9?B'M9?RO\#RFQ^$/B:V^!_CW
MP+)>6)U+Q#J-W>6L@D?RD25D*ASMR#\IS@&L/Q!\ ]4/BJ#Q-IVB^&?$\MUI
M=K97]CKCS1I%/#$L8FA= >"$ *D#I[\>Y_V;XK_Z&2U_\%__ -LH_LWQ7_T,
MEK_X+_\ [93]G'^9?C_D'M9?RO\  QOASX/'@CP7'I,EGH]K?R.T]U_8]JT%
MLTIX!"LQ)PH49)&=N<"O*/%WPW^.'C71+GPAXBO_  /K.G3MM36Y[.1+VW3=
MG*(!M#<8X/X]Z]P_LWQ7_P!#):_^"_\ ^V4?V;XK_P"ADM?_  7_ /VRCV<?
MYE^/^0>UE_*_P/#?$W[/]W#XOB\0:+I?A_Q6DNFVVGW-IXC:6/;)!&L:SQO&
M#U5%W*1ZX/I>U+X-^+-.\,>"Y_"<'A2U\0^']6?5;FWA@EM;&X=U"< ;FR%5
M1DXSC/'2O9/[-\5_]#):_P#@O_\ ME']F^*_^ADM?_!?_P#;*/9Q_F7X_P"0
M>UE_*_P/!]>^ ^N#QIKFO:;X=\'>(O[?<7<HUPS@Z==,/WICV ^9$6);:<'H
M/KOWGPA\3>&]4\*>*OAVV@6VN:-8/I][I\L#V]C>1R,7<H%+-&=[,>^>.>,'
MUG^S?%?_ $,EK_X+_P#[91_9OBO_ *&2U_\ !?\ _;*/9Q_F7X_Y![67\K_
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MKX9TF^T[Q/!KFH1Z9#)!;F./(")G<SN <;FVY_G[%_9OBO\ Z&2V_P#!?_\
M;*/[-\5_]#);?^"__P"V4<D?YE^/^0>UE_*_P.$\8?#?Q!XA^+4WBO3=4@TV
MUD\+76B),K-Y\%Q(S%95 &,#<#G(/%>:Z?\  ?QQ;/X*O(])\%Z3>>%=1MYY
M)[(3-/JBHPWR2R%0=Q SMYR2>1@"OH;^S?%?_0R6O_@O_P#ME)_9OBK_ *&2
MU_\ !?\ _;*/9Q_F7X_Y![67\K_ Z2BN<_LWQ9_T,EK_ ."__P"V4?V;XL_Z
M&2U_\%__ -LH]G'^9?C_ )![67\C_#_,Z.BN<_LWQ9_T,EK_ ."__P"V4?V;
MXL_Z&2U_\%__ -LH]G'^9?C_ )![67\C_#_,Z.BN<_LWQ9_T,EK_ ."__P"V
M4?V;XL_Z&2U_\%__ -LH]G'^9?C_ )![67\C_#_,Z.BN<_LWQ9_T,EK_ ."_
M_P"V4?V;XL_Z&2U_\%__ -LH]G'^9?C_ )![67\C_#_,Z.BN<_LWQ9_T,EK_
M ."__P"V4?V;XL_Z&2U_\%__ -LH]G'^9?C_ )![67\C_#_,Z.BN<_LWQ9_T
M,EK_ ."__P"V4?V;XL_Z&2U_\%__ -LH]G'^9?C_ )![67\C_#_,Z.BN<_LW
MQ9_T,EK_ ."__P"V4?V;XL_Z&2U_\%__ -LH]G'^9?C_ )![67\C_#_,Z.BN
M<_LWQ9_T,EK_ ."__P"V4?V;XL_Z&2U_\%__ -LH]G'^9?C_ )![67\C_#_,
MZ.BN<_LWQ9_T,EK_ ."__P"V4?V;XL_Z&2U_\%__ -LH]G'^9?C_ )![67\C
M_#_,Z.BN<_LWQ9_T,EK_ ."__P"V4?V;XL_Z&2U_\%__ -LH]G'^9?C_ )![
M67\C_#_,Z.BN<_LWQ9_T,EK_ ."__P"V4?V;XL_Z&2U_\%__ -LH]G'^9?C_
M )![67\C_#_,Z.BN<_LWQ9_T,EK_ ."__P"V4?V;XL_Z&2U_\%__ -LH]G'^
M9?C_ )![67\C_#_,Z.BN<_LWQ9_T,EK_ ."__P"V4?V;XL_Z&2U_\%__ -LH
M]G'^9?C_ )![67\C_#_,Z.BN<_LWQ9_T,EK_ ."__P"V4?V;XL_Z&2U_\%__
M -LH]G'^9?C_ )![67\C_#_,Z.BN<_LWQ9_T,EK_ ."__P"V4?V;XL_Z&2U_
M\%__ -LH]G'^9?C_ )![67\C_#_,Z.BN<_LWQ9_T,EK_ ."__P"V4?V;XL_Z
M&2U_\%__ -LH]G'^9?C_ )![67\C_#_,Z.BN<_LWQ9_T,EK_ ."__P"V4?V;
MXL_Z&2U_\%__ -LH]G'^9?C_ )![67\C_#_,Z.BN<_LWQ9_T,EK_ ."__P"V
M4?V;XL_Z&2U_\%__ -LH]G'^9?C_ )![67\C_#_,Z.BN<_LWQ9_T,EK_ ."_
M_P"V4?V;XL_Z&2U_\%__ -LH]G'^9?C_ )#]K+^1_A_F?$W[:7_)9-'_ .P-
M'_Z.EHJO^UU'?6_Q:TE=3NX[Z4Z/&0Z)Y( \Z7C&3GZT5'*NYT<S['TWX^_Y
M.A^#G_7'5_\ TG2NBU75M8TGXM3,UAK%WI=SHL,5L+:VEFMA=>?+G>4!$9VE
M,L<<8]*YWQ]_R=#\'/\ KCJ__I.E>U5('@5OXJ^+\EI']LL;^WMY&A:]O8]!
M9YM/E,<ID@A@W$W$8=8E\T9X<]>JLU[Q)\3[O5;FUAT76/[(W1/NAT]HYHS#
M<6S%DV9RLD9F^7<YP,<'@_0%% 'ANE^*?&^F:SH7AIH;CS-;U*^A!O82);98
MKQYFE^<Y>)K5@JD9"L%'M3O$GBSXK6OBO6;70M O9-+598H7;3O,,&PPXFCQ
M@2Y1IBJ;B6* 84\'U\V=HVI)J#6L1NTC,2SE!YBH2"5#=<$@''M6C0!X3X9U
M3XH6=RMK)9ZC?6^K:Q<QF\O;$Q-:1K*CB8HQ^2-X/,55Z!P.F2*BT[Q-\9-5
MNI+!=/NM+BF;SX[VZTG<\"&WF8PE?E4L)4B7/(^?JV0:][HH \'7Q9\7GTO5
M+Q]%N8]62TC:WTL:2Q@"E82\PGW<R#?-^YY.4VX[G.US7/C'>Z(EG<6=_"C(
MDD,NG:9(TMYB[ 82M\IMV6%0WW0'W'']VOHFB@#QWQ-XL\:6_P 59= \.J]Q
M!;IITOV1-/\ -259II$F,L^?W(6--RDCDC'/2LFUO/C!-J&@RS+)#=ZG9VZW
MET=-;R[#?+)O4Q%]NY%"_,>?FYXXKVE8(UO9+A84$TBA7D"@,P&< GJ0,G'U
M-7Z /G^?Q1\:K?08_-TZYGU"[L;>Z22WTG:MK.4GWP.OSD@F.+G'!DP2H((L
MWWC;XF:;X9D\4:E;QV_FZBFGV^C2V8BD/G0JL3JS-E\7$BY&/N*W<9KW>L^X
ML[2ZD@DN+6*=[:3S86DC#&)\$;EST."1D>IH \M\6_\ "R-/\:6FH>'YI[J*
MUTFU%S&MJ9(+V8W:K*H&<(WEEFR,D #L*P8_%'QHDL;\W6BSVT[S+''Y-B7-
MG)NERH^0B2+:J#> YRP.0&ROT!10!X)I>N?%#7/%_A>;7]-U/2[=;R"2YL;?
M3G6!8FL6W223Y_Y[L5,9^[M4]MQM:QXI^+"^-=3L=%T:Z&FM,;>WEN-.+K;[
M;B!/-!7 =&B>9A\Q^YSM(Q7N-% 'SWJ^K_%RX5M+O8=16.WNXHXI[#26W:DB
M:B5DD=U;]QB!$8#HX=L9Z#I/%6M_%:Q\6ZF_AG3TO]-M[A+>UL7L\"Y#63R&
M0S;A@+,J+TQ\V">1CV"B@#PG3_$WQ;>&P_M2WN[:RDF<M>0:(\]R6"1%89(2
M$V(6:4>8!CY ,C[QW? =YX^AMM>M=;TFX5K=;F;2EN<D7>;B8KYDIY0_< 3H
M$VL"<D+ZS10!X!>>+?BQ!X1M+JQT_5;[63OGFCET(VZ*ZQHQM<?,S LSA7&T
M':?GSC-ZZ\0?&"%?M2VDC6UZTVY(])+2:7$E\L:NJ[LS.8&+[<<[<@'!!]QH
MH \+N_%'Q@75O+T[2Y;BSCL5DADN-,:(WA\B1F=E ;RI1(JJ(RPSQQ\W'JWA
MC^V&\*Z:_B"X6?5)(%DN66'R0'89*[,G&,XZ]JWJ* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^ OVT_^2RZ/_P!@6/\ ]'2T4?MI_P#)
M9='_ .P+'_Z.EHH ^D_'W_)T/P<_ZXZO_P"DZ5[!>3-;V-Q.@!:*-G /0D#-
M>/\ C[_DZ'X.?]<=7_\ 2=*]>U3_ ) ][_UP?_T$T ?($?[5'CZ2&.1M&\/+
MN4-CR9^,C_KK2_\ #4WC[_H$>'O^_,__ ,=KS+X1Z?8ZI\3O">G:E:Q7EG<3
M!98)E#(X\IC@@]>0*[KPY!I?Q TRZU&Z\/Z-HE]HVM:=!;W6G68CANEGN/+:
M&2(DI(0/F]QP>*]1TZ,=X]NO<\;VM:>JEWZ=C5_X:F\??] ?P_\ ]^9__CM'
M_#4_C[_H$>'O^_,__P =K'L?A7I_B#Q)?65U=WFGWM]J=_;V$P2VAMI/)=N4
MB,@D=<K@B-<)TYQ5'P_\,_#-[<>$]%USQ!J5KKGB>W^V6ZVMJDEO%%EMJLQ8
M'>0C<@8'?UK3EPW;\S/GQ+VE^1T__#5'C[_H#^'O^_,__P =H_X:H\??] ?P
M]_WYG_\ CM<MI/PS\+ZA;:%9W'B#4(M:U[2Y]0M8DM4:")HA(2)'W9P1&<8&
M>#GM4-O\,]%DAL]#.M7Q\77NC_VW%"MLOV()Y9E$)DW;MQ4?>QMSQ1RX7M^8
MN?%?S?D==_PU-X^_Z!/A[_OS/_\ ':/^&J/'W_0'\/?]^9__ ([7,Z7\/]%2
M;P?J6DZA=:LM]?64<UZL%O<6"/*PW12)OWHRGC;(N&YZ5!)X!T6]\/:[K,&H
M7FHZI:W5Z)K+2XX/]!6)R$:6)G#[' SNC!51]*7)A^WYB]IB4OB_(](\$_M$
M^-/$?Q T+0;[2M%2UU&\2WD>"*4.JG/()D(S^%?5?>OSO^$W_)9/"'_83B_K
M7Z'XKDQ=.-.HHQ5M#OP52=2FY3=W<?1117&>@%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\!?M
MI_\ )9='_P"P+'_Z.EHH_;3_ .2RZ/\ ]@6/_P!'2T4 ?2?C[_DZ'X.?]<=7
M_P#2=*]>U3_D#WO_ %P?_P!!->0^/O\ DZ'X.?\ 7'5__2=*]JH _,;P[JVH
M>']1TW7-)NEMKZSVR0R%5;8VW'0\'@GK71ZE\1/&>L76GSW^O C3KE+RVAA@
MBAA293E9/+10K-GN0:_0WR(?XH4_[Y%)]GM_^>*?]\BNWZRGJXH\QX1])-(_
M/BS^)WC2Q>.2UUR)98KN2\BE:UA>2%Y'WR!&9251F))0$ Y-=5X1^*UKX9TF
MP+R:O<WU@9GBLB;8VC2.6.1(5\Z*/+9,2\$CKCBON'R(/^>*?]\BN)\>?:H%
MT.WT^^GTXW5^8Y9+3:KL@@E?;DJ>-RJ?PJ7B(R^RAQP<H_;9\-6OC+Q%9ZAI
M-_;ZHB7.DVLEG9OY2'RH7WAEP1S_ *QN3D\U/%X^\80^%?\ A&8]>(T[R#:
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M+PGK5CXAOM8\%_!V^T6QD\'7>EIIVI.HCGO/,C8AE60D!E! ;*F0CMUK'O/
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M^&:?&'_12G_[]2__ !=')#^?\ ]K5_D_$^G\CU%&1ZBOF#_AFGQA_P!%*?\
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MH? O0^0D[3;\SWI_"OPTU#7;JQ;38='MM,\2OI:NNHL?M\1@E=%=G)"!I$5
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M90O<7$I!(1%&6; !)P!VK@_^&@/A'_T-R_\ @%<__&ZW/BQ_R17QI_V!KO\
M]%-7YY&1@,!CFN["X95T[NUCSL7BI4'&RO<^\/\ AH#X1?\ 0W+_ . 5S_\
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MKKYAX'$9VYY/?UI1E13T82C6DK-'#:YKCZY<PW$FE:7IIB3R]FFVHMT?G.6
M)R?>LBO0];^&D>BZ5KTC>*+6YU7P]#;R:EIR6\BF)IF5559#\KXW<D=^/>O/
M>PKT:<HR7N[''5C*,O>W9WOP9_Y+9X1_Z_C_ .BWK]!Q]^OSY^#7_);?"/\
MU_'_ -%O7Z##[U>)F'\1>A[N6_PGZG'6O_)7M3_[!4/_ *,:NR]*XVU_Y+!J
M0[G283_Y$:I;[5M87Q7#H]GIDTEC)%NN+Y1M$!).,$\$X'(Y(R#[5Q35VO1?
MD=\'RIW[LVYII+B5K6U8JJ\2S#^'_97_ &OY5>BACAB6*)0J*, "N27QEX+L
M6-FWBS1X3"Q1HWU"(,K X(.6SG.<YYS4_P#PL+P3_P!#AHG_ (,(?_BJQ;Z(
M7MZ?<ZNBN4_X6%X'_P"APT/_ ,&$/_Q5'_"PO __ $.&A_\ @PA_^*ID^WI]
MSJZ*Y7_A87@?_H<-#_\ !A#_ /%4?\+"\#_]#AH?_@PA_P#BJ!^WI]SJJ*Y3
M_A8?@C_H<-#_ /!A#_\ %4?\+#\$?]#AH?\ X,(?_BJ!>WI]SJZ*Y7_A87@?
M_H<-#_\ !A#_ /%4?\+#\$?]#AH?_@PA_P#BJ!^WI]S5UG5+71-!O]9OM_V6
MPMWN9O+7<VQ%+-@=S@'BH-%U33]:TFVU32[I;JSN5$D<J=&']".A!Y!!!YKA
M/&WC;P?=?#KQ-8V_BK2)YY=+N4CCCOHF9V,3   -DDGM7G?@?Q1>>'<WFGJ]
MW:,?^)EIB<LW;[1"/^>F/O+T?'K@UE.HH22?4X*N9TJ=:%.6TKZ]FNY]-T5A
MZ3JECK6E6^IZ;=1W5I<*)(I8SD,/Z'L0>0<@UN=ZU/53YM4)2U1OKR&PTZYO
MIL^5;1-,^T9.U02<?E7BJ_M2_#UE##2M?P1G_CVB_P#CM5&$I_"KDSJ0A\3L
M>[?\"I:\*_X:B^'O_0+\0?\ @+%_\=H_X:B^'O\ T"_$'_@+%_\ ':KV-3^5
MD>VI_P R^\]UHKPO_AJ3X>_] OQ!_P" L7_QVC_AJ3X>_P#0+\0?^ L7_P =
MI^PJ_P K^X7UBC_,OO/=**\*_P"&HOA[_P! OQ!_X"Q?_':/^&HOA[_T"_$'
M_@+%_P#':/8U/Y6'MZ7\R^\Z#Q5\4K+P=\4]/\+Z["D6E7U@MQ]O!.;:0RLG
MSC_GGP/F_A/)XR1ZB&5T#*0RGD$<@BOACXN?$K2?&_CW2_$&@VE[%;6EB+61
M+V-4+GS')&%9LC#"O1?A'\6H_#\5MH>N79E\,RD):W<ARVF,>D;G_GCZ'^#H
M?E^[TRPDE251+7JCFAC(.JZ;>G1GU114:LK*&5@5(R".014E<)Z)Q/Q8_P"2
M+>-/^P-=_P#HIJ_/!A\M?I1XDT.#Q-X5U3P[>320VVI6LEK+)%@.JNI4D9!&
M>:\6_P"&5?"/_0T:Y^<'_P ;KT,'B(45+FZGEXW#SK./+T/C_#>E&&QTK[!_
MX93\(_\ 0TZY_P"0/_C='_#*?A'_ *&G7/\ R!_\;KT/K]'S//\ [/J^1X_:
M_%JTCMM(T5X;F#2$\-KH]Q<P6L0O+6YV$&:&3.XIT&TL 03P#4>G^/? ^G>&
M+K3[/3;NTEO_  [)I$T46GPG9<%?]<TY;S)%=@/DX"@].!7LG_#*?A+_ *&C
M7/\ R!_\;H_X93\)?]#1KG_D#_XW7'[7#^9U^PQ'D>27GQ*\'W^H:[X@D&N1
M:KXAT%])N+%4C:UM'\H*K*=V77<@P,#;N8^U4[[XA>%=>M-8T+5AK%EINIV>
MFK]LLHD::.:UBV,K(6 :,G)'/!YQ7LW_  RGX1_Z&C7/_('_ ,;H_P"&4O"/
M_0T:Y_Y _P#C=9^TH+N5['$/L>*ZU\0O#/B2W\:Z??6NK6=MJ\-BMA,BI-*S
M6B,J^?D@9?()(SCWIVH_$S3;S7O$M^D5\\&I>'[?2[2&9052:/RB=R[L!-R/
MR.?FZ<U[1_PRGX1_Z&C7/_('_P ;H_X94\(_]#1KG_D#_P"-T*=#S%['$>1Y
M9JGQ:\/76HW&O6-O<V]YJMQ:/?VHTR %8XY$=U-QN+2_<^3A2.,U@)XT\*WW
MB7QGJNL6MVTVK7GVC3;R:SCOF@B\QF,)BE;8I92H#<[<<5[E_P ,I>$?^AHU
MS_R!_P#&Z/\ AE/PC_T-&N?^0/\ XW5>TH)65Q.A7;N['G.O^*?!_C+P?XLU
MJ^N-8TS3=4URP8BU6,W$,BV>&RFX!TRAY!')![8JSI/CBWU=O&7C:\T^8:!I
M;V]YH\EW,IE.HPP>1&&&?F=U97;'38.>*[S_ (95\'YW?\)1KF?7]Q_\;H_X
M93\'YS_PE&NY_P"V'_QNI]K1VU_JQ?L:W9??U/D%FDD=I)&+R.2S,>K$\DTG
M-?8/_#*?A'_H:-=_\@?_ !NF2_LK^$8XGD'BC7<JI/\ RP_^-UZ"QU'S.%X"
MMY'R!WJ[I>FZEK.KVNEZ1:2WE_=2".&&$99V_IZDG@ $G@4S2]/U'6M2L]+T
MRUEOM0NV$<,,0^:1CZ=AZD] ,D\"OMKX0_"'3_ASI?VV^\N\\27: 7%PHRL"
M]?*BS_#ZGJQ'H  8C%1A'3=AAL)*I+79%SX3_"FU^'NBM<7UP;_Q#>QJMW=;
MB511R(H\_P (/?J3SQP!ZIVH_BI:\"4G)N3W/HH1C"*C'9'P)^VG_P EET?_
M + L?_HZ6BC]M/\ Y++H_P#V!8__ $=+12*/I/Q]_P G0_!S_KCJ_P#Z3I7M
M)Z&O%O'W_)T/P<_ZXZO_ .DZ5[50!^6PE@VC-Q$I'8N,T>9;X_X^H?\ OL5]
MJ?\ #07P?(R(;MAZ_P!EGG]*/^&@OA#_ ,\;S_P5G_"O6C7JI)<C/#EAZ;;?
M.OP/E-_B!XFD\/\ ]@R>(XVL# +0Y6+SF@'2$RXWE!@?*6Q5&'Q5J5O-HLL>
MJ6Y;1 1I^]8V$&7,G0C#?,Q/.:^NO^&@OA'_ ,\;S_P5G_"D_P"&@OA'_P \
M;O\ \%9_PJU6FO\ EV)X>#U<_P CY T_Q'J.E^(U\16>LJNJK(\OVEW5V9G!
M#D[LY)#-U]:+7Q)J5GIUWI\&M 6MS%%!+&[J^8XI/,C49SM <9P,5]?_ /#0
MGPC_ .>-Y_X*S_A1_P - _"/_GC=_P#@K/\ A2=>H]X J--;3_(^4D\?>(H[
M^[OEUZ+SKO4(M4E)6,C[7&<K,!C"MV.,9'!R*SK7Q%?6,^J36NJ11R:G&T=V
M?D/FJ9%D(YZ?,H/'I7U__P -"?"/_GC>?^"L_P"%+_PT)\(?^>-Y_P""L_X5
MG[67\@_8TW_R\_(^3I/'7B*:YEN&UV(S2:HFM,VV/F\4863IZ=NGM4X^(WB@
M64EK_;MJR/#/;,SP0M(89BQDBW[=VPEV(7. 3D=!7U1_PT#\(?\ GC=_^"L_
MX4?\-"_"7_GC>?\ @M/^%/VDG_R['R07VSP'4_C%YOAK[#I4ETFHRR6DKWE_
M/;RM$ULP9-I2-6E.X#YI23@8]37%R^-M>FGCN'UR$RQVEQ8JQ6/B&<N94Z=S
M(W/49XKZR_X: ^$?_/&\_P#!6?\ "G?\-"?"'_GC>?\ @K/^%2I26GL_S*Y(
MR=W/\CYWUSXJ6NI^!+OP]!]IDN-0BMH;FXOKB!]B0D$!61%>0D@#=(20HQ[U
MYEYMO_S]0_\ ?8K[4_X:"^$'_/&]_P#!6?\ "G?\-"?!_P#YY7G_ (*S_A6L
M*U2"M&#_ !(J8>G4=Y5%^!\T?!N2)OC?X15)HW/VT\*P)_U;U^@W^S7DOA?X
MS?#7Q1XKL=!T..X74KMF6#?8&,95&<_-CCY5->M"N#$U)5)\TE8]#"THTH<L
M)75SAM4(TGXI:3J4GRV^IVCZ:7["56\R,'W/S 5V_1*X_P >R69\.C3IK1[R
M\O9EBLX8VV/YW57#?P[>I/\ C6GX=M=9L_#\5OKFH+J-Z/O3*FP8]/?'KWK"
M2O!2Z[>OF;7LW'YGR+=874+[Y%/^F7'51_SV>H]R_P#/-/\ OD4^Z_Y"%]_U
M^7'_ *.>H?X:\*?Q,_(\97K?6)Z_:?YFEI.DW>L:M'I=C#"]U(K,BOA0=HR>
M3[5+8Z'J6H6^I7%O9H$T^,R71<!?+'/'N>#Q[58\)ZC;Z7XHCOKB\^RH+>>-
M9N?E=HV"8QWSBMV/QM;WFEZM8R0)ITE_I-PUWQQ=W["-=PQG *JQ .,%FK>/
M*U=L]3"KVM)2J5+2UT[V6GH<,QV@EH5 49/R=!6S>>'=4L9=4AEM89/[.$;7
M+(00H? 7'KU'2NAU+5-!NCKNJ0Z];%]3T<6L%ILD\Q951-RO\N%.5('/.:M:
MAXBL;C5/$T=AXFCMX-;M8)K63<ZHKJ0'1L+\KE1C'<&KTZLUC'E34YW>MK/R
MTZG'?V/<'3;G4(9K2X@MK>"XE,3!BJS'"CI]X$<CM546C'3#?;K;B;R?(X\W
M.W=NVX^[COZUW-KXJ\-V>GW,EY'_ &I&=+TR+[&"5,LD3MYB],$KU(/!QCO3
MM,\1Z3:7]LUYKT5YC7C?-<$,-UNUJ5#$8^7!(4KV(]*7+'N1);)32OY[.^_W
M'GGW0"T*@,,C*=12-NC8K) J,.S)@UW6C^*M/D_LVZ\17GVF:UU.XP6CR;>)
MXL1L %^XK], [>N.*R_%&K6MY:65FLT%W+;&1C<QW<MTX5CPC22(I8=QUQTJ
M6DHWN<]:,J=-U(U;[6776QS&Y?\ GFG_ 'R*FM+V>QNUN;=MCJ>W>JU%<QX3
MJU'N>G^$_%D^A7<FK:;&]Q83MOU+2H^6#=[B ?W_ .\O1Q[XKWO2]4L=:TZW
MU#3;N.[L[E!)'+$<JP_SU'4'@U\?6EU>V][#]@\UKN5Q'#'"NYY7/15'<FOI
M3X9^$]0\+Z)>3:Q=%]0U*47,]M$?W%LV,;4 X+'^)A]X_2O1PTY-6>Q^@Y!B
ML35@X5%>*V?;R\SKO%'_ ")^M?\ 7C/_ .BVK\T4)$:8/\(_E7Z7>)_^1.UK
M_KQG_P#1;5^:2*QB3 _A'\J^AR_[7R/6S'[/S/0OA[X)LO%FFZYJEXNKZA_9
M?D@:9HJQM=S!R<R .?NKCG ))-8^J^%9X;>ZU;2_M+:+'JBZ3&VH*(+D3-'O
M"R19.W SS[4GA?7-!T7SSJWAN[OK@NLEO?6.I26-S;8'*JR@@J>IXS77:I\6
MK?7GU<>(/"(O(;G4+?4[.**^:/R9H81$HE;:3("H!;[I)ST[;MUE-M*Z.:*H
MRII2=F<]=?#7Q=8V&IW]U'9Q6^F74MG<,UV@)G158QH"<NQ##:%R2<^E2:E\
M,?&&E:9>WUTEB_\ 9\:27EM!>QRSVI=E5$>-26#DL,#ZU9\6?$23Q)$RVVDG
M3)CKS:XLS3>:(Y&CC3;C:,@,F[Z'&*[G7_$OA_3]'\6^(K231D\0>(/LS1/I
MFIM>B>5)DE:3RBBF&/Y<E7);/ XJ'4K*UUN"I497:>QYS>?#?Q5:C:WV">>*
MXAM;NWM[Z.66PDE8+&)U!S'DD#/(!X/-1:W\/_%&@6>J76H?8F.F>7]M@M[Q
M)I;<.Y1"RJ21EE^HRN>M=3K7QBNM6F2[CTW4H+B6]@O+R!]3+6I\N02&..,(
M"%9ES\Y;;VH\ ^)M.D^*GB?Q=KC6%GH5]'<W%]I]W,"UPKN9(XXAC,CB54Z=
M!DU?/64>:2(Y*3ERQ9YUKVB:EX;UVXT/5@B7MN%\U(Y X0LH;:2.X!&1V/%1
M:7JDVFW.Y?GA?B2-N0PINK:A=:QK=]K%[DW%[</<2'_:=BQ_G5!F&"2< <DG
MM74K\JYMSCE\3Y3Z?^$_Q>@\.I:Z!KU]YGAN0B.TNI'R^FL>D;]S#Z-_!T/R
M_=^IZ^5?@;\#OM'V7QOXVL_EXET[3)EZ]UFE4_FJ'ZGL!]55X.(Y'4?(?385
M5%27M-QU%%%<YV!1110 4444 %4[JZM;&SENKRYBMK>)=TDLSA$0>I)X JY5
M*ZM+6^LY;6\MHKFVE7;)#,@=''H0>"* /.]9^)FHC4]93P=X?M_$-AX?M8[S
M4KK[>(@ZNAD$=OA6$C[!NY*KR!G)XU='^*7@O6GN?LVI-;P6L<3S75Y$8($,
ML:2(GFOA"Y613M!)ZU#K7PI\+:S>-.IO])BGMELKRUTJZ:UAO;=<[8I43@J
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M?\]M$_\  J;_ .-5]&?+FG?+^'I7.Z%-ZV/&GDV&G)SE'5Z[L^</^%*^-O\
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M^ $7_P 37JK,+)+E_$\>67W;?-^!^;FW_:7_ +Z%&W_:7_OH5^DG_"%>#?\
MH4=%_P# "+_XFC_A"O!O_0HZ+_X 1?\ Q-5_:']W\3/^S/[WX'Y\P>*->MO"
MA\+Q7D8TK[8M\$(4N)!@XW==N5#;>F1FM]_BMXNEF::X;2KB8M=?O9;-&94N
M"3-$#GA&+$XZ^^.*^Y_^$)\&_P#0HZ-_X 1?_$TG_"$^#?\ H4=&_P# "+_X
MFL'BH/>'XFJP51;3_ ^ /#OC#5O#>FS:;9PZ9=V4URET\%_:I<(944JC8;TS
MFKT7Q(\7)*6GOK2]5Y+I[B*Z@22.Z%PRM*LJGAES&A XVXXK[R_X0GP;_P!"
MCHW_ ( 1?_$T?\(3X-_Z%'1O_ "+_P")J'B(-W</Q+6$J)64_P #XCM_BIJ/
M]C:K'?6FGWU]>7=I)#%/9Q/90V\$;JL0B/"X+*5QZ')Y.<<_$;Q.T6L^;+I\
MEUK*S1WE\;9/M+QR_P"L3>,?+C@ @[1P,5]Z?\(3X-_Z%'1O_ "+_P")H_X0
MGP;_ -"CHW_@!%_\35+$TU]C\0>$J/[?X'P=XZ\50>)I-#L=/EN7TW2-/CL8
M9+W8LT[ ?-(X4D G"KU/"#FN-V_]-%_[Z%?I%_PA7@W_ *%'1O\ P B_^)H_
MX0GP;_T*.C?^ $7_ ,36T<>H+E4?Q,9Y>YRYI2_ _-S;_M+_ -]"C;_M+_WT
M*_23_A"O!O\ T*.B_P#@!%_\31_PA7@W_H4=%_\  "+_ .)JO[1_N_B3_9?]
M[\#XC^!F%^/?A3YER9I^A_Z=I:^YM3U;3M'L7O-2O$M8$'+R-C/L/4^PYJM:
M^%_#-C=I=:?X=TVTN8\[9H+2-'7(P<$#(X-7[S3K"_,+7MG#<>0_F1^:@;8W
M]X9Z&N"M65:?.U9'I4*#HT^1.YS7@JWN;A]4\37T#P3ZQ,)(XG&&CMT&V($=
MB1D_C7:]Z2E[U@WS.YT1CRJPM%%%(H**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /@+]M/_DLNC_]@6/_ -'2T4?MI_\ )9='
M_P"P+'_Z.EHH ]F_:,\9-\.?B/\ #?QT=-&I)IRZBIMO.\HN9(XT^]M.,9S7
M%_\ #<:_]$W/_@T_^U444 '_  W&O_1-S_X-/_M5'_#<:_\ 1-S_ .#3_P"U
M444 '_#<:_\ 1-S_ .#3_P"U4?\ #<:_]$W/_@T_^U444 '_  W&O_1-S_X-
M/_M5'_#<:_\ 1-S_ .#3_P"U444 '_#<:_\ 1-S_ .#3_P"U4?\ #<:_]$W/
M_@T_^U444 '_  W&O_1-S_X-/_M5'_#<:_\ 1-S_ .#3_P"U444 '_#<:_\
M1-S_ .#3_P"U4?\ #<:_]$W/_@T_^U444 '_  W&O_1-S_X-/_M5'_#<:_\
M1-S_ .#3_P"U444 '_#<:_\ 1-S_ .#3_P"U4?\ #<:_]$W/_@T_^U444 '_
M  W&O_1-S_X-/_M5'_#<:_\ 1-S_ .#3_P"U444 '_#<:_\ 1-S_ .#3_P"U
M4?\ #<:_]$W/_@T_^U444 '_  W&O_1-S_X-/_M5'_#<:_\ 1-S_ .#3_P"U
M444 '_#<:_\ 1-S_ .#3_P"U4?\ #<:_]$W/_@T_^U444 '_  W&O_1-S_X-
M/_M5'_#<:_\ 1-S_ .#3_P"U444 '_#<:_\ 1-S_ .#3_P"U4?\ #<:_]$W/
M_@T_^U444 '_  W&O_1-S_X-/_M5'_#<:_\ 1-S_ .#3_P"U444 '_#<:_\
M1-S_ .#3_P"U4?\ #<:_]$W/_@T_^U444 '_  W&O_1-S_X-/_M5'_#<:_\
M1-S_ .#3_P"U444 '_#<:_\ 1-S_ .#3_P"U4?\ #<:_]$W/_@T_^U444 '_
M  W&O_1-S_X-/_M5'_#<:_\ 1-S_ .#3_P"U444 '_#<:_\ 1-S_ .#3_P"U
M4?\ #<:_]$W/_@T_^U444 '_  W&O_1-S_X-/_M5'_#<:_\ 1-S_ .#3_P"U
M444 '_#<:_\ 1-S_ .#3_P"U4?\ #<:_]$W/_@T_^U444 '_  W&O_1-S_X-
M/_M5'_#<:_\ 1-S_ .#3_P"U444 '_#<:_\ 1-S_ .#3_P"U4?\ #<:_]$W/
M_@T_^U444 '_  W&O_1-S_X-/_M5'_#<:_\ 1-S_ .#3_P"U444 '_#<:_\
M1-S_ .#3_P"U4?\ #<:_]$W/_@T_^U444 '_  W&O_1-S_X-/_M5'_#<:_\
M1-S_ .#3_P"U444 '_#<:_\ 1-S_ .#3_P"U4?\ #<:_]$W/_@T_^U444 '_
M  W&O_1-S_X-/_M5'_#<:_\ 1-S_ .#3_P"U444 '_#<:_\ 1-S_ .#3_P"U
M4?\ #<:_]$W/_@T_^U444 '_  W&O_1-S_X-/_M5'_#<:_\ 1-S_ .#3_P"U
M444 '_#<:_\ 1-S_ .#3_P"U4?\ #<:_]$W/_@T_^U444 >0_$CQPOQU\70^
=(ETDZ']ALH[,P_:?-W_/(^[(0?WL=.U%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cvm_10qimg18.jpg
<TEXT>
begin 644 cvm_10qimg18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %T B0# 2(  A$! Q$!_\0
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MH GHJ'S8]H;<,')!SUQ2B6,R&,2*7 R5SR!]* ):*** "BBB@ HHHH ****
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MNZ* /+_A?H^I> ?@S8V_BCS9;ZUCFO+BWM4:8P[W:3R8U7).T$* /3CBN?\
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MX=/T^&!K*WA+7<R *APF<YQEL9S@>M=]10!\_>%=%M/A_I?CC4M-T+7+_P
MZI/;?8=$@MY7GC$@"7+I"V)%0%^1C.%/8 U;\'_#K3=/\#>/-%O[JYL/ &J7
M!ETRWN&9'LX-@,C 2#**9,D*PZ+R.:]VHH ^:?$1U3P'8:==:<US:'6;N\U'
M[5=0K-<R3K#N5FBQL,\S;(XXP,1IG W9V]E\4IO$MY^SW<PSZ3<OK^IVEM;S
MPV*2,;:60H)'Q'EMJ98\9Z8.17LE% 'R'XX\):MJ$GC>\T_P_K0TW2M!T_PW
MI=M]FF'VAI2GF2A%R2D8VE@HY*#/2O8?B):WEG^S;J>F:+I5WJ-R=(CL8+9K
M9I9CN"Q[FCP3E0=QX)&/:O6Z* /D;Q-X1U*.VOU\.^&]132?#'@U-/LX(K&6
M-KZ\NB%=P% +$*H+XR2.#U-;VM:'KE]>^%/ %S'JUMX.M?"Z0QNNFO<?;+L[
M8BK9^6.4)DH9057<6QD#'TW10!S,*V'@WP7:PPV]U_9^EV<<,<,:/<S;44*J
MX4%G;@#->,_#6/Q5I7P+\<^+[;1;Y/&FL75_JC64]K(DR3-GRE".H+87! &0
M<XKZ,HH ^0-"TO5M.L_&6J6?@W7YKRV\'P:?!=RVDT<FHWLY+W$HSARYE8<C
MD!#G Q5OQ=X/\._#'POX-L]4N+F>]N)[6ZULRM+-931VT>U4G1 S)"'D&"$(
M)'S#)KZTKC=:\#Z/KOB&/7I)K^PU-+4V37-A=/ \D!;=Y;;3@@-R.XR?6@#P
MD:-KVF>%? VF:=KSZKX=UZ[NM4U;5].L)[VS4E=UO;B!#N$ )("G"DH PQE:
MV_!?@/3]+^..FV[>&;]=,\/^'DBL;F_L]_F7,LS2R2-*%V!E!VX!^4M@  5[
MWHVCZ;H&BVFBZ/:1V=A:1B*&&,?*BCM6E0!X-\0HK_Q9\>/ V@V;ZK86&B-<
M7T^I1Z8\D*714+"@=XS&3C<<G(&>N:R_$_@?_A#?$6B6]O:ZUK>B:Q>W&J>)
MKQ8FN;C4[B*/-M;2"-0!$S%@%P$XP??Z-HH ^08=#;1]2\"^'?&&AW>H7^G6
M^I>)KS1K%9)U@,[E;2T58_EP'+#G"@C&=I-:5KX3\8>%;'X4^'[KP[J.IW&B
MQZAK=RMN'>V@N#EX+=F!VX1FSW/R@+G->_6'@G1=-\=ZAXTMYK]M6U"(03F6
MZ=XC&#E5"$[0%YQCID^M==0!\K^"[76H;#X7Z;JOA_6\1S7WB+4RUA*HEU!F
M;RHVRORD-(S?,0/D%97A&V\27GC3P]XEU_P3K=WK<%KJVLZI<3V,BHUTP,4%
MO\P (2(;549SN&!R:^O:* /DKP3X3DLH_A!9-X2U&WG@DNM9U2<:?+$LEUR8
MHI. !M=\@OT$9V]>;WA/1_%FK:WX:\3ZQI.IQZUIMS?:SXBOI[>2.3.UXX-/
M@R,NFW!VIE,<]37U/10!\E_#WP;KEGXO^&%YKFEZPMQ,^H:_>R/!,5MY9ODB
M@<GA6"G<Q?!(0#L!7H7QFFUR3Q/X9L?["U+5O#,,5WJ%W;65L\PO+F*/-M ^
MT'"[R&PW!*^U>Y44 ?*G@SP?+)K/P<TO7/!MZEII.DW5_<&ZT\N&O)W^[(2"
M%P6>3#$$8!QG KM_C])<:[9>'/ =M8ZI-:ZIJUK)JUQ9V4TJ6]FC[B2Z*0"6
M"X[\5[I10!X9\4O"]YHOP7U[1M)DUG6[O7+Z&,SLTMQ/;H[(C,2GS%$C4X&,
M>H.367J'PUN-0^*U[IUGHMZ/"NO>&+>QO;F25HUM7CF!7 )R'V+PJ\ G)QS7
MT/10!\Z>!_#FJ>+OB)+KOCJUU.+4M'UR>>SLVLWB2UAC!C@_TACB2+!R$CQN
M8EFW <==\?IF/P5U[1+/1[_5]1U*#[/:VUG:23L6WK\QV*0H7[W..G%>NT4
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M)-#*)2\K.I.1[8 []>U=)9^)I)O"-[KSVF?LV_%LI_>KMXQ(/X6[D=A7.?\
M"<1^;N_X0G4-VW9G^S9,[?3[O2I%^($BM(R^#]44R\N182?-VY^7FF(DN-<U
M;4M;TO2VDME07L9N);21C'*AC9P@/J"O([\5:\6:[?PW3Z=9M';+ ]J\DCN1
M+*'F VQ@=>!SGUK,A\=+;HJ0^"M2B4,74)IT@ 8]_N]:?-X\6XECEN/!>I2R
M1'*,^GR$J?8[>* 'GQ]>?V?<WCZ?# HR;<2EB6(9AY9 YW?+G/3\J9=>)M:U
M)A]D>VMXS<V#6Z!V#L)0K$.>Z\D''I31XVADE;=X)O0TS@NTFGN 3V+$K^M=
M]#96I6&9K*%)511P@^3'( /L: ,S2]6DU319WFDAM;R+SHY K\*49DWC/.W(
MSS7 0R74G@Z^T_\ MBW6YL;R)YKQM3?R;T;-Q59.JG'51T->HM::?;RR7C6\
M,;LGEO)M )7.<'\237(ZQXDTG3?^)3;>$[N]B1M^(M-9H,^HPN,T 9EUJ%\O
M]G:M!?7<-I>VL>^TW$R01L N,D[<D]&/.23VKKG\2:+;?8KZZO!;07-ONB\T
M$$C(KEY/'1E1TD\&ZHZR *P:PD(8#H#\M96L>)YM4E@?_A'=9MQ"I0*NGRXQ
M^524>GZ;JVG:Q;M<:;=Q74:,48QMG:P[$=C6E7A$.J:EINI#5M&TO6(;W $B
M/ITOEW2C^!^.OHW4?2O6?#>OP^)-#CU2&UN+1BS1R6]S&4DAD4X96'L::)-Z
MBBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 1CO7-Z\ WB'2%8 CRI^#_VSKI!WKG-
M>_Y&+1_^N4_\XZJG\1C5^#[BW]CMO^>*_P#?(I5L[8,/W*=?[HJEK&L0:+8-
M>7"&2*+#3!&&](^[A>K =P.:;H6KKKFG_P!I0VYBM96S;LS@M+'C(<@?=SV!
MYQ6]SD<5:]C3T;_D$K_OR?\ HQJU>]96C?\ ()7_ 'Y/_1C5J]ZYG\3.V'PK
MT0ZBBB@T"BBB@ HHHH **** "BBB@ HHHH **** "N=\0?\ (<\,?]A!O_2>
M:NBKG/$/_(<\+_\ 81;_ -)YJ .CHI**BX["T4E%%PL+124F:+B*-Y(F^&%W
M"H3O<D_PC_$XI?M$TW%K%A?^>LG _ =34[6UO)<+.\8:11M!/.!4].X%1+-%
M<23,9Y1_$_0?0=!5RDHI7 6BDHHN M<WX2_X]]8;UU6Z/_C]='7.>#^=.U!O
M[VI71_\ (AJDP.DHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %8FL^(+#0VM4O!.\EVQ2*."%I&8@9/ ]JVZX
M7QQ9WEW;6IL--O[C48MYM+FSF6/[/*1@%\G[OKUXH UKSQ5HMGK,6DW-PT=S
M*%/,;;(RWW0[8PI.. >M%CXJT74I$%K<.[/,(50QL&8D;@P']W SNZ8KE+[0
M]>FO;S39K'SQJT]G=2WZ$>7"8@GF @\YRGRCON]JD.DZ]IFOIJ6@Z+##%/*T
M8B*@E$WC);)^7<,G(Z *,4 >ET444 %%%% $5<[KW_(Q:/\ ]<I_YQUT5<[K
MG_(Q:/\ ]<I__:=5#XC&K\/W&#XUATY(;?49M,M=0F@D42QN5\PQ$-@#<0,%
ML9]LT?#^S>PTB]M!);30I.I22V"A"Q12X&WC:&R!WP*U/$>C3:MI\8LI+2WN
MHI4D\RZA$D;*N?D8=P<GZ59T&SGLK!XK@Z<7,A8?V?%Y<>/<>M;=3GE\+-'1
MO^02O^_)_P"C&K5K*T;_ )!*_P"_)_Z,:M6L'\3.FG\*]$.HHHI&H4444 %%
M%% !1110 4444 %%%% !1110 5SGB+_D-^%_^PBW_I/-71US7B/_ )#?A?\
M["+?^D\U)@;^:7-1;J-U9FA+14>ZEW4 /HIFZC=0 ^BF;J-U 6),T9J/=2[J
M!6'YHS3-U&Z@"0'D5SO@SG1;EO[U_<G_ ,BM6^I^85@>"?\ D6BW]Z[N3_Y&
M>KB)G2T4451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<&BW'Q(T?Q0T]K+-Y&EV*+Y80J-SNLK[?O8 (Y_"O5: "BBB@ HHHH ****
M"BBB@ HHHH B[FN<U[_D8M'_ .N<_P#[3KH^YKG->_Y&+1_^N<__ +3JH?$8
MU?A^XYSX@:IIEMIMO:7DT9E$BS"UGCD,5R.5",RJ0#D@@'N!FD^',OVC0KB9
MKB-Y/.2*2&/>5@9(E4C+@')QDX&.:Z#7M-FU&R@-MJ'V"XM)UN(9F4,@89&'
M4]002/;K4>@Z?-9B]NKK4TU&\O9A-/+$ L:D*%"J 3@  =>36W4YY?"S9T;_
M )!*_P"_)_Z,:M6LK1O^02O^_)_Z,:M6L'\3.FG\*]$.HHHI&H4444 %%%%
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M ,@E?]^3_P!&-6I6+^)G33^&/HAU%%%(U"BBB@ HHHH **** "BBB@ HHHH
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MTK8KY_\ A>UO8_$MM-D\,>#=,O/+O;=VT.%UN87@E5") Q^5'!# XYXKZ H
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MX% 'M^1G&1GKBEKSKP1J$?V^73;O[6^HK$$S/SMCCP G7@C<"2>I)QTKT6@
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MC=45% $NZC=46:7- "_>U#2U_O:C;#_R*M?0]?.\1_XF^B_]A.U_]&BOHB@
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M:_\ HP5]$5\\V8W>(=!7UU.W_P#0J^AJ "BBB@ HHHH **** "BBB@ HHHH
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G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189335262912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL-SCI CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,104,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-0916344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">8229 Boone Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">22182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-9460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189335753424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,241,440<span></span>
</td>
<td class="nump">$ 4,145,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">549,835<span></span>
</td>
<td class="nump">520,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">2,347,049<span></span>
</td>
<td class="nump">2,248,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">16,129<span></span>
</td>
<td class="nump">4,245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,154,453<span></span>
</td>
<td class="nump">6,918,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right of use assets</a></td>
<td class="nump">8,680,732<span></span>
</td>
<td class="nump">9,131,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">1,649,020<span></span>
</td>
<td class="nump">1,698,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,644,158<span></span>
</td>
<td class="nump">10,188,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent costs, net</a></td>
<td class="nump">188,294<span></span>
</td>
<td class="nump">197,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Deposits</a></td>
<td class="nump">2,319,101<span></span>
</td>
<td class="nump">2,319,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SuppliesUsedForRDAndManufacturingNonCurrent', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">74,457<span></span>
</td>
<td class="nump">74,669<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">28,710,215<span></span>
</td>
<td class="nump">30,528,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,144,425<span></span>
</td>
<td class="nump">2,009,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">985,657<span></span>
</td>
<td class="nump">1,049,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DueToEmployeeCurrent', window );">Due to employees</a></td>
<td class="nump">705,698<span></span>
</td>
<td class="nump">557,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligation, current portion</a></td>
<td class="nump">1,827,363<span></span>
</td>
<td class="nump">1,771,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation, current portion</a></td>
<td class="nump">204,167<span></span>
</td>
<td class="nump">197,431<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,867,310<span></span>
</td>
<td class="nump">5,585,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations, net of current portion</a></td>
<td class="nump">9,468,149<span></span>
</td>
<td class="nump">9,949,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligations, net of current portion</a></td>
<td class="nump">1,599,496<span></span>
</td>
<td class="nump">1,652,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">16,059,955<span></span>
</td>
<td class="nump">17,313,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value; 600,000,000 shares authorized; 50,018,601 and 47,422,304 shares issued and outstanding at December 31, 2023 and September 30, 2023, respectively</a></td>
<td class="nump">500,186<span></span>
</td>
<td class="nump">474,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">505,950,994<span></span>
</td>
<td class="nump">499,832,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(493,800,920)<span></span>
</td>
<td class="num">(487,091,396)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">12,650,260<span></span>
</td>
<td class="nump">13,214,890<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 28,710,215<span></span>
</td>
<td class="nump">$ 30,528,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DueToEmployeeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DueToEmployeeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SuppliesUsedForRDAndManufacturingNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SuppliesUsedForRDAndManufacturingNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189334486112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">50,018,601<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">50,018,601<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189335446320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 4,352,509<span></span>
</td>
<td class="nump">$ 5,392,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,133,378<span></span>
</td>
<td class="nump">2,258,003<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,485,887<span></span>
</td>
<td class="nump">7,650,549<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,485,887)<span></span>
</td>
<td class="num">(7,650,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(197,696)<span></span>
</td>
<td class="num">(152,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(25,941)<span></span>
</td>
<td class="num">(50,171)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,709,524)<span></span>
</td>
<td class="num">(7,853,509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ModificationOfWarrants', window );">Modification of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(171,552)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (6,709,524)<span></span>
</td>
<td class="num">$ (8,025,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EarningPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">48,470,600<span></span>
</td>
<td class="nump">43,440,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EarningPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EarningPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189334385536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,448,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2022</a></td>
<td class="nump">$ 32,163,207<span></span>
</td>
<td class="nump">$ 434,484<span></span>
</td>
<td class="nump">$ 486,625,816<span></span>
</td>
<td class="num">$ (454,897,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantExercisesShares', window );">Warrant exercises, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantExercisesAmount', window );">Warrant exercises, Amount</a></td>
<td class="nump">447,291<span></span>
</td>
<td class="nump">$ 2,177<span></span>
</td>
<td class="nump">445,114<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, Amount</a></td>
<td class="nump">50,178<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">49,965<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, Amount</a></td>
<td class="nump">91,623<span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
<td class="nump">91,221<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncentiveStockForfeitedShares', window );">2014 incentive stock forfeited, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncentiveStockForfeitedAmount', window );">2014 incentive stock forfeited, Amount</a></td>
<td class="num">(11,100)<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="num">(11,080)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,703,931<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,703,931<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(7,853,509)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,853,509)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,725,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2022</a></td>
<td class="nump">26,591,621<span></span>
</td>
<td class="nump">$ 437,256<span></span>
</td>
<td class="nump">488,904,967<span></span>
</td>
<td class="num">(462,750,602)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="nump">13,214,890<span></span>
</td>
<td class="nump">$ 474,223<span></span>
</td>
<td class="nump">499,832,063<span></span>
</td>
<td class="num">(487,091,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, Amount</a></td>
<td class="nump">48,907<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">48,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, Amount</a></td>
<td class="nump">202,307<span></span>
</td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">201,421<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,383,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,383,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(6,709,524)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,709,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, Amount</a></td>
<td class="nump">4,980,000<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="nump">4,955,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(470,229)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(470,229)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,018,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="nump">$ 12,650,260<span></span>
</td>
<td class="nump">$ 500,186<span></span>
</td>
<td class="nump">$ 505,950,994<span></span>
</td>
<td class="num">$ (493,800,920)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncentiveStockForfeitedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncentiveStockForfeitedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncentiveStockForfeitedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncentiveStockForfeitedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercisesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercisesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189335981792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,709,524)<span></span>
</td>
<td class="num">$ (7,853,509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,004,633<span></span>
</td>
<td class="nump">988,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">2,504<span></span>
</td>
<td class="nump">5,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based payments for services</a></td>
<td class="nump">218,386<span></span>
</td>
<td class="nump">148,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">1,383,909<span></span>
</td>
<td class="nump">1,692,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommonStockContributedToEmployeeBenefitPlan', window );">Common stock contributed to 401(k) plan</a></td>
<td class="nump">48,907<span></span>
</td>
<td class="nump">50,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase)/decrease in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(100,546)<span></span>
</td>
<td class="nump">111,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="num">(98,765)<span></span>
</td>
<td class="nump">212,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncreaseDecreaseInDepositAssets', window );">Deposits</a></td>
<td class="num">(11,884)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(765,078)<span></span>
</td>
<td class="num">(115,285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(8,924)<span></span>
</td>
<td class="nump">13,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Due to employees</a></td>
<td class="nump">148,454<span></span>
</td>
<td class="nump">79,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,887,928)<span></span>
</td>
<td class="num">(4,666,649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(51,650)<span></span>
</td>
<td class="num">(53,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for patent costs</a></td>
<td class="num">(13,211)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(64,861)<span></span>
</td>
<td class="num">(53,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">4,980,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="num">(504,913)<span></span>
</td>
<td class="num">(9,010)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">447,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on obligations under finance leases</a></td>
<td class="num">(426,593)<span></span>
</td>
<td class="num">(372,871)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,048,494<span></span>
</td>
<td class="nump">65,410<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(904,295)<span></span>
</td>
<td class="num">(4,654,819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">4,145,735<span></span>
</td>
<td class="nump">22,672,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">3,241,440<span></span>
</td>
<td class="nump">18,017,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities', window );">Property and equipment purchases included in current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">105,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable', window );">Finance lease obligation included in accounts payable</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock', window );">Prepaid consulting services paid with issuance of common stock</a></td>
<td class="nump">202,307<span></span>
</td>
<td class="nump">91,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinancingCostsIncludedInCurrentLiabilities', window );">Financing costs included in current liabilities</a></td>
<td class="nump">43,019<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 244,659<span></span>
</td>
<td class="nump">$ 277,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockContributedToEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockContributedToEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseObligationIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingCostsIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingCostsIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncreaseDecreaseInDepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncreaseDecreaseInDepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189339057760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A. <span style="text-decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the &#8220;Company&#8221;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#8217;s financial position as of December 31, 2023 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2023 is derived from the September 30, 2023 audited financial statements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Summary of Significant Accounting Policies:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2023 and September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Recently Adopted Accounting Standards</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-13,<em> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). </em>ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#8217;s financial position, results of operations, or cash flows. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em> &#8211; The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189335260912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LIQUIDITYAbstract', window );"><strong>LIQUIDITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LiquidityDisclosureTextBlock', window );">LIQUIDITY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">B. <span style="text-decoration:underline">LIQUIDITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#8217;s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LIQUIDITYAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LIQUIDITYAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LiquidityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LiquidityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189340681616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">C. <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received aggregate gross proceeds of approximately $5.0 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Equity Compensation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Underlying share information for equity compensation plans as of December 31, 2023 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total Shares </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Reserved </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,283,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;<span style="text-decoration:underline">Stock option activity</span>:</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">96,832</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Share-Based Compensation Expense</span>:</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,383,909</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,692,831</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">218,386</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,858</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Warrants and Non-Employee Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following chart represents the warrants and non-employee options outstanding at December 31, 2023:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">8/18/2024 </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7/13/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">8/15/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6/22/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7/24/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">10/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7/28/2017 &#8211; 9/2/2023 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1.39 - $2.18 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7/27/2027 - 9/1/2028</p></td><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">1. <span style="text-decoration:underline">Equity Warrants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity were exercised during the three months ended December 31, 2023. The following warrants recorded as equity were exercised during the three months ended December 31, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series SS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.09</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">217,752</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">447,291</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity expired or were extended during the three months ended December 31, 2023. On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2022. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">2. <span style="text-decoration:underline">Options and Shares Issued to Consultants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2023 and 2022, the Company issued 88,573 and 40,236 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.56 and $2.53 during the three months ended December 31, 2023 and 2022, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No options were issued to a consultant during the three months ended December 31, 2023. During the three months ended December 31, 2022, 5,000 options with an exercise price of $11.61 issued to a consultant expired. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2023 and 2022, the Company recorded total expense of approximately $218,000 and $149,000, respectively, relating to the share-based compensation under various consulting agreements. On December 31, 2023 and September 30, 2023, consulting fees of approximately $134,000 and $205,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189339022208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the three months ended December 31, 2023, no restricted shares of the Company&#8217;s common stock were purchased by related parties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189340681616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Clinical Research Agreement</em>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:right;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company&#8217;s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, <em>Collaborative Arrangements</em>. The Company determined the payments to Ergomed are within the scope of ASC 730, <em>Research and Development</em>. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.8 million for Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of approximately $11.9 million. During the three months ended December 31, 2023 and 2022, the Company recorded, net of Ergomed&#8217;s discount, approximately $0.1 million for each quarter as research and development expense related to Ergomed&#8217;s services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The San Tomas lease is classified as a finance lease on the Company&#8217;s balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the three months ended December 31, 2023 and 2022 was approximately $0.7 million, of which approximately $0.2 and $0.3 million was for interest, respectively. As of December 31, 2023, the weighted average discount rate of the Company&#8217;s finance leases is 8.44% and the weighted average time to maturity is 4.83 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year&#8217;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Approximate future minimum lease payments under finance leases as of December 31, 2023 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nine months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,995,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,741,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,832,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,923,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,015,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total future minimum lease obligation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,758,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,463,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,295,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,827,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,468,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $0.1 for both the three months ended December 31, 2023 and 2022. Total cash paid related to operating leases during the three months ended December 31, 2023 and 2022 was approximately $0.1 million for each quarter. The weighted average discount rate of the Company&#8217;s operating leases is 10.19% and the weighted average time to maturity is 7.74 years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of December 31, 2023, future minimum lease payments on operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nine months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">268,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">746,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,523,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(720,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,803,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(204,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,599,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189338996272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">PATENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;G. <span style="text-decoration:underline">PATENTS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended December 31, 2023 and 2022, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately&#160;8&#160;years. Amortization expense for the three months ended December 31, 2023 and 2022 totaled approximately $9,000&#160;and $10,000, respectively. The total estimated future amortization is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nine months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">188,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189340766480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER COMMON SHARE</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">H. <span style="text-decoration:underline">LOSS PER COMMON SHARE </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and unveseted restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Three months ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss available to common &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,709,524</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,025,061</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">48,470,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,440,387</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.18</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,839,028</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,917,352</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">149,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,986,278</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,066,602</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189340766480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">J. <span style="text-decoration:underline">SUBSEQUENT EVENTS</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On February 9, 2024, the Company sold 3,875,000 shares of common stock at a public offering price of $2.00 per share for gross proceeds of approximately $7.8 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189335239936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2023 and September 30, 2023.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ImpairmentOfLongLivedAssetsPolicyTextblock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Recently Adopted Accounting Standards</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-13,<em> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). </em>ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#8217;s financial position, results of operations, or cash flows. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em> &#8211; The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ImpairmentOfLongLivedAssetsPolicyTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ImpairmentOfLongLivedAssetsPolicyTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189335149920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of equity compensation plans</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total Shares </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Reserved </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,283,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfStockOptionActivityTableTextBlock', window );">Schedule of Stock option activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">96,832</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfCompensatingBalancesTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,383,909</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,692,831</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">218,386</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,858</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock', window );">Schedule of warrants and non-employee options outstanding</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">8/18/2024 </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7/13/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">8/15/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6/22/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7/24/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">10/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7/28/2017 &#8211; 9/2/2023 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1.39 - $2.18 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7/27/2027 - 9/1/2028</p></td><td>&#160;</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock', window );">Schedule of derivative liabilities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Series SS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.09</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">217,752</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">447,291</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfCompensatingBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfCompensatingBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfStockOptionActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfStockOptionActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189331748624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under finance leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nine months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,995,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,741,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,832,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,923,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,015,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total future minimum lease obligation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,758,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,463,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,295,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,827,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,468,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under operating leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nine months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">268,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">746,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,523,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(720,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,803,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(204,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,599,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189340681616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of total estimated future amortization</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Nine months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">188,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189340538320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock', window );">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Three months ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss available to common &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,709,524</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,025,061</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">48,470,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,440,387</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.18</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,839,028</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,917,352</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">149,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,986,278</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,066,602</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189334864368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">138,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non-Qualified Stock Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">15,787,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember', window );">Stock Bonus Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">1,283,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">634,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember', window );">Incentive Stock Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">640,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189339258432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">96,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189335260288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employees Stock Based Compensation Expense</a></td>
<td class="nump">$ 1,383,909<span></span>
</td>
<td class="nump">$ 1,692,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non- Employees Stock Based Compensation Expense</a></td>
<td class="nump">$ 218,386<span></span>
</td>
<td class="nump">$ 148,858<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189335853936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 3)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember', window );">Consultants Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">7/28/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/27/2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">9/2/2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">9/1/2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">8/18/2008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">85,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/18/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember', window );">Series UU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">6/11/2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">93,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">6/30/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">1/13/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/13/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">2/15/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/15/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember', window );">Series MM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">6/22/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">333,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">6/22/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">7/24/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">200,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/24/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">10/30/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options | shares</a></td>
<td class="nump">234,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">10/30/2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IssueDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IssueDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuableUponExerciseOfWarrantOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuableUponExerciseOfWarrantOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189430009344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 4)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised | shares</a></td>
<td class="nump">217,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised | $</a></td>
<td class="nump">$ 447,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised | shares</a></td>
<td class="nump">17,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised | $</a></td>
<td class="nump">$ 29,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesSSMember', window );">Series SS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised | $</a></td>
<td class="nump">$ 418,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromEquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromEquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesSSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesSSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189331290256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Oct. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">2,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,018,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the Sale of Common Stock</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,980,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ConsultingFeesIncluedPrepaidExpenses', window );">Consulting fees inclued prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,000<span></span>
</td>
<td class="nump">$ 149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1', window );">Options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember', window );">Restricted Stock [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,573<span></span>
</td>
<td class="nump">40,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncrementalCostDeemedDividend', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ConsultingFeesIncluedPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ConsultingFeesIncluedPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncrementalCostDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncrementalCostDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189338197408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative )<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 28, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_CEOGeertKerstenMember', window );">CEO, Geert Kersten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncrementalCostDeemedDividend', window );">Incremental cost</a></td>
<td class="nump">$ 172,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncrementalCostDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncrementalCostDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_CEOGeertKerstenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_CEOGeertKerstenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189331261904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Three months ending September 30, 2024</a></td>
<td class="nump">$ 1,995,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">2,741,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">2,832,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">2,923,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">3,015,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">252,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease obligation</a></td>
<td class="nump">13,758,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest on finance lease obligations</a></td>
<td class="num">(2,463,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Net present value of financing lease obligations</a></td>
<td class="nump">11,295,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityCurrentPortion', window );">Less net present value of financing lease obligations - current portion</a></td>
<td class="num">(1,827,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityNoncurrentPortion', window );">Net present value of financing lease obligations - non-current portion</a></td>
<td class="nump">$ 9,468,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189330418160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 1)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Three months ending September 30, 2024</a></td>
<td class="nump">$ 268,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">277,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">285,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">294,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">746,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total Future Minimum Lease Obligation</a></td>
<td class="nump">2,523,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less Imputed Interest On Operating Lease Obligation</a></td>
<td class="num">(720,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net Present Value Of Operating Lease Obligation</a></td>
<td class="nump">1,803,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseLiabilityCurrentPortion', window );">Net present value of lease finance lease obligations - current portion</a></td>
<td class="num">(204,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseLiabilityNoncurrentPortion', window );">Net present value of lease finance lease obligations - non-current portion</a></td>
<td class="nump">$ 1,599,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseLiabilityNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseLiabilityNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189335752544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetOfDiscount', window );">Net Of Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Total cash payment for financing lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 700,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1', window );">Weighted average time of maturity of financing lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Total cash payment for oprating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate of financing lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1', window );">Weighted average time of maturity of operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research And Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average Discount Rate Operating Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvm_LandlordMember', window );">Landlord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinancingArrangementDepositBaseRentAmount', window );">Financing arrangement deposit base rent amount</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research And Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ClinicalServiceTrial', window );">Clinical Service Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ClinicalServiceTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ClinicalServiceTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingArrangementDepositBaseRentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingArrangementDepositBaseRentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average maturity (weighted by amount of the agreement) of repurchase agreements with the counterparty, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(m)(1)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average maturity (weighted by amount of the agreement) of resale agreements with the counterparty, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(m)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvm_LandlordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvm_LandlordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189335117696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PATENTS (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Three months ending September 30, 2024</a></td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total</a></td>
<td class="nump">$ 188,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189338124528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PatentImpairmentCharges', window );">Patent Impairment Charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod', window );">Weighted average amortization period for patents</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PatentImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PatentImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189338131840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share- basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted', window );">Net loss available to common shareholders - basic and diluted</a></td>
<td class="num">$ (6,709,524)<span></span>
</td>
<td class="num">$ (8,025,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted', window );">Weighted average shares outstanding - basic and diluted</a></td>
<td class="nump">48,470,600<span></span>
</td>
<td class="nump">43,440,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares', window );">Basic and diluted loss per common share</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189334288496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">15,986,278<span></span>
</td>
<td class="nump">14,066,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember', window );">Options and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">15,839,028<span></span>
</td>
<td class="nump">13,917,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">147,250<span></span>
</td>
<td class="nump">149,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140189339350912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 09, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock | shares</a></td>
<td class="nump">3,875,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Public offering price per share | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromSaleOfCommonStock', window );">Gross proceeds from sale of stock | $</a></td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .*#3E@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #B@TY8Q2=+7>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+;
M2L0P$(9?17+?3GI ,'1[L^*5@N""XEU(9G>#S8%DI-VWMXV[740?P,O,_/GF
M&YA.!:%\Q.?H T8RF&XF.[@D5-BP(U$0 $D=T<I4S@DW-_<^6DGS,QX@2/4A
M#P@UY[=@D:26)&$!%F$ELK[32JB(DGP\X[5:\>$S#AFF%>" %ATEJ,H*6+],
M#*=IZ. *6&"$T:;O NJ5F*M_8G,'V#DY);.FQG$LQR;GYATJ>'MZ?,GK%L8E
MDD[A_"L90:> &W:9_-IL[W</K*]YW1:\+JIV5U>BX:*]>U]<?_A=A:W79F_^
ML?%%L._@UUWT7U!+ P04    " #B@TY8F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M .*#3EA@'H'WT 4  (0?   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9E=<^(V&(7_BH;.]*K$M@R$;!-FP$M:IOE@(4UGV^F%L 5XUK:H)$/R[RO9
MQF:WXL7UK',1\,<YZ+%DZ4BZ/3#^16PIE>@MCA)QU]E*N?M@6<+?TIB(*[:C
MB;JR9CPF4AWRC25VG)(@$\61A6U[8,4D3#JCV^S<G(]N62JC,*%SCD0:QX2_
M3VC$#G<=IW,\L0@W6ZE/6*/;'=G0)96_[^9<'5FE2Q#&-!$A2Q"GZ[O.V/G@
MN:X69'>\AO0@3KXCC;)B[(L^F 5W'5N7B$;4E]J"J(\]]6@4:2=5CG\*TT[Y
MFUIX^OWH?I_!*Y@5$=1CT1]A(+=WG6$'!71-TD@NV.%76@#UM9_/(I']1X?\
MWI[=07XJ)(L+L2I!'";Y)WDK'L2) .,S EP(\#<"IW=&X!:"[,E9><DRK(]$
MDM$M9P?$]=W*37_)GDVF5C1AHJMQ*;FZ&BJ=''EL3SGJ(K$EG(I;2RI/?<7R
M"_TDU^,S>A<]LD1N!9HF 0V^UENJ+&6!\+% $PP:?J3^%7*=GQ"VL6LHCP?+
M[^GJ"MG7F;P'%,<MGX^;^;G@\_EKO!*2JR;WM^D)Y0X]LX-^#S^('?'I74>]
M:(+R/>V,?OS!&=@_F_"^D]E7L+T2M@>YCZ:)#.4[6M!-J'$3B9Y(3$W(L(\W
M?>@NO1GRGA?SY\7X9?;\9$(%31JB]DO4?AU4CR8*-$(SU7K?T&_TW00+.]GJ
M[QKWW8&QM8+:AHR#DG$ ENPC\U/5XTKT\KXSUB(L=^SN)Q,2J&J(=%TB78-E
M&BN>(&.ZC\C&Q 3KUR02ID?A@;*&4,,2:@B_+BGG&5(H?-46/U/"=7>*5(=N
MK#;8K=NU;[JN;8($A0TA;TK(FSHOW#(F480FJ5"7A7&\@6TD3XWU!ZH:HCEV
M-8C:M>"V*HX@C\4[DAA[D@LV9ULGK&N*=Y(1G#IXTYCR39ALT"_*06Y!4-CP
M/"BH:PJ**U!<:U0H7L@%W3$N-?%2$IF:XQ'L^-D8JCQ8U92S"C4.&".JD6%.
M><@"L+>Y9'7,:V<#&VS0E+7*-$ZM4',?1BK(>0IRP[BYS<(^3RSI$M]7$Q"N
M3(+<T,C;1JYQJF#CP'FDK-MB."FJ^%Z=-C=@V.Z38V1L(]<X5;!Q:B:;TR'S
M/"%L]M^90L'81M!QJJ3CP%'EV!>Q.%;3W:5D_A<UP.A9&GI.I9 D"53/9.3]
M3F&F> RY6S]STZL"^U'?=NP>=E7+V)L0J]SCP%&EK,9/*>&2\NB]Z'*-5+#7
MN6  RYK68I5Z'#BO5!E<S:=$F"U= (RPV?EALXWX@ZOX@VO%']TCHJ<T7AG[
MQ<D%$]MVNHXS'-X8)_UM!"!<!2!<*P#-$I]Q57<DJT:=":AZ/U,UA=3O:6 <
M/B\X>\]&W#9B$*YB$*X5@U[(&YH%JO&&Z]#/F8':A2V'/34M<09NS]C5PN*F
MO%4<PG"&*7C'0:#<1?GYH&Y#IN%O<L%OB/$-FC"FY!.61G1/>&#$;B,9X2H9
MX5K)R(B-C=BPWS(-U0LQM$U:#]8V9:U2$:ZUWG-D]/3!,T<O[) 826&WUY F
M"3%BMA&,<!6,,)QEOL',NRC%.>=L'R:^N8>"+5_'1LXVPA&NPA&N%8Z.G'.F
M\E"$_@QWY_MAV!!C9VANMVVL#.$J(N$+:T,9)J?D/!AL<&V;5]';B$6XBD48
M3C(/+)N:;'47"8PIL$G?'G1O>@/C4A<L;<CG5HG(A</,DOHIUU7GX!5Z"65D
MK+H+)J?1W[A5T$8H<JM0Y,+1127:(%L;>8]7+#+R7<@^KX]&K#;"CUN%'Q=.
M*F753=_\+4DV].PFR 6CI\_+Z?AQNC RMA%XW)--K5J!9Y:H25>^D:J7?\AQ
MX<L("SN>6>>"5?^7TSK9Y]1KD=GVKT"^CN#YEF=YMMQB'F<;JU9U>[X__4CT
M4J9 $5TKJ7UUK<9MGF_YY@>2[;)=TQ63DL79URTE >7Z!G5]S9@\'N@?*#?>
M1_\"4$L#!!0    ( .*#3EB4(CY\A 8  #L:   8    >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&ULK5EM;]LV$/XKA%>T&^#&XHO>\F(@M5TT6)9D<;IA'QF;
MB85*HBI12;-?OZ/L6+9(,0G6+XDD/W=\CCK><Z2.'V7YK5H)H="/+,VKD\%*
MJ>)P-*H6*Y'QZD 6(H=?[F29<06WY?VH*DK!EXU1EHZ(YP6CC"?Y8'S</+LJ
MQ\>R5FF2BZL25766\?+IDTCEX\D #YX?7"?W*Z4?C,;'!;\7<Z&^%E<EW(VV
M7I9))O(JD3DJQ=W)X!0?3BC1!@WBKT0\5CO72(=R*^4W?7.V/!EXFI%(Q4)I
M%QS^/8B)2%/M"7A\WS@=;,?4AKO7S]X_-\%#,+>\$A.9_ITLU>ID$ W04MSQ
M.E77\O&+V 3D:W\+F5;-7_2XP7H#M*@K);.-,3#(DGS]G__83,2. 68]!F1C
M0%YK0#<&M ETS:P):\H5'Q^7\A&5&@W>]$4S-XTU1)/D^C7.50F_)F"GQI/+
MB^GL8CZ;HD^GYZ<7DQF:?YG-;N;H(_HZGZ)?W_UV/%(PCD:/%AN?G]8^28_/
MJ5@<((J'B'B$6LPG;O.Y*,#<LYF/(+IMB&0;(FG\T;X0Z[(4N4*\JH2J#FWQ
MK!TPNP.]D@ZK@B_$R0"62B7*!S$8O_\%!]Z1+;J?Y&PO5KJ-E;J\CR>\6B&>
M+]%"7XCO=?+ 4PB^LD6]=A4TKO1R?QA3PC!CWO'H83<@$P<H/Z3^%K?'E6VY
M,B?7JU(4/%DB\0-J4B6L%-<>_)VA?19'.R.O&5I@Q*-!9"?H;PGZ3H+SNBC2
M1%2HKL020<E$U^]Y5AQ-FQG.>%[?016JRR2_MW'W#5*$LM!C<8>\!4=8Y(7$
MSC[8L@^<[*>BD%5B?_.!,20.,.D2,U&,L)Z7'FY9A4Y6-U+Q% K;[I*T,0R-
ML0/L,^;3#D<++L81(YZ=9K2E&3EI?DYRGB\$2@5(!"JU%B!YIQ/!P3DRN$0!
MO$=*.IQ-7(PICJ/0SCG><HZ=G"\+47(%R?@VUK$E%UCLD6X5L.'BB#!J9XV]
M5H&\%^H -"6E>FI6E2Y9!;0):HARH:S:XYG3%S"&_:A#V +$'HXB3((>RCNB
MB=V4N=+INY"5JOJ)8G/\*"(QZ_*TX.(0"D4/RU;WL%-JG!5@8[I?G7 ,$]1E
M]S)PGUXK5=BM5?^SO&Z\[Q(+H4"$7?XV6!#$/>Q;\<)N]5H7LOYEA4U-(E&(
M/8*[XF5!4L\G$?%[BAAN!0S[KVI]TH3?)FFB8+:M_0]V"N%;&Z"?Y6T_Z%;W
ML%OX3A<+64/+@PK^Q&]380W8HH#0^3!BO!P3"#ND.(SZ:D@KA-BMA$"SK(6[
M_<&FO,61'YA);N(P-!I^U+=(6QW$;B&<U@(IB416I/))]+ T!2WT?!"'+DL3
MY_LA87V%KA4^[%:^?;66MVERS_4F<;AM- I9Z@=6]A9ABTA(@VZK80.&(8[Z
M"C5I%9"X%;"KW&^,@)A"1SR&@VZ66' @-(SV) EIY9"XY7"_J=LI-E:VIMRQ
M* @I[C8<%J#O1W[$>I8>V=D0NH6Q+U_66JY;IM?,NBF,,0LB;/3W-F ,BS/H
M::5)JZ#$K:#]>?.V2$R)Q+ZF&'0CL0 #'SJ:'C4EK9H2MYI>JI4H7\P<4R@Q
MB*1G),Z+N'V6K9P2]X9PG><OL33W<R!M,)]^5UML2%@'E 9]3%L-)(%3^.<W
MEY/?OUR>3V?7\P]H]N?7LYM_K&2=4OKFDX^?Y&T_Z%91B5M1KTIQ)R#;EZA2
M<O%MB-X=>!BZ@!(]\+061PB4>PAI@*H5A_$1K]5*ELF_8GF$M@^3JM*JK%M0
M6:M*P45/ TI,T34RT079C[)59.)6Y(G,,IGWA1BL0^P+TX=?<#0,P$A'R,(A
M(V1(/>8.'W&%IF(ALEM8I<\G>PUH+@JU>;PYL1LB\%.(YG@V?;).G*4/\("6
M46Y,' N!;\^.D[3] G'W"Z?+9:*+(2QF?0+U,<G1@A<)+&XK75/W?5C/OA<;
M6SD+E,5Q1(D7])"F;9- W4T"](MU5J>P\USJ<^IDD5AWG=04^8\LIA$TK<:6
MWHJ-0B_&-.X16=HV!?0U34&3IBN9+D59?6AV]\J:$]2R"2:![Y' (&U!4H)9
M%/<L+=KV!=3=%]Q<WIR>H_.STT]GYV<W9[,Y.KV8HM?6THWSW7/2GAV?!=FS
MXQOMG.SKSRI_\/(^R2O0^SLP]0Y"F(9R_:5B?:-DT1SVWTJE9-9<K@2'V=<
M^/U.2O5\H[\?;+\7C?\#4$L#!!0    ( .*#3EAC9=F6R0(  ,0)   8
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M%G!=H.XO&9-/#;V0-QNWX"]02P,$%     @ XH-.6&KHM';L P  B0P  !@
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MT("SRRS;E)N"</'NG*[R+.<*,Q,Q'?LYP?LYP6TE?Z#2.U*0*J.O0?-(:MH
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MM0H[OP5%,G/NB2Y&Y77GA!Q21A61-$C\>59#90PI@AM?L\[.QB0=W/W=:O_
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M1LUQ]*3[VZ\=#!_^))<NHJOY,]C,Q>@J_KG$"Y[R)(#G]/;>7I"!S7?1F_\
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M=3JX^FI!FHKA@%]M^0@-$D*])UGPT<I@>V2<4GB06I!3:/OPH.%!.N,)T^M
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M^+UEGY?H3C;8./QH)/Y*Y4\3?S$]9ZFTB2Z5@[&D/DBID(FP=%8\)TNN%EZ
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MS=9(IJW*_ZV4AA*O5 F[-(WP$-5"),+"(8ZF$1SE)"&&! Q^W(:9M+46WVL
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*56;6_;. S^*X1W&.X
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MCCI1D*BM:PQ!C(Z5[NEX:>$XJ;U O7IFR>X]'K+B5VI][,XA"Q^[PF[+U?[
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MQ2W2XXO!1G$'9Z&/9G!G&!@:Z?Y%+';%K4:&Q#<-\(?DASORPU:%*#J3"?;
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MV=[^0 Y\,Y__T9C;X@:S!9'&2YA+2N?L@]3$S 0V@:"-'F(/5,B1J)>%O+2
MJ03Y?4ZIV :J0'<-IG\!4$L#!!0    ( .*#3EB(_(;!> (  &<&   9
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M(89(RWBJ.9WF2@/<7F_8OUCOVLL#EC#BY%>1J7S@1 [*8(871-WRU074?JS
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MPO9?H+=AC1.]32VV:1=LMP033)CQM@N58K%-WQ#;]!#;A#8_%E#+;=J5VX5
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MAB\13-DGJ>K<GDY.#@I%T8"U@B+G]9N^-/=P!O#]-P!^ _"M[KJ053FF2*-
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M?9;)F%"XYTAD28+YGVN(V6Y@V,;;P -9;Z0>,,-^BM<P!_F4WG/5,TN5%4F
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M.00@AV8A;SP<M53S-,2*4 UQ$B,O5M"+V<S3(,\ R#.SD--(#6H09?<:SCF
M<VYZ]KV;;QVP"P#LPBQ8&D[51 O0W$NS>Y2E7HP]OQE0?0&T^]#ZW#>=$[-9
ME.U2H9ED*D>R*+X-8S\*.Y"@1 Q;9*Z"&'>D84/6L UK8YI@C-3JBYK@J>3$
M$R\-=3C(%K9A7>#%#58IH.*%PKOW48,,89M61+-\I?>M'Z+;.!I'OJ<@/=]/
M%G''8S;D"-NP) ZL)>A$;?(*6G_1&2%%V(8= 28M.M$Q(4G8ABWQ)VT/A@^R
MA6U8%P?S]R EI [;L#L.3L2 2L**#J0#Z<,QK \($MD=3$@@CF&!@)A.!Q,\
MCA@6"XCI=C AQ3BF%0-A#CJ8D' <XV<2 #,F.B8D',>P<#[>([:T.B;D'.>8
MSOGAZ)B0<QS#SH$Q71T34I!C6$$PYD#'A!SD&';07X,?\(X+><<U[)WW8"J?
MA2#-?5P'$7*.:]@Y'^PR#D42<HY[C,/,6UQU3/ 2[+./-=VAUS$AY[BM<WK[
M.]@57;.*KF+UB5K5YZ3(YP(UC]TA<W#:; '73T7AJ[JDFG*RVE_I[J^CKW\#
M4$L#!!0    ( .*#3EB,WU^M;@$  -T4   :    >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'/-V,V.@C 4AN%;(;T RSE5U(FXFHW;B3= L("1O]!.1N]^
M""[P([.8C>E9D4(X?1?D">GAR]:9OW:MJZZ]B^Y-W;I45=[W'UJ[O+)-YE9=
M;]OQ2=$-3>;'Y5#J/LMO66DUQW&BA]<9ZGAXG1F='[W]S\2N**ZY_>SR[\:V
M_H_!^J<;;JZRUJOHG VE]:G2]WJ^[?1TH=4X646G2ZJ&TX64#AW$$,3A@PP$
MF?!!:PA:AP_:0- F?% "04GXH"T$;<,'[2!H%SYH#T'[\$$4HXRQ@*0%U@*T
M)N2:!'A-"#8)$)N0;!)@-B':)$!M0K9)@-N$<), N0GI)@%V$^)- O1FU)L%
MZ,VH-PO0FQ<_VP+T9M2;!>C-J#<+T)M1;Q:@-Z/>+$!O1KU9@-Z,>K, O1GU
M9@%Z&]3;"-#;H-Y&@-X&]38"]#:+PQ(!>AO4V[Q3;^<?M75SSW.-^[^3:C^^
M:^?MI^7SYN+KG7#6<)IY_ 502P,$%     @ XH-.6 970G>/ 0  <!4  !,
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M_0^P79-:JN;@S[H?K;,O4$L! A0#%     @ XH-.6 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #B
M@TY8Q2=+7>X    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #B@TY8F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .*#3EA@'H'W
MT 4  (0?   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #B@TY8E"(^?(0&   [&@  &
M@($3#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ XH-.
M6&-EV9;) @  Q D  !@              ("!S10  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( .*#3EAJZ+1V[ ,  (D,   8
M      " @<P7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #B@TY8V,2+@:L&  #I)   &               @('N&P  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ XH-.6.3)7@JA!P  _!\  !@
M             ("!SR(  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( .*#3E@]-.BXT@@  ",5   8              " @:8J  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #B@TY8CG/!@]\%   G
M#0  &               @(&N,P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ XH-.6()2#0R/!P  RQ,  !@              ("!PSD
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( .*#3EBZ7Z5B
M+0,  !8'   9              " @8A!  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ XH-.6'<15^^6"   2Q<  !D
M ("![$0  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #B
M@TY8J7H./=0"  "7!@  &0              @(&Y30  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( .*#3EATSUM$[@,  /<(   9
M          " @<10  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#
M%     @ XH-.6"\+,X%< @  / 4  !D              ("!Z50  'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #B@TY8"CHY) L'   V
M%0  &0              @(%\5P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;%!+ 0(4 Q0    ( .*#3ECFZC/,A@0  / +   9              " @;Y>
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ XH-.6,\>
MH\1> P  C0D  !D              ("!>V,  'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6Q02P$"% ,4    " #B@TY8Y#-1QUL"  !0!0  &0
M    @($09P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M .*#3E@W4_3(+0,  &4'   9              " @:)I  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ XH-.6.!W ]*7 @  = @  !D
M             ("!!FT  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #B@TY8L#B[+',"   2!P  &0              @('4;P  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .*#3EB(_(;!> (
M &<&   9              " @7YR  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ XH-.6&]PY,OY!   9!T  !D              ("!
M+74  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #B@TY8
MB[*LV>H"  #J"0  &0              @(%=>@  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( .*#3EBGO;-;^ 0  %,=   9
M      " @7Y]  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ XH-.6- 6[_0V @  I00  !D              ("!K8(  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #B@TY8)LII,R(#   ""@
M&0              @($:A0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( .*#3E@*.-&_*P,   ,*   9              " @7.(  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ XH-.6%6@&P-[
M!   MA4  !D              ("!U8L  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #B@TY8$^@.760"   #!P  &0
M@(&'D   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .*#
M3EAT$!7XC0(  !4'   9              " @2*3  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ XH-.6%( F2K# @  3 <  !D
M         ("!YI4  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " #B@TY8*VM,NJX"  #K!P  &0              @('@F   >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( .*#3EB_/>7H1@(  -<$
M   9              " @<6;  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ XH-.6*[9#^4= P  :A$   T              ( !0IX
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #B@TY8EXJ[',     3 @  "P
M            @ &*H0  7W)E;',O+G)E;'-02P$"% ,4    " #B@TY8=/Z;
M25 #   2%P  #P              @ %SH@  >&PO=V]R:V)O;VLN>&UL4$L!
M A0#%     @ XH-.6(S?7ZUN 0  W10  !H              ( !\*4  'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ XH-.6 970G>/
M 0  <!4  !,              ( !EJ<  %M#;VYT96YT7U1Y<&5S72YX;6Q0
52P4&     "H *@!="P  5JD

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>68</ContextCount>
  <ElementCount>220</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>27</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - PATENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PATENTS</Role>
      <ShortName>PATENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShare</Role>
      <ShortName>LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquity</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - PATENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsTables</Role>
      <ShortName>PATENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/PATENTS</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareTables</Role>
      <ShortName>LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - STOCKHOLDERS EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails4</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/RelatedPartyTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - PATENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetails</Role>
      <ShortName>PATENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - PATENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetailsNarrative</Role>
      <ShortName>PATENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetails</Role>
      <ShortName>LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetails1</Role>
      <ShortName>LOSS PER COMMON SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/SubsequentEvents</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cvm-20231231.xsd</File>
    <File>cvm-20231231_cal.xml</File>
    <File>cvm-20231231_def.xml</File>
    <File>cvm-20231231_lab.xml</File>
    <File>cvm-20231231_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="cvm_10q.htm">cvm_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvm_10qimg15.jpg</File>
    <File>cvm_10qimg16.jpg</File>
    <File>cvm_10qimg17.jpg</File>
    <File>cvm_10qimg18.jpg</File>
    <File>cvm_10qimg19.jpg</File>
    <File>cvm_10qimg20.jpg</File>
    <File>cvm_10qimg21.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="289">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cvm_10q.htm": {
   "nsprefix": "cvm",
   "nsuri": "http://cvm.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "cvm-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cvm-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvm-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cvm-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvm-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cvm_10q.htm"
     ]
    }
   },
   "keyStandard": 172,
   "keyCustom": 48,
   "axisStandard": 9,
   "axisCustom": 0,
   "memberStandard": 7,
   "memberCustom": 20,
   "hidden": {
    "total": 21,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://fasb.org/us-gaap/2023": 13,
    "http://cvm.com/20231231": 3
   },
   "contextCount": 68,
   "entityCount": 1,
   "segmentCount": 27,
   "elementCount": 295,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 289,
    "http://xbrl.sec.gov/dei/2023": 30
   },
   "report": {
    "R1": {
     "role": "http://cvm.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cvm.com/role/CondensedBalanceSheets",
     "longName": "000002 - Statement - CONDENSED BALANCE SHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
     "longName": "000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
     "longName": "000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
     "longName": "000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)",
     "shortName": "STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
     "longName": "000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cvm.com/role/LIQUIDITY",
     "longName": "000008 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "cvm:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "cvm:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cvm.com/role/StockholdersEquity",
     "longName": "000009 - Disclosure - STOCKHOLDERS EQUITY",
     "shortName": "STOCKHOLDERS EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cvm.com/role/RelatedPartyTransactions",
     "longName": "000010 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cvm.com/role/CommitmentsAndContingencies",
     "longName": "000011 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cvm.com/role/PATENTS",
     "longName": "000012 - Disclosure - PATENTS",
     "shortName": "PATENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cvm.com/role/LossPerCommonShare",
     "longName": "000013 - Disclosure - LOSS PER COMMON SHARE",
     "shortName": "LOSS PER COMMON SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cvm.com/role/SubsequentEvents",
     "longName": "000014 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cvm.com/role/StockholdersEquityTables",
     "longName": "000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)",
     "shortName": "STOCKHOLDERS EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesTables",
     "longName": "000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cvm.com/role/PatentsTables",
     "longName": "000018 - Disclosure - PATENTS (Tables)",
     "shortName": "PATENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cvm.com/role/LossPerCommonShareTables",
     "longName": "000019 - Disclosure - LOSS PER COMMON SHARE (Tables)",
     "shortName": "LOSS PER COMMON SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cvm.com/role/StockholdersEquityDetails",
     "longName": "000020 - Disclosure - STOCKHOLDERS EQUITY (Details)",
     "shortName": "STOCKHOLDERS EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cvm.com/role/StockholdersEquityDetails1",
     "longName": "000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)",
     "shortName": "STOCKHOLDERS EQUITY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfStockOptionActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfStockOptionActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cvm.com/role/StockholdersEquityDetails2",
     "longName": "000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)",
     "shortName": "STOCKHOLDERS EQUITY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfCompensatingBalancesTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfCompensatingBalancesTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cvm.com/role/StockholdersEquityDetails3",
     "longName": "000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)",
     "shortName": "STOCKHOLDERS EQUITY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_cvm_ConsultantsOptionMember",
      "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_cvm_ConsultantsOptionMember",
      "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cvm.com/role/StockholdersEquityDetails4",
     "longName": "000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)",
     "shortName": "STOCKHOLDERS EQUITY (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "cvm:EquityWarrantsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "cvm:EquityWarrantsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cvm.com/role/StockholdersEquityDetailsNarrative",
     "longName": "000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "AsOf2023-11-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-11-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative )",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2022-10-28_cvm_CEOGeertKerstenMember",
      "name": "cvm:IncrementalCostDeemedDividend",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2022-10-28_cvm_CEOGeertKerstenMember",
      "name": "cvm:IncrementalCostDeemedDividend",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails",
     "longName": "000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails1",
     "longName": "000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "cvm:NetOfDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "cvm:NetOfDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cvm.com/role/PatentsDetails",
     "longName": "000030 - Disclosure - PATENTS (Details)",
     "shortName": "PATENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cvm.com/role/PatentsDetailsNarrative",
     "longName": "000031 - Disclosure - PATENTS (Details Narrative)",
     "shortName": "PATENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cvm.com/role/LossPerCommonShareDetails",
     "longName": "000032 - Disclosure - LOSS PER COMMON SHARE (Details)",
     "shortName": "LOSS PER COMMON SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cvm.com/role/LossPerCommonShareDetails1",
     "longName": "000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)",
     "shortName": "LOSS PER COMMON SHARE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2023-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cvm.com/role/SubsequentEventsDetailsNarrative",
     "longName": "000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-02-01to2024-02-09_us-gaap_SubsequentEventMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-02-01to2024-02-09_us-gaap_SubsequentEventMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r370"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r370",
      "r448"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r291",
      "r394",
      "r395",
      "r396",
      "r432",
      "r449"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r200"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r25",
      "r27"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "[Assets]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r72",
      "r90",
      "r115",
      "r117",
      "r119",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r211",
      "r213",
      "r224",
      "r270",
      "r314",
      "r370",
      "r382",
      "r402",
      "r403",
      "r438"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "[Assets, Current]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r76",
      "r90",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r211",
      "r213",
      "r224",
      "r370",
      "r402",
      "r403",
      "r438"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "cvm_CEOGeertKerstenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "CEOGeertKerstenMember",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CEO, Geert Kersten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r45",
      "r88"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r45"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Axis",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ClinicalServiceTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ClinicalServiceTrial",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Service Trial"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CommitmentsAndContingenciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "CommitmentsAndContingenciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (refer to Note E)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r130",
      "r131",
      "r357",
      "r401"
     ]
    },
    "cvm_CommonStockContributedToEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "CommonStockContributedToEmployeeBenefitPlan",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock contributed to 401(k) plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r394",
      "r395",
      "r432",
      "r447",
      "r449"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r302"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r302",
      "r320",
      "r449",
      "r450"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $.01 par value; 600,000,000 shares authorized; 50,018,601 and 47,422,304 shares issued and outstanding at December 31, 2023 and September 30, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r272",
      "r370"
     ]
    },
    "cvm_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants [Member]",
        "verboseLabel": "Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultantsOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ConsultantsOptionMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ConsultingAgreementsMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingFeesIncluedPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ConsultingFeesIncluedPrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting fees inclued prepaid expenses"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssets",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deposits",
        "label": "[Deposits Assets]",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r28"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_DueToEmployeeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "DueToEmployeeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to employees"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_EarningPerShareBasicAndDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "EarningPerShareBasicAndDiluted",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER COMMON SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share- basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LOSS PER COMMON SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r111",
      "r112",
      "r113"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees Stock Based Compensation Expense",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r67",
      "r80",
      "r81",
      "r82",
      "r93",
      "r94",
      "r95",
      "r97",
      "r102",
      "r104",
      "r114",
      "r122",
      "r123",
      "r158",
      "r193",
      "r194",
      "r195",
      "r209",
      "r210",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r239",
      "r279",
      "r280",
      "r281",
      "r291",
      "r342"
     ]
    },
    "cvm_EquityWarrantsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "EquityWarrantsExercisePrice",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_EquityWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "EquityWarrantsExercised",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ErgomedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ErgomedMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ergomed [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ExercisePrice",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ExpirationDate",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of financing lease obligations",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r238"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "cvm_FinanceLeaseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "FinanceLeaseLiabilityCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less net present value of financing lease obligations - current portion",
        "label": "[Less net present value of financing lease obligations - current portion]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under finance leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligations, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "cvm_FinanceLeaseLiabilityNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "FinanceLeaseLiabilityNoncurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of financing lease obligations - non-current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total future minimum lease obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three months ending September 30, 2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest on finance lease obligations",
        "label": "[Finance Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "cvm_FinanceLeaseObligationIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "FinanceLeaseObligationIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total cash payment for financing lease",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r236"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease right of use assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate of financing lease",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r369"
     ]
    },
    "cvm_FinancingArrangementDepositBaseRentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "FinancingArrangementDepositBaseRentAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing arrangement deposit base rent amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_FinancingCostsIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "FinancingCostsIncludedInCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing costs included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year One]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Three months ending September 30, 2024",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Five]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Four]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Three]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Two]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent costs, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r256"
     ]
    },
    "cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average amortization period for patents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r324"
     ]
    },
    "cvm_ImpairmentOfLongLivedAssetsPolicyTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ImpairmentOfLongLivedAssetsPolicyTextblock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockBonusPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "IncentiveStockBonusPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Bonus Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockForfeitedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "IncentiveStockForfeitedAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2014 incentive stock forfeited, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockForfeitedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "IncentiveStockForfeitedShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2014 incentive stock forfeited, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShares",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per common share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r285"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cvm_IncreaseDecreaseInDepositAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "IncreaseDecreaseInDepositAssets",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposits",
        "label": "[Deposits]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due to employees",
        "label": "[Increase (Decrease) in Employee Related Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "[Increase (Decrease) in Inventories]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase)/decrease in assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/(decrease) in liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "[Increase (Decrease) in Prepaid Expense]",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cvm_IncrementalCostDeemedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "IncrementalCostDeemedDividend",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental cost",
        "verboseLabel": "Incremental cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/PATENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PATENTS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r252",
      "r253",
      "r254",
      "r256",
      "r362"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PATENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense, net",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest amount",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r86",
      "r87"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for R&amp;D and manufacturing",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r360",
      "r370"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r71",
      "r73",
      "r124",
      "r125",
      "r126",
      "r251",
      "r363"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payments for services",
        "verboseLabel": "Non- Employees Stock Based Compensation Expense",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cvm_IssueDate1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "IssueDate1",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Date"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LIQUIDITYAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "LIQUIDITYAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LandlordMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "LandlordMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Landlord [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "LeasesPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under operating leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Future Minimum Lease Obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, after Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year One]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Three months ending September 30, 2024",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Imputed Interest On Operating Lease Obligation",
        "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "[Liabilities]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r90",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r212",
      "r213",
      "r214",
      "r224",
      "r301",
      "r364",
      "r382",
      "r402",
      "r438",
      "r439"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "[Liabilities and Equity]",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r57",
      "r274",
      "r370",
      "r393",
      "r399",
      "r433"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "[Liabilities, Current]",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r70",
      "r90",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r212",
      "r213",
      "r214",
      "r224",
      "r370",
      "r402",
      "r438",
      "r439"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LiquidityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "LiquidityDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIQUIDITY",
        "label": "[LIQUIDITY]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r161",
      "r250",
      "r278",
      "r293",
      "r294",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r358",
      "r359",
      "r366",
      "r367",
      "r368",
      "r371",
      "r404",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r161",
      "r250",
      "r278",
      "r293",
      "r294",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r358",
      "r359",
      "r366",
      "r367",
      "r368",
      "r371",
      "r404",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ]
    },
    "cvm_ModificationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ModificationOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "verboseLabel": "Net Income (Loss)",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r47",
      "r58",
      "r68",
      "r77",
      "r78",
      "r82",
      "r90",
      "r96",
      "r98",
      "r99",
      "r100",
      "r101",
      "r103",
      "r104",
      "r108",
      "r115",
      "r116",
      "r118",
      "r120",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r223",
      "r224",
      "r277",
      "r322",
      "r340",
      "r341",
      "r365",
      "r380",
      "r402"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss available to common shareholders",
        "label": "[Net Income (Loss) Available to Common Stockholders, Basic]",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r98",
      "r99",
      "r100",
      "r101",
      "r106",
      "r107",
      "r109",
      "r110",
      "r115",
      "r116",
      "r118",
      "r120",
      "r365"
     ]
    },
    "cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common shareholders - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NetOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "NetOfDiscount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Of Discount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "NewAccountingPronouncementEarlyAdoptionPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Standards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonQualifiedStockOptionsPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "NonQualifiedStockOptionsPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Qualified Stock Option Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options issued",
        "documentation": "The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "[Operating Expenses]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "[Operating Income (Loss)]",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r118",
      "r120",
      "r365"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expense for operating leases",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Present Value Of Operating Lease Obligation",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligation, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "cvm_OperatingLeaseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "OperatingLeaseLiabilityCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net present value of lease finance lease obligations - current portion",
        "label": "[Net present value of lease finance lease obligations - current portion]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligations, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "cvm_OperatingLeaseLiabilityNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "OperatingLeaseLiabilityNoncurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of lease finance lease obligations - non-current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total cash payment for oprating lease",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Discount Rate Operating Lease",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r369"
     ]
    },
    "cvm_OptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "OptionsMember",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "[Other Indefinite-Lived Intangible Assets]",
        "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expense",
        "label": "[Other Nonoperating Expense]",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "cvm_PatentImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "PatentImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Impairment Charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of stock issuance costs",
        "label": "[Payments of Stock Issuance Costs]",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expenditures for patent costs",
        "label": "[Payments to Acquire Intangible Assets]",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name Axis",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r146"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r302"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r146"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r302",
      "r320",
      "r449",
      "r450"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r271",
      "r370"
     ]
    },
    "cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "PrepaidConsultingServicesPaidWithIssuanceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid consulting services paid with issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r127",
      "r128",
      "r361"
     ]
    },
    "cvm_ProceedsFromEquityWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ProceedsFromEquityWarrantsExercised",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Equity Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from the Sale of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "cvm_ProceedsFromSaleOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ProceedsFromSaleOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from sale of stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment purchases included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r269",
      "r276",
      "r370"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r63",
      "r66",
      "r275"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r159",
      "r161",
      "r188",
      "r189",
      "r190",
      "r249",
      "r250",
      "r278",
      "r293",
      "r294",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r358",
      "r359",
      "r366",
      "r367",
      "r368",
      "r371",
      "r374",
      "r400",
      "r404",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r159",
      "r161",
      "r188",
      "r189",
      "r190",
      "r249",
      "r250",
      "r278",
      "r293",
      "r294",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r358",
      "r359",
      "r366",
      "r367",
      "r368",
      "r371",
      "r374",
      "r400",
      "r404",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r243",
      "r244",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r319",
      "r321",
      "r349"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions By Related Party Axis",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r243",
      "r244",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r319",
      "r321",
      "r349",
      "r437"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r288",
      "r289",
      "r290",
      "r325",
      "r326",
      "r327",
      "r346",
      "r348"
     ]
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on obligations under finance leases",
        "label": "[Repayments of Debt and Lease Obligation]",
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average time of maturity of operating leases",
        "documentation": "Weighted average maturity (weighted by amount of the agreement) of repurchase agreements with the counterparty, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average time of maturity of financing lease",
        "documentation": "Weighted average maturity (weighted by amount of the agreement) of resale agreements with the counterparty, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r202",
      "r446"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "cvm_RestrictedStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "RestrictedStocksMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r55",
      "r273",
      "r282",
      "r283",
      "r287",
      "r303",
      "r370"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r93",
      "r94",
      "r95",
      "r97",
      "r102",
      "r104",
      "r122",
      "r123",
      "r193",
      "r194",
      "r195",
      "r209",
      "r210",
      "r215",
      "r217",
      "r218",
      "r220",
      "r222",
      "r279",
      "r281",
      "r291",
      "r449"
     ]
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti-dilutive securities"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfCompensatingBalancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ScheduleOfCompensatingBalancesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ScheduleOfDerivativeLiabilitiesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of derivative liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of equity compensation plans",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r31"
     ]
    },
    "cvm_ScheduleOfStockOptionActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ScheduleOfStockOptionActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock option activity"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants and non-employee options outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://cvm.com/role/PatentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of total estimated future amortization",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "cvm_SeriesMMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "SeriesMMMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series MM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "SeriesNMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "SeriesNNMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series NN [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesRRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "SeriesRRMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series RR [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesSSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "SeriesSSMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series SS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesUUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "SeriesUUMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series UU [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "SeriesXMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series X [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "SeriesYMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Y [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Options/shares Under Plans",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r166",
      "r185",
      "r186",
      "r187",
      "r188",
      "r191",
      "r196",
      "r197",
      "r198",
      "r199"
     ]
    },
    "cvm_ShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "ShareIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance costs",
        "documentation": "Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SharesIssuableUponExerciseOfWarrantOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "SharesIssuableUponExerciseOfWarrantOptions",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issuable Upon Exercise Of Warrant/options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13",
      "r67",
      "r80",
      "r81",
      "r82",
      "r93",
      "r94",
      "r95",
      "r97",
      "r102",
      "r104",
      "r114",
      "r122",
      "r123",
      "r158",
      "r193",
      "r194",
      "r195",
      "r209",
      "r210",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r239",
      "r279",
      "r280",
      "r281",
      "r291",
      "r342"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r114",
      "r255",
      "r284",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r323",
      "r324",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r375"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r114",
      "r255",
      "r284",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r323",
      "r324",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r375"
     ]
    },
    "cvm_StockBonusPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "StockBonusPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Bonus Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation Plan [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "cvm_StockIssuedDuringPeriodShareStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "StockIssuedDuringPeriodShareStockOptionsExercised",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock, Shares",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service, shares",
        "verboseLabel": "Common stock issued for service, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, Shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35",
      "r55",
      "r286",
      "r342",
      "r355"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock, Amount",
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service, Amount",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, Amount",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35",
      "r55",
      "r291",
      "r342",
      "r355",
      "r381"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation - employees",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r34",
      "r35",
      "r55"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "label": "[Stockholders' Equity Attributable to Parent]",
        "periodStartLabel": "Balance, amount",
        "periodEndLabel": "Balance, amount",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r38",
      "r39",
      "r49",
      "r304",
      "r320",
      "r343",
      "r344",
      "r370",
      "r382",
      "r393",
      "r399",
      "r433",
      "r449"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r89",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r221",
      "r345",
      "r347",
      "r356"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r247"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type Axis",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r247"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r247"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cvm.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r248"
     ]
    },
    "cvm_SuppliesUsedForRDAndManufacturingNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "SuppliesUsedForRDAndManufacturingNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "[Supplies used for R&amp;D and manufacturing]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r398",
      "r436"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_UnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "UnvestedRestrictedStockMember",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r61",
      "r62",
      "r64",
      "r65"
     ]
    },
    "cvm_WarrantExercisesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "WarrantExercisesAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantExercisesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "WarrantExercisesShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20231231",
     "localname": "WeightedAverageNumberOfShareOutstandingBasicsAndDiluted",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding - basic and diluted"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001654954-24-001793-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-24-001793-xbrl.zip
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M1 *>V2<H!U>3BE<!+!4AJP@H <QL,Y0$L)GGBG;=$B$Q5::"HY?98PCWW9I
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M'4TGVM#4>O$Q4SGEO.)GUR;0M@_1]D9W=\9T7;K+/;0WBOU0'\IRPL.'W";
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MXP\)'"0>.C^%Y'5WOD4J5T -<"7POZX3L6O\T_5P=#T>_O@MM+]#M0$ K8_
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M%%]AR9WJ )@H78%=!UY9B PKPCJ!@B2":LB0A<DC Y6B<2SCB6FH#((4Q2=
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M)+V?(A]EN_YFN2<;%0[]\8)J!3ZB0<QZOX?L%4BY"&CP"?IS+FNGL-)3JJR
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M3 73"&S!SQ!M<%'G>9P^$L<\&!'THLWA:#@!.<'R8@3/,$^N4DDYH:050)/
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M!4V8W= ,/3R[F(X-U:.)3@I0.9P@3 Z!?S$HB<^7;_83:OH;WXL<[X1>'Q]
M]CW<!>6^6%)VUM2]C3$YK&Y?W(38S2U1AV=.[9FAF-M=E2%/[X]YXE(7CH<B
M:<_=RZ4(!#8W]W3NN:SK#1B@+G<8I!Y2KV'MU28'K8"5;^U8E+3WW\EAXK;S
M'V;3?O%>88BX](C^&SAX?YD,*KA-72$OI^F%0"=4*!6F0_WQQ+95KRS6@)FG
M2J(*+KJ *'>4L[S]0B-R@<1G.:]P!RV<_<B!X?J;Y9YL:%,OB>_PBQ>[\M.T
MTCOP.K(M<=FRR\K(K&YV83B>^PY&YE#A!]%CD0IKI:E7@,L[%'\QNY,9PG^=
M<"JG5_2?)_0JQH4NE=+R6%T!.,U3CFA\W>%@8JD<P-4"F>?210D0+8#5 -;3
MBT[,WKU"5AF5BKUZJ2 ](K:?VT,=TEL)0*PBD6KJ&/BZ(S*<R,S2PTT8GO!>
MP!,:FH:&Q;@4K9D)B41K4+0,_VKHDS8W9X/!0(>%\.;("VPUZ-56R0P4FU3-
M6%R2!S0.Y@41I@4DLJT *\.E\U-Z$L(<#B<Z1.CQ<!5B'$ZFZUB("7L8X'6V
M(U:Y;)/T$?L2^!:$-EEDH7Q.+8JS0C?*Y27%P8B /D?#E G3M2)K,)ZH7M2H
M 3//FI\#LH(5&P"XGD 8>Y0*5])I Z5J+M]BY / ;A&GUK[QPZBP9EF4^)V]
MG]"Z!6S?.N'X(2/ND7+566P:)K0_TVD1KN/T;0B9O7?TS(;H4PZ@#9Q8'_EX
M9  88>A;#KZ>&'QUHA=@(.FOWC7YS($;)S!+9;_[L="&Z1_NT%_HQ^0G]!^<
M)._/_Q=02P,$%     @ XH-.6+XFHPF,,   QXT" !0   !C=FTM,C R,S$R
M,S%?<')E+GAM;.5]ZW/CN+7G]ZW:_T$[^V%SJ[:GQ3>92NXMM:V>J.*6/)8Z
MR>P7%$B"-F]HTD-2[G;^^@4HT:)(D 0?$L#.5"4SM@$0OW,.'N>)/_W7]^=@
M]HKBQ(_"/_\D_3S_:89")W+]\/'//^V3#S!Q?/^G69+"T(5!%*(___2&DI_^
MZS__Y__XT__Z\.$?GQ[N9K>1LW]&83J[B1%,D3O[YJ=/,_*G+S!)4?SAP['U
MWP[?^>-,_EGY>6Z^__X33'"O*,SZX#]*[W^YQ>/-(F_FD)&SKG/YHS3_*,]E
M];W1-O+2;S!&,Q@[3WZ*G'0?PV#FHL1_#&=XXK,#H#_.%O_'F=T^P?@9OL3H
M&88$U&SQFO[\/M9-]/(6^X]/Z>P/SG_,R&=FJP_KY6[V:9_X(4J2V38*]F0J
MR?^=K4+GY]DB"&8/I$<R>T )BE^1>QPN\,-__I'\GXWQS3"AP^2/WQ/_SS\]
MI>G+'S]^_/;MV\_?E)^C^!'CF4L?__'E;NL\X7E]\$-"< ?]E/<BH]#Z299E
M?<S^FC>MM/QNQT'^#>5C/AW<//'_F&2?NXN<C+@,W6:U+<A/'_)F'\BO/DCR
M!T7Z^7OB_H2I,9L=Z!%' 7I WHS\^^O#ZOV;SNOSST[T_)'\_N--A$423S'K
M\10C[\\_X;_C465%D@]C_N^S-NG;"Y;,Q']^"3"TC]V_%[HHQ$+X"0:$[MLG
MA-*D=0)-G2XRHWLLY6'ZA%+?@4&OZ5%'&&NNVQ0O5[(3)!MO\X+B3*J2KR'<
MNWA9NJP39AQFX*R+7]FFD?//IRAP\0:U_'WOIV^LD^XXRB4H?0.3I\]!]&T8
MH>M'&3AGO+G[>/S[&&^.89KQ<A&ZV_WS,XS?,-'P'NU[6!K#=.$XT3Y,\4Y]
M'P6^XZ.V%3C&T /1W:U^_;JZ7>U^:YEJI=U@Z2W+6JN@UG48.),'%)!#'V\L
MZ=LNAF$"G6R]MLRGK=O@E?+\[*>9;&.1P!)/>(]O-NU"Q=!SX-SN%[OE>K=M
MF4>IU5 YC9+D'L4$7!1N\14(M0EL;8>ADKNW$_3['M-W^4J(W":W-<T'SX)E
MDV#<A_H--OH.L(-VT#[7EFZ76W=,TV/N/W0-XLT'?X-I3M2VHZ]'IJFT=1M=
MIFY1"OV@NU"5^EUJ7E+?B4F7GIG<=V;RI6>F])V9<NF9J7UGIEYZ9FL8$S7D
MM>W49!_@0K>NCO/M.LSE3@>VC89]@(O/M&WKZ3#"Q>?**@X]1AKG'&;C/KWQ
MJ#-@I51+K]%O!VP$:NUWJ7FU+8;VCB-K%5WW;<;N];-\*1@A[O OSCJ@[UA:
MW)-)A4R9P?*9^BEI-S_\(\T^G$SM'V99R]D]?$2S5>A%\7/VZ8.I-9]4$#EG
M\PB(I3<J65;)-!(\C\R>FR#GY\?H]:.+?&)D5\A_9*3*R(1_ -EW%W:2QOBL
MR$<*H(V";'R VY2:?+SXG)9XHTK?'M"C3[X9IFOXC.A3H[<\GV&1E8O8F44Q
M/LXQ&_(18>R<,;!J##^V^/B265L_.$]^\,Y[+XZ>ZRAUI$O4,MTB^?"GKD?A
M&XPFAL$*R_+WOZ*W)A)7FC+16.)&XQIH5R5ROKIW>$0Z;<];,)%4YD!2&I"K
M4G*!O^Z2&7P.X".=E*4F3+14.-"2"N6JQ+S9QP3#9S]Q8/ ;@O$R=(ECMF;S
MKVW-1&*5 XG; '+8:;?/, ARGW/3/EMJR$1CC=LN2X7%@[Q/* CP;?0%AHVG
MV'D[)N+J_(A+ <6!MLMG%#]BO?&7./J6/C$0N:8#$[4-;M1NA,GC;G;8Q![0
M2Q03M9TX=_>-6T==#R;"F_QN:HU N5S8L&KK1V[CL5C3E(G6%L<K'!4:!_'^
M[ <HOL%S>(SBQMVDU)!-[>"GVU%Q<1'BP_7GP._/^'<U>T=#<S9:\]#Q6C%R
MI#BY<#+3N]"8C=H\U;\:?#P.QX/AD7AG,NMCLMFG64PK/C\:C\C&?FP<X*$T
MLJ/F(OB_[F&<HCAX.QSBS8)?:<Q&=AZ*9 L^/L8DXM;S"758B%UMS49M'BIE
M&T).MY3U_MD^V?#KKBAY*S;R\E,JJX@XD'45.E&,69O1)8M:O2'!53'>X=Q&
M0W]+1S;B\],QF7!SX,<.?E^Y&& 6ZT;FUB[SM5W8>,!/W6S!RH'Z"]?%5$J.
M_[KS0R0U49[:G(WJ/!3/5HQ"4%SN1G&9U5G#3Q%MP,B/XC?X/S?Q+OH6,M"[
MV)B-VOS<C;7X^-$Z.U\V\7T<O?J'W+,V@E=ZL%&=ATK*@I0?Z>\CK)8%_\]_
M:;O/T-NSD9V?'MJ$\KJ>3#*9&,%Z,I^W8",L%Y<E!<E527D7$4/:4Q0VZCO5
M5FPDY:%.UB&Z*EFWR-G'F+>2;.](]!>=K-56;&3EH4;6(;HJ67<Q)$:O[=NS
M'05TFI::L!&4AVI(Q<)%2)??G2<8/J+Z<#MZ2S;:\E#YFI!QL7NDB,S4?T6W
M,(5'SV>SP8/>@XWD_/2]9J05TO_I8P4'UEC^>8EXW,8D_T* KCS[,'M/J";Q
MN9OU[7*]7=[./BWN%NN;Y6S[E^5RMQT:H>O!Q,[8L$\^/$+X<A @%*1)_IN3
M)!U_ =[GM?$^^R'&X>.3+CK83!M">8_=67J#^1P96F5M7P?>(DDP4XXRTXZ'
MVAS8$G2@V[92*O(X[GKI0_'S%<6$\11MRX-=I-0 ^1])D'J% 9Y@\H#P#'TG
M12[YPR)TSW]1:%G/UD'# @<JAJ**P?YFYE'Y/0[X4\@P#[FXC]$+]-WE]Q>R
MX]8?=L?VU.9 DQ1HP,GRL1G4*0R9!W]6(<F-B>*W-6I@2[$5<!Q),UN-G\)R
M@XKE%*C,@PFWZ(4<!,D9FGIN4)L#T] -=[IL:09U"G+F?A=AO(, 3980<;9,
ME!]T,*=X: S$0_B/[MV!#K43S6:91BD,LI9\.'BX<:$[!!.4%7;;>%\3E&&L
MYV=#)R [D@-;U5YAN<L"[12-S8-CQR)AX6,WGC5V ZIFNE[EI)T,U]C G8*Y
M^5SX(CS+].T^( 5S0I=<25^(VM-XP6CJ!6S#=11OLEQCPG:*"N>T/?HINO-?
MD;O") T??3LX2%72R+;F?D"S9<,51/WNMTFRH"O$F_._/++>&H%E&7-8V=LG
MPYL:-(5X]&X7E%<4VU&"^E]1*N4'\"_ =O_R$O@HP7NT^SF*'V[Q\O\"P[T'
M23U;O)&OH[#^6HE'Z#  , QH21-<;3UA%H+AK\SJD?2)-D4"V([EP>EJ="44
MA=#Y:>D.=SZT_<!/L7R22J25:E#MQFG6$8"J:Y*N3Y;CG7$6XOHY<Y;9T5#?
M!TBJ;'B":/R=6='&T#JPA60!+EOIH21G<@_?2-'$=AL-M3V EJ:XE0L<=];5
M$9V^WS9#*Z0=<&)4O,<[?@5<(Z_H78 J:_.Y()?7 >QJ05?(51CK0GJ[1[MH
M^?P21&^H8;'@IK260)8<I$^5[FV@"FD)O$V4.;:WUC72U MXIB[+K8D!@K*K
M"\!";@-_6R4[\YK[ 05!1:I$)DV+?8P0"ZD28EP$NUP @>(X2)GX[:$!5B&S
M8EJ:&W7O6$>ATVM7/74$BJYYMB!^A%$W5@K&0H:'0'LK"Q=;NP)7G6N6(%Z\
MD7=8"LI"T@@73J9/*"Z@9&)A;1\@VYJJ3YUW[? *"2F<3T:F(Q',)4MU[&FS
MA8:GD,4RK4.PJ?ZWGSA!E.QCU&[WZC0,T!3+L2<N!?T0%])R>'"[CWFZP3HX
MMUU;E(")?OR@LI8!<2$;B%/<[&&/R:;Z-QCL:=DX[Q$&E<; @9;D":+[,Y";
MRJ8F7(6,(EZ[ZK$,4PMSRBV!8RDV$N3BTI<SM: *64=<K,RNFR54P. >^NXJ
MO($O?@IIV8&Y%9;> 4#H.4@0E;XOD]JPY9'GG(PN#^0]AA"Y2QB'>"=/%HZS
M?]YG;]?<(L]W_(8CJ[TOT&7=5 5)&NC+P0XP<V9RRO^I?XJ2Y;X!S#F"NB#W
MC+[,:H"5,Z=SK IOY:'-C=P_Y@&8F@RKCO]IL9P99"X (P2_<$Z3I3\V7<B9
M51AS9F=_.!OJ/W[0'%K=,B5>;HWS^S,F]R;.YNQF=[9[%)^] =NF5]3U!YZF
M&9(P%]H./&%0.EI!\TV[/9_LH2#L8I\^1;'_K],:;^-LN1]P%#17A5$>Q^5H
M+5CNB;*52:Z29-^5BX<^P+8\J^JR^9$X6 +*-XV6-L'F<M0-R H=@69#V%YI
M<,I\I*'EFXY;,&YT/S,9.@-9AI[]PS"U"V*^>;R5VNDL1V5#)V"ZIJH*DIDV
M*B-KD9X2@(5@8-L)6=,!2$B'<V&,0Z,SKH22;R9OQW<:ZC 5SPE%L?"&\L.R
MCP:UG-5[?3/ .]!DXQV#3J(P^1K"O>NGIY&*M@"UUA:PW2UVRR_+]6X[VWR>
M;>Z7#XO=:K/>SO[P=;WX>KO:+6^Y6 1(=?9G]#[G=B- 30>@0PFK%9QCIHXE
M9Y)V&+5= '15W:D<V'S66ANQJ<NK'1I?'?X!4Q)3@51SND6O*(BRY/#C9)M<
M( W=P%RRY;D@!O5V!M0X/U@ \M7:?T$AQA;@*2[<9S_,7G0F]0Y;N=?2$<B>
M*;N"Y)+UY!\K1+Z:>P5<AST26+:EZ(*$.?7D4CVHDQ(^+9_5.Z+#:7$741_;
M+<,_-0:>XBB&(%E.0[E*@772P:?%UZR<+$K2 Z0C/5K*UM%[ ,>R'6/:IV,K
M-KZ:>A;9O(["J(2N)=2;T@.XIC07):VZ[W)LPW;2T!G7I'58DR%Z),8VCJL2
MBQS+/GO6#*BZJSC39BD=T$E+O^K>2LWU_1*Y[^];;;R_PSB&]%J[N#&]+; <
M5Z\FC$^#3^VH^-;<.A.@Q2OT Y*UOXL*UJ!C+,DGF/@.X])J'PA 9^Y6P].G
MP=2!D NENOBOSV-07^XCR69*=%T_V*=4FS;NU-P'*)H"X419RXZN4.1K+%[\
M'9%BBLA=O.))/QX?B]EX1WDJ&V696#5H2 !MVZZ6WI\,)\<!7RCQ=66C=]'6
M70WK:[1Y:R6;][FE>[O;W/SU+YN[V^7#=K;\]>MJ]QMODW?!@=$O>XBA._ ,
MAQ+M>66 .W)*,"#)V@%#F\O5/8:[DXF!R-0SLP;=^Y'(*4;Q?5IXM:(5_L\&
M):+:%B!Y+LU%8](YA9NY487R7@N#.TL.XH4W[9<HS-+NOOLLW*%UPT<%E$0Y
MT'HQJA$5Y_HEI;G=1L_0I[VN>FQ/;0YLQ59M01Q];%2G,JP9'&=&%124+ZCF
MB<5J5,"A*3 , R)!&-1,92ICZ@$5"LP(E#38QJ#&;L#2,$T%B3#JP2PV<)QK
MPY33X]HX1F\/5 <JCB#AF#U8U8**<]47MCB]L[ U3==-29"ETW!/HU\7:$!.
M\27=K$Y8[_8C$G<5IQPM_ -3.Z$J.4HE2W\BW*R'<XH[X<!3N@WK8-]>?D>Q
MXR<H.8ABC7&*VA8XBJ7:PF2],_*J'<Z@"!,F6B^>2>E=-EH?V@(;.JXC2+G^
M(;0NP>&;NI$MV,/N>YL]''!_6&Z9/.2%7S^A$'E^2MYC:=G).HP$7$MQ1*G=
MWFN?ZP.6;SY'S;2SU),QF%TW$'#P!=@4S>HTC->M6/G&DS1*Z.'WGZ-XB^)7
MWVF*X>LV#I!5&XGR\NBHB[H>*M]DD2;I',YF^C# 1-Z\6DAJTEQN03KHC3CJ
MC6@5.GC2_BO*)H2_Z2'B(6NZA#9V 0C*DCVU/989U:#8DRX,:+J9-G8!DJ$@
M39 PV!$84$+%^=6VIF6;!S\@E]B!4)ADQ.ZWV='' M;<==#4>#L<[K#($3ZQ
MDL;<L%71'&>,K*(CF?#+;8UWJC7ZEOVI[_7SO3_05:@Z/]:%I YBX5DX@1B:
M;2;]^7G>'=BV[<B"/.0QYFY;13CL03?Z&YI$<,AG2 VRFRBI"V&NM@.RYAK"
ME3%BN,$T0.'\W%H/;\Y\[BG*5.UB-""%A]3ZF/Z7(<]TC8'.' O:<^&B>+KL
M9'0XA9?6QF IW]H,-S!Y^AQ$WYI+,^B,I1EN%MN_S#[?;?[.O31#(0;R'6*G
M\-1*+Z#8D@(Y51#OI0SHCH5<T=9?$V49U((<4U\O>8K7,]?7G-W_WB>'=PEV
MT0-RHM#Q W2&<1<1"MW'T:N/U_6G-_+.]2I\CZM?.*G_>J@BVRK/E_@:<#Q+
M$D['["Q6%R4-WSH3MP@SP_$/K B)+2M._7^UV(4:.@'-T711JJ-?E&]426&A
M#.>R%,>,80?#9DZ=+C0&EBOKMB IMM=G<!-%^$8HY&K=,9$#2U^>EUKPTVSB
MFP#Z3:D0G88!GF0A42(<KR\,_6C%.;2AJP^ ;OAV+*A:_[:[0 M1!D4T4&U5
MA1!W\CY5[-LDG_'TY'1S, H>H<, P+9L-!?$JGA%WO:D$M^P!DR&F#S/>8L.
M_RX"3Q*4,ES\F8< 2+)D0Y#(0@Z[?6<Z#0J&N(!HW,?H!?INZ[6OK2?P/&<N
MBI>W.UL8N5N#^11@,;6*.E6(J_ 5$SB*&Q]A;>P&+,^594$T_(N) @UP]Y(?
M8PE"791.:=)8%R75@@_(:^-TFCH!TS0M29!RR$.9VP%N(9IC^FO\](QWX4VI
M(9<"RCC =#U;%T0/O-@NP$2!2FD1WOQ?. Z)3TONX5MSE8K6KL"S-5,5G\M-
M[&%D=1WR0E#)U"*,J"#C/9X_RTOL++VQ_FNXIOC'Q3CR40>^$*DR?1')%=\'
ME+T-VE-4ZD<!"K1,2Y#$P,N*# ,1"C$X4Q,=K'@S*MN-'FG&,0 T'464*O1C
MBDT/$O2.&N)==KD&*]&UDJ[.Z^YC <DU9%609V*O($(LI"A$*W%YZPZ^'>UY
M"^?WO1\CC &3(7TC]M9T$;HDN"I[JZ%>$-C' +)+7L 10P &,(TJ!#W(D#.?
MO<2P,$IO!>T*,S!\]/'-O=;Z44>H<E>@RXXI2JGBBXM)+?I<.B9H]F0GVACG
M"YB;NB>*]VQL>>E!AD)=M!_B>G)\BFV4ZTG#6$#W7*C^>XD1"SDX5W3#4W80
M<I//F$2GZ(^"V[CAI&GK"C39U31!;J0#6$0_:9C1<R[]EA^)QYB>MOR@TD%*
MZP54VU,=L6\0_?G* KQ0*6YJEX>BW)8+%+&M]7(OX"!9\02)HKCD,J\%GHL#
MIT#)!_3R+K2WR";:T+$(Y1W1O3=VX#]F;&A@,/L8P#1=Q?U!=_4>9,B9SV[C
M%&8O8*?>&#=!H!FN)TI*SMB"TX,,N>!,SLY)@)+_$9/+*PS(:GG ]^;8=[ X
MDS_@57/^BT++0U)TV3ZX_.X$>S=[.,-YP@H[>L!+8^EYJ$D)N>X\@(Y,;?Z#
MWGHXD3)? IVS22>]!"XDT<"2D*8+$L(NE("^4R:7M\ZOSHE17UA(J3,TSQ:E
M:K%84I=3)I<Z=E.S0&40\LS28XK8R406NA2RWOJ)$T3)/D;M-L2A(P-DXZN4
M(#[S2TC>*,3)DS/[56^C1N;FKK>BU^U^'^-3'BO%^!J CWV"_68?QUG-B:80
M&SQ>[^& XFKJ7!"%8C2&G8O#*/3)96#$9P /F%!)*S[-ICU($X_2<1#@2K:M
M"V)HNAR_^U(EYW(_.W/-2L\R1FZB,-D'!%V> TJ>.OF[GSZQN@PR,>XS%C ,
MSZS6</K1>#Z0.#GK1ZS;_PXHLWQWW]79^P/'TEU+$,7ZTLNZ$T%RMO)*P ]3
MA)F0$AG$]YNF -FSA@!!Y$J"J 078F@+\IQS[QO7U0I=D1=BDXUW7R1VZ&[W
MS\\P?MMX6_\QS%[Z#M/C.4(*%4:![Q16<K'ZE3'[,#M1!?_P:;%=9?6N[A^6
MV^5ZM]BM-NO98GT[VW[]\F7Q\%OV>.OJE_7J\^IFL=[-%C<WFZ_KW6K]R^Q^
M<[>Z62VW/(IB;>)'&!Y+EY!]%F-V<_(4J;7QCG(!@U.ML'9M9I3A 3)D"W%Z
M9KU&<IH$9H?E\E/0&"4P9%3@04TR!;%HC<M@ZFXR"JWZ%@>CA=Q?;=>Z6_WZ
M=76[VOU&VX+,\A9T:CW29>=]P(9UCMM5F@'5U*1Y12,9,!$?:WBNG[Z=\#:M
M,3*GAA[ 5%0)\<YO:R1<Y9K$A&>2,EY?4+0H[%99V"GOH/,X/ED?.2\]M"W/
M3=>H1/U=9\I5@J^C%+&MK.,8S$, 659L3Y *RC4\H)XYW1%.<O$=D]3N89R^
M[6(8)I@PQ8B8PA*4YN4E^+"\6^R6M[/[Q</NM]GN8;'>+F[(M9?+1;8.2OO:
M;.L)-%TR8+_C[&*P.JW7#H/@(V@.54&2>YDY4Q.UU!WU)%<QL7WYAQI))#(K
MRJ["**S1726IO)!O-E^^K':'BLU$8[W99'KI<MU3*:TM;58SR>;K)4-'X")%
M[FGF&^X*K)]?IT7:;1R@Z[;-O0!K1_;0?7K]<$]RI=[C Q.O,MJJE,NK,F_+
MQ\1YEAZV1NE[W-(O4>1^\X. I;8,^RA 5S3;XI3M49YHIV7+T!F8CF9I@IRI
MO;A29^5E1C[)U4J*"]ZC^.A:(K5 :0M7J=AA-MOM['[YD)VKF_5L^Y?%PY*+
M<@KC$'.58,AFSZ"FUO0 LJ;-#4ZE;,N38EB4M5W 7%8M2Y"EV$IMZK)KQS;)
MQ;;=VPGZ?8]'6KX6 _.*2TVM6(&^?MHN?_V*S\G9\F^\3LORS!G>%*GI 33-
M\RQ>3Y^7)L5B!ZKK @QD&:*4BVRE-MT"U(IMHLN,Q>79X/J4M.HB9'5PSOZ0
M#\SE : J3H;G4FK[ $6U9)?3\Z_'*-MRR@&9XAN+KLG2'7@0N;8@ 0L,?*!K
MEYV0GI8TIR14>O$69KZRC@!,695508*$^[*V,UB^3_#DQ87?F+E9UP,8FJG/
M[6ESKQ7<Z?V<J17)*RO&G_W03]&=_XK< UAV:T*E*U =Z.J"% SISWM6E(/>
MVJ''$I  8H:3DCC=:4V!XBIP+DCT36<&M*(2\=6:S<LQYF<5.I@F6$S(EI^T
MK:4>@P';,V4T\7-Q".Y!3]J,X.Q,$"81N;#=HE<41-EQ?GR9H8W=#)T!4@Q4
MO;)/B[U=</)]M*9LJ6*^^+1T!*Z+=$,0ZT)?-K)BY/ZX3/2,=O![ATLKO0>
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MOIV/U*9$QAU5D&#PZW*NF1Z<']C-)E>D IEC+7??3[/:3L"S)(F[Z^7Z?.Y
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MECM^_.PEOPH\':OY@M2.[BJ#5R',4>+&K'[1)?(AR,9%-8\*'+6MAO@'IO[
M08JN".+)Z"H%'2%6PJ:N%CQ=YQEF":'6RR'4#\N[Q6YY.[M?/.Q^F^T>%NOM
MXF:WVJRWE$CJ&9=0ZCJ\[<'5;3V!.G>]^;3"K2U+-Q1!HA*9Z5MC(* "FW@
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M5 !%DN;.#WM.O\.[@#F?^L&;?4R WD<Q(1W=E,?0$5A(G7.OAS.(+1V!%KP
M5UZ'[,PEP4E]^5OI"U3;G7./W[D(B^NQ5DJP"N0N.-5U*O@+S'[^@IDT$8^!
MB?^IU!.\SO%UA\]BA#8O62A?^#B*YZ#_F$ W+$OEG0C2D6W4@W $&HSI$!10
MJ#IY(_J."%P;S;G7ZKR:0#51X.2=^%'%J=7#T7$@H,^1C:9B(1U#>,K 3QZ/
M'UIFFKTFG8<"LJ4Z<"KJW&AR<P9]NDFM73 W>V*ZC@0D7;?@5)21L>3F#/ET
MDV4[06ZT^G<="4B69*B\7PF\NM@4D9^\/3^JV#!ZC'H-AS=MR;%Y%UVXI@#1
MX4\W#9@5]W#! ;9LV),)\QI#5MX1\_5*-4ZWNW>JUW# ,B57_>$OMJWPI^NM
MJD%<+R<U'8#N.J;](QCJV@!>P&=5\TD6KQ535V!XAJE/>H_N#%4PSU7-Y!E]
M5ZR]@6<@S9GTS;\/6I']5XVYZ%9//]:@A[VN[\^R+<N4.057]LPQ=V6H55\A
M$W,AY>2E'F<UN":>8NZH!B6G2HC\Y)S"S=RH0N&>8M[C,0(-:I[$.TBM!QNH
M(#@G@O=^C,"3$.^-JHFLC0PH@;@$"Y(X+9 ?_W0B/?X![,AQO/%66,5[]=T]
M#&K$'[>E-@6Z[N%_Q&  TQIH17*)IXFZ<N'O?OJ4);.3 @)/_LLN6N*CKZ%$
M @U5\R  6E#5>%^66[G1SCQ&F,/82G_Y.7Z,GI';5#/AK F8FQI$O%,2FO>@
MBCI"1Y!3<\3Z"'<P= ,\;A,YS]L QS L@W<TRP"9K!"[!E].[1$KDJ]1NO%N
MCW8].K'/F@#%E725=PID^SVR0E(Z"G'2TN]C'^LS+S#(;>QLP?*5;@!3T9-Y
M5QOHRJ!.R/@FE*_"%&%BIO?0;RCI76P%9&0H-F__0$^64('P3?E^0 D,T/L;
M+S>92R)^(=5^2C5?O\"4/*7TMO%.+\(T%$8=.##0;=D3I21?5SZ/A9UOGOBY
MT;2UFBFU.5!E%VF\*SGT9&,S(KX9WN=SR[?UK^P,*G0!LBQ)B+?:,@J3:*C$
MR=,N+?[\!O6 $=^CV$&LN9[MXP#'E&3NFN@(-Y<.4/EF9S^@EWWL/.$I7^0P
M'3PXL!U7TD2SK#(?J./AYQMCLTF?4(SO!PC3ZVD1NK?H%071"YEC^PG;VA?H
M<T^J&A"FP>0.\/C6?3\_<H9LZEU' JIKZ*YHA9![G=0=P%ZB1"MNX#LP.+Z4
MM8M]&-1XHRDM@6++NC&UO;0-S 7JLQZ?=P@?"V^/W**7*/%3\A;  _ZQ-HKP
M/>F8H3M EFU*O,.+>S"D.T)^D2GW&!:)5ZTMNJK,R\$G]XM=%G@RI+SJ&$8F
M3%K?QAIYDJ T62-\GCC!WL5D_R6*W&]^$+0_>]!E% "QCFAR.IVP2/DINO-?
MD5N>,Q:E./7_57QZHWO%UJ&# V1(,O=\V2%<K5-:1J/,=-.RNU&A4ZG8 >,"
M5U<\19"0!EXB5TN4Z69M=R, 2W7:[L,!375471"'!"_9*M-BNDG=/7"W%L3M
M,R"05=,U!?$-<Q6K,VI,-^>[._+6&KP]Q@.FY$&-=_ZW &)U1HSIIH3W -Y6
M#K;'>$#UH.$(8I;B*E5%8DPW8[RC+A,% ;%@,!<<'C@VOF48CBZ(D9N; ME$
MF.EFF6<^@!56C+UZ:K0X2%IZ \LP)<B[XM+HTM,)^LD%-J%WH,[-CTU)<(K4
M9H<<ENXV18OD7)'E>262L;]E_\"-U?,+]./,'?L$XT=$6YNX=4UCH*B.;0B2
M<]6+FA5[?AM2OC&RQ7.$A%:S[JO-_8"F(,L0),9K!#9V STH@+;.:5:W@Q_,
MQN3<+TSN'L5^5//:8;^Q@.Q8ECK%^WSMPAQ(B'*0[M5.O;LH2?!<2-)N%&:/
MJ#?XW^3RN7>WV6YG]\N'+ M\LYYM_[)X6/+UQBUA3&A-0&5PVL^YNA[ ]J#E
M< KW*D_J$TQ\AP2M^,&>1#5T1E4S /#4.70$479:.4'=2+LB'71&UB7FK$*\
MI!!938M7+/LDF7$7'5=5&CG_?(H"_-6D-#?ZIMI[.""9*E(%R2?IRI;*ECJ<
M#..?G:6HHO6>Y'QMO S@9I\F>.<GYT8VH:2-SST' XHF&;(@WL;!7!Y*A$'I
M+76//A^%[C-&>RA@L<=3.,:712$!6\*93;=&.^D_'C MI&H_"J='H$,Y887_
M-8GVV(.B=+LG]7OD0:2;DFR9ML8IXKEGN1Q+EQ'W/&16NE+O/36 )EXG1T$&
MK%ZZA2A.D5.XF1M5*-SKY"SP5NN2#16KIUODD.0%'R4'+1>YA]WX^66?'FT1
ME9W^C3Y <]F="WX40,G0H&C)FPQ"<@V:<"X*1)\A2YF@MIY DE5G+LC6< U.
M=A A"I4N4O4SNZ8U5?LX:P)L1[)$*9["3+C*Q96.Z0+I#%_#5Y3@6^\#_O_8
M=\C]EVBY3?1N[ )<W;9=0;(T^].?#6,E<4&$?8]Y0V@K=CW*\$!U',D11)]L
MN#!=XNPL4:!L!+R:)KG=VPGZ?4^2#E]9_<UJ69_<?OVT7?[Z=;G>S99_$\GS
M7$;7KE/6]0"&Z4'(J31%3YURKEB.(XBCLI6N+#IE#FCB.J4Q5TQ3M.R]<PJS
MZI0Y%.XZ94F^=OA3S?I@30=@:J97?3IT LQIP?/.(6'XTZ: U78!JBY!2Y1\
MY!:ZLS*K!$TL=M5>^>EXCE=A'2+3$66?:Z4X"Z-*P'(F<8IOVD)2,C)3/L[\
M5,DJ2?8D\&,7PS#!ARS]680<8H=1@*S/35DT2U?U.*+SL@]0OA%LV?SNL9+9
M=.E[;P-4B.2YN/I4,W>J,,;WE]_'D8.0FWG\#N)0\-[7!',V=0&:-5>K#S,(
M3G%F5.QA8,>_D/^S88+^\_\#4$L#!!0    ( .*#3E@M\H.4SZP  ,\1"  +
M    8W9M7S$P<2YH=&WLO>MVXDC2-OI_7T5N]QRJUA*V),ZN:G^+LG$W>VSP
M&&IF^OO32Z#$UK20:$G8Q5S]CLB4A, ")"QP@C3KG7?*()2'>.(<&?GU__R8
MF.2%.JYA6S__73F7_TZH-;)UPWKZ^>^M_G6G\_?_<_7_?'WVX#%XU'(OC1\_
MGSU[WO3RXN+U]?7\Q] QSVWGZ4*5E?*%89F&1?_S[?'N+'S<BW]^\>B%YVB6
M.[:=B>;!-/!-U9*LEM1:Y"4EEXZ67@1_GS_9+UO?TRB5E> ]HYGCP/+FX8O8
M;((W!=_"#]6R_Y.E(5_+;.9*L]F\^(%;$KSWAVO$/:C*LG+QG_N[_NB93K22
M8;F>9HUH^"N8^!_K!\!O@T??/!G9=KE\@5\/-7?Q9OC6V/#\FYG M[JWO"O^
MP]4+_N72HT;LHS7^J!$\JE,C?J/AB^@>7UJS2?QD=<^Y\.93>@%/4,<8A3^P
MK02_L:W2RN\<.EZ[*[4+^#8$G&M75*6^:0OY$\$/9F[)L4VZP,M8<X?LZ>";
MI16/[)GE.>MPR+]<^L',<]9.IGD!WP8/NHY7PN7'S"3\:NG-L%\K/XC?3OB-
M7)*5DJI$AHH=9'GB;NE)TZ:Q^X)?+&_+RX*H\._SD3UAWROP?V=77Y^IIE]]
M]0S/I%?P]>^*_.<YL.'7"_[1U_^W5+JQ1T!RRR/7#M4\JI/AG*!LN-=<CSJE
MTM77"?4T@F.4Z)\SX^7GLVO;\N 7I0&L\HR,^%\_GWGTAW?!F/SBZNL%'WIH
MZW/B>G.3\N]+FFD\69?_G;F>,9Y_&<-O+Q5YZA'/F%"76/25./9$LV#NNO$2
M_%(WW*FIS1'%]$N:UWPY(X;^\QFNYZ;S+WBI\>,2)T8=_D]#UZG%_@FO[G+H
M$TN;X)C4N&Q;L$_S:UB=HYD=2Z<__D'G_HI_>(_(&[<P#FYX24%:>S;_M\I$
M* YM_'@I5>ME^>Q*AO_4U6JY5OYZL33@^O%;0!@=B7-K:D_)Q^4"'<?V+H<V
ML))FC343A5UD1@ /]F'BR5PS8>_=&NY(,W^CFM.V]!M S$[[H9Y=E4IRLU26
M$X\? )5/X &^M?5;^,S=:0+ELZM_*CN.C8O??>3*V15\4UDS]JVCC5 7^X/[
M/'_Y **6PO[K?<\>_?&@.3VG[R&[_DLS9Q0VH_^L.2ND:+F],9L#V^<S,K,,
M_L7W_LT#>QX6H-.1,0$<_'S6Z=XNS;,*D#V7PST*)I9JHGR4ULQ[MAWC?U1/
M.,&WDY.7IE;#+<3_9#"YCNO.,IM8'?8L@SGU9AZ:&VA3KIF8#ZO$$VL<:F)I
M=ZR9?F+7]F1B6P=CA(J\$R-$9KD?+JB !*_)_G_>.[G,$5<!"5\%:[Y1>__.
M98ZZ"DC_"DQ1+<N5A),#Z^FR#>:/-_^WYH#7Y+GM']09&2Y] .F=0@FF!%\E
M/7_<&A:Z*G=48Y.S1L84]*4V1P46K[+4R$35N(FNWTG0$G6&P/.TT^Q-J0-N
MI_7$)MK^,:66&[^/[Y@>: HEB^D%V_<]^RG6=Y^B]TR=1^J".3)Z;H$U1E^H
M:4]QHBFW\W=T#MK.DSVA^CV=#*F3=/:-U+-'3GK0T&7H3*::X>!TKX$/GFCF
MX$RA7-+.:BMOKYU558Z=U<6R/\*4+P4V=J^^8K#BTF4A$7@[87&.2W0Q?SYS
MC<G4Q*@$^^R9N>NPE%+@ Y[_<'7FCJV\DOWIVC.'_<6B'Y?^*ME4-ZPR>)PR
MYRCXR]#Q[[%!'<)F2F-#3]>=?RP[0JL_O@H^6G[[E%G[P5^@#!P/78^KQ12#
MWRV^"Z>I1Q[%%2R&X-\$?P>#7"QM1]SN^'JG@C$WN?F[SX^_]V=#%UQD9+\7
M^'\^(^UYO_QETR=$+/]3A\%^3$UC9/AS(#JXQ1:+6(;"8V6RZ,NW?ACNV=6:
M!_B;OE[$#A!N6CB/!&3D,37O:K&3X?K\;])3QL<M?Q_';4&E=U%IB=G\?4W"
M;"LDW9W9MFBM[]8+=<'^!SWH@27F^?Z*V&1MP1MTPYQYQ@OMT]',,3R#@D4Y
M,F<ZU7'%8 1/9QX+R_?&;<VQP!)Q _?FVSS^!1P:J,HV[LK>X*$FE\5J5K)X
MO:8JX"$8/#Y"56^1'KTI;J&;<S@L[4*>I$-!_L.1_P.YOXQIN)#\\&^%D_].
MLW33=G0QZ>\ZWN4 \W2]<<?2C1=#GVGF@FK+D]\CV=C>)2,;V]J]"^WE0(5@
M5 O#YZ9F=;4)71!L:=IYDK(%O<04BRO\)9?4!J/7=;OW"Z6.]P_J@)%HB4VW
M1VIB^N<!MFT^P'(F'E!SO\VCWRRH&KLX0;@1*9!9="K*@=>P(3,3H]FM)X=2
M%LH6FZQOV7']&O84E%IAMW<'I=:ILX(XIZ+H"DH>N0I<I:0F/ %3J[_5A9TH
M?T;\/?@WUM\)E[9*[E:Q%61I& BR(\O*-KK(W97M<DU((99WMW[\\LP]6S\K
M(6A_4<<EA/<>H8O?I+64+[3'/JR[ JD%4H6V7L, 3A]>1-W'1[&Q>&UJ+BAK
MOYZRYSP:3\_>@H++BQ!$T&03H=DB:/C*^_T3(%^PB)/BOO4!MH6X^=UUO-_O
M#<N8S"9BTW%_DG7K%###]:A93[Z=BW\N;9GH@;W-0.!IU9,E?G1Y1TBH0D>*
M0X5N]P2H$"SB:*EP?W\"5 @6<;14^.T$B/#;D=/@/R= @_\<.0V^?S\!(@2+
M.%HJG(1B/@X:),LMKWJ8VH_"PTSI84:W[*3B$KLAJ(A1"!.C$!U!A<]\ N0K
MG.VC)E_AI1\U^0KW_HB)5\0%CIAX14#AJ,EW$E;+"1(O)G34L48XY1?*2H"^
MV=;,Q8)&T4NC7C5'7S380*IM7HCH :45RH3]3W M6.4%&\#*O'!)1T6:L/?)
M^I4<&6V8F#MR9CD%'D$Z=&WKGS/-Q WB-8S^\?CCI$J"U1P9C0(Y]D@]S;"H
M'M2HBDT:UJ04?\.;2*+4LBWXTUT6:?&+.E(*M73=0+!A]TE#[UC7VM3P-/,D
M"+5Q;4=*KTCCU9.@T9OUB$Z7#8Y0(?6.VTU*0-I"7.:$T(6</2:"KAPH+02Q
M<"=,UU"HD*?'1:]"+(I!EZ#)^IYW/]TBU8Q]'[6PJS.&X;XI5(CSXZ)7(<X_
MF"X;&F\44N\D.E5L(FTA+G-"Z$+.'A-!0V7)KRP3S,;.VI$H0B99VP;[I5"A
M-(Z+7H7L_V"Z;+BC[N-%NRC*KBRBLLL^FBD*V?=8,< O]:J+M4A_4KLM$J]L
M9"O$*QN##R=4<V<.O3)<NZ(J]4OX+OAY\%7P-_[^S;O\:UU77^=S'OLRU?LB
M5\4&W['[0&CT27:1N.;9SHZK>/-[_/"&6O;$L.)>FW0U2Z^X6)[]ID4_P(O6
M;.$4_KEY R^6+[ADEVM236?@@L&OOGK:T*3$]>8FH'0,F"BYQO_HI3+]\>75
MT+WG2T66_PK#>T-;!PAZ\$-/#Y[_UGN\:3^6OO4&@][]):E.?Q#7-@W]"[MJ
MDSV[Z7GU[?,7_C@7;%Y77Z<Q4Y.GWA?VYUB;&.;\T@,UZQ*+OA)00IKU9:(Y
M3X9U*4]_G%W][2>E)G_Y>C&-O.JVUQV4^IW_V[XD[%V$?7#;NN_<_79)5M]&
M[EN/OW2ZEP3>]X4@RY0TTWBR+K$DFCI?8&]<S[&MIZOOW<Z@?4/Z@]:@W?]Z
MX7]ZF+'[[>OOCYU!I]TGK>X-:?_G^M=6]Y<VN>[=WW?Z_4ZO>^ )_5MSG\$-
M\&Q+(C?GU^=$E:N5YGXG\=^9"Y)S_N6P9/_J3C4K!J:-J7=V==M[O"?^3;M,
ML!BCQ+?H\@MY=6I<WMBC&9IW6-*ZN$*WIM;*>.MPZ9_!+;K^"+"[.*>K$]CM
MQ2"?[C7G#]*SZ.<]DS4K8OUS!I8E=<SY(YW:CG=&QK8ST3RD'4"$CBZ'MFT.
M-=.T0>;]6")K!?>T6:_4OJQ2EF]U]/^3?WYO/0[:CW>_D<?V0^]Q0!Z^/_:_
MM[H#,N@1D L#8'ZBE$GOD2A5\DG_3'JW^]W"P:]M$A%(H3!J70]@;*(TRY7C
M162XREO;(=XS)7\&=";<PB+@)U"=A.(A*SP]L+>WN1.RA*9+'9U*>/&SKLWG
M% P1:PE.U;.K&SKB/FE9D0B.$R,R#J$>>H]'PKVLNP:+DZ1GWYK/OI4D[#MX
M;'7['<:D1\N_.QIG 0=YX5X'+#2&A\GOR_\AGKWRT?GQ2I'%(!CJ,5R,$I%;
M TQQ@ KR:6;BH\V<1WPU?_,24NOH@>)=A8U&\[ 2(7:7EYR1H>V GU("2V8$
MAN2E_&4%99&7F73L^<@JX;\OM9EG!Q\X> *5?\(]FBHX-&1$37.JZ3J\^N<S
M.>K@!.,_4_9#I8I07>_$_"2S_Q!EX<Q\M-&9$68>Z9/A(F]Z> 7'$FX:@-OV
M7:E_W0$/XQ&D5FO 7(P$9NB%I^_5UR/O0E( R\1@:E3W"R8^2J7ZU\/ *AOD
M=*R1[8#69(=16<C[VIY9GC._MG7Z5I.Z^,34L5_P/2NV2Q,EI FOTNW- HKA
M:K&Q0?!BO_L6D5TKXY\F80?:CXX?GQPQXK[5*77 ?Z-2DIM*K5RI)*"9'R=:
MQRE[IQ[#)P%3Q 9;Q"'_G3F&JQNLKQHQHD".DOF@F-K[8)\ZC_W/I#V9FO8<
MMF"9Q+Y%DE1X'Y,5]H9-_+&R89:6KCO4=?W_N3,LJBPQB@*,HJI-\LVV+0K_
M?V;2%\W15UE&>G_\:-U\U*7YJ&=7_9D!O-"0U0]R#U?H$#5RV.,Z'?G,>#D#
M+]LQ81&9V3O^QES#/WO.P'Y=4D3U\MG5OPQJ6=J^Z</D4<]Y 'T(XB>=NJQ7
M<)9HJ1AOYIGQ-!]LF(?Y?XTIU^F1.53/KE15:<1A:/]1R17)YD^6V&,R=6 [
MC:EF$OJ#CMC%3? Q2#E,V^Q_)B(RSJ=W0P*9I>50[0T(:F=7=?E-E.GS^T%X
M9X\T\^$91&:,[0'^;%6NE9J5FBP"^A8>U-]=>,RD4YPWL=C$);0NS!DZ#42#
M+82]T.GAD;BCL[6X\XPX;)74H3J9SAQW!LO%6 T\P<P'1?TT_(P,B*&>ULB[
MS&3\K*(&D23G_MVX\I[=D8'AF2C42%L;/1/6BFN];[1GS^/=KM'>-PM\2N2]
M_GPRM,U/[N=BJ]9-$.,_(:S:/T;/V >: &__^]F 3QY# 2""5_=N#>.+MKFB
M#AE#+6F8!H_8PMI9==Y;+7-Z/N*[-]3G-,YH2[N)T9U_W1>;F *5 ?OQF.RJ
M;T#AV[=N00.46?>W?INTV.B:M7['3\>Y7PS2L72,95 RG)/1,QW]02982_#Z
M3%G$!^V2A:5&/BF?R;/FDK%A@D6CF288.)@!1$/GSYF!9@Y8-T/J/P#O#"V=
M,H:1E"KFZ'Q[)V(FA7(3;"#\&M-H1(=O00?AHU.'CBC32(I*6#;7)9_@?4!B
MXLY S+K/-B::@QR9]ZQYJW-_U99GB5/D/_;7\)EHEDX^J;A$F#O@!+X>_A<6
M@(^S)^$W. G_-9@+==D<V!PUUR--F>C:W#W/RJ&\GCD.C,+SK"@GP+^=N4OX
M5<ZN?D,W;<6C]8LD2-<F8<+U^#."">#J+$B.4 423@S/ YJ#CS%"_P9>8)IS
M0E^H,R<=E$%X4P1XO#>:I_%$XPJ:%^] A$S!NU^QYQ]G\*.*7$7L N1F)H\.
M]DL#\@GWI?Y%+:OG_@/>L^'"Y+4IC/PY$Y0[ZU'.IQ[..X0Q=3]G!M+('N(6
M^IA= JE:@'2=3 4P:,0$]XT2;01N%A;8 NV01N ':U;LIP1VL13[A3L!=,,H
M3B R@*P3\.[G*'_A;2"UT%-\(D^._>H]!]^>@SBF;&HZ'1L6JSA@H:&__=10
M5?G+N@FRKY4OP6-O'O"_EX('UDXO>!$BU7]VS52#)PV+\QW8HB4U4"I137))
MQ$_/'SJING"*0/QY* K]B0QMS[,G2Z[2CN&'.X0*WYH('/@'#!/KG4EUG_.*
M2IC8T?>Z*RVAMV*+2QI\OK<)95C*XUS#'C_9SCS& V /L8T?^0^M. -E< ;B
M).LF-VSOFQ-HR8,.VN>"FF,UE-;\3U\0'W0^&2&$+>O;S#4LZKHI"A<;Z^N.
M=PGLO#^R^]8MS^R=>Z=E.UZQ'R.>@J7\PE9RS1>2!E?5M06Q)QYX&&^P1C'_
M$VM#&^,X'X]Y=B"J+9MY8S.76[(P+*\WCRFB!6,8QS+G./BK 4.CB8PKL-$X
M?3%<)OHMS1H9FHF&+U9IX<-X<E#7'-TEF&<V]'6IG?(G[7.<57J><U?'?0;C
M-71*/@'YF,<!VP@&_5(@:+-U_WG?)<[@L&;E(?=QS3L(AS35\GZ)9^!*UPZ(
MKU3.STEE%5D>$='I9SP29LDR5]6"; >?8-<^)_PH,NG-/"8O@<"YWQP\FR1"
M$M#/T>W;BMQ_PNC6X5?\+HGEE2X$;R/JB_8A'*,1B"Z?'+-F$]WV=#HRP&<X
M(_X_W)_/.MW;,X)GR-F _J'[J-AFI3:2(E<D%1LK+,]V70KO&#;^E@Z=F>;,
M29V=E*L<Y-3"6Q7SSK/X,6?KTY[=7UWI=@W(5OYFR]^I#$>H?N#SZ?#966Q7
MBH#.H/V?0:G3O6EW!YSLD1U)()JFVA,M#1VJ_5'2Q@"12Z*9K]H<6U D%G1O
M9GW,?0YX=:%/%LW30*3X(^J&.S6U^258N:S D,D+S[9'9U>#UK>[-IX>O(9)
M "7ZY!0/J0=;]-!Z') .N>UT6]WK3NN.@#CM/=[[IZ3$/E>7C>WJ!_+?Q'<]
M>YJ%(=3QZ(0HYX>*$OE[<E@;;M5V:V[=S*PY_@%$WZ&WXT3BB_E]YWH"?AEJ
MHS^>''MFZ:41'NJ[_&DTHG0\WAMEUT18,Q)"7S7R[*!Y_-/019?#TJF%(;5O
MFJE9(PK^(:6>2S2/O&F_0#[-+&VF&Q[5>4E.GTX]_Q$YZ-"@[=V,3K@_6<N5
MLD ('+/_[ V!%T?VXCQRKSV-<F_8HI/%O'I3RL_-+(K@//@9#6J7>/#]+7\C
M3V,+R2BCGS!'5PJ.%O7%>>1H^N=ZCF9AL6?;!"?(Q3(KI?Z%\&Z\!8=OX/!J
M?CC\6-Y9"(S,!,9HO%Y@7&ON,[DU[=?"!-@D(&J%@!#XG0<]/%4(HIT%T=C%
MZDP/GO1LLI!(MV&5SD(VK9SY#\+*^9 V#8&@5T@;$<V10W&LH?KI"/5\E=\.
M.85[S=*>F&#XNTMN#'<TXTTET0II69HY=PUFS2PD"4H77C"(SSQ2=V:NQCQ.
M6( H.;)7\A*R.!B_E7V6+W\<R\,4_HGUN ;8 WBP$WD8/C"#OU$$F#9>">$2
M;6C//((-U*E''@WWCU-F;%702,7>F+!@[.RXJN(S=N7C&+O"(A%@RYLN8^H'
MQQY1?<9NERF8]@2T\;&\4P09$"$%@8^P8NSG,_5LS\P8%&B%3#D% YO7='4X
M$\9T'CXBLA;<<)S<\"'>K0CN+<SANQ7I,]C73,I<53]Q%VFS@RKSN\O:E3'-
M2?63UILY\F*/Y9V"28HL.7&J&E5?'%3?B(/L!^JQ Y8=BY]882W8]\_)!;<*
MRUGY?:?P9D+-%PNUC[,28 KM'\_&T/ *C5_(D$+C'V7^VS6>SJ[Z\&K-._60
M5_T C'RHTZI'=!QTY935T 16BIRU(F^.B\82+]&0&9\B_4HG$4[QSU4R*F"5
M&FPXJPIA'(-/"H""U6[[^T-%$!ML)HT-9G\Z-M6I6'9B*.X*/?]0;$),"+#P
MZQ[R2K]]0[ZU[EK=ZS;I_]IN#_H?>J0O>.'KL^%1!DAZ22S[U=$RT5<Q P9R
M24?TGL4%J\-3G'L]1'JX%1=;O-\5%VRS3-/X-GFQLGB/4IXG?F[:U^W[;^U'
MK/;>? ]EP8Z"D:[??ACXM),E(@+Q/KHQ;:O?7]+7 H IWE;?WA%A/;*B^#P
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MO3$[YB W2V7Y=_^H]N^1(]GW%,O'5\]R\^A0QW5G[RL9KTL5597*<HJ#9'G
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M"\OKP%GE8D.+#15LP&)#BPT5>\"3WM#CJE?KMQ\&?L&:S K6U-BMX[F5OWZ
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M!RL3*!;>EW #[@V B;7R!PF[JBPI]88H6!,_C<7(PNY%I#KQ;-@+*[SY'4E
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M/_;""E__W9R?1L'O/8>72LWT^>*)4!,LVL)Q4/M)&8>RM)S/03 (RU4$(:X
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M?K)@Y+>&Q484CF>!,_1L3%W)EWA#=OC\PC\C#[@-N75%'BQW-S46%<Q!D4H
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MK5.31[%7=7F<O1/8%5QQ@0L+3VD@/CTR@M&&8 CZ\;FHB  ,+Q9 R3V&[_\
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M\4@T&'C<5F),',.)XQDS47:KIU$^[G2PMDN\]'N!";^T&E6;SW/5&'Y#-C,
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M)%K+*,DM\W4\7P)F;M_//0U2=4-2E_:'#=NJ4CYYK PO0?^P[9 H04!\BCA
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MT@JF .!^7*V'10-WL.>,//1H4;Z0R^D*5&:COO+HJ#&IG4OK*V>(8)Z8G)-
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M1@M1 3W+,\,8]31;4[3.[P+?F"B59P=&'X2!SRO0UZTD,E$90!?H2ZF\0*)
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M"PM246 IBVV]&-%#/G?O3S5[D%.& &7?!.CD>4._+D)BZ77$N9'R@N/HW@V
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M&=S.FN:\;#?(! _<BAQ252#!BB-HEWL>*:H@317O8&QZ(E=B*\8P"NNL^$P
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M$+83  , Z#+H]P7\>8$NX>%?)B D(KY"@NM0?0VX!,+#NX2;/VX!N%8_7#N
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M.FN=V3G0FD%)PZ2CPX;"7J$X<CI*$FUD9ID+BP,_/?]T3?P%<=^VLY_=U\P
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M9.0M6I,@J[D,=!86T$0.(4^PP%3^ZD2"^(PJCT,\%8WYVC$>O.1>40&DE^L
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M&P]&'9GU!S">AD/.#\#HXSM(Q5;4633F@NJ 2_9\O36>Q1AR- CA AS3'+&
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MKG\K%Q%2+E3DLJ!C_98+!=7U-P$1.L83+DQB254L(_M'3[D_89.\BLZLZ'C
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M_R(JY,WOG]NW/JS<<=U86FE3_X#Z]E/&Y_S$:K^2IF#J2B5L&C6GMLB9^>U
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M_GO2=W[8Z [X'"2 JO3?BB9F0TE9*&GK@DM]TI&]+9[1%(K#@U\)OMDX/OF
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M,93*QO$3;.\YT^RR3O@9_1IMRTA&EJ#=\L?PEGO/%^.^CXP5A[*MO+,O[Q!
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M-\24/2[QI90K)DO"2R^+%GOJ7VK"R6@"T1VP+VEFB*YF=?6%H_2G(?.O%CZ
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M/ KC%@[4I%L=Q4KH<\W;PS6R+77G%W[-7S=('V<W@!XKS5J>2/WQT=F1R<5
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M_FEO4_(.L!E[^):HN<]I\84Y$NI,^U(W;*\_?<=YYFJ;?S/U94,."4TQQ$,
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M+L4EMT,_AJ4. [.+'^2F/-<[<$"X3!K<JPPA+,RJ1_G;Q[PO-M;7^N/<([K
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M$AX_RH9T8D7DXEMBE5TJT+K[O)GBQK#J0;)/\QRWG[]->.#.HA;>[.F(DN_
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MQQ<DM="K:F#" T(1%^ ^"PX%E7*?E\TZTO%6CM<3B :KKCU/8A'XQ':=67&
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M49X-S<=.+(BJ[SASC>\%39YWT9*<ICY^LL)17U%0=TBW0[Y74"CW=E?>0ZQ
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MJ;L-K\BHW9D+LNV'&YO=/5_5PV:X3JIACOT2W?Y7>]\9U52WK1T%!0%%I(.
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MIJ".C!5,2EC8M-2!& GKS]+2/_CZ@(&^LTA=8D[(J?Y.<RN-6+]IU=<(N:.
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M0J;=7550\,<QG.$V>O6KVV@\$&+:ZOM2\7/+=HB;3;;9)R,6GAW))<T3&8*
M(94$N.Y<S!%E_QF@'?7MB?VC/CT\).HE93_&6.$]D748K79ZS@F$M03]62V<
MUQ)S?)[$H3M@1)%Z&#8+6W@P"OIT^BN@(WT'4;5#B[<F[?)[Y+_9:.09X'?I
M;U\Z%6B%FL06@TC P-?LKPD<($DC%@Y(F$ST[XP] [3*$@3. %_XEHDTUG^K
MR'7[G0U0!O<36/Z8%T)/K:* T+_-7)I'*-Q28L#CYM.OX&D[)@-2T+7>#@[\
MP^UM[X5;>W:/HJM[$J(9C'VQTO/VS]BA[%Z3/73.(I]S']=5NL,-%6M_1QK
M<<(];*T:SKB=0[X#?B R/RS,1.VOF" P%,[:%G,Z+TTC^GC'QZ*>J_1719*(
M-CRWX=5RR#6JK'Q4)E]F!#!V6Y8KC U)#,7.M4V.I=P).6C5JJH.O)\16*-J
MHDU+$3> ZDS'#D"9WBRW1X"VN!S. &W&*"@3:#&"!,TF%.SX=B&F/UC*0]I,
MWKVF//#@@$-IS5^D;_YB]*]]>K&;%"%;REO*",U+5([7/HQN>'MUC>A'/@>:
M_9H,(-TTVZ$4GR_O(_+948?XEF3.(4'XLC/  PL2OAOFS@!A)7E-<I5MPC ,
M*%A4X65.=5G(SA;+_J7RQ<J/TA-\/V\$/\L'Q(HU<W@5?:9H"KB(,VP,<7>0
MFSW4**N&J&U*)<QZ(]P<#$T\JAX7O)YP^/KZ7!.F\O0G).?"S@BFWA;8X;2<
M\>EW4@IG30QI(VG9O_$,0*=&D&!N3S]F)^UZ%PY(:E=Y]6 >!)@U$S[<)O9)
M #<UEG5*JQ/;G,A$.B-L+?6[FV+O49"[YXJ^"[B^QJ\5TG]OU$%$<OM*;Y$R
M6&_W6C-&[:9:SR=/EC[72!ISU^:3X .RTZRCGPB\#>@]=$]*E$B]28)2! B=
MH21T!A@8;\2+5I*  [R_C9X+P0PCR@V&D"KUY5@\RK@MY-7D8Z)N0L_.P>9.
MG\=Y=@^56SGSZ9>F\,?+]X;W6!<K!_?0!79/YNRTKC_G9/FD3-?1CS0Y:A)J
MKSVG@MW>(#MN.7G)A;<1_6?!G@31[?=59X"XU 7'#1+' ._MGP&,AV<KG(BL
M>&.-NE%)Q,;4C%'+G'+YV(W!XBT.,[6T!^SG;MZ[&26UU:4[SB.)Q'"PS>Y,
M F6R&P:+0]^^8N2I]B]F0\Y#REY+7YA)&,ZSZ]AS*]?0I"O^Y0S"#L"88"NO
MH 3FJ3, CB%K@602%0^X\?D,'$]MQ_!<T=VH$05J-$1JW72'(%YD @J6!,K
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M&ZHJ+U>I %4O;0>J[>52O.Q /0^9OM-F?GSJOPK,3>7CBC"671N)W.QAYTS
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MM1#<<6Y*W!#>%=CS[]$_6P_2I6']/%L_[IUNN&W^/J;K;.*_ %!+ P04
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M'0!B;!0W5%8T%&8 *C$*&C$*HAO   "@8*#\=@#^=J"@HJ%C8&)AX^#B(1N
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MJJ ].2)_6ZZA'3"3W70WU-ZR>\J0LK^K<CDUQ^4M$'"P$AW&L;NOQ(]LU/;
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MN-"9F=6.T,]WUY(E5.F_K'RF6F% %.Y)$>LN*&[D$^4Q\=R2C500]ZD%3Y
M\=FE4 AFA: (G]I=9$5]\O>O;M?>?:O&+%XGF6]T(0[%G4_PWK_F&%)R/3T;
MTV8G9VDX"3E/HTUN5JA/?\TZ-L#&RR6>&'\8)'%Q:,R6'9Z?WBG2= :V/)@_
ML2NZ*JN/4I8):8[_J2N& .!T!S@<0Y^X$\Q[6-X*/S\\OVU]J  -9JZ-:B.:
M)AT<C'_-,3R?G9)FQMHP*V2O:CAQ7I<PIV[2Z\!6&Q_E\B4Z@U$ZIXJEG<RV
M)^T0)@(LTJ_U&$0#MR1(Q#_ZLH5F]\I]Q37;8"BL3]4A(@[*]3)<GD(]S2T(
M4PI^;."W)&D8;IZ\_MWGT[>G+E$W?A]*+B6\<K"R&4P"+1>6I+/Q<?GMNPO"
MS:C"DF6W/0<SSF$E*2;L,R!VAC>^ME[#P^\-<SP(.]7+Y;/V?V#1?QI?MWJ3
M5._%?BXX@E>;YAL$-.NNVC<^%]8I>)U:_D5%F]3I_48?(]J!%9J ZG3^M*#^
MDC43J"5R)$:VJO.3A=JZY&'_J%"'/-M4%F$;TA_5<<]L]9YRI)V 1$X=%8=[
M=%Z4.D\KR9ODSJ3YMWPS$6KA:^9(/K4')(TX!9*HN8CWA0MFBL#9A)?N-[>&
MTP0P3^KGC!9WK@NBI+H7F_)>>E1@7"P(I]15']<N/(]3[.#A?[&0.!XKQGI9
MV0A3R9WWC[C9@QC*N3HV\0K>4^ZO- '246E, #'W8KX!RJD[GU 2!L% 2>5>
M6?8O]1C@Q(L6"T\*4"NS>?BNM3[Y!*2768-[FHVLZYV-%:,THNPSRR6(?\XD
M>3T5+RPHW)/7&:]M-:-90&&6SN1-<<N#,L2T14_Y<\WXB51UK:D12KVD,8Q4
M?#3^P]&52H4I_@65GB^U5:)/!&<AB@*I^G\BZ.:MKCX0@C4Z)CU4R1*HS.5(
MD]P2DNS!%;D9X(U V'IIT0GE-%1Z;?GG8?MV! *PS)QD=_B>:*'(]"BBH-SV
MGE4=@;=3J')NUW/BT//8YI"]#D^T-(>0LLK&(@3 6M[!#,F/'(96:JO7F?H9
M/*6"M\E:1Y3(;'].CK=OD+0?_T  \JA!OC,ZT0@ 8Q("$ "\HYPN6VK,[A[Y
MZ<<U3HB,!(+_,AYO^\DA $RC^($_Y=K/LVQVRC).B&!ADKP(P&MR!&#"NQ@M
M+S<A(C*F<UQ%@0(/3X&-W:HA0B2!'?K:$_?#L0L0$GLB6G#[=-+9EIP"[O.C
M X:EJ0D"M:3@2?12*]#(2:YHG1]A/*U1<&8=LOP4>/^<06Y,>^#9 R,,9*\\
MJ+,BJ[S0JQF:6>TF&>B=F_N(ETRFA+KCL8VN$@+ 3)W?L<N9&_&*5$,!\.\(
M67@Y]%V7O*U6R_V6%+N7G"LA^1:,;R!290X-IK3Z2\;S!ND$PO!UC4COVL::
M5/-;R?Q7%#]NVUJ]<@AL1\FLZGR&#-2&NY1<.36'[+_Q+[M)F..^$,6J()=^
M..[^X)[!@D3-$),6WU<+5@=\K"LG@>9"KD]M8Q>[58Z"<^5^)V5 2W?N&^+-
M3C.<+50BL0&_O+9CF[A=\<O4JL*"G)VO7:2GM6;,.9_4UMF^!1AW<;#DX/+)
MTJ?\'4S:(_O+IWQ6",#%0. VG1OR,OOOEW=%VD0?>ZNZKBBEA<)>*-M?4-4.
M&C^Q8M5XY* [Q'?O)YHS&D9UMMTX!#Y\(!@Y+\=6.Y:_]U+UU1<\TI<K]NM6
M=L'+J"!)I3RU,NN3R ?<W$>Y2:QG/%](% <:KRD]L3AV==QHQ [*Z;G>%U'P
MDS/,G7@[KR_XS"R^\/9[-/Y'K-ER*2( <<\0@'8.>)3-=#E#]TA:(.ZY?'%N
MA.*7?S53C+8_MF^(K ;>8M?#$X>-Z5Q-6)"=+(<@  ?,RS= (79,N+6KAD.>
MNX65JH)24XH[0#K"8D]$'6VG$%F(8O9\/"W6G6</X_5UGN#PE$,.#LJ&KL3*
MB)MA,OSB#OE<_16&>P&O]>AQ$(!XJ_JKRB,@7-&G(3R3FU1#2UE#@13P'P@*
MA:O142,"P$(>BP 8(6<EV'W<4VC$]F^6&OFG:6C[NO'"*:W3_*(+_#./2$RY
MU-M.R3<J7:E,UFEOWN!.0>Q'LH6SO3&SS8OT_;/6WU3O3N"P+&C1'J&AKT0X
M1AVPMDQRY]>#:@7R&T0\[RD]J%.K.". X6>@^J*JR4/N*@T5F\ZR]%^?]24]
M2HZT,]PP[F .>DS#(K5O4B39AE;^?[*2Z5^RTFRXS(; JN,MCL@O*W&[TK,C
M.ZG_9276WZTTLB>B95B\J)^LVA0]38XT$/I\B:<638DG\J1X\9<! ?^H:4;6
M2!0ORI*3PO8ORGE1SU8YTV?65A" #<N*C_-7D1=DD2N2"$ GE6W6F1$#+.;"
M^;YX!&=N<=Q?8;?EQH:ZD^=2S-MZT\<L-=4@XS,@UVMU-[@7Y9&M34OLVC8X
M=V+=<)3.&DXW?L1>'\[2\%6_0 3U[0/F&N6\3?LH+U%<E1S"*CEHR*H,J8T2
M<-P=IY+G"15N:\8X05X53Y#G165O2UEG &M+=J^353T#B6 @J>#EM^$-:P_.
M-KTG>:Y- [<!EP"6[,Y6G3]UKLQ'MAFS[1MFXPC ?@8"</NB27KK'W%A% &H
MW?OR*S $K&= @TNMD\'VK04;XZE/(Q^#LL3P=5F2L(=*9<48@WR#TX!A_'=Y
M3QI2*UF\)3<BE,V7=#"5DY0'@UR<$X-C;'-F:^= -)P$=5\N\2)59M:H4N49
M7\>':4[=4[[<U]@1]YLQN]S;UU13/+U\+7C:C=J;SZE>BB(*0)E--'07VX34
M6/Y7H%30P.6XX+#L&[XRG:^!]\6M8;]%D0?4(?\J5W*!/T#V4/4/E+B3#7I5
MP9\L44JG10;N2M9^II;X'1H6^CR_PT>6Y"C/7:$I>@J%9\]XFO 76&Z+%]6/
M"OY0(VE_VW,S8QFL"^=,9_#X#'=I-=:Y#M&"\,(^@AT;7)'SG+J4V5)5@50[
MX2^%A4X_Y=!I/P*A[B:AT*)'NN1K9%-,9TS!8#<-+I21J9$U+/6&7>-%%Q/I
M;/UZ",\7]N#+V#HB7F[;>\EO/O;GZD03X:]);2H5DZ)L+1.ZW[V59C."6FHT
M0LX&J1<+IBL3"]/U#\%4VN;> >:GRA6-_O[[BV4]TA1>8>HS[@W<!X4SO >'
M+R\E;A=UAG,M-41O>8S'57_4>*(%M7KW^!K_[3'U#0I+;/-WOYF:2$^]0(UM
M.?#"S6OD"):EKM7-5%JO>'FF7-TT>>YELJ5*)43SV?)S<02K?;,<8'-4>H$Z
M>;9W=C8M.'1968(G/J#3U&G!$)U"M'<QOYZJ@_X<98?T)?XA3=-5#_=OOZ6X
M2.":M@V+,I"Y<\E&\HS9_UXP+;_VN QRMYP:O#X38T^/#?O0E#"SQ15:EVG4
MQ7\J7#?FNK ^A3^]C+%@N+ SJ6*?;[!KQ<$R4/>DM ]MBS%XV."$$.2<^Q,\
M:HO./^CJDCPP>]];0]%01J!>E-8\)C^BL6!A>=&@-BWVI]\8E,'L\\#G*U9"
M_S*3POM0U301V#O=NVN9<W.=BK=6RZ<XIE<;",!XM $H$IHZ"5PU^>A.JJ$\
MA60'@#\3KI032]@'21$DBT%# '+9*G,;'2D"^Z["9 X8 \^?UGZ^[_ ;QJ93
MW_S=1=U'HD[^5]3YI_/ZFS=30Q;\!M#YICL"I17':V*W*J]P!* OFLDQOGU1
M9B!S)?":6##0U\DFE]W-34-!G^FO,$>3MR=*73>M(R&>E58&Q^'VCA430N1-
M:C/CF]?OA]PC&20^/)(]TL(]!Y\!:;QN]2 .%2 80_%>FE'NM/U1.9- P,G6
MW,,V0JT03MW8SPD"LK0(0+!CLN-'#:0_E:GRZC*>D*E9/HRN+"\A:VE.&9S?
M8B9W$7D#<,*T!>\GC/F]I6\MI6&#+']TF[C7GEF\.XQNY+'@>S;1!/Y]! 4T
M)FH7S1:Y+[A$C_(4S\C>4.$NQLZF3>8&29[*A-F;%^K/[8K7_WP3 S:4"$=G
M^C#6/Q^+#NDX%_+4@M@L&[*UZ/:2U<6(VJN7/*"U:7CH)"<FRHH ? /-:\B2
MVG$;#*K5U5@OK711][Y-/);&Y/??N_@; ;(?FQ6K#.SOR4, 9I%>Y3+3[7^4
M:$FSX+83+5ZG2HM%6T(.U('T=B9;?-X/.]F]F+=YRMZ/. F\#U(Y5(>24ZY,
M\GZIT4EY;EAU+I'*?+JT*AQ5O6))$$>#QJ@E+5C?DN O<7#CD>J),?7#46;>
M,D'8_,Q."^?(-;O*IF9EWJ,6-,UM(,'E2K8T:6MQM(96[641H"+E_]C6I) $
MJC]MU?Y/9":EY"))"%O@<B("H"ADH\.[9JDF$RK]?P'JIY,P6 #4$=[)@0 \
M534V=@G@%VV&;-]] ,(_)B<"%A7W8MW?0-/U[=&^WXPTTYJX[EZZ+)3[?RY-
MP-I6UZ\0F@:U+=<NRF,>9=D%"URG^31]"U7$+\I[T"]T6M5%%%)G2MG"Q]$M
M$TY]65"ZN+S07VTHY[Q9T* 9V_63\#W9G@L1 7PTD  D<<U[P0U4$Y&KL*]D
M76;TH"3F\G%Z$5![@%6.G +>/"DGYGKU)X%A,(GU*BP&0IF/>8N%HW1CF?H-
MUZP OXI^V'Z&8RSX .P9X<XMLKJ0XB%-V63E6*FV\I2XS+Y_G:UY_6MNA^_E
MGHCNZ)((M'7-8Z:-YOM*)NFPY9IQR@!;JKGM%P1 ^AI^#V?C:@T$.HY.JP]M
M,<Z':FI!'HU6V.@P6*M*&,8*P4[U6!F#WQ$N)!]P?J6?:TIG'>\.5<E7'G.W
M?)43P-YB)A/5QMPZ(YB-8]U.M!E(93S?.CV3[NS&'#,@Q(HZHO02TWE'J<(E
MD+B-!0R]O70[R0B<.[.F'HEU)RC\8LYR]+@]#5.>L-0CNW_\E?0G0DI,'71Z
M.2S&B:-R(NQZF'H6_2C'K?ARU9TK67U3'*%']TN&2YIK[2KTP/X0Y///YEN>
MEY+4WTBV7PRWQU<PH"/Q\/Y+X.PGTQOLTB>6<LA 1?*7 E6?WQ/Q,8APP=V[
M6;/C*]_HN.&.L"%3T1X$0$VR]=;_),:VNIS.52M2;KQHNI+;H3*GODLYN9KJ
MC78_QKL89747YQ&4?5EZ6\CE6A_\?C#1NZ,6H/L7/#'"?/<:%S.5*]Z4S?3@
MYB$9Z946<ZIMLD.R/BNX^+B?PAK'A)_XA,V8/%&Z<XDAP4Q<]7<]V$C4!NVA
MT8I[CX?@GS)C&C<D#_Y#BF+\WPN0Q+@328P#W@))]99-K8GI>+C!(2V#0LWA
MR2SW\:/G7LE1LA(O4(] 5(T_@T*F\[C*N7<HHB8?-8_T_%0<0XUNZ-C?U_8+
M)-A(]I  <=D:\]M^7DT_%.Y5^)@!AWQ])7L@\29J:@E%>:5ZVFXE86)K:>G*
MSE,G[MIY!/>!U,@:$?K&>87/9]452_/_.C]-(O^0+I?HM8=G"L(I;YBF-!18
MU/\5Y:Q4[<TP]G+]^VRU=Z$71@!B8PD#?SY% ';"K5#IINFZ'QN#U:S=288=
MQ05=%!?IE+]C00J1P45.Z3T81@$-6<E4/ D@@\G'OABOW.3W?P>7@FM(9]SS
M%_A^4;$_^OZF/5R:<B^+XJ0^NG#&W7:^H#4" 1CL-.C/PRUM7]S8WC<!_>)&
M&S,R!'ZO*[WVNTQ8H>%5UO7.7L:!8Q7G_?KXI\ZW/_#<;G-6?+3].58)JXJ@
M6&N\86S3A_2!9(NJSNBE-'9,S<C0:- :ALRG ">MFDA"_I$5TM<U^65_1J>-
M!?+F-8G^.C?ZG<"1> "HS!IRUCWI]PIRW,WMJS]Y="1XQU=^E( =X1AWW,4H
M!5B0@E8!D7X*< 8D]9,ZP8)Q<TJS>U'H5M?.2@]><I79/Q/VXHBEQ.+J%T4[
M)1NJ[VB5:Z/T:E9(-*UO/.&-<)@XO3SO?8GQ<+.3<S_&,-OGB@Z9W.&"V=)W
M ^@FW1J-WR2,S(A2S>:1J>,P)%DY%(N\/,K!:/#37V!01K(4.2'0RO3\BC&!
M_R.D><<P7&<KHH5W;IX@ #<XE2F=[QW?"VHC $6B[><H:CCI6AH*ZN_^R\[1
M?R$MDVL>L;E=^:-KP\!;;?"4/%Y%986S-:ES[1<#)>+'E.J;X=]%#<Z;5OW\
M!7V$@TOV9],NRUZ;?>U"SS9+%KSE/ O=G6K*DG5,KQIHP1_#PH+T+BM-2IKB
M^V!&2Q4&E\A[LB?R7H*&MO36X^6'(,H>#_L-71YOTP5<^(*\L]_K=FUW2]1F
M1U)(/\SH7-YYN><Q"^!ED/XY)4+KZVJ2^J<<G/AO^>@NP^\O#OR'7=,0 %B4
MCQ*2S5WW:0/7^)!DKE<W.EW\D<?!T!B04S72*U\[S0OB4I(X*N&"Q6I)1A'\
MXLO=NT%__+K^4*%0L%.N<E"T/&K>T;LY1GKOJ]( +LA22:G-K B2IH3FT8*M
M:SXN#E=7O'G4YP-Q\J:-HN=R[$RS [_X4.=);2?,'SKHK9D:U8?&+Y"E>G__
MMTQ#P%/A#YG&5'DKQ3\RC9>_91I^?/^W_#0P1C2EJ_V26.:&V>" *^9DEFAU
M$@'08+C[P@U01\(PTIVF%)?M]Y-B5.,IA^)ZC:8@MD75IB^_0)J.K.8^=\C!
M\=1HROU5$*OA9TU1!/^L@@#DI!VT"#?[L>7S%F28W@ J*;3]K-*"D>BQECF_
M;WSY3AAJJ6JJJOP;E-+^,I0:CTELTA1C<]3\*Q19)Z?75>05Z71]2T-?>>'B
MH:JL ( V.[:1T$AGC/H@7OAX/GBO1*#+CMO1*SA-Y:60]6.B_H+W].*X@(7J
MR7,\;]@ASR PPJP] "RHPW6A,5''M8T A!PZFI]PU\Y)\JTL\I\-MM9[C*VZ
M-X:L)*F'HS$DT=[K6,_BVL']C6\\3#KW.-4#TDU^"(XKCS)]A>MS!JZ<MOX2
ML885ZC6CET'VYG5<UU@$X%257+'&GF1O]= MY02E/I6ER3*:^=23U<QH&[_#
M,@NG1S;!=-ZZSF!O_R5\=ROT9^;(&EC$_4Q\I7*"B(4U9*O5V$V-SJVFH#+=
M[A'0T)GRI_^)9K1TM\)FI.@3;Q/%Q??TIE?.NX>R5$O43=5-8Z_AH]8MG\,_
MA%_'\6<(KR]LMSIJVQH:VG)IU=6&,(:(:D4[8:WJ6/WRP2BI'6P-](6-QC9>
M%B?TB1M#"69B9]7!?7RSZ@/E!8;H]-A2^V%-D(8Q1T.M,;L9Y1?/ZW+\!L03
MJ1" N<"'$TF?0(\KAM9SQ8,G/GF4'PKH@*8.N^-DI'"SL*4_>!29V.#A5;00
MUU[Q7C&_*%JX(?)99!\1&Y&LXQBW"#MX0)2699G*.-=@>5QO,[?#]7FBA<_2
MTL_=]B.SO=PWSX>0U/U8S6-CWA-=P<.A@Y$!W&<9YFP6\=RD&B\=1$#>+[)=
MW==&21>-A"N*#?74N)2LDF<)J#_&F7M@&7??/^]Q@TM,%TS"A"_K8NNN-)PM
M4>BTZI<<H;BA,DFOH-*4AQ?[$EZZ=LZ*&DHY>,$JGZSF=VZDIH=[0.W10F(6
M=3]2*=3-S/N,SL 5*JL2>NLQ*I(:Y0^5OVM$G[T.W\&::9P/)-PWL!^Z29@?
M=;IB< P5]2@6CF818(GRW[0#N&:\T8Z,E*$PDASKP9]43C 81EN(4L"KY&^@
MD]V/ATZR[K2OXIC>4 FUP_!M*GA#[%:S*-E/%+\EC#SK#;W^MH&?H57IW@MY
MVQ#M2 X5C\S9\-[T#+AZO9MAZ2!A5F+5Y%#"$6EW0;/9+#PFYTI+(.'W':_P
M.R/\4L1W!7\,HT22PQZO.P&:IZ^85,=HNT43(Q ,Q<V&WT/&YR^)A@A 1V^Y
MFLUHMZ<TB[[]>J-O,<^;A.%8F$]^@!PN\-9P5*S4;DDX4B5RP/ V,IB_@8-K
M,P[S@O%T)6/]:P[A.R#.O(*@^H^U:&O63_'4Z5N#<?S.4 WW54-5+GV>2IA&
MN1RZ.2_+\F-<+HY;(IV&:988BZGIW"F>(H%44>4YAL&?OH2RC#H7=05>?AQ<
M-@8*PY=?K%&I[(?D14@.\5$O)=>S>H/X+"=A,K:V&--],2#*E0:,W+@] E#'
M_ONTVBR&B7QO$AG*O?)Q,D*,V[>J;L=+)=8W:C,EJ[[<_&H/#>4\_2;WF-<8
MTRFDS1\2.I4[Y<T+L9?D+>M!@_;2>)+?X/ (2^L;SV\]HI#D68^Z9,V:0DFO
MM#[;]<DSD*^T.?HB_[;*5')6PF46K=N$_DP(;SY$Q/$4Z#3!>Y.RC=7JOO1H
MP?W4,/0TD65LK1%O])K23P(!,'5$IL4F><4C[4A_*#F>AJF"3'+IK88!__,[
MQ5TA34#V5\(LGV8\A6*H;^<5^%(Z^1N2\&"V,BA00N 9,KM@F3MTW53;Z%B"
MO3!X)ALR$A/X>,3Q?;%>GUA"5FDS\5^0:CR7^RMYL5%8-]>B*A!"7N!>T-?D
M?MK54'\K%\K"',Y&'$CU]-&M[V%E6R.02BB?GK@MX59KJK:!3/>.X[F.[2?[
M+H>.TNX$)[[W&6>R],Z0JNZQ_3;.V%M^.+?/:[(#G\*22]((7:T,/)T$;85!
M?LN-<ZJ.'M\DK]%0H6,D&;2Q<"3(-.SJB$ZA;D\IW./!V;BVTG^!)?,X*NW2
MYG?OV>@-'],=H-=9"%O\(?VYC!2<7"FH=58E6>!8PW[WDVO+":O2^<49C^2L
M*:L=7I(]K/J\SZ9& <B;3@>+"'"?^3DZE^@L(WZ=[>9SOI6Y973\R1O-)C;N
M^+;O1KN4<]/_IVE_V=:2&>^Y^V!@^=WVXHWS,&^Z^^WR N\@O&K[%@$P$2T3
M?+GIO[Q"81RQ9#^R@TP\9PFN1A" QAM7M3.>RX& D4:L#7K+)884,H<(OZIF
MO,H^WF)H@&K%$XD[&7*1-T3"LBY5!X,+M]/S-.23*_&Y(!(C ;\)R51KJ1]]
M#,_F<TO.0(-#!Q9?,'@<M%W:4V4RRC9B'U6J.FPP/->4W!_E\)Q+##BP/Q/M
MJW36V2G^]2C6[C^KMH#;9*=**?5,]:[9O[5[8'CPHZ4.]SH#93]#N^G!Z?77
MI@/OL/#:]GO0]WV%4D+EZ ;::8>J=4XBSPUYA&,:U-JS*_CG.^$RM:F6=>E/
M8K1W.E6\[KA*0H&\:^QU4G:/YA$ AHS 9W.W<A>E&F8NHLL'"$!$X/G]\<#C
MC?95'3M[.+OA(HO1HI5KI_)2P>:(5,.^,1!,5,%@)5U[\&/K::3[9ER*\V>B
MJZ8OL,#>2E1*U"+&*[(LRW[&4R)S=?Q.3X/^UPB >2E#%TCB<9/8H<YL7W3%
M0E_>GK@/V&F')[5KY>(VCQ*S-- 2]A+)%)*1> E$PAQW]X@7]Z&1&E4,,H'P
MUM6<\O6!DSD9O4$EE-N@UC%O[$4 ?K^A$'F#_R"<-/"_7)+-^>?<C%^^WU?X
MW!@C<BNSEG*'(6AZ>V0*R?OC1>7H(?UYN]55[I!8K'03I+T;[\?0K"XU[3?B
MZ%Z5I@#M]V5>@=UI.C6K^Q7&M5V.ES-RESIQ;>OXGV^[*-=: P^Q9AJ6Z=6:
MX<3C2*;$>_>%C39O2Z!^O.T7(TH(_]L)(-V?9N\7]\9!$J8_<*7F8E0U)(NZ
M0K*H!_L5" #I3 D2B-]B86ZSY=9YU HIM3A(A2).N;W;U]*FVO<7^W9-VLWX
MBL"Q-V_:^Y$S?_BOSGP]'WBC^6HKYKKN%+E.!$DI">DR:^40&3&INX4%@$C3
M,&G :QX(GX2XWV5?JHV4#Q$G@V=6[;<6*JE,Q"B#*O,QJ:2TU#$9@OP4;(5:
MQ/VZ-&*.-1K;&V,DSE'R'C@]C4N@"M5UZL"BK%*JHH!Z%D$M@2>:\Z/E7@F.
M)-A%R5Q$Q*7Y7Y58@S>].CD5%WXN=-0[O&O]/VQE^H.(EN3/G3#H7$W:(0#G
M;WNLKN$7D27M*2?TMW=(6)\G.YZ4P(Y]=C\XTF0D9N:/%VW?CF_?SEAF'JMN
M^TZ?$A\2\,HLQ<HLU?@=^T@>^Q@%(PND8Z7_=BF&!J8V"6RE#VRUN%XZ]UXZ
M=\&J%6Q! 'PDD3)\UKJ#_&P065G[YRTU JD'&V&2,GO,@>?/DVJV?6?YUG9%
M@*LG2+O_>A'ZIN23/;D1AS>3R._L=T-"Y>\\..67L:?^0(Q3D,EAV"\.;3_5
M7$HPA81!5LORR8L]AHONB$M?C4A1K'Q;6%GW11<2$G?'3>879(<G!%\9SS5D
M4]E(-;08_\H23B5'SWNCJ9PI03H>5;W-Y&&.()[\RQ3"3G56*H5'\8=](V*#
MYC&@>5V4M79<:)[ZB7'11]B#-2YN]BTNJD<6AH,L+I51>]>4[M\Q_&_&,$V[
MV@EM#*3.4PA68PGF]$>)$0#@Y 55E<-;,4H"UH]XA.T])D4FKBL,>-#YSJ_@
M79^^",%%36504 _I8^M>'$]+QI0EI2K**L7?B?OG89#JJPS\%?>B<7"0:,%)
M:XL,F$5GDE=P]]$*Q1.Q)S5JQ/:ENE@E#L)9WF3X[?>XN?596B:.*JK(->EZ
M:KX=?? K$ANA80H&N'B?E\] MB.$;#/]W2-]15FGR )&71)3^+ 7!/D.^Q;[
MV6)=;%\0$>[KQB\OV$3:8BQ5.(6N#TCTM'"FRSY1>N3OZW"90YBH-L4RM9JP
M1CGWBH1?@0D!2"X579(*'Y%R3INI-.QL<F@N "_(59@\VL,MQRUBDJ5D=7I,
M1&GRL[+P3R$KN=W-O0E32+^KX.&=T)?IS3LKE:$023DA)KJJ!=VQ.YZ4TCM7
MO?S@J$:O[6V0)PC;0R)QZ"R:WKFBD3# %3A2<-:ZSSLBZ#WE@B56LNT[ONT[
M8YKE;^UW(_79-2W LY7>W<+[W'LKUH)^;/*L^*Q,8%30>RM&]C(T.]/H.#Q_
MT3.'Z"9 YH;]6?MV6M?LYJ)_3NR-O^/=?;:W.N3OA?(DIA1#?U\I,I$[_,-:
MT?]8//IO!9I&CM!X8]\0!BBTRI,6P-5Q@73!X72CTS+G9K-M8^RD?S5M^S>$
MZ.')1I9I-Q[PLK;NCIUAW<3XA&6- \:U2-BG)>YX&=34="L&%+!8_E3GXZM;
MX*=LGR4Y2529SKO[,##:;_=6OCUUE0!%[TV@#?[[Y2N+5A_/&(;40(,L*555
MX@$$H(+P["44M&K+$,8'G9'XXNPH?OCNIS";MV^ODIE$]K/V%09:WN@6&JR/
M;VJ-)893U^ZE>OI/QA31V0X(F;[W(<P 'W]\NF210I\I-%R9X5KW8$B)&[ZS
M)W,SW0_^P=;>T8YC[."U4G>")CF!*JLPJADS[5E<<,SSSJF(\S:VZCRVU%&(
MM+:ZJ6&A$O+DS-NWT;X4>%XIT]5^'SEU5CN])O6BW9HUN9Z8+[<D$]2B[*D<
MFM@*MYI7^/E,'0E6R#D^Z@NS5#OAX]13=(WIJW#6U=%8"!BAIV^)9WUM7:[\
MC<P<I/%Y(TXZTWK@Q6%? 0* ARLXG9!B&, Q =X.!Q$(:(P?GB\^ .D)X<6R
MKWD5  RJ&/@N$(!];5X"Z#Z<A(@*FMU5V&T8C:L0.WHFL/TF/L-CUT1F#1-2
M40E:P?8C<F)0LS?G]]9L?K?1%Z<B_7GMJZ2<_QJ-Z7T84/S%1DWR)>N49=B=
MG9.#V$.9S =J17<>#>L8;([[O@R*>TOL4X_\E/*LFP(2W/&DY.9X>,T_V8/0
M&NGVO98Z4;@E7Z'5)JR\NO&WW1Z<';>'N4(B>/$7!-,T+#B_C[RY3D'2 _"(
M:]IVA1N=C/ZD](,]@T2C0>?"!2!;SOUO^2_PXN;EODNBG)==1@M7!$)M4V]9
M)SSK85*Q)6F;&JK*>Q&M^NF  $'NSF^A.OA%<0,N1.NFW+9IA:!B+\_5%I^"
M"96\48> L=F$)KE'7SYJ"/"*=I#MM..N-DPZ@N9)9P6;YU''1S&2,YW.^MZ\
MD$-)K^Y[/OW$[W13]08TM U,D!Q& '2K#Z0#6]_8DAQ-U2(="C#Z5U)0<':W
M+Z*>XE'Q)?;&U_&.Y$+OHT%&*W;7BXN\/3>Q/"'R/1'=$8;GJFD"OZ_U__?O
M?^P**![^;3U->T9L@LU4]V/@AD)5#M?VXO.C:KR[W56&:S+;G8?HG1&<I??^
MP]T9_^.=]+HIZ;)E]+FCO_@Z J#88R0U)>Q97.)K33#!XJ"=BA8BG2>U_PW:
MLF0:>2Y\4=UH"@LGKL0;K2KJD$^+N,[F^@Q,KKFFYMEE52/]6$5#4%[.CWW>
MHT/NXU1MBU(TCR>\[[C)FQRX(MJC>[9SMM\^E^4)>@/YN>LQ5&%?:/!D($N/
MK[/T2:!G\"0XHZ[)YV<Z676]H>+(*^+81\A$UD?;$1G:8RV:B<!M&]6[X.</
M<.4+]'N_UD'?=>8H+B_1.OGOO7WW@WYU9@3#-XOC->50^W&@[TEIEC^]/_VP
M!Y'-;6*?>4'GZ\>[==6?<:SJNO,&.$I,@9U9=778*=C)PGOU8@*<42B\MTOM
MT=K(Y]NYM/WJJ[M0>]GD5X?:J8IG64.+YQ'^W'RG]8'=8;D;U"]3NA=/-/R'
M,@LV#NQA$9CS5H%^& OD/RPC7K+PH]E@'.M.2@0>X1,V6KIE#+Z,D-G=;#_7
MG!7F(<_CE2_#DI@)*YG[Y7S3!$Q9_>-_^6/]/$&4_]LWW>HB71.2ONRA( #Q
M.FT?JK(*KPNK30WGG7^[#LEY;L"9&_R_V;>-$Y]AF?W,X?R[1"A%R>BS]<J-
M)N!'<.R<*I6N' 'UY?)6FRBL[/VDW?GMO!Y\L)1?UNWSL;N2V5M-%]H3YNUC
MVH;Y[ROJ6/4;EE14^Q$&9U7H-L1W;<;"QX>.Q>5R C(2YK$ #A/L!1R.$@XZ
MKG&K/Z,U:-W20L*C)%[>=_:5N@@ ?4S+Z&B5$O1@7LB1H+W<DPM)EW43O.$7
MEV):CF$FY= 6L$ZWS%,;9+B\2/F-&<Z6'(QR9$S]0A?OZ%4>\C,7A@RRX]LS
MIMG'2LA/#:&KYFC>:'D[DC8BL42[592ME*V?Y<[Q][K\=\9+S.-A=Y(R2-,-
MG=WM&>*(0+.5&,X7D0154Y=>F#Q/1KX>16(VK&3GUZX=#5-\_]U?QM'Z?=U;
MX_>(JO#;="8C_=UN!<, WJ4I01#\,L].YO3A[-C%68L2G/V&]^[#8>"Y557N
M_VZ7.E)0VQ,9,K>];;?LY]MIUR>ED_!]_#\P:\>,D-Z72674ZUA:=/%7,\D-
M>MAGZT@WE,(WGSO*B+*AC?*9,%5J;_K/TPFL#P%C'&_[0AFF*RD0 #J#$QGI
MUKS+2 DF2 T",.D;C #$]7CQ9I]7-?TP]^._L/QNZ5+'=,.B^FM<EV5VE9 U
MMG&0NR\%O\;=,?L\;_1&HY]^;.*75420Y]MWG+]8]R^KI2//S^"??O%RV"]>
M?C.$O/*&G_L^1M*=[&.=<VL1:(T2%9*R52$]+/BKW\T$Y" =]C:?Z,8* ;CA
M+GO_..3KV;D4?I-GM_S412EG;KNXC,J?L39R>O<*XL"]![8(0!Z&/[&IY%ST
M$M.8[JQF/0(P5K9C\Z>+S/^.<,EHMQE+/$_;6?D6Q2@U#[+2Q5H[5!II,:2<
MWPA+OK(!A,%)#G5G9&ZW8J&J(%,]!. X;;LXA_#_E6*L]620=XD!U-[!8Y6'
M@\5F':ZO&WT-VC.E#%R?[-J>6'.\(S/1!+?+]H,Z8<L[ ;Y9"$"+7SQ'NE*Z
MQKC)76QFX^^G"N\VLNSI[944R/$2O&N]072D>CPJ6^-;4VX:KY!-#.G)_)>$
M)V1^K00J@%Y?5F0C,]C^X_S?EB4B;<YJV."C,O*3@S)+3'N^4J0:II^SB_]L
MZQ/99F/"J.9X)7/O^=1K%A:6DBIU!.!#L]8H#(FP-ML!Q\:V\;#*+PP7E1-!
MX@S_T%1FE6?:W_Q7BZS<_Z1\$7+4RE,@6'?U]FF.PW/\-YZ5F.7ZQBKF_@13
MIC["(U)*SK+T]0KRCH*>PN,+BBX)G*\U_^*>9K)MKK7E>]*Y[*$S2[9<NY5V
M!Z^H2'#,=)A2FU[7B= UY! IYC9D$^ZGC13YU1E\X)MO;724;#JPYD=1P$E\
M/Y7]2LJV+@?7(&G-^L9M%@A#VZ0O^EKU*%DIS3)-<;#QD9K[T@/;^1^Y-77U
M\6NQ6V:D*TCT&C16';0JP?TVD8JJ 31S*P/?[LF<;?/>G5K!!Z<"MT=,;S?&
M,,0?;E^:Y"$ TBX(P#)[[']TAS=O+S)#)+G#:>5!FG[<HB7[:]5;:$_!'DZN
MU9E0U.;+DV\ZPJ)#EF.Z<?Y9^XXP[P5D#RD( .YM5%HYBUR)"K>IJ?QJ39HV
MF[YH3RO%$^J'IC7&@:,%HW?7@9"\@UG3LWU7!"# %,:U?-/#NVWJ(\E0.@U7
MNN)_^'O#BO_1D//W=D3_WS3;_2_-**9+$0"6VU0R.R@0KN3/\6OSE:&.Z5QE
M^_;$-AS6#M6I#S5/7NZY>7,V/TJK?*0/ID )].C*XAH8XII,HBI@JW>='BR>
MTLY90$[$M[DE@=8_ T?[X*++JTJ7F6$P6.!Z-)SL>O>&RB.BX*[H-0(@PP!=
M#PQA 'LPG)T@ #$B4'4,\,.4?[0E_6<'LA16I:;_;*?QA]L!QG_^2Z0H__IG
M4#Q'2I#<-A!XAU%64\G^X/[+$_(01_.V-3GOEE(6)W3[T1=).Z9S/K&PZT$$
MP"\-4*1@] ] C=^E%", HQGM5S]R<-VT1_^))X;_Z(X]/X9B[^3CHOYEP4!^
MR\F&RJ:6T1?UTX)W3VCR:U(V'!0G^X]-$J+HT&)0J+:"&/[2B_3H[ ^O:F=#
M\^L3)?E^/+J<B<)*0?_F?X55,BJ*5:CF/J6.1=F&4QVK^VU:>DX"Z/ T@1R0
MNO%#(GR/7Z6?3A8-Y.'VYQ0+6Y8E/DVM[&[\6K,X!]/.]"AV(#KRUU6UXH,%
MHV*''O@.K/AG^R)#D@2I66380YKJP":9A\*\5TJ;+WHH<U<'0@_^> ]G@\N7
M9HK;O-,\,P3 +4#K0"."A[;8HN><(8DW^6^]Q+E\:3,*7# =B.61.>+=!.8&
M1YVNP]?@6MY(PN@<^-"?%##Z6XU2"L,5Q6G1N"S^OUL_5MH2 KC%=?_/_C/(
M_Q^"A9C[?P!02P,$%     @ XH-.6#CA%(Z+:0  [78  !    !C=FU?,3!Q
M:6UG,3DN:G!GY+IE5!S;NBY<!$T@P0DNP3VX6P@6%L&"-A(@>!J">YI @.!!
M @GNWA"D<4D@>'!OW-W=NF]G[;7W6OM\>]]S[CGC_KCCJQYOC^Y957.^-I_Y
M/K,*.8E<  B>*:HH FAH:,!+U = 3@/R "8&ZD#_]8V%B8F%<Q\'!QL;AP 7
M[^Y]8@(28B("(B*2AS04)&349$1$E(R4U+1T# P,)!1,K$ST+#3T#/2_.D'#
MQ,+"P<;!Q\'!IR<E(J7_/SZ0WP!"'#3K.V_0T1X!=PC1T G1D#\ .@! PT3[
M_0#^.-#NH&-@8F'CW+V'B[H 1@#<04-'OX/2'V4 ZJP?ZCR 08A)Q, GAT6L
M:8;]R(F$_UU,)@[CD_+OI%I#!TP"YLX!=^^1/22GH&1F865CYQ 4$A81%1.7
M?ZJ@J*2L\DS[A8ZNGKZ!H<4K2RMK&UL[%U<W=P]/+^_ ]T'!(1]"PV+CXC\E
M)'[^DI25G9.;EU]06%11606KKJFMJV]M^]'>T=G5W3,\,CHV/C$Y!5]<6EY9
M75O?V-PZ/#H^.3T[O[B\^F47&H".]O?C7]I%B++K#BHL&-B_[$*[X_'K D(,
M3 8^+"(Y36PS)^)'_.]P2)[$9)9_O\LHH'5 :NX\=(^,27"1^?"7:;];]E\S
M+."_9=D_#/O3+CB AXZ&"AXZ(2 #7/-$:'!ROAA[?>+)6-N<W!.EHD4JH4JT
M]R8;?>Y]61:Z5D(Y^+1)?-LP7:7F<Y_;Z\P\G)P2@XV2670?-VC*D%4-096N
M0VX!R-9;9SS7^8></94J@V:</[_3OA;<B'LL142YI)B?*ZST\3?"-"6HA.V;
M.O<PMIS'>1-2^1<U\J/+8TRP%MUHU2^9#<[W/GQ15#?)GM'I>V@X<KI+-J\_
MO"9@,,-NL\*A]Z9?('# #BQ4SZPB]:5,0:.V,9BJUT?O6++7O_U9)H=P1$I:
MX&'Q21A1;$(=)Q*@];10;8P=W]?P&Q2>6HEZ&"OALLE8P  A?J*V\QX.2G4C
MQ7#N%+3G<J"AQM+%I@\<#$L7Q&/+2JX%GGN[96!K&O6G+^VRODA^'CPQP%M0
M,O!@I;.7&&PE>2 P,IX_WJB4N\'WPXTJ&)_O$5M69$[L$_%=!8P4[54/6.B:
M;E/?E@DL/'L[@7(WV=AVEZ<='%'Y9$B\)E,7&!^P4Q/<Z4AMSXH34MW]6IWS
M6C:NC_"R;M+=0O1Z5F!7MG=4$UXA%&DR(3_,.N98<YL&X.),N%!_!-#KNC,Y
M0QLH3W0X>[=][@N#GQS)W6_D^_+*'4&*SE)Y(F7KUHON6>^W&T;6RCUC A+=
M(L=+NR\A8<139N$>)J&K""O1MQ$7&B\K4E\Q@.=_X4I6@4L'QJEP;KQKH)S1
MFN#U6^K#5JL8X778#V@KZHJ!FZD*_ESF],>"M-:_99^"?I<(5W!)/XBSV2Z<
MFU)S6H&E?/W.V/4X6 5+D^1<9EG+SO V*OK^S$3S&U55"S=&KE>EWYS\O<G.
M^FV=FUO7%&])$WFR,;SUSN)RLAC(X[,RK;_3S5*O)PWJX6768U%;!SYO)])4
MT&ANJAP!]XV=MH):*?1\4O#B_&6(;!TPK]CZ2 !-!92\> W#E5)\F-"_R$,D
M1LGR2@QM=#%DP>Z4ZF^G%2P&H(;?EW"-21L[&NJ"UHV+/^'48L1-Q[+!VGVH
M2'1 X<7V$BH\I7GZ&4&JW8S4F.B%0OI;[BT;((I5T/PI+V6"EO!>-V-&I\OS
MGSRV0PHDP:R&XKJ*T&*X39*]R9P "<8C)ONZ%9=O.C23:6/>%+Z3%C$Q65P9
M.V^+TSKGPB7NK1:Q%27JZ8X+5QC/&2DY.I+/''5]UU$J9'F74% "EC$==E,C
ML-?UL+GR^*G0ZUOP)!;WU=G"\?.ATR8!DY'^S)Q9[K&RST.AVGOEVH&!,]9-
M$H*<V8:)!R42,D2;(E=IF;F3QKC%35+R1DRR']^OXZ9]6<ZSZX@L-K1/>DJ9
M&VJ!,?7-*5CK+J;RCAR&Q@@HP';';LC@S*/<A"L2)T97C%)@C>'YBX5E*:4F
M&ZU),X57*J6V3O M/3H[ V*U^V<9*9^[C'_0^>J$4W6YW1>'7Y&Z1BT)?=+I
M(,>BH*")%C0(VVB!Q^5RNU"NAU<Y/IAILR]4>6.=2JD0-3>[!@X?^Z#Q1BR3
M9?:C<$+)YD:IA_JA8ESA_!1\LM]!>L)N(D:%<E7RZW=G=8NX"#T%M;P:C)%)
MMJPP>>)M%37K%XI6HAK\ZAFEUJJ'>8'%=IW/JFJ_./1\8539G>,54M(*\I_!
MAMT5*2*V=7![H?F"L1'FIV@LYD!8FJ40LX2]IB-YYVVM(%Y3&%N?Y1:\O30:
M@]CX+M5 FH3-N-!,^\R"TQ.]244HB:9L:^-Q9X)X'JS(AI+VD^<XD>" Y[DY
M[^.GC/(U@1T>CSOL!S>KEGGTG"UI+2TZ]X08\GUEPN7!3/J_G5MU:B4\_30L
MTK',QW[<?'/G@<]"&F=2]93%HBT7[UX9PXB0E-LC4PZ*3'9'HN"83_S&:(^:
M@]NMU/*F9NS<ZU,&]^JK]/2-UE?P'L_X+$%?J&;&Y<QK=U.I&92X<?IAP8^F
MGTSP<G/M+L>K'"^&JSW&[RG4C$BQ)GURI1I-X#G>LT1JKR9K%PI>40([K<F1
M@,^3M)[PZ+CXXXB5O<T.(U5UQ7YVJTXZ6L4\>M*G^D-+SA<.0U1\G?R:H' M
MSO6.])/<MT7]N"C[0=Z0#X+;Q;N&:H84K@4OO<CZN&5\/C;Z7M>MP^N+.(SV
M;#)BED):DZ+2%^4*51@H?>OU:YLK=5A Q265]#([JY=[;S U)ERGDVT%Y_&W
M*0-MX6JER3@UNN4)GGNL8L?X>UUM@8-TAN<IVNZ#11*S633,@X<-O1 "VW'Q
MD#/+L=/9CNCL[]8TO4_;)WNN<SZRNK] CX)],<LK$6>I\<K:3J0,-)6G3=/"
M%<O09HK"_JP:J_HN)6:X:2TL5X([<.HRY2QU<9L;6Z6N9LCB59HRXB96H++6
MB)TY]*Q,<@CV8?'"VY?1.F>V;TDE*W9NJ6\WU4D@EM: .K+!JW\G)4*O?$@K
M'WS*W5D=$J-F =VL/[J05[U6H4SX B:>Y_%ML QGYURO)/V&/GJM2U:7T[0>
MZB@H):^?KJKJ'C6A4G.--T)(H!G*Z/82ES@E;H1TWS5^63/?AVASOG"5R."K
M(Y%GT5['_HO:$1KZBJ YA0=FLGC)2D;EK*)2G(F#B"'K(GO#CN0WQ^VTT4R1
M9_8&2U$&*Z_9;A=9GCSP^M;N<\LMI-M=?'>D1;M?DBY'Q7HI&U>QE9M*I>:K
MXLLWPS+[3(P3,*5E52B9#(EAGUN171)MF>U=D$\MMZ'^FM+69WA/)[W3][+?
M<KX5KHVO.OLTYG^LKBN6YWW/ZVM \X.0JX9?,&:ZEI^@P6PN/+7D6URT853_
MW/(/:"[TAT<Y:)L2VI'[*([IMZ]/&RQT]^I$EYK"2=X*7EXS^$CO'*GV22,Z
MVSWF[@]R[X&YW.QM7HFPZ>>6J'Y*Q%-_T ;XN<"_%(!FY;,\LW5AP9OF(SR[
MV95!(F1\T^#^H7DQ1ZCW+8G+)7[<ST.HN?$3*?*M)%B#'&\H"Z%8JJ7K"#3>
M(8J__+CV?+/[^Z8!@FIDGV5HU[5RO2DMLRPXDI+BT8L TIE.BU@- =XG7F5N
M.=EI/>.L4]L^*;P_PDG&):5L,YL:GM='WA \-KHI;G A4I+SMP\=%]SEH)'7
M&73@<F-T<2BF#;)TL)JL,[HL^+8L,< <#>C5CKQABX#K<F@TU*U=\;R[K5DR
M?G)M<JW0NUD,MB:[I+&PM9 =8!F4=4RMO]9-CZ+W4]Y((@A:";[6D'?R5S[*
MQIR6[@3T'!64!-:T=O0X8-$TL(/23-LEW@=36[&XW9GU"<IX=K^YCY=;QKC<
MKIG727]S+X([0&\+\S;GZ'1:*',1%<=;]P:[LF;)GNSD=GV[U)$%CDW&%#%M
M=WGK!<[<I]*H"N"V-8>V'FG,E<G7$MH3#HY,%M0A=D7QH2";KGXLCOY""S\G
MBQ+;>JEB)H^DH-)/UB37-[EA#$V?S^'/G7TFJH:49#[ZR ATZ3@XNF[;^WS>
MQVKP*U:P+Q2;P;"GF'OJN:  4^2;D#S6X16DVU63-B4D=U0L*]P.2XCUJF"O
M_O",A*"N-;) 93EEH@J<FSL _GC)6[?X\$QDCOXP=T6\H\DI;RN\X'7E.]?+
MU,4@_=<V*[IWJZ)4&.OZW.E(&$;VN$YPU<SG5%RK1V-*<W3<<8IR(G;6X]Z9
M1(:QBR?:J[V35VQ(E[YH%=TK91T^Z=6V8$D9@F\>0)M^5M3783RC)OC /_M<
MG7K"E"=..+/@(MDP86[M:ETU2@(L+<;TIHQ+<X^WAIZ/Q_M:KW!WK=!T:GK+
MT/=,A,V$XF-V@7E.X)X8Z=OALZ?74E/+E*_$GV<N&6,M*X"VFQQP#<KV\^N.
M8_+BE?PCJ-!O+5S1T4GIWN]8-8[ONH5'.F^M@VJB5/;!D,JU,"5PR..NG6F^
M- #]:[OW>/AB*J/L,95ZM66L!NE*@NZGR0>!+D1.NZ"+;+CAUJ,7U:^/38/$
M34/ C0(T>Y_LAK8>-#A^&5<P8S!O5X8\\?'68W2%JW_8]Y5CLBTP\8S:NLT<
M&>85TYVU:.7*B* '@IDF&F*^TQ3+_#:R<](D+4%%[IOL65F.QDK!E-:\,LIN
MMSJ6)+J1Y44+>WB6EENB/]]9:.0)955VS8WN>QK\^.'KGC8<-(DOH5<ZH/5A
M7[E"S\1^-7F-B97::[)D:FGG(O)!MGC"]X#T$@C>!*\4G!7N5:T <4L3XMW[
MN2C'FL <NCX:]R+?\FNJ1)JQ7]F,#3PZC+M,>E:X=-S]S-WN8]>2Z>Q"#PXY
MN@]UNIV:7*FK@1M5=&5C^>3DU$:X8,"3 FJ'!.W*-7JG6+$RJW;RW%W)P*GF
M]0&"383I>TFC])9TY015T&LE>T&5R&_=;(K,7]&VYX?K005DW>N.&' C)5NS
M[&X7AT<&TEZ6+^O0ZK@(5= W3=K#'K.Y46TP/Y]5QS>M@'="2CR%A%BKU'B4
M':P3^Y" :KUS48H,\VBL"GK$A/PB$KCW/>-B_UGUR/B6#*.*5?.7M5BY-RM%
M!> ? 7)X]B/7FO"X.+OV@MS"]OFEXZ6\1.LW O=3W]=\+-RPY"'V&&67274R
M/ NK[T]=,B54=?1AR>3)2#!TF&)29V+DP-;!1D_M%"W335:MK!T%N[$OS+K9
M49C',9'B/6Z;H?,>R4X:_UKGZ)/FM>1#1R2=BW_V6GSTL.0>E#DA]WZ]P(,Z
M/2V7?16W8I7%EI :(L\ SC:G1UTQ[=Y+1RK4T?'$E,MT0=[,S-37QJ^IDV8%
M!JHB+>0'WQ+I&S<&JRKO/@6][5__&8?-6>G@]3KJ<TG?@X$78\W$F^YO2489
M*K\DBT1*:BFEQ XK/D;3CHL(.WWV_*3N? 3:%M>P:=%[@TMS%B6I6F(?LSDN
MS->[2E\=N7SO8^E,Y'RK5Z>S"\B$PO8$$I(HGG(@KL(*%T+#,:H(L7(S\EZF
M]IF0+[!U%Z]R4O)S7&\G"="DXH/KN\Y(+ \>&IZL2H-]WIOU>-Y&!=0G;PH;
MGGBXP&WKY9K2!)@^,*59<;U8B)P$#N$-="'C-<+-:,/9#<>-;53*1%JJCRJ)
MB@<DV=&3=MC9G,'Z=G<ETNY;Y-J<2Y./WX]\?W@1J#U*.[[-SE'%SC7)F":]
ML"5@F)27Z+=X/4 J\MZ\L5J9"YSIKG5,M'/II:-R^<7BI,PR*UVB3KJ/5N]@
M7@D68M \)KCKK7KM'F0>*UB9@#-[G+K2U>ERM3P.G=F<HQ]O9K!_Z.U0(MA@
MKVI3(MD).Z8X]]W3B 4ZE"0G<C15^NK$[@2H,+:7-K+FY;:$YL9V;/FH479S
M<6G_C/DM%I-GX&C9B6<YJ>LP/C$.GDI[:+I[I1/!-YU84YL$^D*!]0H31P&M
M=L;9LRS#26WZJ9W@WN"LD#UCNUNR$VNXZ[1$H'"#&X;PV4!^3PUA-S$@HD9=
M_%[*6=5;1R!_SGZ.+\;-D<!(?YN]@(X%<V3-EC[4=&6*'IQ\+^JY1,I$XXAM
MX71&JL2I@)":UH32R,HH;T3S4\\Y\] <>N*(13G14L;6(S7HQ=FQ(2@\4ETU
M^$YUHH<P0OG=5+/-$CE5\"#_#VN8MX[(>!;_JKI:CU.#TL>+"^A !+VBWEA.
M&'.DJRUCJDCLU/&C6)E$=_&$!?-BJ;1X2:5E*377AN!#YARORHB2AFHF>BSM
M<Q!3>D]37H1.X12SN1'/GN=L&I0EERP:/V3\:/L:5SEAH^IC5P HD%S!Z"O5
M!^8H#GQ\ QOQFO!&,>&T^J"Q$[YNKP*36:XVWV2^JOW6%0%:8)ET]W,!<Z15
MT++OKAO'FS=O_#;6=P*GSJT_7W#,:X^SAHV?_S3F;$N,4Z!R9-T=P98 28V1
M(+A/RG2%4O-LS[QU4['2\UN_@IXT:#[\BF@Q'"J,KTL=<HKF^(KBAF'WV++\
M_TDXZ7X0J3YXY\'$+ZB%"8A3$\9BDQQF=;Y# L3WY9' '4-_(9N2EAU])+#!
M4 !9D->\#:>[Q1#"O\&Q T:S*I! N042R C.1 +O[BN=<4%."$9E#A@*T+7"
M>A'MT8@ RA $AA#=9#D2&)370 +?@C/N/^/DO2:3N<*QH[L@&(68=R(!N=^'
MHO078OO_W5!1X;0R*[^?T!5T5I(TUS>;R EMW@X5-=L>]Q??XHR'SQ_OEB&!
M^7E$$Q4(X0=# M?72& BXT%IV*IPS<VU/1(X/T<"98KC2" =#$$@D,#I!GIQ
M5AT[N0*Q"I/X45; 3]]^_[="^5C)F.V-'H1;XN]42,37%NL)DP#X_U-N'4N'
M.&(&R@9OOTA2^5S$)$#T'$L-<(W78X>UK$^;(H&6EEOOO[I$EL:8M ?L>'DV
M@03V]Y& 2204"4C#D<#M+1+8'L364W!._HM+L^TA ]4M2  "N3I!&QLRRONK
M1_\2!L#-]7\RI.W*;1$."V*J1J#YAQ>SA(>%Z,*U;G0(W.IK*DN22H0>?P>4
MT;(Z>(%8ELI54P$@^5>BZYY=N'FE%CYOYQ%C"&) R_U47<"T@-]?R>-KMMB@
MU!"UK!\@4F5I$!_[+&[0=7V>HM,;J%M2OR3;0P0B@2>D7\5U:9NX7"[,UVST
M5:BR*BI2@C$B"$&!N?]ZN/]$A!#+?IQIY<9JC5*Y2,"R^PY!C]5Q?$IGW$>^
MN7KQ#B3PWD6%SGVTH/]-12U=@LV=LG#N4]5TW#GYG"_2P]_?ZJ=;U#M0C8$J
M2;NP&G>9+V(L2@;L%_W(MGIE;51!>3E/CT)Q5E;JV- Z".+2U+Q#;AB3U&^N
M6VX1D,-L!&$?*\)O'A4BF8M![/MG2"!,HV?(+THB-<$%0#RCM]6)ZI01T>([
MBKB7[U1P8X+2Q7EK:WQ,>ESRTSOF:K555>'+>\$=.YB7+N^23DPOE 33+\\A
MUS=(8%GI+^-D/&!5=:2:]<Q_47M(PB]G29MTF)55$.@%E],B3Y#Q$:-V+9,;
M;EFYCTIO(V+4;"!5:Q3)KOADK\OA2=]S(0.U5:*4IVRG#%) TU&2Q034%$@T
MT/Z5&%!&WX0(0JXV61'^]B850G27#VQ0V3>L?@L,HG]QFUU_/>[CTJ%9&=T?
M67]^<X::42V.",&S,>A8V.5#(VHG=$@0ZUE[R\WU+!)8D( $24.8U":<&MSV
M+W<MD<#;^1N;Z3+(@#WO-<I1R\\1DS6H#/=IN<%V/,CYZY_LY&[,":?Z>#T7
M3_>S.>&^Y6GQPHC=RYZ/?)M]GGO1V.U08JW@-1^)AHU$=<HWNC&6O9E4+/1?
MO[].[2SK->ES\EK9U#;)BHYEB='57HW">J.R>5HF_/4BILSN(7=NLAK/@):R
MVFBZ;<RP4 3>#O;%Y[.73E%.JLX1/JHR8>,>[BUU=?5D$Q4]O_4W/O&F9VAV
MN$LOXJNSUG3Q'9RESIR0_O#S]_<:C?<, 0IEQZ;C<LQ:Z4^#%Z8=$W-,(#_M
M[I$2UZFIY6O)<TR'P:*5<AJ<9='M&JQR[K>\AMV.3FY"P5VQ)TJ4!2^/IK^^
MC!(!<,F,O $E0;1\/XM#RF-UK[W217L5;NZ;:5R%HU+<X)\]92EW]/)7C7XF
ML93+A,:2#?HJ@;-5N/CE&.KY51S"5%X!*O$S3A/N@-!HWZ%]V]E!XSF9>,2;
M',LD=79]+W\B\X7;_?CCD;D&?'Q[]V:F@]L\F%5L)V;/WHLO[O4+"P'26?ZB
M,D2VM")IPPMV>EI;9.N:_-,*N1UZKR0>%[+-E;1)C:[0>I&&WT8OGU4HA,UK
M!_Z0Z#6:39X=W[>ON7WF$GFQ0),1O))T=L6&[C^TVUXE;$^;7FA[MEO 'D;S
M!,*'!,92/O(_BSAC6H>Z(NB00#2HY>HF&84"V2B<CD9-G^9.1,"H)P0AY8""
MJ"/'VWO^PFQ98<"_DJZ)$\_36:QMU9@?YF[?G-]54Z^+"G6:^(K$+FO8;P@-
M<"@SQ>RT@8()O4+.,R\OC_O%+>::'H4!*T)J6!T#K7RMFBOVY(S!(M;TB\H=
MLJ*E+3"+BSB$0D-+!@KR@UX_B$?KLZ.\W]!+.@8M5N%-;5:XEN<YG&_F8"_)
MK'FW%B?_\1&[5?L4*_IA:596K&""<)0"7@3.2V]"E6>JBV#BWLF^Z*?#KR)?
MD>T&H.//M5R,ID^*F]Y<B]S>0@YS*:53BDCD_471?2"1<OG%AEMZ[HRWIL1*
MQT2RDH0#M=E)QJ#K]NJ-?,G'&_6PW%'/J&&C[VQ>("!-IVZY6H9R C$V ME@
M!*/6!UVH.%-X]=,'4CA=>7ZQ$PB_9230K"#"S.EBLCH9RTYD,ZX\94S^BC\E
M4$M/O/JJ(RZO'J0"YM+ >B5/[,#(M!RHQS@A>!Y*4RI<R<;TV@%_5>W[;:K>
M1\JIW*+J"0UC69::CRH477A216-J2>XO40C[^/]3MOUWI&NTI+34@6N/:RU,
MC#LUF2C3\J4>S0>H-QLZ9^\A]LW-)&0^'PDL%1S=R*'@5)CN?!,)7!2-9?GS
M-[800 ;Z0FZO( B.:-X?=,?'9B@T24>!+=20#9TF<^*5HEZZNJ590!X9??3U
M5H72>S,0@Y5@)  *E1QZ.!DUB 3F.KPGC!4 9R0P^9#.P6>_? ,)V+L>P1TK
M4G=J.V;6\T3S9VP\'GX(];#/?EY,%Y^E^N2[]G4V:S[,M4H#FT=2AG4JZ.O(
MB1Q@'"!3GIIA0=[A=Y?4&=ZK6UD=-=Y7->W)2*4ENF"I0^N/!>WY3RUZ;-BI
M6]<(BSW:FNBI2>S[H?G52I21@G4N[P )W'BCP'-B9?Z*]+6N2$C+\O ^HH4%
ME9X%Z%9A;!EW_I4TQJ)&L8*"EY)WT02W15<-*,P2K,RH[7)6NF8?+(AVRG\O
M Y782LID=I]EL\18K1T&&CD$J2<I/9EQ"0,ZQX1J]R7I[K<9&BE.5!_^!D14
MY"T]P'4EG8SZ%+GT^&&;B%TVP.&/[?A9MVM3%I-$4_8N_.NIO%!NCUTHM4-,
MA\5' ; HEQA6S7T%)EM!,'48#?G+8KQ E>+0XK!8)?I+&M"&BWJI]]*$5N48
M8[)"5>7C'E)6 _*\P;N7P=A"[A,:,7L.X'TR\IP01TX6^3L"\R1E,RHG5C!2
MRF[J+Y-;DR=BA1QA8@W%/I$L2YS%*J66-?8!([)%U,!4-X!W"@5)=#E"?PSN
M3<766G+(86,0V.V^J@YU7).,Z7,A.^/18;4T2FO4=&/>M[E^!U5P.=*?TY^=
MGME<6UK%6HUE=WB.PQAX[$U9=]:GA_!'!>L.6;2UCRCL/ <KES2&);-0B5@9
MSM<:T'G+X*/3X+/M$ZY?BE&4]12_ZFM75V:KZE7MPX*B=' E_V>%GXJR(J1S
M_-A0)H]JYT*;/?,W=[7D [NVV*H:T)S#0G;)5I;[(]+/@]2>]?UZ3/;MWV'<
M?U<XJ=KF#S<]D(!I'&1#IU)_CA8%KZI_8&W&_:3_.!V_C0MU5UU:P"J']F&J
MB<;3W,MH))"JG2?1>2Z@TU4Z(JH?AGDPZT6_^SQD-(KT/$S70QS[*Q_%C"QB
ME3&< F5I$''%PL6XE9OG[D0_IE\%;TF5X)=3X$E]AX:MWC"^JC<)M,_^XC%@
ME<NL+?HYDRG%^NL).3DYZ2BJT"!=\@X)N0&+A+E=!U>V)*O6UCXPB]JWC<'&
M(=C;>=.YMX#G(DM;^$_EHAY%H<$VX84B9N-HN:#N(7?/AS:O*)P9#[U7;&@V
M?SB (V=<V -_3<V>)#K"X17&$G1(EMRJP\=8H51P$IP@QHC3Y9P2./%N7^\U
M3UZMP?B28)3RJ\DGPG(+U B8!\QBNINYN4:J)/G9<[R-[W7+0 #[:\6?\*PP
M]H1?-:9@J>)]+437,(I:T&'?7I-"DMC4H)\I<!=O"1WF=ET;S"0*%"%<K][!
M8^?;KKB+!-VOC*OL?AH%13BK:QN>:*\GNG.23R0Q1XP3*V&F$/9T/1%)$)6*
M)IF5,2Q/5@_:X\D, -=Z_@SD4,*^U%U56&E+,W\"F25Q,3;8XF?CY7:H\4M:
M9)D^KWXL6BP4*12TXQT^:WL\_8,I4C-6.71#G1'#>S1-MPD%,NZ0\]66BR)J
M[;''OX@S+ZKB3&^0N3Z:O]'1;@YI!]LI!)T&J->^[$8GC#B^,8D?Y1U#&[0*
M^]:0;%0!$]%2 ?,KRKDJ@YBL4YSMUL_V$E%=8B-N:RZT5A+5_("17R2JIJKE
M\E+F?+>EM6C&LUB^NK8FP+ZU[$T[(ZWVD5/ZLT\4TM%[Z-ZQ%2R'9'&.&'&J
MKCJ,6C]]JQ?P6XN00*O%XFUUY-ER>-L'B"L2$*$X64KGFNN^;:T;')[@98V2
M%"%MF^Y^*Y]3C&O%^LUJLY\S;XO#R!+7A:5LQB<Z*XS#/[-H3B@JE;DUXNNF
MB=XB;X2A:9@0C6&O>LQ*\F_Q;4[4,3N6KV-BMOCQA39-&)' 1ZZQ \40LR4H
M#X3@8OJ[4]-XEE!R$\?6Y)WORW%[TMCGH*3MK.S>HKIN7:VU"G?ILH/Y#F[.
M'])\HS<RU@)JT@FR]8\DZ;L[2!L6)MS\EL*%*ATK5.HM!KWUVJZL0_(/0FZX
M:5CFM@S*N*O(7R6X633E.7Z9I&U2*<U;;H<;KR*![]L@&F^QO.-'(J$DEXQ\
M03\^2ZE:!_;99&*7?/JPGC3,LXW '+ ;>2NB;W0!,9[(L<TJ'RIEJJ[W>M2-
ME_KL74J4W>YZNTK0>/!'D'$?657N0AKYW2BAZ5H*_(-7WA-]!'FI?@<>2^[I
M0M^N+4O+7-RK-WFFL'#0PJ*>(3Y!+823K;T.$@;:ZBL'K#E_<_C$DZ1A^3B@
M:^9,IM5;MUOI4O/3:EGC%4)/.O) _<>&I,%BG5 X']O[7B;V=9[QF1#L@V):
MPHN/;KVWSR3"57MM=ASN5U)]_NVM&=V/]#E3[TN)Q=VQD][%2-X?P?9T6-W%
MQCC6P<;%'AXM''$$SH63#]:2B^:W*C:]?S[>?I@PG$Z=6Z%&W>FJK!/\,"UP
M)%<A8_D@ZEBK1KAS5G4)S%WYI?I6@>LM\PA38N^Q<,HRDUX[O':LF>YBI(-2
M/4B(YLD./G[X"J@0[F'@L9A#L8>EIGWP92QS_(:NP,8C8?S<8R]OIV\)'U:=
M34$1Y\KD6R(F51[QPH?2 _:EIBJUS-5OHZ0T,WZ%]@1Q^B6S*C*[]56_4X<?
MIU;MJSJ0T@M306T4+L;(_3MN]$O^&52A21T'YS?>QG\LU\#K(84_7I#X0_38
MES9\I9/T1R45\I+#/1_@#17.$T@=X;SV7JJO/U8/34Q\5N\&S3W1W:?.6LQ(
MF+4"?:(@OWR'&SC0!+@BB.L/H'-13 ?Q"17Z>Y>1+<;SN]8IMUZEL740G([Y
M@PCXW(Q(JI=S0WY*4;&RLU-J!A[:MY._ 6S[%JWTL.NL[K9J0]6H>;T_ELXU
MN[0G*T4T]MJ&N@-:QOUH0FL$X7:S#_XMCJX#=%G]_H;WI^IT2.&/FD1^+B?9
M?)=*OF\+KK1K)?:)"8EO'R;8.! NUH::"#10C<8$</8+E;V[,NX,@S;*Y\QU
MO^Y^$S?@*" 8SG8_+KA_52;54DL[PF_,I1C_'G^<3LX2-/?3WK4 '"-,T2/,
MN.VZM?QAZY4T%KA;YG0,"70D(@C]Z!!^TPA$R\68B7'$I2T2$+AN64@V,4<"
MGIIKO.=!*%;;RIL-&:B$S$\@ 4J9Q8=#+>M3+?O;2"!2HKD5)KV_AP0"7GN%
MWRXJ?6Z9(XU$ CC-J"]I**I8-KU!,=CWIHHH'-1%T=4RA*")<<!H0TL#XF[9
M&N_-">FGHEV]BOK6-<X@C+3'5($#RRJ_;@__Q^UV[)+,&7T44?9T?/@ZMM2!
M5Z/-UB.'5)'"S:SGO,<B9,K3>[4R\DFF?)!&SECI^R-01T,U"?5WYJ[WND:4
M&P,G K4AK0)TM^C0E@,.0['<R>C9<XC3\&7Z[KW?;XFGY'XO,@B:T_\1^AA<
MFDCT1G; Q1!W,?5^A];\FU-B,20P55@H,IA3V%*%6$58[9TB#G*.'Z*\V()R
M V1][&]N8+UAI.2]N:[YQ32RCG:HJZY_&0C[Y3W:7W[4%;EY="5R<_7[!=DH
MEU,A_$"_7#[2V(!9Z 'QN"&V_FFZ?T^R'7%0XGBAZ&IZ>>YX??7[-L2C*]X_
M;LSU<G]@Z#>/JD\QIG[I$/W+ "I4;P__Z&WHGUUG.WN&J[V'V+]@&4#%A>17
M@/3G#\(W6HZWYL]/4<&/OE X,;T\_=M("O-FAND>YY#OPKXH+;)_1L/+(8OD
MJ"[_-/+1E<R?JOSJ>MG>&>*IK1ZOS&K+F'E2DOY[?V>.?VR@_-(<Q;X0OWRR
M>_')[F^JC\U2D,^PR[AUSB[GTW *_,T95+]OX0S_RK0L)#"0B4J5@5^ITD(
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M3GBD*C99F5P2#12?HF6W9+?F^*4$,D!E>GTQO_C"=59>YR&W(W0:#NKZGB:
MD?M.XQO>R@,OZ%6 /<@^LL6F)LJX2:1 --=Z1M>/?+]J&@60*-S=SU2"@U'+
M1Q7D?+  4G&"!"Z/ A&W83)__O0.SE+RL^9SHAGET=@%5Z ';MA-ONSAZY)J
MMVK+V#A;TZT9 6<+")]SDE\FCV=6!KZHJ(P:%]TU9NS2,@ZA6(9Q-F=ZC$ZW
MD\8QP:N<)(.IGI"J6OQTF \RAB7O"K^9 4^OT;]VZU"0B)1(0-%4BW^W-R;J
M!Y$;X1&"<JB<7-OF)"P_.'I2 CH'C\;TN7ULHR8H>=-12!G!4? -??!>[WC+
M"C=J!9CH1@)#8)#^6A8[NT!>R2J;G$AN^IJ: HE.2B>C1\;%NU/0-E3F1T<_
M9T)D F]%\:6EIX-Z06%'])+I[CPLG938LM)QJKDKU<_%6(CT[; )"/2*DS&M
M943H.OQEPELFX0ILW?FS%Z_]O>@B=9J&&C6EIF(GVO/@W$62+14,*]1QZ4[&
MQB1C!CSA>Z8K9&)44/SVV#;OKQ>UK4>U-J =&]]<&J5E]4#%PZ=O3)CF>/B[
MV>X\O*;$9UNFZ'QK7YR57OT):GG.>X1+GG#U%D93XM17ZE51Y#]PYD85#54_
MX]9#!-)=\L *PPRC;5F'_+JXS."3VP3;:FY.4+^LKO8JP\M[M:]O=UNK-[)R
M9QLB#/_=GN,_%>BOQ_^3_;1:_%#"/IY0"Y+'31-7=H()O53/*NFQ&8:>KYF\
M7X8W7!VGDWNJFXY)JI&59T?RK42Q);#S,L703L6JK>0-OCU8&,166)A6+#_P
M"VH8<.+3814AK'I=9^Z^ZR!+@^6#9LRL.0*_++$ /Q,U;V \#T<GD_4+!9*:
M9#$]H>O1C3H//[B%L_,P?*V)VLR*4JPAXLZQ'TI/6>T'L"?"SHI*!UNGSY_F
MOQ5YA9],(R!+W9Q;8)=H@A^\9,QK6UL3IE+),L\>BA&9G\:965]74UZ>=+3W
M*@". S=X%?.U((Q?/VX0$-!I1-6VCV;G!R$;3RJD'QG.FOAR'+I%1C8FBFAO
MG,?(XSTS6'%_UUKT;C16]HX_=UFD),L<F2,);ZC@^*!>:1:/=A>=\'Q+BMOR
MMF&"1T)]4%#3;62K$7Q&L:)-4*V.29%"%\,-@WJM67X$07/1P_N M:U.4LP/
M51/FU&L<R@<'U39<$ZJ76]#Y[%*9.LXMYX)-[>A(&H46>'>X110.3>$\-U39
MG7DTTE-37 Y9ZB<?)Y' BXMOC!2BF[)TR@87Z?*-XS P+8V<]&Q.+XE(3"W[
MJF0!K5 WP,<AMY!46.2YW"8NM3TU9Y^PM"718$]!_^15+'NIS"AG48 >Q/P-
M7Y_OX2'Q=P3+J)LIY5;,9C.3?M;A@R!(@TI0X_6'X2$B@T=4ZI^'JI4[%:E/
MH'3DMF^E1V%];Z58.G7KHZ3LVP0V^4WA#6Q3M)8Q7=1!OA3X%FGQ:"?@#F@N
M?*O:4*TC$T,\Z*IKO'J GN@Y(U"GL^4>(!#U!6IW^<5!FDDX>5%,>F#)<5?4
MM86 IV2"4*)B'D>O!_[]#4&S+[21,,(ZR2H=NR.22K8),3#FJU"R99@?R##J
M/\:(8;"E$"_)9RFKAP-:D5QY-8@]$J\7YHN=W'YL"Q^X88('M[@Y5"B<V9Q>
MBYG7AH:E"Q I%Z^QBVY(FWS:=?V7A4 '6GRQ,SZ&+DV)B+=7&I4/(1>6UN&2
MAG A>@3MIQ:5=I92EE*KV^(72"##%*%D>I"]:YA_>P<)'(DC@2!;3:6?NGX_
MYV%;Z2>X2*!K&T'B5_:/2Z&4;#6?#<X%=AUSTK9 7M#?\"F+_0Z^!::KY]J,
MX48*=ZR9BON\.;)PV)/K7'P!'E83/ML2?6WER61I<_:8WBEP]+"/6W?1O4;$
M2=7@S1;5WO"XJD&&%TE%(CHVC3?ER #).:4'61A;WN.L,#8 )>CI*#P4R(;\
M 8=-V[BH\O/C.(K]F6(C 068PWDAJ%+EAN_D5FE(@531['_'[O^G;/^SKU&E
MY<&,(2PO":5_5[G@FG!<]X>5N"H"OA1G;ZLFZ48DL"3I$>OIQ5B9:N)5RJ@,
MIIWH)ZYA=9#J=%\P]^?UE:J-W?XF_MLP3K-GMRE;0*X'M2L3>E0V:]).,6[K
MX7S;H@_YJ2J?M6<YX@@3YP[UR>U\[Z7N+D":S%*8ISB2DQ19(=0L.68;3WX\
MXB%I/5=5W TS#;EJGVLIM-,MGV02,/+:M>?JW_3^ 7YP2<>@X8E.'P/WE\+]
MD7+AL!/UV?061[=VT\@A,Z?7=J$6O#+J0 'E7@JJKB;3RL'[J.A5V@O[;SV?
MUZC_6M-@ S=>S.X?5^)0]#XI22Z[-SF[I>NQ[_6VPI",H]!U$<1('7%LS$W*
MP[ZG&F&RL;Z;ZX,[7< 4=:3OP?G4O2J0?!U[6R][="%A$7Q3EQT37Q'*R/E1
M?#S2PC[)>"[;[GEJH7"J>T$O]3:Y7QUM<$*A#=FJ(14)K+\W=[LOM],AC2F&
M1X-G$_'S?;7XX;YATNMA]3PYP9^4BNJ?WT4DV5[>\7#G1>6' O49BE@Q]#U$
M-*LCPNWF$(SZXITW(8*F5Y<R5]S%/A>1SV;@$#P_&<T3307-#_]9P?T_*+[;
M?)\:BR^WM5@V.=51&V&:LM47G?HJ]SP6F!":F2!<PL=! N#M SO(ZQ<?.+@.
M5 B<'D>>9PP<1,Y[>J"0^X*")_O@^>?$<)RX7B8OYF>?N)ZEQ\>D_*WX1F_S
MEK#QQJ!TF<$-)4R='7,O73/_P7$&I*!M@DY0NKX100)$@LE@W6O5<ECM:!GW
M,Y9)X=U/_4L])<^E-7+2>Z& JS0C$HAY>[S:#9>A^ZP7ZIF\)/*#TY3.%JYJ
M4V$K3&2<\S)%+-4#S1\)N%K#FSSTQUVGRW#O9M<K7+_BZ[U7U\9?3KY4PPJK
MJ8W@_L'.ID7NJ/%&27[ NZ.$63#>TJ+RODDJV:HHNS$(M+D6AENXG8Q]H[T#
MV5UDGX=[[]_B]B&!=W=!?H5V.]>?KY61 ,<-Y&<K8F2B9</$\0;GF4S5Z?[5
M0]2<O4-479!MLO*W2WXSW97R002AZ/FW]]G7ZB9((-.MY8"!TRY,:(]V6*:G
MA?CAGZULO_=F_*LW>%:D3TA5]%'9C_8_&_\V!.CO0RSN,MX4'_)!_FR-_G,P
M:!';1*W/_ZLZ#/\K'8;_U 'V+W3X2P 2KU5_]>6)!!:>Z/2IOJ@9H>?_S:O#
M:;@V4F1I_KT;V*RJ@<9'O;X!(_H159#U<AG%^D'.R;5I3$HYR=*ED=Z2&P1>
M/W&+6_8KY*JW4"ADL!X)7!!\<N;6ZE >:Q[,E@HM?)!KGI_\_F8#"=2TT)^=
M7/,V?6F!UR^C(P&2[=\'QG'#)YF:G :U+VJR:Y&&-LEUECT32J>RJ1=:A<+&
M5@B%1@/();OO?#&]+D[+A]>8C;U^%6K:K\-:+L4.NI[_Z&<5[J[BMW_S<WQ,
M4J5JN?52*F2:^(8#5@U;VF1T<5K$# T6?N<;(I,+[BTV>!HQYYSRP']").<"
M"2B/-:IX94RK4R=6*[P=N9>>1#/O(6-(B3A?80W-2=(UC;[\G!02)A1N[*,8
M_8.26MS(>0YGP<43NB:F2.44/=Z@&OD$ <>NC5-#T["L[K_;N6HB?VCQ_2W+
MH5*$8.BNFSYX5W-<0D&BAND]&9<38N.F>!RZ<RI\T.CN,:+ DKF"$3/"0''8
M+]!_W^*YMG.\H3M(2DA*4HV#+_MY#E-*3NIP<]*&8_!,9HBW81\H4O,%_D[5
M F3@&Q*X9UJU97IRW_0&AV[1F#7113%L+6],4B-Q3=17@B1A^J-7W@%ZX'D4
M'[QD>MX^UL@(VA%.K<F(1AR>X?L]JDDT_Z?_;%;YGJ/0AUWFV'D5%2L=9H(9
MM-HSBG:Y?+NDG/+)SF);>PNIGM2>N+MW'E-T/C/J\ACON"71?/'W=?W?2HDC
M/J0S=_[VK1HJK73[+#Q]$%(\_WAQQ.;?/1R-K+_P650M[BW>WXF'-=1W?I$J
MY!-C".W7J^ONWD_:*<AXX&-450T[R*D^.\AQDJ=4HGQW_H+0GS-S5Q_!A,(Z
MA_T-F1,&'4F#,I7%,DR[.?H0]63-I([9O*CQ6=S&?NR>C =>HC=LZ-E9S1P'
M<[ E?))-.@))&=8?G-,TNCY0_EU>6%VIZP:#>7O>.Q!5IBZK7<'WEP+&/(EN
M2]SJBY^"R\V@:O:W(44SFY'4WNWMTZ:SH4OLS%4A+'[?3824)&2=7=H!/S.U
MF;OT!,I;4IS=;RD]RV%0/8/*9I'():IT_L.?_91#NF*&^!P$Y)_T9]UC=513
M:N@C/-??W=@NE>$:;ETE&US8>(:T-[,T5")&1QVMPL8%'!MKOT0?1)$]KF4B
M1M6RI[>D"X:F'?B4GN]N\"TR-KSISJ(_,(TNUL4N+6F_;K%PO<_$E<T511&V
MXNTRWG3@<YJ!^9]%Z^]5VCH2@#];UJJY $/.*'+#6#VSZV-Y&S\*^*]O1L&"
M):D.TD84#DY']#>%$PX:><W<8W'2#![?NUE8[9:*]CZ_A<A63G QP>J#F*,4
MV#8?[>EICQ)NFFCF(/H1=X>%/&&<?JRN'V6^X+D8298_F>K7)%_051/HA2JJ
M-9CZ;'@NHY8GK*9%1^(;N8K#+%L"FQKG3JS(%<:GW82KEJRI?7 H_"*N,TWT
ML,W66R0TO2V!V$;X*IOMG67L0[.NWTZZ)>/@318ZMVDW5,47 6##8W7G<Z*[
MI0Q1B\.X(=1[GM^_"PU.W_"65QT*37R 9A_M[W&3]76Y5/:8UF=ZX[W4JHEY
MSE_30/?=MF;.%U9H9\)TF!@L3;5EF!C*$G!C/VR[*^B4/Z_8.C!P:!'A6GH+
MPZ>VHR.#S=\W\*S;=862]>/6M0R-K::CK^GL- QH3\.\)>?1?'G=%I4;!9A+
M\I\'[.Z;WUE\'\I)]R7PE.[9Y $2:#7F;+OZ<9675M'NX@2FR8EFZF.QB-Z+
M\KD^SQHH?T!DKWQ>'5XL[2W]^"+(XV#K?*GBHE_"YF6CI1K&MV;U^ KPT53S
MV;%Q=&OR:N/%ZG*J2O;C\' _:>>0(H=HT5O[NN0SGP,C^/%6K"WT>. L$?;P
M 7>:Z?[GRAJA"FG\C=YEV&&6$I=A]9AN+/N4Q1LLK!5JZGO<*Z9,L"H(YFKF
ME&=HH.F%5_P*U1"*-0BYSGWZ:7]PZ?&6)EILRE/F!*LT?1CJ,&!BVA9T+?,S
M-HRMF/]W*M_;C"KL\U"+BC$=$I 3*C2H.8LS4G$4:NPE^5AN5N>!'A.F;FY9
MGGFA.9!K,0/:C@0_FC:=SFE_WF%S%T"XD0:5A6;S(P$;NP07:RK)!O/:Y?2E
MTUP(_=J1B$V)''@)?Y=H7;OJFC7Q'=U4_^[4=NHLQT!<"61@A>Y\!0E$/CS"
MO:1\H<N4,/<(,1BZ/ K%S-!>8ZB1"'?_/JOKFVJ!@- C@1;6&YN6CZ9=(S=L
M-YPBW6-(8/T(__H(TA'-JH<$TKMD]E$TA1)"WQ*3>Z%YH>L85XP$_CX [7/4
M&B?S$3(?AQ#T#4 H)BXJ+1HT_Z712[SE!B&'!-ZJ7PS]4L8TB"[(ZO(OC2M;
M2.#X$OOV4F99J8MWQ?8MR5O2Y+\TZL#G31"#,+=1[N:NG,O#2U:7"*? -+9+
MS)O(>K:L+W+_AWSG'[PGTCXI/\SL4+'X?E1FB7"\@>]E[#2WS;<4+@CK+*O-
MLKNB2KL/-PE:IYV6?<6%, 7OHW?,/IY)FZ8,GXY$ .Q?[QE%_^5E#Z4.\14$
MQ0%/S1*N#UESLEI%PBKW*-T<J9;L<HK3  S0KS\8"''#&#5K&72]SAD]PQU+
MFJ(V?DUN*L"X_FTS92FG9M 5!/+!!1E3]N"X+M</B^Z.Z4XN1&2@WWNCO#PZ
M$8":'QN'3RYXG]5+,QV\./?.RZ8IMN?SFI^Z,JRBM54YFM_F%X[^_,"K\UFR
M^D7=(?$/C0L1M<'$MB$[[]6S0G/']3"]REK04[P: O_OU:*S[P;&_:66!A2&
M3K:W>V]EGE7!ZIO YP+R][+[YTIE>^F@UK.>,JTU24_KI=:#78LCI6V3UE0-
M7B_;I&DYO^)0Q"7NEK)O%1P(-1&<:'0\2-9+-!D1!(N85M9&[?7((M1^'O:7
M=Q4> \:'UXWKMJQB?:8H#@Y;[I4)(?:LOZTBYW:$96?K#S#QE^BB.3"%EO)$
M+7]J??"0^E3R &VW./OB;<?R;Y;#)]L&7#K0DR6&IX^QZ?@5.GL_-@9M8<-<
MA8ZIWPJ.2=K*^.^YA59-3[D.T/H%2,FKXG$[#H&9S+A\0I>Y:P(4]:!^8O_8
MQ/T_%>J)#RTKG)F0B7W$B-V\::,]^@_3(]+!ENUS)& +<RR;%R*<31I8C,Z^
MZ2[("JND_R^N*?^3:N!+[6%(,-BZ,6#9"!:ERH^QU==#]$:Z\<JU-*EQ6>M
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M4!F&)'?=).PZ)J!&Z2>-[P<(GPS7>EAF,&_TUQ4>6E.;Q0?C/+# _F([[^J
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M<A@?61M$!R\Q,F@Q<)N)"1CPH T)EOXF(6L=WXSUU-VD>KZ$M%8#%*.Z]-M
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M'"G::C;[85",( ^UG5]JAAUS76/5%7M5\PS.:@)6X*D_PX<35L%Y'S'5]HD
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MD.^K&DX;XQGVXG[F)31-75"TP$"6>9=>LV-^=+)RGHU[>, #KQSS6 88X*#
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M_Z$*RP,]L><"\H#!M\L,I*#[(CC26GC'[&:I>\[X7*]?B'I5D1-(4L%J0BW
M%$&S6-8+UY=K0 2!%W?,C4;=Q5_LJ5Z6-'3$OLMABVET:+]K-R[%*@X\<PUO
MW:=ZQR=#O<[(,.C'%,#GKFJG_(K'W;EF\U0[EO;V"K?5%\TN\3N*%EW%8%"4
MF=C^C5#XJC,APE->5;^=72M*R7DUP2)$Q0SGAF9,_K486>D;BD; CAO):Q^F
M4.&;H HIV:(?6=,SL!$?&>8'163*Z@_:5I,/U'N:*(SE$"2?O""&\)V5LC#8
M1K&?L+OP6%*>.K?J]9JTCYTD2?41\:-AI:*M$+I&9GNX5[[>L)L_EEL_H8/>
M.4^W256O=%M/17%4D!(!-;?'6IQXOT-:*Q-#O;WSTOPM>Q0-G'NJ,6%A>J7R
MV^/*KXGV^]'\K047GU\*//1;)MQ/!8ZC;_M)#OH9+C$1(-)T$O736LHDY1QA
MM#3(47R_[]VN$5:6]$.(M!_J9:8;-:GFX3 HH<E&Y[["U-/88J?(&L[].H$'
M= H"8CLF3"W^MHLW"O;S%T6@&-R+^A!_A-"#;]P5>$C+,_CNE<?GCOEK]-4N
M;2Y-U,($_0@[:C=#MGWWT32$Z>KKEA;!&>Z\K;Z7<11A@=_7#;]NI )'N@BJ
M!=C@]@L(3%CQZYM64D3BZHDR:5[#MZ>'[#U5]_OE<2B&$+8+<TD+(%HPBGE@
MKW2G!#9^>V9#7-NA\C3EAD#QS%HZ_=$ORZXCZ#LF2B%C$B(_4&W-T.I^N@QC
MDNDHG_"DN>V'BHH<N1Y6@1V"VK#OR^F'>CPRPE[3;5I>]GY,N>N)MGKP[?.1
M^:D=?@,SFE11C4X%G81?,6+B)YE$>V0!_0%T^R(-I9OQX"E8W%9EBZNW,Q"4
MD!OQ.D>RO2\[NHZ.?FP5!O>4&Z?JV'(I=""-IGNOZ;WRX;(CYI-^3_=IAWCO
MJT8:Q,)GK_=:\*S>O G[D]3Q4%Z8M]3:LRXI 2%?\K@;+549"BYSM26W.Z9"
M(^I=X"IM4]_D\S_*J8VMU87,3C[#%N;$NY8!F!RFNSYD6 N3P5X/8$XSMD.J
MEVZ\!(]5GYSGPM)CO3UMKA/0??&:>!,H6!4QKK_$!VQD""%<0$'N!--%OC2+
M(909V(UVI!5?-F^N/>NG6&&D0LPNHH%;7G,M+5S@[)FIK3'/./O4DH:/*PU?
M$ZDG*^N>21UU_N"@HOCI9=O&R-N(((&C >/]>'O4'5.5-LK$$U=5GN89Q;I%
M*_N[UNZ$W0^G9'9EX!A-(%+^JX=!\4?90AI=40,9ZTK%K#TO3W[D0(&^GF;$
MBH+7LI6^@ SA1HW6YND<\[Y(9>GF>48\;]CE)Z^!HFEC)>*52,M(?7&VW6>J
M+G5)'7SDAC.;<RPU@VZ)\*C8176$PMIKY1S:B"AJKJ>9?H%6RW=H6*7"BTK]
M'!!O<C<#6$?NP%%O0"%^H$7=02?J7L[9SHAN+-V+VK/:YR[]L[]2@1VD)-Q8
M>5"8 7M)9U^D9E$(/O-<FG$(I?26TL#TTVN%][6!P(T72Q0C7L/?4R%1/%7&
M_D\V5R?=/FH1Z;$ZZ?.Q&4Z5?&7ZL);NNF?ZD1QKV:?I.Q1_LZ6MNNBS@YZ$
M?GBXJG>^L<1-RUI%?2K2U_E@LJ8'*\9243>XC)"X&-(.X/XR(MRKK\%X'U8#
MJX]M):5N!6U.\9,[%+V)>J#(9'1BQ('3Y4[R^D1TV%XBVZO(D)%EV-&HX^)9
M;E7<S'02-VL"(RN=8S^NG4S.J/DM/X(A/\6<J0V)I/?NDT((GK;Z@:X3^\=H
M0)(_ANKMF9KG+2/I>JP-LRYYP'K#R+TT,FO2[H3T0U5Y$,\GO>=MFN2<K]79
M \5+GOPK _D_E H^F*.HLK'-"(S E]_S9>(7FF6\U9]HX)5POY[8+W?A,C/P
MOK%\S3Y#4HB02B[DWIZ1CH""C)WZ9"E^IS1^]1CN"#ZP0Z4WG&;B3RS]:&;3
M'JCSE64^U&.9EDO8)(]1\ =3=:3RO77O)X#E1Y4,+2D8+MH86KF9\Z?U/-UF
M3J\,BDH?CYFSEQ$8<I>&Z#4YHH0:X1]7VEK/#9Y?*Q "DSUR@2:0WY+8M3DN
MFN/8-PG@^#H&^G)\WYV'15*:4IZT*-EOJ0"Y;/6L>N!;^3"U- =.T[ ?'7Q/
MUIQ$U=+2VDF((*Q$J.9"#C1ID[X=)WPW^F='9+[8.K]1!D4%/.K-@B%D@2J*
M0)7&YFNJ0F1R9HPD7ABW:PN7[8:9:C9TFVY6J__IF+ 8S':_"NQI?7>YY+VR
MLRS)2OEW?;V5P+.@Y6$A!O-62KWQL=2<I#K=\+POYWA5EBMS,WB[-,C%&WKR
M]!TT9TK7*WX^R&3LR45 6D[.1]% >%6:6.-T20>!J9E"ZV4NJ0O-5L1UJ6>Z
M!*!0&=PO58/<VT@0X0,[?3[O?)9OBU/Z;)4D:>EQ/LOZ\:J8+%I&A$@SD6$9
MMV@8K ?ESAMV4+1P.[YTG)RILR1SLCB\WRF^D>&P6KM(0L'7.OL(#]9Y5/0.
MIF)WU,D^PA[)7L4B,.U(=L,X\NP#%5\":(;@(<.A'Q\";+'(OA^/>-4\AL)3
M/9QULHID,T_^J2V)0_RM/..L:"H([MQ*1%,OZ&<Q6NPNR;'7F[VG+C'S]3[[
M\QLKU.<Z($I""+S(7?YC^)148I>'(O("UOK\Q86W]>%.ZJ*4OTBT[?YSA3$I
MV<_KE&@ 'AE<$]=L&YS[P41F1.L-=TL$N]^1$-84.(,4X;L4^82'W7C($:8R
MBZ49)]!7853\_B"R6W;JAX35FRB'L23XWO<IB75<53B2<AX>+;23YVB+!N0%
MT4#)='S?]FD_S/LQ;0U&W$X>[SBH%!&TRM E&27<RGS,Q?QU#EB0!3U8EWF=
M/U9O6FINM%E39U8BN4ZR&,WBVUZ7VGNGBI*_(CC%TC/\7EI1X1*T'L<FD*H#
M>KW*G-Q/,^348-RMY^9Q6O*:L9W;4)*GV:,BH0!(RI<,O"[5BU=8WX77?4Z;
MG4,#V,;-C<:EV.V]/RO7]";OJH/H21[<QWX*X/XDH>C@65G9:X[DQ3C<4-VF
MT-;$[">U(?;WV"_Y*?1[O0:Z'SNR)$V'F!QX"\_YR7T=J9HG[%AD$/%-0+76
M1J$VYPBA,*/2Q_L)3+ZG+[9Q3V/ML'N;@OSN@I?"ZNT=L^2(FR2\M>98!5*H
M[,Q39*?4 !I6X5?J1 @(B@RV'Y'Z"N(D;_<B$5[I9"#J=#]BB68M#]SAOF-I
M8DY@AV(9J5<5?FO4T#:7>YGDXB^3,?3P1T OH2<I*_6DQOV#3KHIA:/2X;:!
MS0P6!(Y7G6E4%E^96_+$I!ID:/9)D3*!)<I(P$E[4Q7@+;& AR[FY3(D9DWQ
MO=M[05'-+2J;%TE"*!!!_6F)->&XN.F6'RF\+$S*,7MS*J&DTH[6+&9*QX?;
M1<@.R[_[1VP20"RRE#X,0P.T=A*AK_F2%K:W1"JM+9)9J\HMI=_2Q5HWDU].
M%Y(]MKV6@&/?SI7AJ'>PR/"HH[F1:VP/*7&>&$DHD?+5V]K0^NNT.[FKV-VD
MGH,NW#LJL1T/L=9I3UL@(76]C6&VBR0$&]IR>4'@?'G.MP8_Z!]GWJ*V<*W)
M2&DS&T;1(]@54:T7N*&."[3DVBWYD7W-L_?Z4S/)7M&QB_<;'423&R:OQ:N/
M"9?8K3<R[;L7&&_PV9 93?=8T:3DX;IHLB43JO=\H\&NX04ML,1-+U+6?@+3
MMNW,Q?P0 EM_]0RU__)VEQ0-]-CT5 +302^>V8H#\^4(,+SFNU%N=!@W4MHV
M9[8%%.OXDBWFW7+ZF3$Y)?,-OBK"9TX[6BKP_@7GD"K?;P5"!#RB3ZN_J=K8
M"'26RPE)IECC>% YK?YZYCKTE2OMJ,'>40I4YA# "I_QG*)OWCU73._P<K]^
M2&H:"-ILKF1_+'91R]+ M!BH#]^-)^I OLD=%SIJP-U-CFS^)7IQ]P1GVPX+
MLF",E!I!JN)&IC5[N#H,"9B4C,16[/I96_&G\^Y?+GX+-OF* /_R_<:@U;[U
M,,3840_IX!E;V<A>>XWTSME7<9R@H!TS^WU!LZ^5(_4.=?GAPJ;X8*+[-G"D
MB'87]DQMV,\XOS>GQ6Q82N+X@!A-KZ-_MI8,\_Y<C;M_V5S')[EKU3[6"2T*
M%;>?E_[0\3^Q87\30R+6"_@R/-],S8-FMUV;"FXVDA/:>%'1Z'$6Y9$5/\T6
MB+?$1GR\@*(:J3<NA32KYWEYML:9"&R(U.6E#CI047VN4>&*)\VPUOIQPBD1
M_0';"U>XR;D(%-%(C)AN3QTV,5Z?ZHWHSY\T2?=/G.)X4K2SPZK$<"!^D?$Z
M4+HT_.? U#Y2/$\F.]9GK)SF</SGA&A ;8G$O[U%\#^57%];Q\\;IQ*.QW4F
M1C/M [WD;[A8'K3<9WQ+QLDCJOY&99C';5J3HP86:1'=&YOC6/A X*>RE">[
M<*X\0*XI#SPWMZN6B"K(=]"/J:JA!=<G9GYSC)ST2)I.I\0WP)9M7XJ"U<B3
M YI_*WHBE3D3X%3AU?A"HY+1W!F;^\]?!';[=S"?DW9*A4]F!8I+:_^0X(6Q
MX>KX*ZQ29RF93<+P6F\7ID>+/%BP$M\TH#_M=?^@^9 F:>S+)JU_;T0:LG;)
M#MKS*C*$6LRB4TQ:D:5R%=[XWGOA@@<;S(1(,$A^JA>^7?#N'7\1$&!]76='
M'!='O#0*,P%E&7[.BTR,8'-*X29B!(G&Z$+:DVC5ZB >"[U*X["[A[9Q*Y-*
MNL;^V4ZR;'"\,E7$VZ9;:4^JK[933KCXD@,FURQW;O""EN8ANZ?':,#P8 #7
M5=X+DW"%YLDW(975)?E>GB@RDIVSDLE'#G%9\[6'E9R[<E\H'RYX[+_^6@P-
M1@-3C%2T/\KAMN^.]@@WIV9$SF72W$D%-@;37%;[.;_%T]_3E>YG%UL-E)X*
M1Z"!ED8B1 I#!HPX+0OQYLD^1K3F.A=O4FE_>:_;Z!U48T=?2S@M:O&=3K;=
MP1KNU" :5*\E5$:"R'X('S;?B)^TTQ>)-^GRV&]OWF +MB;SYEW!N]/^9#50
MIBZK?OA7W_M%5=P%&ZC%8G BP9Z$O24LM@=63,1*G<5620I3^E5IF:?&-;0.
M9(5S_!LEQ#!1BH][;??SIAW6[A8ME0=^=H&PB7!KDY#O<[6VD3@(882V97!*
M:\TU06)=W%GU?9ECCT"N[6]H(&,?#<QGHX$VS8H]E&\'&@B(1@,4>AR9^!>\
M:&"M'G*ZC@;V=5[\O:EN. =V8T_3V1[3Y3D(J4OWMX:ZS\.!LK_WI/"/=@99
M_T]=LAK3D_P?/2ECN@U@10--BA@\EMW=AW;P$2+T=5$]L,ACWP^=Z=-*V(\A
MW[ZE0S4D?-;"U]# 0EX5])P2TR7\#J2Y;N%UJQJG9DC$:N*]#Z;IT2[U%U8B
M5()W6RWB[EG+F#_".BVL/G<_-)9G!8N*6UV#-T*?[!N"[!V)#>;$I?@\.KMU
M0Z>H8B#XKU##M)PLA0B];<X(RQV"[\@BW:#67&N2SN@23>=%9+_U>WDOZT0[
M=SR6. \2KAR[DCLX0#G.JAA@=4(!OA X1+W1!\5AXLTK"2DT%H\&'C6,HZ[Q
M(;0@+6KVS%8(LVV2<X0Y//>86_T@0/8X%=1[EC%YF>2-!F33H%V0YJ3?78C^
M[L+5G!CI#]Z_W7)*"RMY6ZW9\LJQ^LG"^UN%D]<@#>?ZKB9:6F_3K>LD+'ON
M]MZ^7_7M^ULTX&CJ=F0.S]^8=XA_6I6J\H$7GLW/?Z"LN6>D>DHR5+ !.KCV
M!0V484+^B/3)J1PL1>2_71UYBA-3--"/:;HWB 86/T]ZH@'II3_6IXA<X[I_
M$N1P#G1Q!$$4BOR]96$;.9:Y]3SR-!IUR83BC*R!'$Z!+DX@[<6:#Z^3_ZU0
M_/RQJ&0SECFT.KQ7;%4KP%.5]"!8N9OPBPF9(@!-)@QJ$U7?=Z_^9'D/([G\
MP?EL?.+U'RU)/Y@L_Q)WZH ![N3Z[.#%$ID-43K?'F_4($73I$T$GJ<2SIWO
M;);V/.EPBLIABC$-+'GA%$T5P>N:(ZE%%UMOVM<7CM?[43C'F=C**3-M-V=:
M0EQ/]9'J,%5R+DKCN^F7J]*JTJ26#]]]TG'#AO[G._X?"DU=8JYECOVA VW"
MB,?8E]*-NPG5A>%GKHNV'71[MVBJ(/CUU;06W<JNIS9?&>=GS)WR&R7TB_S\
MUKY[A"M AH<Q.KW+7&!'?9=OQ5PUWGIDJV.J7]^?A.!!6Q_9B8MXQ*"IS AJ
M$:7C^+N%[;&S8.O)G"*_O-N%]L7[,TT8Z&M3 I/>(8GC\JN^S?>UD=J)-C'G
M?+GVX%\$G5^ RWGG$BO]CT;[\6'CZKH__?TO^-% %_\(:/L>&CCGE3CE/5YH
MJF1"QC/(H9J=T4#64IG+GCG6>Y10@WKN)R1'%.1K0(*V,AJ(N1MZ>44 F>&8
MS++9/U1H_W=8F<P2G2?9987?N$JW_ZJ\+)]V2 V-K+HTL/,T\JY1UMI527L;
M=_]6*<5SC=[7!O>YL>$WQ7NUAOU K.#R2VA+I5VJL;$ZY2='[LW]6<%?G(5<
M7[Z?1>TEE4KNKQ]IX*:;>:D=C.[1J83L9 >VK,2[I^R^TGBJ.[&B%.Q7M6S)
MU]D'SH/_E(AL#*;W24JO"+/FSSGPCE,DC8UPV(E/Q*NZ'7\L#?Z4%<AJ-WBR
MIS&MIN#O\-<VP6OE.&91J_(%G5?&&YIGVBJ'JJR*Z['5_,?2Z]BS%,;;V:@
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M4X%T*UTO/54/.J9 YJ=-S:5N_QM&[:HPRNY?H)0OH9=O;__V7?PVC1\1EVB
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MP'65W29%*C-&8M2"6<!/3U)%>(\&(0(TY3P!/;-E\$V:9OYS&&9W+_C00)?
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M4=!SWB=G 8T9EY] R] IR,0CT)4B:#)WC$$#N*O]*3\AD0<,\B+AYZX]5R_
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MO_D2BOB$3\-_^D0$,%2H&G0Z8W^< ]^(X5WZ(DY/25!%)KE:"Z4T2!$^JF^
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M:CWXE3D?I:4O3=<6U^Y:I2_MYEMGDM2X75R8:C^M'BE>/G0LM31\_BK'24N
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M.!.S";]M'HS.5@,85F.>+K(\G0:E"AY\_92=V)"%NU0P]*F(/NFR@N9H/[N
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M_4"YAXIV'QT#\\%#+.0%D$> >RBHJ/>0\T<"0+9Z(]L!:/CW"1YS2Z$3JG[
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M1("_%TWIEMOP"P3@?,L6 <@<TCV/1K[3>R, =^Y(YG\ZOC60]\9Y=SYP*XD
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M9ON;J/3$U[Z[Z:7\$PD_%OZ:E_-/N)89_MH_M"4 _[Y]^,S+_IP(3N+%;H\
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MC)6VDTM7/N]GTD9IBB9[X4O.5%O,)]P,:D0<OG>3'P(B?(-ZJ#0K"ET4PR/
MJ!$B:B#]+8N1LF<69?XO41G68J>B6 *B,FCUU48E'T!<;:"\NXI^$5]4_UG9
M/I0F O@"W@#(<UNW(JI4)=&? 5 S4+<5I0$ZXX<<?$T*TRJ5IHJA.IH6P?J^
M_0Y"AT.::YX" #8'.6J+K$BNAY)%Z/=\Q9Y99*!!&VI Y.?95@<+5>93\2$
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M]:DG1ZV2FF,+#':/9A9>.CO;%T@[F4:JW0 :/NW]S,:5P9W&5B#@;A#J71N
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ML)LC0B+[ >7D4%H@&MO$4,$CR+&L)#M8\&4Z8U89;GZ.5:5HRQ@>8*MF:C.
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M0/D:%_34PY2C8ULM6B_;16 7"7ZE-]LQ(;%&Z6"BB&.F$_8Y@Z<@_"ERU#.
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M>@(</[&CG[)<E=;T865<Q=KIJ>[P]6YF3!6%X@HYX9$4MISA;$TMOXL\KL2
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MS:0:>-*0$M-J88"' J3RKF5<Z$/D(4OS)MJZC2[D8^"H(C6S2;X-;YA>26^
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MLA\!4RYQM3COH,P#"5S^GB5AF2AM>I&?$^_=WI@&J75FGR(]F]VJ>]#8K V
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M'+L!M!3[FQ:H!;X5DY0E.^_4@Y3(->.>;0P?(\2F&CV/<V\./R3)/CXMLK-
M7SB7S^+6!+=$%NVK.\X3+/40R9V8.CO4GJ1?<B:I&2?*D.U(Z@N"!2[!Z5U$
MEP?J'BOU4*5[_CH?.EW?%-DA0+S(;Q]O/8?YW59+9C,>85*\3FTP3ZS^6PFK
MF847[JN3GG&<1FDYP'#X:<(X]F7&"Q)7%4&8F7Z9I,J0OVG$)$D U7""X6!
M08;5H,J1$A\&!AJ,6&':C!3<E2=E[3P:'ZVO#Q4OII7ND_^?:ZP]^Z2SUCA5
M7NBYG=IZ[M7.>Q;W:C8?C>?6U6RYG-UZ\,8N/N!D6U B8=$^N9U>;9ZU5?OK
MAY=OY,=Q:QE^_Z,>?79./SFZ.L%>>*)]/=@G#\RO,0RKOGE.ZW6F:T)7$M^K
M=N!TB[>=[@G@.9W__C2;OP;Z_P!02P$"% ,4    " #B@TY8RA^E\BX.  #4
MA0  $               @ $     8W9M+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0
M   ( .*#3EAV\Q'KZ@P  %R0   4              "  5P.  !C=FTM,C R
M,S$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( .*#3EA>S/F2[!(  +(2 0 4
M          "  7@;  !C=FTM,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M .*#3E@#DKL 54   (5' P 4              "  98N  !C=FTM,C R,S$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( .*#3EB^)J,)C#   ,>- @ 4
M      "  1UO  !C=FTM,C R,S$R,S%?<')E+GAM;%!+ 0(4 Q0    ( .*#
M3E@M\H.4SZP  ,\1"  +              "  =N?  !C=FU?,3!Q+FAT;5!+
M 0(4 Q0    ( .*#3E@0JJ_"_DL  '%6   0              "  =-, 0!C
M=FU?,3!Q:6UG,34N:G!G4$L! A0#%     @ XH-.6- -_#5N3@  8E8  !
M             ( !_Y@! &-V;5\Q,'%I;6<Q-BYJ<&=02P$"% ,4    " #B
M@TY8HCXMLCUB   "=0  $               @ &;YP$ 8W9M7S$P<6EM9S$W
M+FIP9U!+ 0(4 Q0    ( .*#3E@5LS<@@4(  ']-   0              "
M 09* @!C=FU?,3!Q:6UG,3@N:G!G4$L! A0#%     @ XH-.6#CA%(Z+:0
M[78  !               ( !M8P" &-V;5\Q,'%I;6<Q.2YJ<&=02P$"% ,4
M    " #B@TY8(8'[":E8   690  $               @ %N]@( 8W9M7S$P
M<6EM9S(P+FIP9U!+ 0(4 Q0    ( .*#3EAJI+8Q=WX  (2.   0
M      "  45/ P!C=FU?,3!Q:6UG,C$N:G!G4$L! A0#%     @ XH-.6!0A
M>F8@"   5E(   P              ( !ZLT# &-V;5]E>#,Q+FAT;5!+ 0(4
M Q0    ( .*#3EC]O'P.JP,  '@0   ,              "  336 P!C=FU?
>97@S,BYH=&U02P4&      \ #P"E P  "=H#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>cvm_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cvm="http://cvm.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvm-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-10-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-09_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="From2024-02-01to2024-02-09_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-09</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-01-11_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-10-28_cvm_CEOGeertKerstenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:CEOGeertKerstenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-28</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-11-01to2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-10-28_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-28</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_ConsultantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_ConsultantsOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_ConsultantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_ConsultantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_IncentiveStockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_StockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-10-01to2023-12-31" id="ixv-5730">0000725363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-10-01to2023-12-31" id="ixv-5731">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-10-01to2023-12-31" id="ixv-5732">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-10-01to2023-12-31" id="ixv-5733">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2023-10-01to2023-12-31" id="ixv-5734">2024</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="ixv-5735"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-5736"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-5737"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-5738"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-5739"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="ixv-5740"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-5741"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-5742"
      unitRef="Shares">50018601</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-5743"
      unitRef="Shares">47422304</us-gaap:CommonStockSharesOutstanding>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2023-10-01to2023-12-31"
      decimals="INF"
      id="ixv-5744"
      unitRef="USDPShares">0</cvm:EquityWarrantsExercisePrice>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="ixv-5745"
      unitRef="USD">700000.0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="ixv-5746"
      unitRef="USD">100000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="ixv-5747"
      unitRef="USD">100000.0</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2022-12-31_cvm_ErgomedMember"
      decimals="0"
      id="ixv-5748"
      unitRef="USD">100000.0</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:PatentImpairmentCharges
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="ixv-5749"
      unitRef="USD">0</cvm:PatentImpairmentCharges>
    <cvm:PatentImpairmentCharges
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="ixv-5750"
      unitRef="USD">0</cvm:PatentImpairmentCharges>
    <dei:DocumentType contextRef="From2023-10-01to2023-12-31" id="ixv-6263">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-10-01to2023-12-31" id="ixv-6264">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-10-01to2023-12-31" id="ixv-6265">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-10-01to2023-12-31" id="ixv-6266">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-10-01to2023-12-31" id="ixv-6267">001-11889</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-10-01to2023-12-31" id="ixv-6268">CEL-SCI CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-10-01to2023-12-31" id="ixv-6269">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-10-01to2023-12-31" id="ixv-6270">84-0916344</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-10-01to2023-12-31" id="ixv-6271">8229 Boone Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-10-01to2023-12-31" id="ixv-6272">Suite 802</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-10-01to2023-12-31" id="ixv-6273">Vienna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-10-01to2023-12-31" id="ixv-6274">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-10-01to2023-12-31" id="ixv-6275">22182</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-10-01to2023-12-31" id="ixv-6276">703</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-10-01to2023-12-31" id="ixv-6277">506-9460</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-10-01to2023-12-31" id="ixv-6278">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-10-01to2023-12-31" id="ixv-6279">CVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-10-01to2023-12-31" id="ixv-6280">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-10-01to2023-12-31" id="ixv-6281">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-10-01to2023-12-31" id="ixv-6282">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-10-01to2023-12-31" id="ixv-6283">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-10-01to2023-12-31" id="ixv-6284">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-10-01to2023-12-31" id="ixv-6285">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-10-01to2023-12-31" id="ixv-6286">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-02-07"
      decimals="INF"
      id="ixv-6287"
      unitRef="Shares">50104231</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_755"
      unitRef="USD">3241440</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_756"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_757"
      unitRef="USD">549835</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_758"
      unitRef="USD">520368</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_759"
      unitRef="USD">2347049</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_760"
      unitRef="USD">2248072</us-gaap:InventoryNet>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_761"
      unitRef="USD">16129</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_762"
      unitRef="USD">4245</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_763"
      unitRef="USD">6154453</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_764"
      unitRef="USD">6918420</us-gaap:AssetsCurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_765"
      unitRef="USD">8680732</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_766"
      unitRef="USD">9131987</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_767"
      unitRef="USD">1649020</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_768"
      unitRef="USD">1698243</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_769"
      unitRef="USD">9644158</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_770"
      unitRef="USD">10188126</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_771"
      unitRef="USD">188294</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_772"
      unitRef="USD">197704</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepositsAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_773"
      unitRef="USD">2319101</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_774"
      unitRef="USD">2319101</us-gaap:DepositsAssets>
    <cvm:SuppliesUsedForRDAndManufacturingNonCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_775"
      unitRef="USD">74457</cvm:SuppliesUsedForRDAndManufacturingNonCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingNonCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_776"
      unitRef="USD">74669</cvm:SuppliesUsedForRDAndManufacturingNonCurrent>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_813"
      unitRef="USD">28710215</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_814"
      unitRef="USD">30528250</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_779"
      unitRef="USD">1144425</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_780"
      unitRef="USD">2009786</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_781"
      unitRef="USD">985657</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_782"
      unitRef="USD">1049581</us-gaap:AccruedLiabilitiesCurrent>
    <cvm:DueToEmployeeCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_783"
      unitRef="USD">705698</cvm:DueToEmployeeCurrent>
    <cvm:DueToEmployeeCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_784"
      unitRef="USD">557244</cvm:DueToEmployeeCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_785"
      unitRef="USD">1827363</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_786"
      unitRef="USD">1771804</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_787"
      unitRef="USD">204167</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_788"
      unitRef="USD">197431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_789"
      unitRef="USD">4867310</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_790"
      unitRef="USD">5585846</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_791"
      unitRef="USD">9468149</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_792"
      unitRef="USD">9949565</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_793"
      unitRef="USD">1599496</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_794"
      unitRef="USD">1652949</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_795"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_796"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_797"
      unitRef="USD">16059955</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_798"
      unitRef="USD">17313360</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="fid_340"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_342"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_344"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_801"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_802"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="fid_332"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_334"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_336"
      unitRef="Shares">50018601</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_335"
      unitRef="Shares">47422304</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_803"
      unitRef="USD">500186</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_804"
      unitRef="USD">474223</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_805"
      unitRef="USD">505950994</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_806"
      unitRef="USD">499832063</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_807"
      unitRef="USD">-493800920</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_808"
      unitRef="USD">-487091396</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_809"
      unitRef="USD">12650260</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_810"
      unitRef="USD">13214890</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_811"
      unitRef="USD">28710215</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_812"
      unitRef="USD">30528250</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_816"
      unitRef="USD">4352509</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_817"
      unitRef="USD">5392546</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_818"
      unitRef="USD">2133378</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_819"
      unitRef="USD">2258003</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_820"
      unitRef="USD">6485887</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_821"
      unitRef="USD">7650549</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_822"
      unitRef="USD">-6485887</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_823"
      unitRef="USD">-7650549</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_824"
      unitRef="USD">-197696</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_825"
      unitRef="USD">-152789</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_826"
      unitRef="USD">25941</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_827"
      unitRef="USD">50171</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_828"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_829"
      unitRef="USD">-7853509</us-gaap:NetIncomeLoss>
    <cvm:ModificationOfWarrants
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_830"
      unitRef="USD">0</cvm:ModificationOfWarrants>
    <cvm:ModificationOfWarrants
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_831"
      unitRef="USD">-171552</cvm:ModificationOfWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_832"
      unitRef="USD">-6709524</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_833"
      unitRef="USD">-8025061</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2023-10-01to2023-12-31"
      decimals="INF"
      id="fid_834"
      unitRef="USDPShares">-0.14</cvm:EarningPerShareBasicAndDiluted>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2022-10-01to2022-12-31"
      decimals="INF"
      id="fid_835"
      unitRef="USDPShares">-0.18</cvm:EarningPerShareBasicAndDiluted>
    <cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_836"
      unitRef="Shares">48470600</cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_837"
      unitRef="Shares">43440387</cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_838"
      unitRef="Shares">47422304</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_839"
      unitRef="USD">474223</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_844"
      unitRef="USD">499832063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_849"
      unitRef="USD">-487091396</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_854"
      unitRef="USD">13214890</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_880"
      unitRef="Shares">17724</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_883"
      unitRef="USD">177</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_921"
      unitRef="USD">48730</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_922"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_923"
      unitRef="USD">48907</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_886"
      unitRef="Shares">88573</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_889"
      unitRef="USD">886</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_924"
      unitRef="USD">201421</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_925"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_926"
      unitRef="USD">202307</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_895"
      unitRef="Shares">2490000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_892"
      unitRef="USD">24900</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_927"
      unitRef="USD">4955100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_928"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_929"
      unitRef="USD">4980000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_898"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_930"
      unitRef="USD">1383909</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_931"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_932"
      unitRef="USD">1383909</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_901"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_933"
      unitRef="USD">-470229</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_934"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_935"
      unitRef="USD">-470229</cvm:ShareIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_840"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_845"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_850"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_855"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_841"
      unitRef="Shares">50018601</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_842"
      unitRef="USD">500186</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_847"
      unitRef="USD">505950994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_852"
      unitRef="USD">-493800920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_857"
      unitRef="USD">12650260</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_858"
      unitRef="Shares">43448317</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_859"
      unitRef="USD">434484</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_864"
      unitRef="USD">486625816</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_869"
      unitRef="USD">-454897093</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_874"
      unitRef="USD">32163207</us-gaap:StockholdersEquity>
    <cvm:WarrantExercisesShares
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_902"
      unitRef="Shares">217752</cvm:WarrantExercisesShares>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_905"
      unitRef="USD">2177</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_906"
      unitRef="USD">445114</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_907"
      unitRef="USD">0</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_908"
      unitRef="USD">447291</cvm:WarrantExercisesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_878"
      unitRef="Shares">21331</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_881"
      unitRef="USD">213</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_909"
      unitRef="USD">49965</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_910"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_911"
      unitRef="USD">50178</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_884"
      unitRef="Shares">40236</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_887"
      unitRef="USD">402</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_912"
      unitRef="USD">91221</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_913"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_914"
      unitRef="USD">91623</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <cvm:IncentiveStockForfeitedShares
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_893"
      unitRef="Shares">-2000</cvm:IncentiveStockForfeitedShares>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_890"
      unitRef="USD">-20</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_915"
      unitRef="USD">-11080</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_916"
      unitRef="USD">0</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_917"
      unitRef="USD">-11100</cvm:IncentiveStockForfeitedAmount>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_896"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_918"
      unitRef="USD">1703931</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_919"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_920"
      unitRef="USD">1703931</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_860"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_865"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_870"
      unitRef="USD">-7853509</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_875"
      unitRef="USD">-7853509</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_861"
      unitRef="Shares">43725636</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_862"
      unitRef="USD">437256</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_867"
      unitRef="USD">488904967</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_872"
      unitRef="USD">-462750602</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_877"
      unitRef="USD">26591621</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_936"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_937"
      unitRef="USD">-7853509</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_939"
      unitRef="USD">1004633</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_940"
      unitRef="USD">988543</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_941"
      unitRef="USD">2504</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_942"
      unitRef="USD">5078</us-gaap:OtherNoncashExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_943"
      unitRef="USD">218386</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_944"
      unitRef="USD">148858</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_945"
      unitRef="USD">1383909</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_946"
      unitRef="USD">1692831</us-gaap:ShareBasedCompensation>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_947"
      unitRef="USD">48907</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_948"
      unitRef="USD">50178</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_950"
      unitRef="USD">100546</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_951"
      unitRef="USD">-111537</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_952"
      unitRef="USD">98765</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_953"
      unitRef="USD">-212687</us-gaap:IncreaseDecreaseInInventories>
    <cvm:IncreaseDecreaseInDepositAssets
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_954"
      unitRef="USD">11884</cvm:IncreaseDecreaseInDepositAssets>
    <cvm:IncreaseDecreaseInDepositAssets
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_955"
      unitRef="USD">0</cvm:IncreaseDecreaseInDepositAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_957"
      unitRef="USD">-765078</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_958"
      unitRef="USD">-115285</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_959"
      unitRef="USD">-8924</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_960"
      unitRef="USD">13346</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_961"
      unitRef="USD">148454</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_962"
      unitRef="USD">79087</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_963"
      unitRef="USD">-4887928</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_964"
      unitRef="USD">-4666649</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_966"
      unitRef="USD">51650</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_967"
      unitRef="USD">53580</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_968"
      unitRef="USD">13211</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_969"
      unitRef="USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_970"
      unitRef="USD">-64861</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_971"
      unitRef="USD">-53580</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_973"
      unitRef="USD">4980000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_974"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_975"
      unitRef="USD">504913</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_976"
      unitRef="USD">9010</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_977"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_978"
      unitRef="USD">447291</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_979"
      unitRef="USD">426593</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_980"
      unitRef="USD">372871</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_981"
      unitRef="USD">4048494</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_982"
      unitRef="USD">65410</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_983"
      unitRef="USD">-904295</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_984"
      unitRef="USD">-4654819</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_985"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_986"
      unitRef="USD">22672138</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_987"
      unitRef="USD">3241440</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_988"
      unitRef="USD">18017319</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_990"
      unitRef="USD">0</cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities>
    <cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_995"
      unitRef="USD">105318</cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_991"
      unitRef="USD">714</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_996"
      unitRef="USD">1853</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_992"
      unitRef="USD">202307</cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_997"
      unitRef="USD">91623</cvm:PrepaidConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:FinancingCostsIncludedInCurrentLiabilities
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_993"
      unitRef="USD">43019</cvm:FinancingCostsIncludedInCurrentLiabilities>
    <cvm:FinancingCostsIncludedInCurrentLiabilities
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_998"
      unitRef="USD">0</cvm:FinancingCostsIncludedInCurrentLiabilities>
    <us-gaap:InterestPaidNet
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_994"
      unitRef="USD">244659</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_999"
      unitRef="USD">277853</us-gaap:InterestPaidNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_680">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;A. &lt;span style="text-decoration:underline"&gt;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The accompanying condensed financial statements of CEL-SCI Corporation (the &#x201c;Company&#x201d;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#x2019;s financial position as of December 31, 2023 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2023 is derived from the September 30, 2023 audited financial statements. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Summary of Significant Accounting Policies:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing &#x2013;&lt;/em&gt; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013; &lt;/em&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Share-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt; (&#x201c;ASC 718&#x201d;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company accounts for income taxes in accordance with the provisions of ASC 740, &lt;em&gt;Income Taxes&lt;/em&gt;, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2023 and September 30, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets&lt;/em&gt; &#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Recently Adopted Accounting Standards&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2016-13,&lt;em&gt; Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). &lt;/em&gt;ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#x2019;s financial position, results of operations, or cash flows. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt; &#x2013; The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements. &lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_689">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_691">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_692">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing &#x2013;&lt;/em&gt; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-10-01to2023-12-31" id="fid_693">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <cvm:LeasesPolicyTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_694">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013; &lt;/em&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.&lt;/p&gt;</cvm:LeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-10-01to2023-12-31" id="fid_696">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Share-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt; (&#x201c;ASC 718&#x201d;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-10-01to2023-12-31" id="fid_697">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_698">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_699">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company accounts for income taxes in accordance with the provisions of ASC 740, &lt;em&gt;Income Taxes&lt;/em&gt;, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2023 and September 30, 2023.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <cvm:ImpairmentOfLongLivedAssetsPolicyTextblock contextRef="From2023-10-01to2023-12-31" id="fid_690">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets&lt;/em&gt; &#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;</cvm:ImpairmentOfLongLivedAssetsPolicyTextblock>
    <us-gaap:UseOfEstimates contextRef="From2023-10-01to2023-12-31" id="fid_700">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. &lt;/p&gt;</us-gaap:UseOfEstimates>
    <cvm:NewAccountingPronouncementEarlyAdoptionPolicyTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_695">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Recently Adopted Accounting Standards&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2016-13,&lt;em&gt; Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). &lt;/em&gt;ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#x2019;s financial position, results of operations, or cash flows. &lt;/p&gt;</cvm:NewAccountingPronouncementEarlyAdoptionPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_701">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt; &#x2013; The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cvm:LiquidityDisclosureTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_681">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;B. &lt;span style="text-decoration:underline"&gt;LIQUIDITY&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#x2019;s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Due to the Company&#x2019;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;</cvm:LiquidityDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_682">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;C. &lt;span style="text-decoration:underline"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Proceeds from the Sale of Common Stock&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received aggregate gross proceeds of approximately $5.0 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Equity Compensation&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Underlying share information for equity compensation plans as of December 31, 2023 is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Total Shares &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Reserved &lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,787,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,283,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;634,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;640,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;span style="text-decoration:underline"&gt;Stock option activity&lt;/span&gt;:&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Three Months Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;&#160;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;&#160;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;96,832&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;45,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Share-Based Compensation Expense&lt;/span&gt;:&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Three Months Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,383,909&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,692,831&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;218,386&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;148,858&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Warrants and Non-Employee Options&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following chart represents the warrants and non-employee options outstanding at December 31, 2023:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Warrant/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:9%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;8/18/2024 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;7/13/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;8/15/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6/22/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;7/24/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;10/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;7/28/2017 &#x2013; 9/2/2023 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;110,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1.39 - $2.18 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;7/27/2027 - 9/1/2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;1. &lt;span style="text-decoration:underline"&gt;Equity Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Changes in Equity Warrants&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;No warrants recorded as equity were exercised during the three months ended December 31, 2023. The following warrants recorded as equity were exercised during the three months ended December 31, 2022. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:9%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,752&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,291&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;418,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;217,752&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;447,291&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;No warrants recorded as equity expired or were extended during the three months ended December 31, 2023. On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2022. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;2. &lt;span style="text-decoration:underline"&gt;Options and Shares Issued to Consultants&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the three months ended December 31, 2023 and 2022, the Company issued 88,573 and 40,236 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.56 and $2.53 during the three months ended December 31, 2023 and 2022, respectively. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;No options were issued to a consultant during the three months ended December 31, 2023. During the three months ended December 31, 2022, 5,000 options with an exercise price of $11.61 issued to a consultant expired. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the three months ended December 31, 2023 and 2022, the Company recorded total expense of approximately $218,000 and $149,000, respectively, relating to the share-based compensation under various consulting agreements. On December 31, 2023 and September 30, 2023, consulting fees of approximately $134,000 and $205,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-11-30"
      decimals="0"
      id="fid_1062"
      unitRef="Shares">2490000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-11-30"
      decimals="INF"
      id="fid_1063"
      unitRef="USDPShares">2.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-11-01to2023-11-30"
      decimals="-5"
      id="fid_1064"
      unitRef="USD">5000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_702">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Total Shares &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Reserved &lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,787,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,283,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;634,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;640,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1000"
      unitRef="Shares">138400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-12-31_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1001"
      unitRef="Shares">15787200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-12-31_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_1002"
      unitRef="Shares">1283760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-12-31_us-gaap_StockCompensationPlanMember"
      decimals="0"
      id="fid_1003"
      unitRef="Shares">634000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-12-31_cvm_IncentiveStockBonusPlansMember"
      decimals="0"
      id="fid_1004"
      unitRef="Shares">640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <cvm:ScheduleOfStockOptionActivityTableTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_703">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Three Months Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;&#160;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;&#160;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;96,832&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;45,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfStockOptionActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1005"
      unitRef="Shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1009"
      unitRef="Shares">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1008"
      unitRef="Shares">96832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1012"
      unitRef="Shares">45400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <cvm:ScheduleOfCompensatingBalancesTableTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_704">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Three Months Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,383,909&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,692,831&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;218,386&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;148,858&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfCompensatingBalancesTableTextBlock>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1013"
      unitRef="USD">1383909</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1014"
      unitRef="USD">1692831</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1015"
      unitRef="USD">218386</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1016"
      unitRef="USD">148858</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_705">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Warrant/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:9%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;8/18/2024 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;7/13/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;8/15/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;6/22/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;7/24/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;10/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;7/28/2017 &#x2013; 9/2/2023 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;110,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1.39 - $2.18 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;7/27/2027 - 9/1/2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesNMember"
      id="fid_1017">8/18/2008</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesNMember"
      decimals="0"
      id="fid_1025"
      unitRef="Shares">85339</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesNMember"
      decimals="INF"
      id="fid_1033"
      unitRef="USDPShares">3.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesNMember"
      id="fid_1041">8/18/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesUUMember"
      id="fid_1018">6/11/2018</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesUUMember"
      decimals="0"
      id="fid_1026"
      unitRef="Shares">93603</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_1034"
      unitRef="USDPShares">2.80</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesUUMember"
      id="fid_1042">6/30/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesXMember"
      id="fid_1019">1/13/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesXMember"
      decimals="0"
      id="fid_1027"
      unitRef="Shares">120000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesXMember"
      decimals="INF"
      id="fid_1035"
      unitRef="USDPShares">9.25</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesXMember"
      id="fid_1043">7/13/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesYMember"
      id="fid_1020">2/15/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesYMember"
      decimals="0"
      id="fid_1028"
      unitRef="Shares">26000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesYMember"
      decimals="INF"
      id="fid_1036"
      unitRef="USDPShares">12.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesYMember"
      id="fid_1044">8/15/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesMMMember"
      id="fid_1021">6/22/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesMMMember"
      decimals="0"
      id="fid_1029"
      unitRef="Shares">333432</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_1037"
      unitRef="USDPShares">1.86</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesMMMember"
      id="fid_1045">6/22/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesNNMember"
      id="fid_1022">7/24/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesNNMember"
      decimals="0"
      id="fid_1030"
      unitRef="Shares">200087</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_1038"
      unitRef="USDPShares">2.52</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesNNMember"
      id="fid_1046">7/24/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesRRMember"
      id="fid_1023">10/30/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1031"
      unitRef="Shares">234009</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_1039"
      unitRef="USDPShares">1.65</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesRRMember"
      id="fid_1047">10/30/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2023-12-31_cvm_ConsultantsMember_srt_MinimumMember"
      id="fid_1024">7/28/2017</cvm:IssueDate1>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2023-12-31_cvm_ConsultantsMember_srt_MaximumMember"
      id="fid_1050">9/2/2023</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_ConsultantsOptionMember"
      decimals="0"
      id="fid_1032"
      unitRef="Shares">110000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_ConsultantsMember_srt_MinimumMember"
      decimals="INF"
      id="fid_1144"
      unitRef="USDPShares">1.39</cvm:ExercisePrice>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_ConsultantsOptionMember"
      decimals="INF"
      id="fid_1040"
      unitRef="USDPShares">2.18</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2023-12-31_cvm_ConsultantsMember_srt_MinimumMember"
      id="fid_1048">7/27/2027</cvm:ExpirationDate>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2023-12-31_cvm_ConsultantsMember_srt_MaximumMember"
      id="fid_1049">9/1/2028</cvm:ExpirationDate>
    <cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_706">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:9%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,752&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,291&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;418,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;217,752&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;447,291&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock>
    <cvm:EquityWarrantsExercised
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1051"
      unitRef="Shares">17752</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_1052"
      unitRef="USDPShares">1.65</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1053"
      unitRef="USD">29291</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesSSMember"
      decimals="0"
      id="fid_1054"
      unitRef="Shares">200000</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesSSMember"
      decimals="INF"
      id="fid_1056"
      unitRef="USDPShares">2.09</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2023-10-01to2023-12-31_cvm_SeriesSSMember"
      decimals="0"
      id="fid_1055"
      unitRef="USD">418000</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1057"
      unitRef="Shares">217752</cvm:EquityWarrantsExercised>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1058"
      unitRef="USD">447291</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:IncrementalCostDeemedDividend
      contextRef="From2022-10-01to2022-10-28_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1061"
      unitRef="USD">172000</cvm:IncrementalCostDeemedDividend>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2023-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_1065"
      unitRef="Shares">88573</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-10-01to2022-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_1066"
      unitRef="Shares">40236</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2023-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_1067"
      unitRef="USDPShares">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-01to2022-12-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_1068"
      unitRef="USDPShares">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1
      contextRef="From2022-10-01to2022-12-31_cvm_ConsultantsMember"
      decimals="0"
      id="fid_1069"
      unitRef="Shares">5000</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2022-12-31_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_1070"
      unitRef="USDPShares">11.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-10-01to2023-12-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1071"
      unitRef="USD">218000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-01to2022-12-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1072"
      unitRef="USD">149000</us-gaap:AllocatedShareBasedCompensationExpense>
    <cvm:ConsultingFeesIncluedPrepaidExpenses
      contextRef="AsOf2023-12-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1060"
      unitRef="USD">134000</cvm:ConsultingFeesIncluedPrepaidExpenses>
    <cvm:ConsultingFeesIncluedPrepaidExpenses
      contextRef="AsOf2023-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1073"
      unitRef="USD">205000</cvm:ConsultingFeesIncluedPrepaidExpenses>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_684">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;D. &lt;span style="text-decoration:underline"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the three months ended December 31, 2023, no restricted shares of the Company&#x2019;s common stock were purchased by related parties.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cvm:IncrementalCostDeemedDividend
      contextRef="From2022-10-01to2022-10-28_cvm_CEOGeertKerstenMember"
      decimals="0"
      id="fid_1074"
      unitRef="USD">172000</cvm:IncrementalCostDeemedDividend>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_685">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;E. &lt;span style="text-decoration:underline"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Clinical Research Agreement&lt;/em&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company&#x2019;s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, &lt;em&gt;Collaborative Arrangements&lt;/em&gt;. The Company determined the payments to Ergomed are within the scope of ASC 730, &lt;em&gt;Research and Development&lt;/em&gt;. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.8 million for Ergomed&#x2019;s services. This amount is net of Ergomed&#x2019;s discount of approximately $11.9 million. During the three months ended December 31, 2023 and 2022, the Company recorded, net of Ergomed&#x2019;s discount, approximately $0.1 million for each quarter as research and development expense related to Ergomed&#x2019;s services.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Lease Agreements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#x2019;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#x2019;s Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The San Tomas lease is classified as a finance lease on the Company&#x2019;s balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the three months ended December 31, 2023 and 2022 was approximately $0.7 million, of which approximately $0.2 and $0.3 million was for interest, respectively. As of December 31, 2023, the weighted average discount rate of the Company&#x2019;s finance leases is 8.44% and the weighted average time to maturity is 4.83 years.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year&#x2019;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Approximate future minimum lease payments under finance leases as of December 31, 2023 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Nine months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,995,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,741,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,832,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,923,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,015,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;252,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total future minimum lease obligation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,758,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,463,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net present value of financing lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;11,295,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less net present value of financing lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,827,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net present value of financing lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9,468,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company leases two facilities under operating leases. The lease for the Company&#x2019;s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $0.1 for both the three months ended December 31, 2023 and 2022. Total cash paid related to operating leases during the three months ended December 31, 2023 and 2022 was approximately $0.1 million for each quarter. The weighted average discount rate of the Company&#x2019;s operating leases is 10.19% and the weighted average time to maturity is 7.74 years. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of December 31, 2023, future minimum lease payments on operating leases are as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Nine months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;268,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;294,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;746,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,523,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(720,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net present value of operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,803,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less net present value of operating lease obligations - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(204,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net present value of operating lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,599,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cvm:ClinicalServiceTrial
      contextRef="From2023-10-01to2023-12-31_cvm_ErgomedMember"
      decimals="-6"
      id="fid_1104"
      unitRef="USD">12000000</cvm:ClinicalServiceTrial>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="-5"
      id="fid_1100"
      unitRef="USD">35800000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:NetOfDiscount
      contextRef="From2023-10-01to2023-12-31"
      decimals="-5"
      id="fid_1105"
      unitRef="USD">11900000</cvm:NetOfDiscount>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2023-12-31_cvm_ErgomedMember"
      decimals="-5"
      id="fid_1101"
      unitRef="USD">100000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-10-01to2023-12-31"
      decimals="-5"
      id="fid_1106"
      unitRef="USD">700000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:InterestPaid
      contextRef="From2023-10-01to2023-12-31"
      decimals="-5"
      id="fid_1108"
      unitRef="USD">200000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="From2022-10-01to2022-12-31"
      decimals="-5"
      id="fid_1109"
      unitRef="USD">300000</us-gaap:InterestPaid>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="fid_1115"
      unitRef="Pure">0.0844</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1 contextRef="From2023-10-01to2023-12-31" id="fid_1110">P4Y9M29D</us-gaap:ResaleAgreementCounterpartyWeightedAverageMaturityOfAgreements1>
    <cvm:FinancingArrangementDepositBaseRentAmount
      contextRef="From2023-01-01to2023-01-11_cvm_LandlordMember"
      decimals="-5"
      id="fid_1117"
      unitRef="USD">2300000</cvm:FinancingArrangementDepositBaseRentAmount>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_708">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Nine months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,995,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,741,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,832,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,923,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,015,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;252,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total future minimum lease obligation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,758,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,463,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net present value of financing lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;11,295,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less net present value of financing lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,827,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net present value of financing lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9,468,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1075"
      unitRef="USD">1995000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1076"
      unitRef="USD">2741000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1077"
      unitRef="USD">2832000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1078"
      unitRef="USD">2923000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1079"
      unitRef="USD">3015000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1080"
      unitRef="USD">252000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1081"
      unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1082"
      unitRef="USD">13758000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1083"
      unitRef="USD">2463000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1084"
      unitRef="USD">11295000</us-gaap:FinanceLeaseLiability>
    <cvm:FinanceLeaseLiabilityCurrentPortion
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1085"
      unitRef="USD">1827000</cvm:FinanceLeaseLiabilityCurrentPortion>
    <cvm:FinanceLeaseLiabilityNoncurrentPortion
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1086"
      unitRef="USD">9468000</cvm:FinanceLeaseLiabilityNoncurrentPortion>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="-5"
      id="fid_1111"
      unitRef="USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2023-10-01to2023-12-31"
      decimals="-5"
      id="fid_1113"
      unitRef="USD">100000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="fid_1103"
      unitRef="Pure">0.1019</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1 contextRef="From2023-10-01to2023-12-31" id="fid_1116">P7Y8M26D</us-gaap:RepurchaseAgreementCounterpartyWeightedAverageMaturityOfAgreements1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_709">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Nine months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;268,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;294,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;746,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,523,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(720,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net present value of operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,803,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Less net present value of operating lease obligations - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(204,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net present value of operating lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,599,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1087"
      unitRef="USD">268000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1088"
      unitRef="USD">366000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1089"
      unitRef="USD">287000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1090"
      unitRef="USD">277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1091"
      unitRef="USD">285000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1092"
      unitRef="USD">294000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1093"
      unitRef="USD">746000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1094"
      unitRef="USD">2523000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1095"
      unitRef="USD">720000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1096"
      unitRef="USD">1803000</us-gaap:OperatingLeaseLiability>
    <cvm:OperatingLeaseLiabilityCurrentPortion
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1097"
      unitRef="USD">204000</cvm:OperatingLeaseLiabilityCurrentPortion>
    <cvm:OperatingLeaseLiabilityNoncurrentPortion
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1098"
      unitRef="USD">1599000</cvm:OperatingLeaseLiabilityNoncurrentPortion>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_686">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;G. &lt;span style="text-decoration:underline"&gt;PATENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;During the three months ended December 31, 2023 and 2022, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately&#160;8&#160;years. Amortization expense for the three months ended December 31, 2023 and 2022 totaled approximately $9,000&#160;and $10,000, respectively. The total estimated future amortization is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Nine months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;23,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;54,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;188,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod contextRef="From2023-10-01to2023-12-31" id="fid_1130">P8Y</cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1126"
      unitRef="USD">9000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1127"
      unitRef="USD">10000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_710">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Nine months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;23,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;54,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;188,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1118"
      unitRef="USD">23000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1119"
      unitRef="USD">29000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1120"
      unitRef="USD">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1121"
      unitRef="USD">22000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1122"
      unitRef="USD">19000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1123"
      unitRef="USD">16000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1124"
      unitRef="USD">54000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_1125"
      unitRef="USD">188000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_687">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;H. &lt;span style="text-decoration:underline"&gt;LOSS PER COMMON SHARE &lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and unveseted restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Three months ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net loss available to common &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(6,709,524&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,025,061&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;48,470,600&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,440,387&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.14&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.18&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In accordance with the contingently issuable shares guidance of ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Options and Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,839,028&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,917,352&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;149,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;15,986,278&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;14,066,602&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_711">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Three months ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net loss available to common &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(6,709,524&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,025,061&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;48,470,600&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,440,387&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.14&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.18&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock>
    <cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1132"
      unitRef="USD">-6709524</cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1133"
      unitRef="USD">-8025061</cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1134"
      unitRef="Shares">48470600</cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted>
    <cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1135"
      unitRef="Shares">43440387</cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted>
    <cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares
      contextRef="From2023-10-01to2023-12-31"
      decimals="INF"
      id="fid_1136"
      unitRef="USDPShares">-0.14</cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares>
    <cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares
      contextRef="From2022-10-01to2022-12-31"
      decimals="INF"
      id="fid_1137"
      unitRef="USDPShares">-0.18</cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares>
    <cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_712">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Options and Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,839,028&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,917,352&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;149,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;15,986,278&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;14,066,602&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2023-12-31_cvm_OptionsMember"
      decimals="0"
      id="fid_1138"
      unitRef="Shares">15839028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2022-12-31_cvm_OptionsMember"
      decimals="0"
      id="fid_1139"
      unitRef="Shares">13917352</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2023-12-31_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_1140"
      unitRef="Shares">147250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2022-12-31_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_1141"
      unitRef="Shares">149250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_1142"
      unitRef="Shares">15986278</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_1143"
      unitRef="Shares">14066602</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-10-01to2023-12-31" id="fid_688">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;J. &lt;span style="text-decoration:underline"&gt;SUBSEQUENT EVENTS&lt;/span&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On February 9, 2024, the Company sold 3,875,000 shares of common stock at a public offering price of $2.00 per share for gross proceeds of approximately $7.8 million.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-02-01to2024-02-09_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_1145"
      unitRef="Shares">3875000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-09_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_1146"
      unitRef="USDPShares">2.00</us-gaap:SharePrice>
    <cvm:ProceedsFromSaleOfCommonStock
      contextRef="From2024-02-01to2024-02-09_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="fid_1147"
      unitRef="USD">7800000</cvm:ProceedsFromSaleOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
